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Diabetes is a well-known risk factor for periodontal disease; however, the pathogenic links 
between periodontal disease and type 1diabetes (T1DM) are not completely understood.  
Therefore, this study evaluated, longitudinally over 6 months, the impact of periodontal disease 
and its treatment on clinical outcomes, glycated haemoglobin (HbA1c), high-sensitivity C-
reactive protein (hsCRP), lipids and local and systemic levels of pro-inflammatory biomarkers 
[matrix metalloproteinase-9 (MMP-9), B-cell activating factor, resistin, epithelial neutrophil 
activating peptide-78/CXCL5 (ENA-78/CXCL5) and interleukin-8, (IL-8)] in patients with 
T1DM. 
57 T1DM and 43 non-T1DM patients were recruited.  Pre-treatment, T1DM patients had 
significantly lower diastolic BP, non-HDL and cholesterol compared to non-T1DM patients.  
T1DM periodontally healthy patients had significantly higher bleeding on probing (BOP) 
scores compared to non-T1DM periodontally healthy patients.  Serum MMP-9, resistin and 
ENA-78/CXCL5 levels were significantly higher in T1DM patients compared to non-T1DM 
patients.  Furthermore, T1DM periodontitis patients had significantly higher serum MMP-9 
levels compared to non-T1DM periodontitis patients.  Regardless of diabetes status, GCF 
MMP-9 levels were significant predictors of clinical periodontal condition.  Moreover, 
T1DM periodontally healthy patients had significantly higher GCF MMP-9 and IL-8 levels 
compared to non-T1DM periodontally healthy patients. 
In T1DM and non-T1DM patients, all clinical periodontal parameters significantly improved 
at 3 and 6 months following non-surgical periodontal management (NSM), and both groups 
demonstrated significant reductions in GCF MMP-9 levels at month 6 following NSM.  
Furthermore, following NSM, GCF IL-8 levels significantly reduced at 3 and 6 months in 
T1DM patients and at month 3 in non-T1DM patients.  In T1DM patients, HbA1c showed 
0.45% and 0.90% reductions at 3 and 6 months following NSM, respectively, although these 
reductions were not statistically significant. 
In conclusion, NSM led to significant reductions in GCF MMP-9 and IL-8 levels, and these 
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1 Chapter 1. Introduction 
1.1  Periodontal disease 
1.1.1 Definition and classification 
Periodontal disease is defined as, “any inherited or acquired disorder of the tissues 
surrounding and supporting the teeth (periodontium)” (Pihlstrom et al. 2005).  These 
disorders may be developmental, traumatic, inflammatory, genetic, neoplastic or metabolic in 
origin (Armitage 2004; Jordan 2004).  The term “periodontal disease” commonly refers to 
gingivitis and periodontitis caused by pathogenic bacteria within the dental plaque biofilm 
that forms adjacent to tooth surfaces on a daily basis (Pihlstrom et al. 2005).  The disease 
progress is also influenced by host susceptibility, age and smoking (Pantlin 2008). 
Gingivitis is defined as “inflammation of the gingiva in which the connective tissue 
attachment to the tooth remains at its original level”.  Gingivitis is the mildest form of 
periodontal disease affecting approximately 50-90% of adults worldwide (Albandar and 
Rams 2002).  The inflammation is confined to the soft-tissue compartment of the gingival 
epithelium and connective tissue and is readily reversible by means of simple and effective 
oral hygiene practices (Pihlstrom et al. 2005).  Gingivitis always precedes the development of 
periodontitis, and no evidence from around the world indicates the onset of periodontitis 
without gingival inflammation (Albandar and Rams 2002).  Periodontitis occurs when this 
inflammation extends deep into the periodontal tissues causing loss of the supporting 
connective tissue and alveolar bone, leading to pocket formation or deepened crevices 
between the soft tissues and the tooth root.  Severe periodontitis can result in tooth mobility, 
pain and discomfort, impaired mastication and eventual tooth loss (Pihlstrom et al. 2005). 
Periodontal disease encompasses a wide range of disease presentations, and hence the 
recognition of these diseases requires an accurate diagnosis to be made (Highfield 2009).  
Various systems of classification of periodontal disease have arisen which assist clinicians in 
identifying the different presentations in relation to aetiology, pathogenesis and treatment 
options.  Classification systems also allow clinicians and researchers from around the world 
to communicate effectively in a common language.  The most commonly used classification 
systems are those of the American Academy of Periodontology (AAP).  Table 1.1 presents  
the classification of periodontal disease as modified from the International Workshop for 




Table 1.1: Overview of the classification of periodontal diseases and conditions. 
“Localised” suggests periodontal disease involving ≤30 % of sites and “generalised” 
suggests periodontal disease involving ≥30 % sites (Armitage 1999). 
I. Gingival diseases 
A. Plaque induced 
1. Gingivitis associated with dental plaque only 
2. Gingival diseases modified by systemic factors 
3. Gingival diseases modified by medications 
 
B. Non-plaque induced 
1. Gingival diseases of specific bacterial origin 
2. Gingival diseases of viral origin 
3. Gingival diseases of fungal origin 
4. Gingival lesions of genetic origin 
5. Gingival manifestations of systemic conditions 
6. Traumatic lesions 
7. Foreign body reactions 
8. Not otherwise specified 
 








IV. Periodontitis as a manifestation of systemic disease 
A. Associated with haematological disorders 
B. Associated with genetic disorders 
  
V. Necrotizing periodontal diseases 
A. Necrotizing ulcerative gingivitis 
B. Necrotizing ulcerative periodontitis 
  
VI. Abscesses of the periodontium 
A. Gingival abscess 
B. Periodontal abscess 
C. Pericoronal abscess 
 
VII. Periodontitis associated with endodontic lesions 
 
VIII. Developmental or acquired deformities 
A. Localised tooth-related factors that modify or predispose to plaque-induced gingival 
diseases or periodontitis 
B. Mucogingival deformities and conditions around teeth 
C. Mucogingival deformities and conditions on edentulous ridges 
D. Occlusal trauma 
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The severity of periodontal disease can be characterised on the basis of the degree of clinical 
attachment loss (CAL) as: slight (CAL of 1 or 2 mm), moderate (CAL of 3 or 4 mm) and 
severe (CAL ≥5 mm) (Armitage 1999).  Currently within the published literature there 
appears to be a conflict and lack of consistency with regard to the definition of what 
constitutes a periodontal case.  Table 1.2 shows two different case definitions of periodontal 
disease which have been used for epidemiological surveys in past research studies (Tonetti 
and Claffey 2005; Page and Eke 2007). 
Table 1.2: Case definition of periodontal disease used in past research studies. 
Both these studies have used CAL at interproximal sites of non-adjacent teeth as their main 
criteria for defining periodontitis; despite this, there is recognition that the diagnosis and 
detection of periodontal disease cannot be based on measurement of a single variable.  CAL 
is a measure of the cumulative lifetime experience of periodontitis, and hence provides very 
little evidence of the current inflammatory condition of the periodontal tissues and therefore 
it is essential to consider additional measurements, such as bleeding on probing (BOP) and 
probing depth (PD) measurements.  Additionally, both sets of criteria took into account the 
potential error in measuring CAL, to exclude cases without periodontitis.  Hence, the 
threshold for interproximal CAL was set at ≥6 mm (Page and Eke 2007) or ≥5 mm (Tonetti 
and Claffey 2005). 
The AAP’s case definition defines ‘severe periodontitis’ as being present if there is a 
minimum of two teeth with 6 mm CAL and one tooth with PD of 5 mm (Page and Eke 2007).  
Based on this definition, it would seem possible to include a subject into the study who has 





 European Workshop 
(Tonetti and Claffey 2005) 
American Academy of 
Periodontology 
(Page and Eke 2007) 
Incipient or moderate 
periodontitis 
Presence of proximal attachment 
loss of ≥3 mm in ≥2 non-
adjacent teeth.  
Presence of ≥2 interproximal sites 
with CAL of ≥4 mm (not on same 
tooth) or ≥2 interproximal sites 
with PD ≥5 mm (not on same 
tooth). 
Substantial or severe 
periodontitis 
Presence of proximal attachment 
loss of ≥5 mm in ≥30% of teeth 
present. 
Presence of ≥2 interproximal sites 
with CAL of ≥6 mm (not on same 
tooth) and ≥1 interproximal site 
with PD ≥5 mm. 
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distal aspect of second molars where a third molar has been extracted.  The benefits of having 
a high threshold for identifying periodontitis cases must be weighed against an ethical issue 
of missing periodontal cases, and if the criteria for case definitions are to provide a robust 
basis for research, it is essential to include cases which have suitable levels of disease to 
generate data, from which valid conclusions can be made.  With regard to substantial extent 
and severity of periodontal disease, the 5
th
 European Workshop in Periodontology provided a 
more robust inclusion criteria, requiring subjects to have interproximal CAL of ≥5 mm 
present in ≥30% of teeth to define the presence of periodontitis (Tonetti and Claffey 2005). 
Further to these case definitions, the AAP updated the case definition for population-based 
surveillance of periodontitis by providing and including a case definition for mild 
periodontitis (Eke et al. 2012).  The initial report (Page and Eke 2007) did not define mild 
periodontitis as it primarily focused on validating the utilization for self-reported questions 
for predicting the prevalence for moderate to severe periodontitis.  In the updated case 
definition, criterion for assessing moderate to severe periodontitis remain unchanged as 
previously published (Page and Eke 2007) and are included in Table 1.3. 
Table 1.3: Updated case definition for periodontal disease (Eke et al. 2012). 
From a public health perspective, it is important to track mild periodontitis in populations as 
this type of disease is most responsive to preventive care and oral hygiene practices to control 
and prevent periodontitis and is crucial for predicting those populations at risk for developing 
moderate to severe periodontal disease in the future.  It is also essential to include mild 
periodontitis in case definitions in research studies as excluding this would underestimate the 
Updated case definition American Academy of Periodontology 
No periodontitis No evidence of mild, moderate, or severe periodontitis. 
Mild periodontitis Presence of ≥2 interproximal sites with CAL ≥3 mm, and ≥2 
interproximal sites with PD ≥4 mm (not on the same tooth) or one 
site with PD ≥5 mm. 
Moderate periodontitis Presence of ≥2 interproximal sites with CAL of ≥4 mm (not on 
same tooth) or ≥2 interproximal sites with PD ≥5 mm (not on 
same tooth). 
Severe periodontitis Presence of ≥2 interproximal sites with CAL of ≥6 mm (not on 
same tooth) and ≥1 interproximal site with PD ≥5 mm. 
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burden of periodontal disease especially in the younger population who are more likely to 
have a/the mild form of disease (Eke et al. 2012).  Previously, Eke and colleagues determined 
the accuracy of periodontal prevalence assessment methods by comparing two methods of 
periodontal examination: partial-mouth periodontal examination and full-mouth ‘gold 
standard’ periodontal examination, and found that partial-mouth periodontal examination 
greatly underestimated the prevalence of periodontal disease by at least 50%, leading to high 
levels of misclassification of periodontal cases (Eke et al. 2010). 
1.1.2 Epidemiology of periodontal disease 
Over the past 20 years, epidemiological studies have attempted to provide information 
regarding the extent and severity of periodontal disease in various populations.  In 2009, the 
UK Adult Dental Health Survey reported the prevalence of approximately 66% of adults, 
aged ≥55 years, having moderately advanced chronic periodontitis [with loss of attachment 
(LOA) ≥4 mm] and 25% of adults, having severe periodontitis (with LOA ≥6 mm) and only a 
small proportion (4%) had LOA ≥9 mm.  Additionally, 17% of adults had healthy periodontal 
tissues and good periodontal health was more commonly seen in adults <45 years of age.  A 
majority (37%) of adults had mild levels of disease, with PD restricted to a range between 4-6 
mm (White et al. 2011).  This survey revealed that although periodontal disease is prevalent 
in the UK population, severe periodontal disease occurs in only a relatively small portion of 
individuals (Steele and O'Sullivan 2011).  Furthermore, visible plaque and calculus were 
present in 66% and 68% of adults, respectively (Chadwick et al. 2011; Steele and O'Sullivan 
2011). 
Similar findings were reported in prevalence studies of other populations, for example, the 
recent update on the prevalence of periodontitis in adults (aged ≥30 years) in the US (the 
National Health and Nutrition Examination Survey 2009 to 2012) reported that 46% of 
adults, representing 64.7 million people had periodontitis, with only 8.9% having severe 
periodontitis (Eke et al. 2015).  A previous prevalence study in the US of 7,447 people, found 
that although over 90% of people aged ≥13 years experienced LOA, only 15% of them 
showed signs of severe disease (with LOA ≥5 mm) (Brown et al. 1996).  Another study in the 
US of 9,698 people concluded that mild periodontitis is widespread in the population 
however, moderate to severe periodontitis affects only a small portion of people (3.1-9.5%) 
(Albandar et al. 1999).  In contrast, a study of 853 Brazilians reported a much higher 
prevalence of advanced periodontal disease, with 52% of individuals showing severe 
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periodontal destruction (LOA ≥7 mm) (Susin et al. 2004).  A prevalence study in Xinjiang a 
rural area in China, reported the prevalence of mild, moderate and severe periodontitis was 
28.9%, 10.2% and 8% respectively (Awuti et al. 2012).  An epidemiological survey in the US 
from 1988 to 2000, reported a reduction in the prevalence of advanced periodontal disease 
from 7.3% to 4.2% (Borrell et al. 2005).  Despite these results being lower than previous 
prevalence estimates for advanced periodontal disease, there still remains a significant 
number of individuals who experience periodontal disease which could lead to tooth mobility 
and subsequent tooth loss. 
The differences in periodontal disease prevalence rates reported over the past years may be 
due to methodological variations, such as, the practice of full-mouth versus partial-mouth 
examinations.  Additionally, the past few years have seen clear improvements in periodontal 
health care, awareness and improved provision of dental care (Steele and O'Sullivan 2011).  
Smoking also plays a vital role in the development of periodontal disease (Kinane and 
Chestnutt 2000) and it has been estimated that up to 50% of cases of periodontitis are caused 
by smoking (Tomar and Asma 2000).  The current smoking prevalence rate for smoking in 
England is 19% (Niblett 2015).  The last 40 years have seen a decline in the percentage of 
smokers within Western populations (Pierce 1989; Molarius et al. 2001), which may have led 
to a decrease in prevalence rates of periodontal disease in different populations. 
1.1.3 Pathogenesis of periodontal disease 
Periodontitis was for many years, considered to be an almost ubiquitous condition in which 
dental plaque was known to be the sole aetiological factor.  Landmark publications have 
changed our way of thinking about periodontitis, such as the initiating role of plaque bacteria 
in gingivitis (Loe et al. 1965), the histological evidence of inflammation in the periodontium 
(Page and Schroeder 1976), recognition of the differences in disease susceptibility among 
individuals (Loe et al. 1986) and the important role the host response plays in disease 
progression (Page et al. 1997). 
Initiating role of the plaque biofilm 
Periodontitis results from a complex interaction between the immune system and 
microorganisms (Sanz et al. 2011), which can be further modified by acquired and 
environmental risk factors (Zee 2009).  Dental plaque is a microbial biofilm causing 
periodontal disease.  Biofilms are defined as “matrix-enclosed bacterial populations adherent 
7 
 
to each other and/or to surfaces” (Socransky and Haffajee 2002).  Initial biofilm formation 
involves the adsorption of salivary mucins and proteins resulting in formation of an acquired 
pellicle.  Oral bacteria bind to this pellicle and to each other in a highly specific succession of 
species.  In healthy periodontal sites, the biofilm consists mostly of Gram-positive bacterial 
species, while only about 15% Gram-negative species are found.  In contrast, diseased 
periodontal sites demonstrate an increase in Gram-negative species to approximately 50% 
(Tanner et al. 1996).  Accompanying this shift in microbial composition from health to 













 during periodontitis 
(Tanner et al. 1996).  Although there is evidence that the microbial biofilm plays a role in the 
aetiology of periodontal disease, it is less clear whether it initiates periodontal disease non-
specifically or specifically.  The non-specific plaque hypothesis states that, “periodontal 
disease is due to bacterial accumulation, irrespective of its composition”.  This implies that 
no one specific species of bacteria is more significant than the other in its ability to cause 
disease.  In contrast, specific plaque hypothesis states that, “periodontal disease is the result 
of an infection with a single specific pathogen”.  This theory may help explain why although 
many patients have substantial plaque deposits, only a minority suffer from severe disease.  
However, to date, no one specific pathogen has been linked to chronic gingivitis or 
periodontitis (Hasan and Palmer 2014).  The multiple pathogen hypothesis states that, 
“periodontal disease is the result of infection with a relatively small number of interacting 
bacterial species”.  However, the major difficulty lies in establishing the possible 
combination of species that are important (Hasan and Palmer 2014). 
The concept that not all microbial biofilms cause periodontal destruction was highlighted in 
the consensus report of the World Workshop on Clinical Periodontics in 1996, which 
concluded that Porphyromonas gingivalis (P.gingivalis), Aggregatibacter 
actinomycetemcomitans (A.actinomycetemcomitans) (previously known as Actinobacillus 
actinomycetemcomitans) and Tannerella forsythia (T.forsythia) (previously known as 
Bacteroides forsythus) (known as red complex microorganisms) must be considered as chief 
periodontal pathogens (Hur 1996) with the following recognition that Fusobacterium 
nucleatum is also a member of this group (Teles et al. 2006).  Molecular techniques and 
cluster analysis of subgingival plaque have shown that certain bacterial species co-exist in 
“complexes” (Figure 1.1) and have demonstrated a strong association between P.gingivalis 
and greater PD and increased BOP in periodontal disease (Socransky et al. 1998).  Another 
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study showed increased proportion of red and orange complex species (Prevotella 
intermedia, Fusobacterium nucleatum and Eubacterium nodatum) in patients with 
periodontitis compared to subgingival plaque from patients with healthy tissues (Ximenez-
Fyvie et al. 2000).  Additionally, the relationship between clinical periodontal parameters and 
red and orange complex species is also mirrored for supragingival plaque samples (Haffajee 
et al. 2008).  However, these bacterial species have also been identified in plaque from 
patients with healthy tissues (Loomer 2004; Sanz and Quirynen 2005) highlighting the 





Figure 1.1: Overview of microbial complexes in subgingival plaque. 
In subgingival plaque certain microbial species have been found to frequently occur 
together in “complexes”.  This figure shows a diagrammatic representation of these 




The dental plaque is a source of a number of antigens including leukotoxin, lipoteichoic acid, 
peptidoglycan, lipopolysaccharides (LPS), fimbriae and extracellular enzymes (Travis et al. 
1997; Fives-Taylor et al. 1999).  The bacterial challenge stimulates an inflammatory response 
and causes direct damage to the periodontal tissues.  For example, gingipains produced by 
P.gingivalis facilitate bacterial invasion into the tissues and contribute to periodontal tissue 
destruction (Genco et al. 1999a; Imamura 2003; Andrian et al. 2004), furthermore, LPS from 
Gram-negative bacteria like P.gingivalis, stimulate host responses via specific host receptors 
(Dixon et al. 2004).  Indeed studies over the past 20 years, have suggested the initiating role 
of pathogenic bacteria in periodontal pathogenesis, confirming a limited number of bacterial 
species associated with severe periodontal disease (Tanner et al. 1996; Socransky et al. 1998).  
However, variations in disease experiences are not matched with microbial factors and 
individuals may harbour pathogens without displaying progressive periodontal disease 
(Cullinan et al. 2003).  Hence, although periodontitis is related to the existence of certain 
pathogenic bacteria in the subgingival biofilm (Socransky et al. 1998; Haffajee et al. 2008), 
the presence of a pathogenic biofilm alone does not cause periodontal disease.  A host-
bacteria interaction and the complexity of the subsequent inflammatory response are essential 
for the development and progression of periodontal disease. 
Host response 
The accumulation of dental plaque causes inflammation to develop within the periodontal 
tissues.  The blood vessels within the periodontal tissues dilate and become more permeable, 
allowing fluid and defence cells to accumulate at the infection site.  In order to combat the 
pathogenic bacteria, first, a large number of neutrophils [polymorphonuclear leukocytes 
(PMNs)], followed by lymphocytes accumulate within the tissues, crossing the junctional 
epithelium and migrating into the periodontal pocket (Page and Schroeder 1976).  The PMNs 
are a critical component of the innate immune system; they maintain periodontal health when 
subjected to constant bacterial challenge from the plaque biofilm.  PMNs are protective by 
intent, by their ability to phagocytose and kill microorganisms.  The vital role PMNs play in 
innate immunity is highlighted in congenital disease such as Chediak-Higashi syndrome and 
leukocyte adhesion deficiency syndrome, in which genetic defects alter the functional 
responses of the PMNs, leading to recurrent microbial infections and severe periodontal 
disease in these patients (Lekstrom-Himes and Gallin 2000).  However, along with their 
protective function, the PMNs release potent lysosomal enzymes, cytokines and reactive 
oxygen species (ROS) which cause destruction of the periodontal tissues (Van Dyke and 
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Vaikuntam 1994; Johnstone et al. 2007).  Contributing to the destructive process in 
periodontitis is neutrophil hyperactivity leading to the overproduction of antimicrobial and 
tissue-damaging ROS (Fredriksson et al. 2003).  The host response is essentially protective 
by intent, but results in local tissue destruction, sometimes referred to as ‘collateral damage’ 
(Preshaw and Taylor 2011). 
If dental plaque is left undisturbed there is a continued cycle of microbial challenge and host 
inflammatory responses.  Hence, in addition to tissue damage caused by the pathogenic 
bacteria, the residing tissue cells and the infiltrating host defence cells contribute to 
connective tissue breakdown and alveolar bone loss (Bartold and Narayanan 2006).  
Handfield et al. demonstrated that host cells respond to bacteria by activating intra-cellular 
signalling pathways leading to cytokine secretion in vitro (Handfield et al. 2008).  The 
activation of the inflammatory host response relies on the ability of the host cells to recognise 
the presence of pathogenic bacteria and their by-products.  Within the periodontal tissues, a 
diverse collection of host receptors enables the host cells to recognise microbe-associated 
molecular patterns (MAMPs) and orchestrate an immune-inflammatory response which 
reflects the bacterial challenge.  An example of this type of periodontal pathogenesis is the 
ability of host receptors such as LPS-binding protein, membrane-associated CD14 and Toll-
like receptors (TLRs) to recognise bacterial LPS and fimbriae (Dixon and Darveau 2005). 
In vitro research experiments have demonstrated that bacteria within the periodontal tissues 
stimulate the secretion of a wide range of pro-inflammatory cytokines such as interleukin-1α 
(IL-1α), IL-1β, IL-6, IL-8 and IL-12 (Sandros et al. 2000; Kusumoto et al. 2004).  
Furthermore, when TLRs interact with the periodontal pathogens there is a release of a 
similar range of inflammatory cytokines and antimicrobial proteins from the host cells 
(Jotwani et al. 2003; Dixon et al. 2004; Eskan et al. 2007; Eskan et al. 2008), highlighting the 
important role host receptors play in the immune-inflammatory response in periodontal 
disease.  The activation of specific host receptors by bacterial MAMPs allows the periodontal 
tissues to direct an immune-inflammatory response appropriate to the pathogens present 
within the biofilm.  However, this defence mechanism of the host causes the majority of 
periodontal tissue destruction leading to the clinical signs of periodontal disease. 
The persistent nature of the plaque biofilm also results in the activation of the adaptive 
immune responses, leading to infiltration of T and B cells into the periodontal tissues (Page 
and Schroeder 1976).  An appropriate adaptive immune response to the bacterial challenge 
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relies on the balanced production of different subsets of T cells by the host tissues.  The 
production of Th1 cells leads to cell-mediated immune responses, with the activation of 
macrophages and the induction of B cells to produce opsonising antibodies, which facilitate 
bacterial killing.  Conversely, the production of Th2 cells provides humoral immunity, with 
activation of B cells to produce neutralising antibodies.  Th1 and Th2 cells have been found 
to release different but overlapping sets of cytokines, but despite extensive research, their 
contribution to periodontal destruction has yet to be clearly defined.  Some studies support 
the hypothesis that Th1 cells are associated with healthy periodontal sites and Th2 cells are 
associated with periodontal disease progression (Gemmell and Seymour 1994; Bartova et al. 
2000).  However, elevated Th1 and reduced Th2 cells, in sites with periodontal disease have 
been found in a few studies (Salvi et al. 1998; Takeichi et al. 2000).  Interestingly, some 
studies have demonstrated the involvement of both Th1 and Th2 cells in periodontal disease 
(Gemmell et al. 1999; Berglundh et al. 2002).  Despite the lack of consensus about the role of 
different T cells, it remains clear that the balance of cytokines produced by innate and 
adaptive immune responses is a key contributing factor in whether the periodontal disease 
remains stable or progresses (Okada and Murakami 1998). 
Biomarkers in periodontal disease 
Tissue destruction in periodontal disease results primarily from an upregulated immune-
inflammatory response stimulated by prolonged exposure to plaque bacteria.  This 
inflammatory response is characterised by increased local production of pro-inflammatory 
cytokines [particularly IL-1β, IL-6 and tumour necrosis factor-α (TNF-)] which result in 
breakdown of collagen fibres, osteoclastic activation and impaired wound healing, leading to 
the clinical signs of disease.  The vital role cytokines play in the host-inflammatory immune 
response has been demonstrated by analysing samples from both human and animal studies 
(Gemmell et al. 1997; Landi et al. 1997; Okada and Murakami 1998).  Cytokines are soluble 
proteins which bind to specific receptors on target cells, initiating intracellular signalling 
cascades which result in phenotypic changes in the target cells via altered gene regulation and 
are effective at low concentrations (Seymour and Taylor 2004; Preshaw and Taylor 2011).  
Within the periodontal tissues, cytokines are produced by the infiltrating host defence cells 
(lymphocytes, neutrophils and macrophages) and the resident periodontal tissue cells 
(fibroblasts and epithelial cells) (Takashiba et al. 2003).  Most cytokines are self-regulatory, 
having the ability to induce their own expression and have pleotropic actions on a number of 
cell types (Taylor et al. 2004).  Cytokines are fundamental to immune and inflammatory 
13 
 
responses, but also contribute to tissue breakdown; for example, IL-1β, IL-6 and TNF-α have 
biologic activity which underpin tissue damage in chronic periodontitis. 
Periodontal research has largely focused on investigating IL-1β concentrations in gingival 
crevicular fluid (GCF) and gingival tissues.  IL-1β is believed to play a major role in 
periodontal pathogenesis, and several studies have found elevated GCF IL-1β levels in 
patients with periodontitis (Preiss and Meyle 1994; Figueredo et al. 1999; Engebretson et al. 
2002; Zhong et al. 2007) and improvements in periodontal health were accompanied by 
significant reductions in GCF IL-1β levels following periodontal treatment (Engebretson et 
al. 2002; Thunell et al. 2010).  Additionally, IL-1β has proved to be a potent inducer for 
connective tissue degradation and bone resorption via the induction of matrix 
metalloproteinases (MMPs) (Birkedal-Hansen 1993).  Elevated levels of IL-1β and TNF-α 
have been found in gingival biopsies obtained from diseased sites compared to healthy sites 
(Stashenko et al. 1991).  Both IL-1β and TNF-α can cause upregulation of adhesion 
molecules on endothelial cells and leukocytes, stimulate chemokine production (which in turn 
recruit leukocytes to sites of inflammation) and induce the expression of inflammatory 
mediators such as prostaglandins and MMPs which have the ability to potentiate 
inflammatory responses (Preshaw and Taylor 2011). 
MMPs are known to play a crucial role in the regulation of periodontal tissue turnover in 
health and disease (Uitto et al. 2003; Sorsa et al. 2004; Sorsa et al. 2006; Li et al. 2012; 
Salazar et al. 2013).  MMPs are controlled and inhibited by tissue inhibitors of 
metalloproteinases (TIMPs).  A balance between MMPs and TIMP activities can maintain 
tissue integrity, while an excessive production of MMPs or TIMPs can result in increased 
tissue degradation (Jacqueminet et al. 2006).  MMPs can also process cytokines and a variety 
of other bioactive non-matrix substrates such as chemokines, immune mediators and growth 
factors, thereby mediating pro- and anti-inflammatory processes (Sorsa et al. 2006; 
Giannobile 2008; Hernandez et al. 2011; Butler and Overall 2013).  The primary source of 
MMPs in the oral cavity is the PMNs, which enter the oral cavity through the gingival sulcus 
(Gangbar et al. 1990; Overall et al. 1991).  MMP-9 is present within the granules of PMNs 
(Hartog et al. 2003), but is also expressed by a variety of other cells in the healthy and 
diseased periodontium (Schiott and Loe 1970; Sorsa et al. 2004).  The main collagenase in 
periodontitis is MMP-8 followed by MMP-9 (Sorsa et al. 1995).  MMP-8, MMP-9 and 
MMP-13 in GCF, are the most widely reported MMPs in sites with active periodontal disease 
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(Lee et al. 1995; Choi et al. 2004; Tuter et al. 2005; Beklen et al. 2006; Kumar et al. 2006; 
Soder et al. 2006).  Additionally, studies have reported significantly elevated plasma MMP-3, 
MMP-8 and MMP-9 levels (Marcaccini et al. 2009a), GCF MMP-8, MMP-9, TIMP-2 and 
myeloperoxidase (MPO) levels (Marcaccini et al. 2010) and serum levels of MMP-1,    
MMP-3, MMP-9, IL-2, IL-8 and cyclooxygenase-2 (COX-2) (Li et al. 2012) in patients with 
chronic periodontitis compared to healthy controls. 
Chemokines are synthesized by various cell types, including epithelial, endothelial and 
stromal cells, such as leukocytes, monocytes, fibroblasts, mast and bone cells.  Based on 
functionality, chemokine molecules can be homeostatic and inflammatory (Moser et al. 
2004).  Homeostatic chemokines are expressed in lymphoid tissues and bone marrow and 
play a crucial role in immune surveillance, haematopoiesis and adaptive immune responses 
(Murphy et al. 2000; Moser et al. 2004; Esche et al. 2005).  While the expression of 
homeostatic chemokines is constitutive, the inflammatory chemokines are induced by stimuli 
such as pathogens, cytokines, and growth factors, by cell-to-cell contact or by chemokines 
themselves.  Chemokines found in both GCF and gingival tissue are thought to play an 
important role in the immunopathogenesis of periodontal disease (Silva et al. 2007).  The first 
cytokine identified to have chemotactic activity was IL-8/CXCL8, which was found to be a 
chemoattractant of PMNs.  IL-8 has been detected in periodontally healthy tissues and has 
been associated with PMNs-associated low subclinical inflammation (Payne et al. 1993; 
Mathur et al. 1996).  After cessation of tooth brushing, a rapid increase in GCF IL-8 levels 
was found preceding clinical signs of periodontal disease (Garlet et al. 2005).  The levels of 
IL-8 in GCF and gingival tissues were found to be drastically increased and correlated with 
disease severity in patients with periodontitis (Tsai et al. 1995).  In contrast, one study 
reported lower GCF IL-8 levels in periodontitis patients compared to healthy controls (Chung 
et al. 1997).  Plasma concentrations of a chemokine, neutrophil chemoattractant and activator 
known as epithelial neutrophil activator-78 (ENA-78)/CXCL5 were significantly elevated in 
smokers with periodontitis compared to non-smokers with periodontitis (Lappin et al. 2011).  
Additionally, the authors reported that periodontitis patients had significantly elevated plasma 
levels of pro-inflammatory cytokine IL-6 and chemokine ENA-78/CXCL5 compared to 
periodontally healthy subjects (Lappin et al. 2011). 
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1.1.4 Quantification of biomarkers 
It is essential to have sensitive methods for the precise quantification of biomarkers while 
assessing levels in clinical samples, especially in GCF samples, for which sample volumes 
are very small.  Various techniques are available to detect and quantify biomarkers, such as 
bioassay, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), and 
multiplex assays for the simultaneous quantification of multiple biomarkers. 
Bioassays have been used to study and monitor the effects of biomarkers on biological 
systems in vitro, for example, to assess the impact of adding specific cytokines on responses 
of cells in culture.  For example, primary human gingival fibroblasts cultured with IL-1β or 
TNF-α of different concentrations, showed a concentration-dependent stimulation of 
production of IL-6 mRNA and IL-6 protein by IL-1β and TNF-α  (Palmqvist et al. 2008).  
Further to this, the impact of IL-6 on the osteoblastic differentiation of primary human 
periodontal ligament cells in culture was assessed by quantifying alkaline phosphatase 
staining histochemically (Iwasaki et al. 2008).  Samples usually contain many different 
biomarkers and the contamination by more active substances may influence the results.  
Hence, this technique is not ideal for biomarker quantification in clinical periodontal studies. 
The principle of the RIA is based on the competition between the antigen (within a sample) 
and a radio-labelled homologous antigen for a limited number of specific antibody binding 
sites.  Subsequently, the amount of radio-labelled homologous antigen is quantified by a 
liquid scintillation counter.  The amount of radio-labelled homologous antigen present is 
inversely proportional to the mediator concentration in the clinical sample, which is 
calculated from a standard curve generated from known amounts of mediator.  RIAs can be 
used to detect various mediators.  For example, a study demonstrated the use of RIA to detect 
GCF prostaglandin-E2 (PGE2) levels in patients with gingivitis and periodontitis.  Patients 
with periodontitis had significantly higher PGE2 levels in GCF as compared to those with 
gingivitis (Offenbacher et al. 1981).  RIAs are very sensitive testing methods, despite this, 
they are lengthy to perform and the availability of more rapid assays to assess biomarker 
levels precludes their use in clinical studies. 
ELISAs are non-competitive immunoassays, which are based on the principle of capturing 
test antigens by an antibody which is coated onto the wells of the microtiter plate.  A washing 
step removes any free antigen, and then a second antibody is added which binds to the 
antigen present on the plate.  Following this, the plate is washed to remove any unbound 
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antibody and then, a ligand is added.  The ligand is a molecule which binds to the antibody on 
the plate, and itself is covalently coupled to an enzyme such as peroxidase.  Following this, a 
washing step is performed which removes the free ligand.  The bound ligand is then 
visualised by the addition of a chromogen, which is a colourless substrate and when acted 
upon by the enzyme of the ligand, produces a visible coloured end product.  The colour 
intensity and visibility in the reaction wells is determined by optical density scanning of the 
plate, and comparison with a standard curve determines the quantity of the test antigen 
present.  ELISA testing has been used in studies to quantify biomarker levels in GCF, saliva 
and plasma samples in patients with periodontitis (Zhong et al. 2007), and also to quantify 
biomarker levels in GCF following periodontal management (Engebretson et al. 2002).  
ELISA can only be performed to test a single biomarker per sample.  This is a major 
limitation given the increasing recognition that biomarkers function in networks in 
periodontal disease pathogenesis (Preshaw and Taylor 2011). 
Most recently, methods to simultaneously quantify biomarkers have been developed, known 
as high-throughput multiplex immunoassays.  Based on ELISA technology, two basic assay 
formats have been developed: planar array assays and micro-bead assays.  In planar assays, 
various capture antibodies are spotted on a 2-dimensional array, acquiring defined positions 
on a pre-coated microtiter plate.  A standard curve is then used to quantify biomarker levels.  
In the micro-bead assays, various antibodies are conjugated onto different populations of 
micro-beads, which can be differentiated by using fluorescence intensity in a flow cytometer.  
Similarly, this method also utilises a standard curve to quantify the unknown biomarker 
levels.  The MULTI-ARRAY (Meso Scale Discovery) and the Luminex-based Bio-Plex (Bio-
Rad Laboratories) platforms are most suitable for biomarker quantification (Fu et al. 2010).  
The micro-bead assay was used to quantify multiple biomarkers assessing changes in serum 
levels in patients with diabetes, following periodontal therapy (O'Connell et al. 2008).  
Although these multiplex immunoassays are advantageous, an important limitation is their 
high cost, limiting their use in large clinical studies (Thunell et al. 2010). 
1.1.5 Factors influencing the susceptibility to periodontal disease 
Cigarette smoking has long been recognised as a risk factor for periodontal disease and 
subsequent tooth loss (Tomar and Asma 2000; Genco and Borgnakke 2013).  A risk factor 
analysis suggests that 40% of cases with chronic periodontitis may be due to tobacco 
smoking (Brothwell 2001).  Smokers are approximately 3-4 times more susceptible to 
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periodontal disease compared to non-smokers (Tomar and Asma 2000; Calsina et al. 2002) 
and those having a longer smoking history are at a higher risk of developing periodontal 
disease (Linden and Mullally 1994; Hyman and Reid 2003).  The importance of smoking as a 
risk factor for periodontal disease has been supported by a consistency in results across 
several studies, the strength and dose-response of the association, the temporal sequence of 
smoking and periodontal disease and biologic plausibility (Genco and Borgnakke 2013).  
Grossi et al. demonstrated that the amount of CAL was greater as number of pack years 
increased, and loss of alveolar crest height was positively correlated with the number of pack 
years of smoking (Grossi et al. 1995).  Mechanisms by which smoking can adversely impact 
the periodontium have been reviewed by Heasman et al. and these effects can be divided into 
several categorises related to the effect of cigarette smoking on: microbiology, gingival blood 
flow, PMNs phagocytosis, cytokine production, CD3, CD4 and CD8+ T-cell subsets and 
periodontal healing (Heasman et al. 2006).  Chronic smoking has a long-term effect on the 
periodontal tissues and impairs gingival circulation (Bergstrom and Bostrom 2001; Dietrich 
et al. 2004).  Smoking leads to peripheral vasoconstriction possibly associated with low doses 
of nicotine.  Vasoconstriction leads to reduced gingival bleeding and hence it may appear that 
smokers have less gingivitis compared to non-smokers.  The compromised microvasculature 
response in smokers may lead to reduced oxygen tension within the periodontal pocket, hence 
favouring the overgrowth of anaerobic bacteria such as, P. gingivalis, T. forsythia and 
Treponema denticola increasing the risk for development and progression of periodontal 
disease (Zambon et al. 1996; Genco and Borgnakke 2013).  Furthermore, smoking alters the 
composition of the plaque biofilm, by increasing the pathogenic bacteria which cause 
periodontal disease (Eggert et al. 2001; Haffajee and Socransky 2001; Shchipkova et al. 
2010).  Smoking has deleterious effects on the functioning of PMNs, which include impaired 
migration and chemotaxis (Seow et al. 1994), and increased PMN elastase, leading to 
degranulation in the neutrophils, making neutrophils more prone to bacterial challenge (Soder 
et al. 2002).  Increased concentrations of GCF levels of TNF-α have been detected in 
smokers, suggesting a more destructive inflammatory process (Fredriksson et al. 2002; Genco 
and Borgnakke 2013).  Smoking also leads to elevated numbers of CD3, CD4 and CD8+ T-
cell subsets within the periodontal tissues, associated with greater periodontal breakdown 
(Loos et al. 2004).  Research has confirmed the benefits of quitting smoking as a part of 
periodontal management, which proved to be beneficial with greater PD reductions in 
smokers who quit smoking compared to those who did not (Preshaw et al. 2005).  A 10-year 
radiographic follow-up study, showed that progressive alveolar bone loss significantly 
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reduced in those who quit smoking during the study compared to continual smokers (Bolin et 
al. 1993).  Furthermore, smoking cessation is found to alter the subgingival microbial 
recolonization.  Fullmer et al. reported that following non-surgical periodontal management 
(NSM), the microbial profile in smokers remained similar to baseline, whereas the biofilm 
composition altered reflecting a less pathogenic subgingival microbiota in those who quit 
smoking, (Fullmer et al. 2009).  There is need for long-term follow-up studies of those who 
quit smoking and non-smokers to determine more clearly the benefit of smoking cessation on 
the periodontium.  However, existing studies strongly suggest that a part of periodontal 
management must involve an attempt at smoking cessation (Genco and Borgnakke 2013). 
Besides smoking, systemic conditions such as cardiovascular disease (CVD), pregnancy and 
diabetes mellitus may increase the susceptibility to periodontal disease.  The 2013 consensus 
report of the European Federation of Periodontology (EFP)/ AAP Workshop on Periodontitis 
and systemic diseases concluded that there was strong and consistent epidemiological 
evidence that periodontitis increases the risk of developing future CVD (Tonetti et al. 2013).  
Periodontal disease contributes to a low-grade systemic infection and inflammatory burden, 
leading to cardiovascular events and stroke in susceptible individuals.  The impact of 
periodontitis on markers of inflammation in serum such as, high-sensitivity C-reactive protein 
(hsCRP), IL-6, plasminogen factors, white blood cell counts, and on serum lipids, brachial 
artery flow rate, intima media thickness suggests that periodontitis has a negative impact on 
such CVD surrogates (Kinane et al. 2008).  Chronic periodontitis leads to the entry of 
pathogenic bacteria or their by-products into the blood stream.  These bacteria have the 
ability to activate the host inflammatory response by a variety of mechanisms.  The host’s 
immune response support atheroma formation, maturation and exacerbation.  Additionally, 
there is a correlation between the subgingival microbiota and pathogenic bacteria detected in 
vascular lesions.  Periodontal treatment often elicits a transient increase in systemic 
inflammatory or pro-thrombotic mediators and a decrease in endothelial cell function in the 
first 24-48 hours (D'Aiuto et al. 2013).  This occurs mostly due to bacteraemia and trauma 
following treatment.  Hence, it would be beneficial to minimize potential bacteraemia by 
emphasizing oral hygiene and carrying out periodontal treatment in multiple sessions rather 
than performing a single intensive treatment session (Tonetti et al. 2013). 
Pregnancy-related periodontal disease has been associated with adverse outcomes such as 
low birth-weight babies, pre-term birth, growth restriction, pre-eclampsia, miscarriage and/or 
still birth (Sanz et al. 2013).  Maternal periodontitis has the ability to directly or indirectly 
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influence the health of the foetal-maternal unit.  Research has identified two major pathways: 
one is the direct pathway, where the oral bacteria reach the foetal-placental unit and the 
indirect pathway, where inflammatory mediators circulate and impact the foetal-placental 
unit.  The consensus report of the Joint EFP/ AAP Workshop on Periodontitis and systemic 
diseases reported that periodontal management has been shown to be safe and effective 
leading to an improved periodontal condition in pregnant women, and NSM, with or without 
adjunctives such as systemic antibiotics, does not reduce overall rates of pre-term birth and 
low birth weight (Sanz et al. 2013). 
Diabetes mellitus is emerging as a worldwide epidemic whose complications have a 
significant impact on quality of life (QoL), longevity and healthcare costs.  The bidirectional 
relationship between diabetes and periodontal disease has been long established, 
hyperglycaemia is associated with adverse periodontal outcomes and severe periodontitis 
adversely affects glycaemic control in patients with diabetes and glycaemia in non-diabetic 
individuals.  There is a direct dose-dependent relationship between the severity of 
periodontitis and diabetes complications.  Emerging evidence supports an increased risk for 
diabetes onset in patients with moderate-to-severe periodontitis (Chapple et al. 2013).  The 
relationship between diabetes and periodontal disease is the main focus of this research study, 
and will be discussed in detail later. 
1.1.6 Management of periodontal disease 
The most important and initial step in periodontal management is communication with the 
patients, behavioral change and risk assessment and management.  Most forms of 
periodontitis can be treated with NSM, described as ‘root surface’ debridement (RSD), which 
involves the disruption and removal of the plaque biofilm and calculus, without intentional 
removal of the root structure, in order to reduce the bacterial load, thereby reducing tissue 
inflammation (Turani et al. 2013).  Mechanical debridement, is the “gold standard” for 
management of periodontal disease which aims to disrupt the subgingival biofilm, eliminate 
and reduce pathogenic bacteria, therefore allowing a shift in the microbial population to those 
commonly associated with health (Preshaw et al. 2004).  The presence of supra- or sub-
gingival calculus impedes effective oral hygiene, hence calculus removal remains a key aim 
for periodontal treatment as it improves access for cleaning by the patient (Turani et al. 
2013).  In most patients NSM in combination with good plaque control is sufficient to 
stabilize the disease process (Heitz-Mayfield et al. 2002).  The concept of complete removal 
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of calculus deposits is viewed as unrealistic, and periodontal healing occurs despite the 
presence of residual calculus, as detected microscopically (Nyman et al. 1986; Cobb 2002). 
While considering which method to use for NSM, a systematic review found no statistically 
significant differences in PD reduction for moderate pockets (5-7 mm) and deep pockets (≥7 
mm), clinical attachment gain and BOP between ‘traditional’ treatment strategies (e.g. 
quadrant-wise basis at two week intervals) and single visit ‘full-mouth’ debridement (FMD) 
strategies (Farman and Joshi 2008).  A few studies highlight that the FMD approach required 
less instrumentation time to achieve similar results as quadrant-wise therapy (Koshy et al. 
2005; Wennstrom et al. 2005).  Although single visit FMD requires less chair-side time, 
higher level of post-operative pain may be experienced using this approach (Apatzidou and 
Kinane 2004; Wennstrom et al. 2005).  The use of subgingival antiseptics (e.g. chlorhexidine 
irrigation) does not significantly or predictably improve treatment outcomes of FMD.  
Therefore, all treatment modalities (i.e. quadrant-wise RSD, full-mouth RSD with 
chlorhexidine, full-mouth RSD without chlorhexidine) can be utilised in the management of 
periodontitis (Sanz et al. 2008).  While considering instrumentation techniques, no 
differences in effectiveness have been reported between hand instruments or powered scalers 
(sonic or ultrasonic) (Kinane 2005), and outcome of treatment was comparable when treating 
patients with chronic periodontitis using either of the methods (Wennstrom et al. 2005; 
Aslund et al. 2008).  However, powered instruments are quicker, and current treatment 
regimens focus on utilising ultrasonic instrumentation for biofilm disruption, using multiple 
and overlapping light strokes of the instrument (Kinane 2005). 
In clinical studies, the use of tooth loss as a marker of disease is complicated, as it may 
require a long-term follow-up period.  Therefore, surrogate markers of periodontal treatment 
commonly used are reduction in PD and BOP, and gain in clinical attachment (Hujoel 2004).  
The two most useful targets to set for treatment outcomes are BOP and the number of PD 
sites ≥5 mm (Turani et al. 2013).  For example, a good target to aim for would be to achieve a 
BOP score of <20%, however this figure can seem a little esoteric to patients.  After 
recording pre-treatment periodontal indices, it is important to highlight the sites measuring ≥5 
mm and count them as a measure of extent of disease to help set a target.  This enables 
something to aim for and a very crucial sense of achievement for both the clinician and the 
patient once this target has been achieved (Turani et al. 2013).  Studies generally do not 
specify a set of predefined criteria for success of periodontal treatment.  There appears to be 
an assumption that if a patient attends a number of treatment sessions their needs have been 
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met.  Within clinical trials it is difficult to manage patients until the end-point, hence at the 
end of the study the patients may be categorised based on their treatment outcomes as 
responders and non-responders (Hujoel 2004; Armitage 2008).  The presence or absence of 
BOP as a marker for inflammation of the periodontal tissues is a reliable marker to detect and 
monitor periodontal inflammation (Lang et al. 1996), but despite this BOP has proved to be a 
poor marker to determine risk of disease progression (Lang et al. 1986).  In contrast, the 
absence of BOP suggests the absence of inflammation and therefore is an important indicator 
of periodontal health and stability (Lang et al. 1990; Joss et al. 1994). 
The benefits of successful periodontal therapy have also been demonstrated in biological 
samples collected from patients, pre- and post-periodontal therapy.  For example, levels of 
inflammatory markers such as MMP-3, MMP-8 and MMP-9 in plasma (Marcaccini et al. 
2009a), MMP-8, MMP-9, TIMP-2 and MPO levels in GCF (Marcaccini et al. 2010), IL-8 
levels in GCF (Goutoudi et al. 2012) and MMP-1, MMP-3, MMP-9, IL-2, IL-8 and COX-2 
in serum (Li et al. 2012), significantly decreased following successful periodontal therapy in 
patients with periodontitis.  These findings collectively suggest that efficient periodontal 
therapy plays a major role in reducing the overall inflammatory burden seen in periodontitis. 
1.2 Diabetes mellitus 
1.2.1 Definition and classification 
“Diabetes is a group of metabolic diseases characterised by hyperglycaemia resulting from 
defects in insulin secretion, insulin action, or both” (ADA 2014).  The American Diabetes 
Association (ADA) classified diabetes mellitus into four general categories based on the 
aetiopathogenesis of the disease which are namely: type 1 diabetes mellitus (T1DM) 
(previously known as insulin-dependent diabetes mellitus), type 2 diabetes mellitus (T2DM) 
(previously known as non-insulin dependent diabetes mellitus), other specific types of 
diabetes and gestational diabetes mellitus (Table 1.4).  Of these four categories, T1DM and 
T2DM are the most common forms which comprise the bulk of cases reported. 
T1DM occurs due to the destruction of the β-cells of the pancreas, usually leading to absolute 
insulin deficiency, whereas T2DM occurs due to the progressive defect in insulin secretion on 
the background of insulin resistance.  T2DM is the most prevalent form of diabetes, resulting 
from insulin resistance, with or without a secretory defect.  T2DM usually occurs with 
increasing age, and is commonly associated with environmental and genetic risk factors.  
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T2DM is usually preceded by a long-duration of abnormal glycaemic control and is an 
integral part of the metabolic syndrome associated with dyslipidaemia, hypertension and 
hyperglycaemia.  T2DM has a stronger genetic aetiology compared to T1DM, however 
environmental factors such as smoking, diet, exercise and obesity have an impact on the 
development of T2DM (Stumvoll et al. 2005).  Gestational diabetes usually occurs in the 
second or third trimester of pregnancy and can put the mother and the baby at risk of 
developing T2DM in future.  It is currently estimated that one in seven births is affected by 
gestational diabetes (International Diabetes Federation 2015).  The other specific types of 
diabetes relates to diabetes occurring as a result genetic defects in β-cell function and insulin 
action, disease of the exocrine pancreas, endocrinopathies, drug-induced diabetes, infections, 
and immune mediated and genetic syndromes (ADA 2015). 
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Table 1.4: Etiologic classification of diabetes (ADA 2014).
I. Type 1 diabetes (β-cell destruction usually leading to absolute insulin deficiency) 
A. Immune mediated 
B. Idiopathic 
II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin deficiency to a 
predominantly secretory defect with insulin resistance) 
III. Other specific types 
A. Genetic defects of β-cell function 
             1. MODY 3 (Chromosome 12, HNF-1α) 
             2. MODY 1 (Chromosome 20, HNF-4α) 
             3. MODY 2 (Chromosome 7, glucokinase) 
             4. Other very rare forms of MODY (e.g. MODY  
                   4: Chromosome 13, insulin promoter factor-1;   
                   MODY 6: Chromosome 2, NeuroD1; MODY  
                   7:Chromosome 9, carboxyl ester lipase) 
              
 
5. Transient neonatal diabetes (most commonly 
ZAC/HYAMI imprinting defect on 6q24) 
6. Permanent neonatal diabetes (most 
commonly KCNJ11 gene encoding Kir6.2 subunit of β-
cell KATP channel) 
7. Mitochondrial DNA 
8. Others 
 B.    Genetic defects in insulin action 
             1. Type A insulin resistance 
             2. Leprechaunism 
             3. Rabson-Mendenhall syndrome 
             4.  Lipoatrophic diabetes 
             5. Others 
 
 C.     Diseases of the exocrine pancreas 
       1. Pancreatitis 
       2. Trauma/ pancreatectomy  
       3. Neoplasia 
       4. Cystic fibrosis  
              
5. Hemochromatosis 
6. Fibrocalculous pacreatopathy 
7. Others 
 
      D.     Endocrinopathies  
             1. Acromegaly 
             2. Cushing’s syndrome  
             3. Glucagonoma 






        E.     Drug or chemical induced 
               1. Vacor 
               2. Pentamidine 
               3. Nicotinic acid  
               4. Glucocorticoids 
               5. Thyroid hormone  
               6. Diazoxide  
 





      F.     Infections 
             1. Congenital rubella 
             2. Cytomegalovirus 
             3. Others 
 
      G.    Uncommon forms of immune-mediated  
             diabetes 
             1. Stiff-man syndrome 
             2. Anti-insulin receptor antibodies 
             3. Others 
 
 H.   Other genetic syndromes sometimes    
         associated with diabetes 
             1. Down syndrome 
             2. Klinefelter syndrome 
             3. Turner syndrome 
             4. Wolfram syndrome 
             5. Friedreich ataxia 
             6. Huntington chorea  
 
 
7. Laurence-Moon-Biedl syndrome 
8. Myotonic dystrophy 
9. Porphyria 
10. Prader-Willi syndrome 
11. Others 
IV. Gestational diabetes mellitus  
 24 
 
1.2.2 Epidemiology of diabetes 
Diabetes mellitus is one of the largest global health emergencies of the 21
st
 century.  Every 
year more and more people are diagnosed with this condition resulting in life-threatening 
complications.  The estimated global prevalence of diabetes for adults (aged 20-70 years) for 
2015 was 415 million, and it is estimated it will affect 642 million by 2040 (International 
Diabetes Federation 2015).  In 2015, the International Diabetes Federation (IDF) estimated 
seven countries to have greater than 10 million people with diabetes: Brazil, China, India, 
Indonesia, Mexico, Russian Federation and the US (Figure 1.2).  Furthermore, in 2015 the 
prevalence of diabetes in the adult population was highest in Tokelau (30%), followed by 
Nauru, Mauritius, Cook Islands, Marshall Islands, Palau, Kuwait, Saudi Arabia, Qatar and 
New Caledonia.  Diabetes affects individuals in both rural and urban settings, with 35% of 
cases in rural areas and 65% in urban (International Diabetes Federation 2015).  In the UK it 
is estimated that one in 16 people has diagnosed or undiagnosed diabetes (Hex et al. 2012).  
Since 1996, the number of individuals diagnosed with diabetes in the UK has more than 
doubled from 1.4 million to almost 3.5 million (Diabetes UK 2015).  Today, there are 
approximately 3.5 million people in the UK who have been diagnosed with diabetes, and it is 
estimated that this figure will increase to 5 million by the year 2025.  It is also estimated that 
almost 549,000 people in the UK have undiagnosed diabetes (Diabetes UK 2015). 
Whilst T1DM is less common, it is increasing by approximately 3% each year, particularly 
among children.  Every year, approximately 86,000 children develop T1DM and when 
insulin is not provided, the life expectancy for a child with T1DM is very short.  The number 
of children (aged 0-14 years) with T1DM worldwide is 542,000.  The top ten countries for 
number of children with T1DM are the US, Brazil, China, UK, Russian Federation, Saudi 




Figure 1.2: Estimated number of people with diabetes mellitus worldwide and per 
region in 2015 and 2040 (aged 20-79 years) (International Diabetes Federation 2015).
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1.2.3 Type 1 diabetes mellitus 
T1DM is a chronic autoimmune disease in which an individual’s immune system selectively 
destroys the insulin producing β-cells of the pancreas, resulting in hyperglycaemia as a result 
of lack of insulin production (Skyler 2007).  Why this occurs is not fully understood.  T1DM 
accounts for only 5-10% of all cases of diabetes and slightly affects males more commonly 
than females (Ostman et al. 2008).  T1DM usually occurs in children and young adults with 
peaks in presentation occurring between 5-7 years of age and at/near puberty (Harjutsalo et 
al. 2008).  However this opinion has changed over the last decade, and age at symptomatic 
onset is no more a restricting factor for the diagnosis of T1DM (Leslie 2010).  T1DM appears 
very suddenly and is currently incurable.  The risk factors associated with T1DM include 
genetics, family history of diabetes and other environmental influences.  The underlying 
mechanisms leading to increase in incidence rates of T1DM are still unclear, but could 
possibly be due to viral infections and/or changes in environmental risk factors.  Genetic 
influence or more children being born from mothers with T1DM does not solely explain the 
rapid rate of increased incidence globally (Soltesz et al. 2007).  Therefore, in addition to 
genetic factors, environmental factors also play a crucial role in the development of T1DM 
(Atkinson et al. 2014).  Currently, interest is growing to establish the influence of 
environmental factors on the pathogenesis of T1DM.  A plethora of environmental factors 
have been purported to influence the epidemiology of T1DM, such as infant and adolescent 
diets (Knip et al. 2010), viruses (Yeung et al. 2011; Stene and Rewers 2012), vitamin D and 
vitamin D pathway constituents (Svoren et al. 2009; Blanton et al. 2011; Cooper et al. 2011). 
1.2.4 Diagnosis of diabetes 
Historically, a diagnosis of diabetes was made with fasting blood glucose level higher than 7 
mmol/L (126 mg/dL), or any blood glucose ≥11.1 mmol/L (200 mg/dL) with symptoms  of 
hyperglycaemia or an abnormal 2-hour oral glucose tolerance test (ADA 2012).  In 2009, the 
ADA modified their guidelines for diagnosis of diabetes and included glycated haemoglobin 
(HbA1c), a test to determine the average blood glucose concentrations over 3 months, of 
≥6.5% as a method to diagnose diabetes (International Expert Committee 2009).  HbA1c is a 
surrogate marker of plasma glucose and gives an indication of a patient’s long-term 
glycaemic control and is utilised to set appropriate management goals allowing patients to 
achieve adequate glucose control (Home 2008).  The widespread clinical use of HbA1c to 
monitor long-term glycaemic control has been established following publication of data from 
 27 
 
the UK Prospective Diabetes study, demonstrating a relationship between HbA1c levels and 
diabetes-related complications caused by hyperglycaemia (Stratton et al. 2000).  The 
biomechanical basis for glycosylation of haemoglobin has been established (Higgins and 
Bunn 1981).  Glucose covalently interacts with the primary amine groups on lysine residues 
of haemoglobin to produce HbA1c.  Glycosylation of haemoglobin is the best studied 
example of intracellular advanced glycation end products (AGEs) formation.  HbA1c forms 
slowly and is irreversible during the 120-day life span of the red blood cells.  The extent to 
which HbA1c accumulates depends upon the average glucose concentration in plasma during 
the preceding 2-3 months.  Thus, HbA1c has proved to be a reliable index of diabetic control 
(Gabbay et al. 1977).  HbA1c as a marker for glycaemic control has several advantages 
including, convenience (fasting not required), greater preanalytical stability and fewer day-to-
day perturbations during periods of illness and stress.  However, these advantages should be 
balanced by the limited availability of HbA1c testing in certain areas of the world, greater 
cost, and the incomplete correlation between HbA1c and average glucose in certain patients.  
Additionally, it is important to take into consideration the patient’s age, ethnicity and 
anaemias/hemoglobinopathies as interpretation of HbA1c levels may vary across individuals 
based on these categories (ADA 2015). 
In 1998, the ADA classified diabetes control as good, moderate, and poor metabolic control.  
An individual is said to have a good metabolic control if HbA1c is <7%, moderate metabolic 
control if HbA1c lies between 7-8% and poor metabolic control if HbA1c is >8%.  Analysis 
of data from a large prospective, multicentre study demonstrated a strong correlation between 
HbA1c and plasma glucose levels, which confirmed a predictable relationship between 
HbA1c and hyperglycaemia (Rohlfing et al. 2002).  The understanding of this relationship 
allows patients and clinicians to target, on a daily basis, appropriate plasma glucose levels 
achieving the recommended HbA1c goal of 6.5% (NICE 2008). 
Diagnosis of T1DM 
At disease onset, T1DM is associated with the classic triad of symptoms of polyphagia, 
polydipsia and polyuria, in addition to overt hyperglycaemia, which remain the diagnostic 
hallmarks in children and adolescents, but to a lesser extent in adults with T1DM (Atkinson 
et al. 2014).  Other symptoms associated with T1DM include lack of energy, extreme 
tiredness, sudden weight loss and blurred vision (International Diabetes Federation 2015).  
Individuals at increased risk for developing T1DM are often diagnosed by serological 
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evidence of the autoimmune pathologic process occurring within the pancreatic islets and 
specific genetic markers (ADA 2014).  Despite efforts being made to standardise diagnosis of 
T1DM, the typology and causes remain unclear especially among adults, where the diagnosis 
of T1DM versus T2DM can be challenging.  Approximately 5-15% of adults diagnosed with 
T2DM may actually have T1DM with islet autoantibodies present (Tuomi 2005).  If this is 
the case then perhaps 50% of actual cases with T1DM are misdiagnosed as T2DM, 
suggesting that the number of T1DM cases is vastly underestimated. 
It is critical to accurately diagnose T1DM in order to avoid complications and provide 
optimal care.  Additionally, the accurate recognition of diabetic ketoacidosis at the advent of 
T1DM, is key to survival (Usher-Smith et al. 2011).  A majority of T1DM cases present as an 
immune, if not autoimmune-mediated disorder, which means that the disease pathogenesis 
has an immunological contribution (e.g. autoantibodies or genetic associations).  However, 
not all T1DM patients have these characteristics, and although not commonly used, this has 
led to the classification of type 1A diabetes (autoimmune), comprising 70-90% of cases 
having self-reactive immunological autoantibodies and type 1B diabetes (idiopathic), 
represents those patients whose pathogenesis remains unclear.  Other factors which 
complicate diagnosis of T1DM include the increasing problem of obesity and increasing 
diverse genetic mixtures due to social changes and migration (Atkinson et al. 2014). 
1.2.5 Pathogenesis of T1DM 
Most reports on T1DM pathogenesis, suggests that T1DM develops following the 
autoimmune destruction of the insulin-secreting β-cells of the pancreas (Atkinson and 
Eisenbarth 2001; Bluestone et al. 2010; Todd 2010; Atkinson 2012).  This results in absolute 
deficiency in the production of endogenous insulin (Daneman 2006).  The existence of a 
chronic inflammatory infiltrate affecting the islets of the pancreas at symptomatic onset of 
T1DM is the basis of this observation (Atkinson et al. 2014).  Our understanding of the 
pathogenesis of T1DM is derived from analysis of serum, pancreatic specimens, and 
peripheral blood lymphocytes obtained from T1DM patients (Bingley 2010; Roep and 
Peakman 2011).  Research related to these constituents has proposed that a series of 
functional defects in the β-cells, immune system, bone marrow and thymus collectively 




Within the pancreas, specific destruction of β-cells occur when macrophages, dendritic cells, 
CD4+ and CD8+ T lymphocytes infiltrate the pancreatic islets (Atkinson and Eisenbarth 
2001).  As β-cell depletion reaches an advanced stage, there is an acute onset of symptoms 
with a likelihood of accumulation of ketone bodies in the blood due to lipolysis in the 
absence of insulin necessary for glycolysis, leading to fatal, acute ketoacidosis (Daneman 
2006).  Another principle is that in patients with longstanding T1DM, the pancreas is devoid 
of insulin-producing cells and the residual β-cells are incapable of regeneration.  Both 
concepts of pathogenesis have been debated in the past (Butler et al. 2007; Gregg et al. 2012).  
It has been suggested that although a majority of patients with longstanding T1DM have very 
few β-cells, if any, there is evidence of β-cell regeneration in infants and young children, but 
not in adolescents or adults (Keenan et al. 2010; Gregg et al. 2012). 
Studies analysing the pancreas of patients with recent onset T1DM suggest that 
approximately 70% of islets show complete absence of insulin (Keenan et al. 2010; Gregg et 
al. 2012), approximately 20% islets contain insulin, only 1% of insulin-deficient islets are 
inflamed, and many pancreas have insulin-containing non-inflamed islets that seem normal 
(Gepts 1965).  Although symptoms of T1DM occur when 90-95% of the β-cells are 
destroyed, diagnosis of T1DM can occur when nearly two-thirds of the islets are devoid of β-
cells (Foulis and Stewart 1984; Willcox et al. 2009).  The most predominant cells within the 
insulitis lesion are the CD8+ T cells, followed by the macrophages (CD68+), CD4+ T cells, 
B lymphocytes (CD20+), and plasma cells (CD138+) (Willcox et al. 2009).  A key 
distinguishing feature between T1DM and T2DM is the presence of autoantibodies against β-
cell autoantigens.  At disease onset, a majority (90%) of the newly diagnosed T1DM patients 
have one or more of the following antibodies present: those reactive to insulin, glutamic acid 
decarboxylase, insulinoma-associated autoantigen 2, and zinc transporter 8.  These 
autoantibodies are present months or years before symptomatic onset, and usually appear at 6 
months to 2 years of age in genetically susceptible individuals (Atkinson et al. 2014). 
T1DM is a polygenic disorder, having nearly 40 loci known to influence disease 
susceptibility (Oresic et al. 2008).  The human leukocyte antigen (HLA) region on 
chromosome 6 probably provides one-half of the genetic susceptibility leading to the risk of 
T1DM.  Additionally, of the several HLA types, HLA class II demonstrates the strongest 
association with T1DM, where its haplotypes confer to the greatest disease susceptibility and 
provide disease resistance.  Additionally, class I major histocompatibility complex molecules 
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also seem to influence the risk for T1DM.  Most of the loci associated with T1DM risk are 
believed to involve immune responses, in support of the notion that genetic influences 
involve pathways which collectively contribute to immune responsiveness.  This mechanism 
may explain the variations in rates of disease progression to T1DM in adults versus children, 
where minor variations have been noted in genetic susceptibility (Howson et al. 2011). 
The natural history of T1DM model that was originally put forward in 1986, and updated in 
2001, and modified subsequently, proposes that at birth individuals possess various degrees 
of susceptibility for T1DM.  Although the proposed model has stood the test of time some 
modifications have been made based on the knowledge gained over the years (Figure 1.3).  
For example, environmental influences can occur in utero, and could possibly continue 
during the first few months or years of life, thus influencing onset and continuance of β-cell 
autoimmunity.  Physiological events, such as immune system development and turnover of β-
cells, may contribute to disease pathogenesis  (Atkinson et al. 2011).  Genetic susceptibility 
facilitates inherent immune dysregulation and results in early β-cell destruction, i.e. altered 
autoantibodies and amino acids associated with T1DM.  In most patients, changes in glucose 
tolerance and insulin secretion occur months to decades after detection of multiple islet 
autoantibodies (Bonifacio and Ziegler 2010).  It is unclear as to why not all individuals with 
anti-β cell autoimmunity progress to overt disease (<5% with T1DM associated autoantibody 
progress) (Eisenbarth 2007).  Metabolic changes in T1DM are associated with reduced C-
peptide response (Sosenko et al. 2010a), increased glucose fluctuations (Sosenko et al. 
2010b), and an overall rise in plasma glucose (Ferrannini et al. 2010) prior to disease onset.  
Once a critical amount of β-cells are destroyed, symptomatic onset occurs and need for 
exogenous insulin-replacement arises.  This symptomatic onset occurs after a silent phase 
which lasts for months to years, which could, in genetically susceptible individuals with 
multiple autoantibodies, be considered asymptomatic T1DM.  Loss of β-cell mass possibly 
affects the performance of the residual β-cells and other islets cells.  Following diagnosis, the 
ability to retain remaining β-cell function (assessed by C-peptide production) is 
heterogeneous, with respect to time taken to reach an undetectable stage, while a number of 
individuals who despite decades of T1DM have the ability to produce C-peptide (Keenan et 
al. 2010).  Therefore, T1DM is considered to be a heterogeneous disease, influenced by age 
of onset, genetics, and intensity of diabetes management on the ability to sustain β-cell 




Figure 1.3: Model of the natural history of T1DM. 




1.2.6 Complications associated with diabetes 
Patients with diabetes are at a higher risk of acquiring infections and life threatening health 
problems than non-diabetic individuals.  Consistently chronic hyperglycaemia is associated 
with long-term dysfunction, damage and failure of various organs, notably the heart, kidneys, 
eyes, nerves and blood vessels (ADA 2014).  Diabetes-related complications are classified as 
microvascular or macrovascular.  CVD is becoming a more common diabetes-related 
macrovascular complication as patients with T1DM live longer (Melendez-Ramirez et al. 
2010).  Diabetic patients have a higher incidence of peripheral arterial, atherosclerotic 
cardiovascular and cerebrovascular disease.  Additionally, hypertension and lipoprotein 
metabolism abnormalities are often detected in diabetic patients (ADA 2014).  T1DM 
patients have a ten-times greater risk for cardiovascular incidents than matched controls 
(Orchard et al. 2006).  The Pittsburgh Epidemiology of Diabetes Complications study of 
T1DM reported that cardiovascular events in adults <40 years of age to be 1% per year and 
were three-times greater in patients older than 55 years (Maser et al. 1991).  The 
Epidemiology of Diabetes Interventions and Complications study, which observed T1DM 
patients for long-term complications, reported that intensive diabetes management reduced 
the risk of cardiovascular incidents by 42% compared to conventional management (Nathan 
et al. 2005). 
The microvascular diabetes-related complications include retinopathy with possible loss of 
vision, nephropathy with potential renal failure; autonomic neuropathy leading to 
cardiovascular, genitourinary and gastrointestinal symptoms and sexual dysfunction; 
peripheral neuropathy increasing risk for foot ulcers, lower-limb amputations and Charcot 
joints (ADA 2014).  The risk of developing microvascular complications reduces with 
intensive insulin therapy.  Diabetes can also pose a threat to oral health.  There is an 
increased risk for periodontal inflammation in patients with poor glycaemic control.  It is 
important to effectively manage periodontitis in patients with diabetes as optimal oral 
hygiene is the key to prevent tooth loss, promote a healthy diet and improve metabolic 
control (International Diabetes Federation 2015). 
1.2.7 Management of T1DM 
Patients with diabetes should receive appropriate care from a physician-coordinated team and 
diabetes self-management education must be an integral component of diabetes care.  
Glycaemic control is fundamental for the management of diabetes.  Prospective randomised 
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controlled trials (RCTs) and epidemiological studies have demonstrated that good glycaemic 
control is associated with decreased rates of neuropathy, retinopathy, nephropathy and CVD 
complications (ADA 2002).  Diabetes-related complications can be delayed or prevented by 
maintaining blood glucose, cholesterol and blood pressure levels close to normal as possible.  
Most complications can be identified in their early stages by regular screening programmes 
which allow management preventing them from becoming more serious (International 
Diabetes Federation 2015). 
The management of T1DM warrants the need for immediate exogenous insulin replacement, 
a treatment modality whose therapeutic practice lasts a lifetime (Atkinson et al. 2014).  
T1DM therapy in modern countries often incorporates the usage of insulin analogues and 
mechanical technologies such as, continuous glucose monitors and insulin pumps for 
improved management (Hirsch 2009).  The IDF recommends that of all the different types of 
insulin available, as a minimum, quick-acting human insulin and a long-acting NPH (Neutral 
Protamine Hagedorn) insulin must be available to all T1DM patients (International Diabetes 
Federation 2015).  Following initial diagnosis and metabolic stabilization, few T1DM 
patients maintain the capacity to produce endogenous insulin.  Although, the secretion of 
endogenous insulin is typically low, maintenance is important as it is correlated with less 
severe hypoglycaemia and less retinopathy at later stages of diabetes (Steffes et al. 2003).  
Thus, preserving endogenous insulin secretion following disease onset is progressively a 
therapeutic goal, and may involve mechanical technologies, intensive insulin therapy, or 
immune intervention to disrupt destruction of β-cells (Atkinson et al. 2014). 
Several methods of insulin therapy exist for metabolic optimization.  Using multiple daily 
injections, basal insulin is provided by long-acting insulin analogue and prior to meals, rapid-
acting insulin is administered, based on carbohydrate grams consumed, i.e. basal-bolus 
therapy.  Over the last decade, the utilization of continuous subcutaneous insulin infusions 
(insulin pumps) has increased considerably (Pickup 2012).  A RCT in adults with T1DM 
reported lower HbA1c levels with sensor augmented pump therapy compared to insulin 
injection therapy, and a higher proportion of patients reaching HbA1c target levels 
(Bergenstal et al. 2010).  A meta-analysis reported that insulin pumps lower HbA1c levels 
more than daily multiple insulin injections in T1DM adults, having comparable rates of 
hypoglycaemia (Yeh et al. 2012).  However, whether insulin pumps are superior overall than 
multiple daily injections for the optimum management of T1DM is debatable, as outcomes 
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reported in research studies have substantially varied (Pickup et al. 2011).  In addition to 
enhanced insulin preparations and delivery methods, advancements to optimize metabolic 
control and lessen hypoglycaemia include self-monitoring blood glucose reports, point-of-
care HbA1c tests, and real-time glucose monitoring system (Atkinson et al. 2014).  Real-time 
glucose monitoring system has proved to reduce time spent in hypoglycaemia and lower 
HbA1c levels effectively (Juvenile Diabetes Research Foundation Continuous Glucose 
Monitoring Study et al. 2008; Juvenile Diabetes Research Foundation Continuous Glucose 
Monitoring Study 2010), and is the most appropriate method for highly motivated patients 
who have continuous poor metabolic control and are to wear this monitoring device willingly 
(Ahmet et al. 2011).  With real-time glucose monitoring and insulin pumps improving 
diabetes care, both technologies are now being used together, known as sensor-augmented 
pump therapy.  A clinical trial comparing multiple daily injections with sensor-augmented 
pump therapy demonstrated a significant improvement in HbA1c levels with less 
hypoglycaemia in the group receiving sensor-augmented pump therapy (Bergenstal et al. 
2010; Bergenstal et al. 2011). 
For future diabetes care, efforts are being made to combine insulin pumps and real-time 
glucose monitors with computer algorithms that could facilitate interpretation of glycaemic 
control data for patients and optimise glycaemic therapy.  This new system has been tested in 
T1DM adults and has so far reported favourable outcomes (Breton et al. 2012), with 
improvements and reduction in risk of nocturnal hypoglycaemia compared to conventional 
insulin-pumps (Buckingham et al. 2010; Garg et al. 2012).  Furthermore, new insulin 
analogues, incretins and other hormones such as insulin degludec, incretin GLP-1, hormone 
pramlintide, and leptin hormone therapy are being tested for their ability to enhance 
management of T1DM (Atkinson et al. 2014).
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1.3 Periodontal disease and diabetes 
1.3.1 Epidemiological association between T1DM and periodontal disease  
The prevalence and severity of periodontal diseases are higher in patients with diabetes 
compared to healthy individuals (Grossi et al. 1997; Poplawska-Kita et al. 2014).  Patients 
with diabetes are at a three-fold increased risk of developing periodontitis compared to non-
diabetic individuals (Mealey and Oates 2006).  A number of reports on the relationship 
between T1DM and periodontal disease have included children and adolescents.  T1DM as 
such does not cause gingivitis or periodontitis, but T1DM is found to alter the response of 
periodontal tissues to local factors (Newman et al. 2006).  Previous studies have indicated 
that gingival inflammation is significantly increased in diabetic children compared to healthy 
children (Bernick et al. 1975; Gislen et al. 1980; Cianciola et al. 1982), and diabetic children 
were found to have more gingival inflammation in spite of having similar plaque index scores 
(Sandholm et al. 1989b; de Pommereau et al. 1992). 
Table 1.5 presents a summary of research studies related to T1DM and periodontal disease.  
Cross-sectional studies found gingivitis to be more prevalent in T1DM patients compared to 
non-diabetic controls (Hugoson et al. 1989; Siudikiene et al. 2006).  T1DM patients were 
found to have significantly higher amounts of plaque and gingival inflammation (Novaes et 
al. 1991; Aren et al. 2003; Orbak et al. 2008), LOA, bleeding to plaque ratio, PD 
measurements (Dakovic and Pavlovic 2008; Silvestre et al. 2009) and  greater amounts of 
alveolar bone loss (Novaes et al. 1991) compared to non-diabetic controls.  Longer duration 
of T1DM is associated with increased gingival inflammation and PD measurements (Aren et 
al. 2003; Xavier et al. 2009), greater CAL and missing teeth (Al-Shammari et al. 2006)  and 
more severe upper and lower anterior alveolar bone loss (Hugoson et al. 1989).  A few 
studies reported that factors such as smoking, diabetes-related complications  (Al-Shammari 
et al. 2006) and poor metabolic control  (Dakovic and Pavlovic 2008; Xavier et al. 2009; 
Hodge et al. 2012; Poplawska-Kita et al. 2014) were associated with periodontal disease 
severity (Silvestre et al. 2009).  A study including both T1DM and T2DM patients reported 
an increase in periodontal destruction in all patients with diabetes, with higher amounts of 
plaque, gingival inflammation, bleeding sites and LOA in these patients compared to healthy 
controls (Lalla et al. 2006a).  The evidence of periodontal disease was indeed present in 
controls, but the presence of diabetes clearly conferred a significant risk (Lalla et al. 2006a). 
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Some studies found no differences in clinical periodontal parameters between patients with 
T1DM and non-diabetic controls (Akyuz and Oktay 1990; Novaes et al. 1991; de Pommereau 
et al. 1992; Sbordone et al. 1998).  One study investigated the prevalence of periodontal 
disease using the Community Periodontal Index for Treatment Needs (CPITN) and reported 
that 44% of the T1DM patients aged >35 years had a CPITN score of 3 or 4 (suggesting that 
at least one tooth had PD >3.5 mm) compared to 12.5% of the non-diabetic controls having 
similar scores (Pinducciu et al. 1996).  Another study utilised the Periodontal Disease Index 
(PDI) and found no significant differences in clinical periodontal parameter scores between 
T1DM patients and controls (Luczaj-Cepowicz et al. 2006). 
Longitudinal (5 years) observational (Firatli 1997) and experimental gingivitis (21 days) 
(Salvi et al. 2010) studies revealed no differences in periodontal parameters between T1DM 
patients and healthy controls prior to and post-study.  In patients with T1DM, with the 
exception of CAL which significantly increased after 5 years, no other changes in periodontal 
parameters were noted at the 5-year follow-up (Firatli 1997).  An uncontrolled 2-year 
longitudinal study utilizing a partial-mouth periodontal assessment method, found age, 
smoking and duration of T1DM to be critical risk factors for the increased prevalence of 
severe periodontal disease, and the presence of periodontal  disease to be associated with 
other diabetes-related complications (Moore et al. 1999).  A longitudinal study including both 
T1DM and T2DM patients, collectively reported a significant increase in CAL and % of PD 
sites ≥5 mm at the 5-year follow-up, particularly in uncontrolled diabetic patients (Demmer et 
al. 2012).  The authors concluded that in addition to diabetes status, increasing age, lower 
education, current smoking habit, elevated hsCRP and baseline CAL, were predictors of tooth 
loss (Demmer et al. 2012). 
1.3.2 Inflammatory mechanisms linking T1DM and periodontal disease  
Inflammation is the key feature of pathogenesis linking diabetes and periodontal disease.  
Diabetes alters the host environment, and increases a patient’s vulnerability to periodontal 
disease due to alterations in the inflammatory response to microbial challenge (Mealey and 
Rose 2008a; Salvi et al. 2008).  Both T1DM and T2DM are associated with elevated levels of 
markers of inflammation (Dandona et al. 2004).  The inflammatory state gives rise to 
diabetes-related microvascular and macrovascular complications, and chronic 
hyperglycaemia is known to activate pathways which increase inflammation, oxidative stress 
and apoptosis (Brownlee 2005).  Past research has demonstrated that consequences of 
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hyperglycaemia over time, such as vascular damage and hyperlipidaemia, not only result in 
diabetes-related micro- and macro-vascular complications, but also increase a risk for 
development of severe periodontal disease (Noack et al. 2000b).  Both gingivitis and 
periodontitis are considered as hyperglycaemia-associated diabetic complications (Taylor 
2001; Lalla et al. 2007c). 
A large body of evidence has established the prevalence, severity and extent of periodontal 
disease in patients with diabetes.  However, understanding the mechanism behind the cross-
susceptibility between the two conditions is currently lacking (Hodge et al. 2012; Chapple et 
al. 2013; Moodley et al. 2013).  One hypothesis is that chronic hyperglycaemic precipitates 
the formation of AGEs by the irreversible, non-enzymatic glycation of lipids and proteins 
leading to loss of protein functionality (Sima and Glogauer 2013).  The binding of AGE to its 
receptor (RAGE), found on the surface of immune and resident tissue cells, causes an 
increase in production of inflammatory mediators such as, IL-β, IL-6, and TNF-α (Lalla et al. 
2001; Kim et al. 2005; Lin et al. 2009; Sima and Glogauer 2013).  Once in the circulation, 
AGE can initiate a chronic, low-level inflammatory response via the AGE-RAGE axis (Katz 
et al. 2005; Hein et al. 2006; Katz et al. 2007; Nah et al. 2007).  AGE production results in 
the formation of ROS and enhances oxidative stress, leading to endothelial cell changes 
which contribute to vascular injury, implicated in diabetes-related complications (Vlassara 
2001).  The accumulation of AGEs within the periodontal tissues is also known to upregulate 
periodontal inflammation in patients with diabetes.  Within the periodontium, a number of 
cells express RAGE, including fibroblasts, oral keratinocytes, and immune cells (resident and 
invading), such as monocytes and macrophages (Brett et al. 1993; Bierhaus et al. 1996; Katz 
et al. 2005).  The interaction of AGE and RAGE within the periodontium leads to an 
inflammatory response through the upregulation of molecules such as MMPs (Nah et al. 
2007) and osteolytic activators (Hein et al. 2006) which potentially damage the periodontal 
ligament and alveolar bone.  Additionally, AGE enhances the respiratory burst in PMNs, 
which significantly increases local tissue destruction in periodontitis (Wong et al. 2003).  
Moreover, AGEs have a detrimental effect on bone metabolism, leading to impaired bone 
formation and repair (Santana et al. 2003), and decreased extracellular matrix formation 
(Cortizo et al. 2003).  The increased susceptibility to periodontitis in patients with diabetes 
may also be due to the apoptosis of the matrix-producing cells which significantly limits the 
repair of inflamed periodontal tissues. 
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Patients with diabetes are known to exhibit defects in PMN activity such as impaired 
chemotaxis, microbicidal functions and phagocytosis (Alba-Loureiro et al. 2007).  The PMN 
require energy for proper functioning, hence PMN defects may be attributed to the metabolic 
changes which occur in diabetes (Alba-Loureiro et al. 2006).  Depressed PMN chemotaxis 
and defective PMN apoptosis are more likely to be found in diabetic patients with severe 
periodontitis compared to those with diabetes and mild periodontitis, leading to increased 
PMN retention within the periodontal tissues, and increasing tissue destruction by the 
continuous release of MMPs and ROS (Manouchehr-Pour et al. 1981; Graves et al. 2006). 
Figure 1.4 is a schematic representation of the proposed two-way relationship between 
diabetes and periodontitis (Preshaw et al. 2012).  The heart of the two-way interaction 
between the two diseases is the exacerbated and dysregulated inflammatory responses 
(orange box).  The hyperglycaemic state gives rise to distinct pro-inflammatory effects which 
impact on various body tissues, including the periodontal tissues.  The adipokines (produced 
by adipose tissue) include TNF-α, IL-6 and leptin.  The hyperglycaemic state causes 
deposition of AGEs in the periodontal tissues, and binding to the receptor RAGE resulting in 
release of cytokines and altered inflammatory responses.  In the diabetic state, PMN function 
is altered, resulting in an increased respiratory burst and delayed apoptosis leading to 
increased periodontal destruction.  The local production of cytokines in periodontal tissues 
may, in turn, affect glycaemic control through systemic exposure and impact on insulin 
signalling (red arrow).  All these factors contribute towards the dysregulated inflammatory 
responses within the periodontal tissues in response to the bacterial challenge in the 












Figure 1.4: A schematic representation of the proposed two-way relationship between 
diabetes and periodontitis (Preshaw et al. 2012). 
 
A few clinical studies have demonstrated that T1DM is associated with elevated levels of 
circulating inflammatory mediators (Antonelli et al. 2008; Van Sickle et al. 2009; Redondo et 
al. 2014).  However, evidence relating to circulating levels of cytokines and chemokines in 
patients with T1DM and periodontal disease is notably lacking, and only a number of studies 
have investigated the link between these two conditions (Salvi et al. 1997b; Salvi et al. 
1997a; Salvi et al. 2010; Passoja et al. 2011; Poplawska-Kita et al. 2014; Surlin et al. 2014; 
Lappin et al. 2015).  These studies have focused on analysing varied biomarkers in collected 
samples of saliva, GCF, gingival tissue, serum and plasma. 
Table 1.5 presents a summary of research studies related to T1DM and periodontal disease.  
A previous cross-sectional study showed that T1DM patients with periodontal disease 
(gingivitis or periodontitis) had significantly higher GCF IL-1β and PGE2 levels compared to 
non-diabetic individuals with similar levels of periodontal disease (Salvi et al. 1997a).  
Additionally, in the same study, monocytes from T1DM patients, when challenged with LPS 
produced significantly higher concentrations of IL-1β, PGE2 and TNF-α than monocytes 
from healthy controls (Salvi et al. 1997b; Salvi et al. 1997a).  It has been previously 
demonstrated that T1DM patients were more likely to have decreased levels of the marker for 
bone formation, osteocalcin, signifying a decrease in their ability to form bone in the 
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presence or absence of periodontitis (Lappin et al. 2009).   Serum levels of IL-6 (Passoja et 
al. 2011; Cutando et al. 2015) and TNF-α (Poplawska-Kita et al. 2014) have been found to 
play a significant role in periodontal tissue destruction, especially in those patients in whom 
T1DM is poorly-controlled (Poplawska-Kita et al. 2014).  Elevated circulating levels of the 
chemokine IL-8 have been involved in poor clinical outcomes in T1DM patients.  Elevated 
GCF (Salvi et al. 2010), salivary (Dakovic et al. 2013), and plasma (Lappin et al. 2015) IL-8 
levels have been implicated in the cross-susceptibility between T1DM and periodontal 
disease.  Recently, plasma levels of chemokine ENA-78/CXCL5 along with IL-8 have been 
found to be elevated in patients with T1DM (with and without periodontitis) compared to 
non-diabetic subjects with healthy periodontal tissues (Lappin et al. 2015). 
MMPs can be considered as host-modulatory agents, as they are capable of altering and 
activating proteins and certain chemokines (Giannobile 2008).  Increase in GCF IL-1β, and 
activation of plasma MMP-2 and MMP-9 have been found in patients with diabetes 
compared to healthy controls (Mealey and Rose 2008a).  The expression of MMP-7, MMP-8, 
MMP-9 and MMP-13 was found in gingival biopsies from patients with T1DM and 
aggressive periodontitis, with the expression of MMP-8 and MMP-13 being more intense in 
T1DM patients with severe periodontitis compared to T1DM patients with moderate 
periodontitis and non-diabetic patients with moderate periodontitis (Surlin et al. 2014).  An 
experimental periodontitis study in Wistar rats with and without T1DM demonstrated an 
increase in collagenolytic activity of MMP-9 in the gingival tissues and higher MMP-9 levels 
in rats with T1DM than controls (Silva et al. 2008).  The significant increase in MMP-9 
levels during the inflammatory process suggests that this enzyme was involved in the 
inflammatory mechanism in both normal and diabetic rats (Silva et al. 2008).  Some studies 
have reported significant positive correlations between biomarker levels and patients’ clinical 
periodontal parameters (Passoja et al. 2011; Poplawska-Kita et al. 2014; Lappin et al. 2015), 
and HbA1c levels (Lappin et al. 2015) and hsCRP levels (Passoja et al. 2011).  While other 
authors reported no such association between biomarkers levels and periodontal or 
biochemistry data (Dakovic et al. 2013). 
1.3.3 Association between periodontal status and glycaemic control 
The most significant diabetes risk factor for severe periodontitis seems to be hyperglycaemia.  
For instance, the US National Health and Nutrition Examination Survey III found a 
significantly higher prevalence of severe periodontitis in adults with HbA1c >9% than non-
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diabetic individuals after controlling for sex, age, ethnicity, education and smoking (Tsai et 
al. 2002).  Periodontitis can alter the periodontal tissues into a pro-inflammatory environment 
via increases in inflammatory mediator levels, which additionally play a crucial role in 
impairing insulin signalling and worsening glucose intolerance (Lagervall and Jansson 2007; 
Merchant et al. 2011).  Previous research has demonstrated that intensive glycaemic control 
can delay or prevent the onset and slow the progression of microvascular complications 
associated with T1DM (DCCT 1993).  Diabetes is a well-known risk factor for tooth loss in 
patients with periodontal disease (Lagervall and Jansson 2007; Orbak et al. 2008), and 
evidence suggests that inadequate metabolic control is the key factor causing this 
complication and that the number of remaining teeth decreases with increasing HbA1c levels 
(Demmer et al. 2012). 
A number of studies have reported on the association between periodontal status and level of 
glycaemic control in patients with T1DM.  Some authors have reported a significant impact 
of glycaemic control on periodontal disease severity, with increases in HbA1c levels 
corresponding to increased periodontal destruction (Aren et al. 2003; Dakovic and Pavlovic 
2008; Silvestre et al. 2009; Xavier et al. 2009; Hodge et al. 2012; Poplawska-Kita et al. 2014; 
Lappin et al. 2015).  Hodge et al. reported a higher prevalence of severe periodontal disease 
(27.2%) in poorly-controlled T1DM patients (HbA1c >7.5%) compared to non-diabetic 
controls (20.5%) (Hodge et al. 2012).  A recent study by Poplawska-Kita et al., found the 
prevalence of periodontitis was 59.5% in poorly-controlled T1DM patients (HbA1c >6.5%) 
and 40% in those with well-controlled T1DM (HbA1c ≤6.5%) (Poplawska-Kita et al. 2014).  
Severe periodontitis was more prevalent in poorly-controlled T1DM patients (26%) than in 
the well-controlled diabetics (20%) and healthy controls (5%).  Additionally, clinical 
periodontal findings in well-controlled diabetics were comparable to those of the healthy 
controls, indicating that good metabolic control is a key factor in protecting patients with 
diabetes from the development of periodontal disease.  The authors concluded that strict 
metabolic control plus good oral hygiene practices might protect patients with diabetes from 
progressive periodontal disease and subsequent tooth loss (Poplawska-Kita et al. 2014).  A 
longitudinal observational study including both T1DM and T2DM patients reported that 
uncontrolled diabetes (HbA1c >7.0%) was associated with greater CAL and increased 
severity of periodontal disease relative to diabetes-free individuals, whereas in those patients 
with controlled diabetes, no such disease progression was observed at the 5-year follow-up 
(Demmer et al. 2012). 
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Table 1. 5: Principal studies investigating links between T1DM and periodontal disease. 1 
Author, Year Subjects Age 
(years) 
Study design Principal findings 











Longitudinal Patients with diabetes and periodontal disease had significantly higher serum TNF-α (1.79±0.19 
pg/ml), IL-6 (0.57±0.07 pg/ml) and CRP (0.39±0.11, mg/L) levels compared to healthy subjects 
(0.82±0.17 pg/ml, 0.38±0.05 pg/ml, 0.21±0.08 mg/L, respectively), (P<0.001). 






Periodontitis (P): 23 
Healthy tissues (H): 19 
20-56 
(36.4±9.9) 
Cross-sectional Significantly higher plasma IL-8 levels in the T1DM+H, T1DM+P and P group compared to the H 
group, (P<0.001).  The T1DM+P group had significantly higher plasma IL-8 levels compared to the 
P group, (P<0.05).  Significantly higher plasma ENA-78/CXCL5 in the T1DM+H, T1DM+P and P 
group compared to the H group, (P<0.01, P<0.001 and P<0.05, respectively).  No significant 
difference between T1DM+P and P group for plasma ENA-78/CXCL5 levels.  Plasma IL-8 and 
ENA-78/CXCL5 levels and BOP correlated significantly with PD, CAL and HbA1c levels. 
(Poplawska-













Cross-sectional Severe periodontitis was more frequent in T1DM-PC compared to T1DM-WC patients.  T1DM-PC 
patients had significantly higher HbA1c (9.8±2.4%) compared to T1DM-WC patients (6.0±0.6%) 
(P<0.01).  T1DM-PC patients had significantly higher fasting glucose and CRP levels compared to 
T1DM-WC patients and healthy controls.  T1DM patients with periodontitis had significantly higher 
serum TNF-α levels compared to those without periodontitis, (P<0.001).  Serum TNF-α levels 
correlated significantly with number of sextants with PD 4-5 mm. 





[moderate: 3 & 
severe: 2] 
Aggressive periodontitis 






Cross-sectional The expression of MMP-7, -8, -9 and -13 in the gingival tissues was positive in all patients with 
T1DM+AP.  The gingival expression of MMP-7 was positive in all T1DM+AP patients.  The 
expression of MMP-8 and -13 was positive in all cases with T1DM+AP, but was more intense in 
those with severe periodontitis. 
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7-18 Cross-sectional Salivary IL-8 levels were significantly higher in T1DM patients (474.47±716.76 pg/ml) compared to 
healthy controls (101.99±68.32 pg/ml), (P<0.005).  No significant difference in salivary IL-8 levels 
between T1DM patients with and without periodontitis. 
(Demmer et al. 
2012) 









Relative to non-diabetic controls, uncontrolled T1DM and T2DM were statistically significantly 
associated with progression of CAL and 4% greater increase in % of 5 mm PD sites/mouth during   
5-years of follow-up, whereas controlled T1DM and T2DM was not associated with CAL or PD 
progression. 








20-55 Cross-sectional Prevalence of severe periodontitis was higher in all T1DM patients (24.1%) and T1DM-PC patients 
(27.2%) compared to controls (20.5%).  CAL was significantly higher in all T1DM patients and 
T1DM-PC patients compared to controls, (P<0.001). 








Results of the experimental gingivitis study revealed significantly elevated GCF IL-1β and MMP-9 
levels in T1DM patients compared to healthy controls, showing differences between the 2 groups at 
7-21 days and 7-14 days, respectively following cessation of oral hygiene practices. 
(Xavier et al. 
2009) 
T1DM: 168 7-19 
(13.0±3.5) 
Cross-sectional Of the T1DM patients, 20.8% had gingivitis and 5.9% had periodontitis.  Diabetes duration and poor 
glycaemic control were significantly associated with periodontal disease severity. 








Cross-sectional T1DM patients had significantly higher BOP, PD and LOA (50.5±26.4%, 3.12±0.8 mm and 1.29±1.1 
mm) compared to healthy controls (18.4±18.5%, 2.18±0.5 mm and 1.29±0.4 mm), (P<0.01).  In the 
presence of similar plaque levels, T1DM patients were more vulnerable to periodontal disease than 
controls.  Diabetes duration, diabetes-related complications and poor glycaemic control were 







6-18 Cross-sectional T1DM patients had significantly higher plaque index (PI), modified gingival index (mGI), 
bleeding/plaque ratio and PD measurements (0.9±0.3, 0.7±0.3, 1.1±2.03 and 1.5±0.3 mm) compared 
to healthy controls (0.7±0.2, 0.5±0.3, 0.69±1.28 and 1.4±0.2 mm), (P<0.05).  Severity of periodontal 
disease correlated with metabolic control and duration of diabetes. 




5-14 Cross-sectional T1DM patients had significantly higher gingival inflammation than healthy controls.  The amount of 
plaque, inflammation and calculus increased with age in both groups. 
(Lalla et al. 
2006a) 
T1DM & T2DM: 182 
Controls: 160 
6-18 Cross-sectional Periodontal destruction was increased in diabetic children compared to controls and periodontal 
disease severity increased with increase in age.  Diabetic children had significantly higher amount of 
plaque (1.2±0.4), gingival inflammation (1.2±0.3), % of bleeding sites (23.6±23.9%) and LOA 
(1.8±1.1 mm) compared to controls (1.1±0.03, 1.0±0.3, 10.2±13.6% and 0.8±0.9 mm, respectively), 
(P<0.001). 
(Luczaj-




14 Cross-sectional No significant differences for PDI between T1DM patients and controls.  Only maximum scores of 






10-15 Cross-sectional Despite having similar oral hygiene habits, children with T1DM were more prone to calculus 
accumulation and gingivitis compared to non-diabetic children. 
(Al-Shammari 
et al. 2006) 
T1DM: 72 18-65 Cross-sectional Greater CAL and missing teeth were associated with longer duration of diabetes.  Smoking and 
diabetes-related complications were associated with severity of periodontal disease. 
 
(Aren et al. 
2003) 











Cross-sectional Both T1DM groups had significantly higher PI scores (1.29±1.36 and 1.53±1.51) compared to 
controls (0.39±0.46), (P<0.05).  Significantly higher mGI and PD were found in T1DM-LD patients 
(0.62±0.98 and 2.62±1.44 mm) compared to T1DM-ND patients (0.21±0.31 and 2.07±0.81 mm), 
(P<0.05).  Glycaemic control affected PD, salivary pH, buffering capacity and peroxidase activity. 
(Moore et al. 
1999) 
T1DM: 320 32.1±0.43 Longitudinal 
observational 
Periodontitis was associated with diabetes-related complications [retinopathy (39%), nephropathy 
(18%), peripheral neuropathy (22%) and peripheral vascular disease (9%)].  Smoking, older age and 
longer duration of T1DM was associated with increased prevalence of severe periodontal disease. 
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Table 1.5: Principal studies investigating links between T1DM and periodontal disease. 1 








No significant difference in periodontal status between the 2 groups at baseline and at 5-year follow-
up.  Only significant change in T1DM group was increase in CAL at the-5 year follow-up.  CAL, 
glucose, fructosamine and HbA1c levels were significantly higher in T1DM patients compared to 
controls.  In T1DM patients, CAL was significantly correlated with duration of diabetes, while 
fructosamine levels significantly correlated with mGI scores. 




5-65 Cross-sectional 16% of T1DM patients had a CPITN score of 3 or 4.  For patients >35 years, 44% of T1DM patients 
had a CPITN score of 3 or 4 compared to 12.5% of healthy controls. 




5-18 Cross-sectional T1DM patients had significantly higher plaque (1.23) and gingival inflammation (0.58) compared to 
controls (0.81 and 0.15, respectively).  Although PD did not differ between groups, upper and lower 
anterior alveolar bone loss was higher in T1DM patients compared to controls. 







20-70 Cross-sectional Patients with T1DM-LD had increased alveolar bone loss and PD of 4 and 5 mm compared to 
healthy controls.  Irrespective of diabetes duration, gingivitis was more prevalent in T1DM patients 
than healthy controls.   
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1.3.4 Periodontal treatment outcomes in T1DM patients 
The high prevalence of diabetes together with the increased risk for periodontal disease and 
impaired wound healing requires an investigation of the healing response to periodontal 
therapy in patients with diabetes.  Patients with T1DM have been found to have a good 
response to appropriate periodontal therapy and their response to therapy is similar to non-
diabetic controls (Westfelt et al. 1996; Christgau et al. 1998).  A number of interventional 
studies have been conducted to determine the effects of periodontal disease and its treatment 
on clinical periodontal parameters in patients with T1DM (Table 1.6).  Some investigations 
have found a significant short- and long-term improvement in clinical periodontal parameters 
following appropriate periodontal management (Bay et al. 1974; Seppala and Ainamo 1994; 
Smith et al. 1996; Westfelt et al. 1996; Christgau et al. 1998; Llambes et al. 2005).  Other 
investigations have reported significant improvements in clinical periodontal measurements 
when NSM was provided with and without adjunctive doxycycline (Martorelli de Lima et al. 
2004; Llambes et al. 2005).  These authors also reported that improvements in PD and CAL 
(Martorelli de Lima et al. 2004) and reductions in BOP and PD sites measuring ≥6 mm 
(Llambes et al. 2005) were more evident when doxycycline was used.  Periodontal treatment 
with and without adjunctive antibiotic therapy has been found to not only improve the 
periodontal condition but also contribute to improved glycaemic control in uncontrolled 
diabetic patients (Grossi et al. 1997; Taylor 2001; Singh et al. 2008).  Westfelt et al. 
demonstrated that periodontal health could be maintained in both T1DM and non-diabetic 
patients over a 5-year period with non-surgical and subsequent surgical periodontal treatment 
(Westfelt et al. 1996).  The long-term response of periodontal therapy and stability of the 
periodontal condition in patients with T1DM will largely depend on the level of oral hygiene, 
the periodontal maintenance provided and level of glycaemic control (Llambes et al. 2005). 
1.3.5 Impact of periodontal treatment on glycaemic control 
The prevalence, severity and progression of periodontal disease were found to be higher in 
patients with diabetes; despite this, these patients have a good response to periodontal 
treatment (Seppala et al. 1993).  The response to periodontal treatment in T1DM patients has 
been found to be similar to the response seen in non-diabetic controls.  However, it is crucial 
that diabetes is well-controlled, as periodontal disease recurrences will be more frequent and 
more difficult to control in patients with poor metabolic control (Seppala et al. 1993; 
Tervonen and Karjalainen 1997).  A few investigations have found no significant influence of 
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metabolic control on periodontal healing (Tervonen et al. 1991; Westfelt et al. 1996).  There 
is a lack of evidence in the literature regarding the effects of periodontal therapy on 
glycaemic control in patients with T1DM.  Only a few interventional studies have been 
conducted to determine the effects of periodontal disease and its treatment on glycaemic 
control in T1DM patients (Table 1.6). 
Williams and Mahan reported that reductions in blood glucose levels and insulin 
requirements were seen following periodontal treatment in diabetic patients with “gross 
evidence of periodontal disease” during the 3-month follow-up (Williams and Mahan 1960).  
A number of investigations into the effect of periodontal treatment on metabolic control in 
patients with T1DM have reported no significant change or improvement (Miller et al. 1992; 
Seppala et al. 1993; Aldridge et al. 1995; Smith et al. 1996; Llambes et al. 2008).  A few 
investigations including both T1DM and T2DM patients have reported a significant 
improvement in HbA1c levels following periodontal treatment (Williams and Mahan 1960; 
Wolf 1977), whereas others reported no such effect (Westfelt et al. 1996; Christgau et al. 
1998).  Some authors have reported that NSM could improve metabolic control especially 
when adjunctive doxycycline is given (Miller et al. 1992; Grossi et al. 1996; Grossi et al. 
1997; Iwamoto et al. 2001).  Doxycycline has both host-response modifying effects and 
antimicrobial properties, and a probable non-enzymatic inhibitory effect on glycation 
(Hungund and Panseriya 2012). 
1.3.6 Impact of periodontal treatment on inflammation in T1DM  
In patients with diabetes, clinical interventional trials have shown a significant reduction of 
acute phase protein levels, such as fibrinogen (Christgau et al. 1998), and CRP (Lalla et al. 
2007a) following periodontal therapy.  Research studies related to T2DM have shown a 
significant reduction of the pro-inflammatory cytokine, TNF-α following successful 
periodontal therapy, whereas although other pro-and anti-inflammatory cytokines such as IL-
4, IL-6, IL-8 and IL-10 reduced post-treatment, this reduction was not statistically significant 
(Correa et al. 2010).  In contrast, some studies reported no changes in biomarker levels in 
diabetic patients following periodontal therapy (Talbert et al. 2006; Lalla et al. 2007a; 
O'Connell et al. 2008; Geisinger et al. 2016).  Factors such as periodontal status and the 
adjunctive use of systemic antibiotics may possibly explain these outcome differences 
(Correa et al. 2010). 
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Research studies related to the effect of periodontal treatment on levels of local and systemic 
biomarkers in T1DM patients are notably lacking.  An uncontrolled study reported that after 
periodontal therapy, no statistically significant changes were seen for serum IL-6 levels, 
however, those patients with higher serum IL-6 levels presented with poorer periodontal 
healing as compared to those with low levels of IL-6 following treatment (Passoja et al. 
2011).  A recent study in T1DM and T2DM patients assessed the effect of topical application 
of melatonin (1% orabase cream) on serum TNF-α, IL-6 and CRP levels compared to healthy 
controls treated with a placebo orabase cream (Cutando et al. 2015).  The authors reported a 
significant decrease in gingival index scores, PD measurements, serum IL-6 and CRP levels 
in diabetic patients 20 days following treatment suggesting that melatonin could modulate the 
inflammatory action of these inflammatory markers in periodontal disease, though the authors 
did not propose a mechanism of action in this regard. 
Clearly there is lack of evidence demonstrating the effect of periodontal treatment on 




Table 1.6: Studies investigating the impact of periodontal treatment on periodontal health, glycaemic control and biomarker levels. 






Changes in periodontal 
health 
Changes in biomarkers Changes in HbA1c 





















Significant improvement in 
mGI and PD. 
Significant decrease in IL-6 
and CRP 20 days following 
treatment, (P<0.001). 
Serum TNFα, IL-6 and CRP 
significantly correlated with 
mGI and PD pre- and post-
treatment. 
Data not reported 
(Passoja et al. 
2011) 
T1DM: 80  
(at baseline) 
 
T1DM: 58  
(treated & reviewed 8 








8 NSM Improvements in PI, PD and 
BOP.  Response of NSM was 
poorer in patients with higher 
post-treatment serum IL-6 
levels than those with low   
IL-6 levels. 
No significant change in 
serum IL-6 following NSM.  
Significant association 
between serum IL-6 levels 
and periodontal inflammation 
(BOP and PD ≥4 mm) pre- 
and post-NSM. 
NSM had no significant influence 
on HbA1c. 
(Llambes et al. 
2008) 
T1DM: 60 
 T1DM-group 1: 30 
T1DM-group 2: 30 
T1DM:  
35.3±9.0 
12 NSM +/- 
doxycycline 
Data not reported Data not reported Mean baseline HbA1c was 
7.64±1.81% in group 1 (NSM + 
doxycycline) and 7.51±1.36% in 
group 2 (NSM - doxycycline), 
and following treatment HbA1c 
was 7.71±1.74% and 
7.45±1.29%, respectively.  There 
was a non-significant HbA1c 
variation of 0.07% in group 1 and 
-0.06% in group 2. 
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(Llambes et al. 
2005) 
T1DM: 60 
 T1DM-group 1: 30 
T1DM-group 2: 30 
T1DM:  
35.3±9.0 
12 NSM +/- 
doxycycline 
Significant improvement in PI, 
BOP, PD and CAL in both 
groups.  The reduction in BOP 
and PD sites ≥6 mm was more 
evident when doxycycline was 
used. 
Data not reported Data not reported 
(Martorelli de 
Lima et al. 2004) 
T1DM: 22 
T1DM-treatment A: 11 
T1DM-treatment B: 11 
T1DM: 35-55 48 NSM +/- 
doxycycline 
Significant improvement in 
PD and CAL in both treatment 
groups.  Statistically 
significant difference in PD 
and CAL, between groups 
only at month 12, favouring 
adjunctive doxycycline group. 
Data not reported Data not reported 









16 NSM Significant improvement in 
PI, Papillary Bleeding Index 
and BOP in all groups. 
Data not reported NSM had no significant influence 
on HbA1c. 





45-65 240 NSM +/- 
surgical 
therapy 
Significant improvement in 
PI, PD, BOP and CAL 
following treatment. 
Data not reported No significant change in HbA1c 
between baseline-24 months and 
24 months-60 months. 
(Smith et al. 
1996) 
T1DM: 18  26-57 8 NSM Significant improvement in 
mGI, PD, CAL. 
Data not reported Non-significant increase in 
HbA1c of 0.10%, from 8.18% 
before to 8.28% following NSM. 
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(Aldridge et al. 
1995) 
Study 1 
T1DM: 16 & 
controls: 15  














8 NSM Data not reported Data not reported NSM had no significant influence 
on HbA1c. 




At 1 year follow-up 
T1DM: 38 
[Well-controlled 




At 2 year follow-up 
T1DM: 22 










24 NSM Both well-controlled and 
poorly-controlled groups 
responded well and equally to 
periodontal treatment. 
Data not reported Non-significant reduction in 
HbA1c levels in both groups.  
(Miller et al. 
1992) 
T1DM: 9 Data not 
published 
24 NSM + 
doxycycline 
Improvement in BOP. Data not reported Non-significant reduction in 
HbA1c from pre- (9.44±1.69 %) 
to post-treatment (9.01±2.01 %).  
Only those patients with 
consistent improvements in BOP 
scores showed a decrease in 
HbA1c post-treatment. 
(Bay et al. 1974) T1DM: 57 
Controls: 49 
20 1 NSM Significant improvement in PI 
and mGI in both groups.  
Data not reported Data not reported 
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(Wolf 1977)  T1DM & T2DM: 91 16-60 48 NSM + 
surgical 
therapy 
Data not reported Data not reported Following treatment, a limited 
comparison of 23 responders and 
23 non-responders revealed that 
significant reduction in 
periodontal inflammation had a 
non-significant association with 
improved metabolic control.  The 
authors concluded that this was 





Type not specified: 1 




Data not reported Data not reported Significant reduction in insulin 
requirement and noticeable 
reduction in blood glucose levels 
was seen in 7 out of 9 diabetic 
patients. 
Table 1.6: Studies investigating the impact of periodontal treatment on periodontal health, glycaemic control and biomarker levels. 
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1.3.7 Other oral manifestations of diabetes 
The oral health of patients with diabetes has been the subject of several studies in recent 
years, and while these patients are acknowledged to have a greater susceptibility to 
periodontal disease, even very early in life (Lalla et al. 2006a), the possibility of detecting an 
increased prevalence of caries in patients with T1DM is controversial.  It has been proposed 
that hyperglycaemia is associated with reduced salivary secretion and increased glucose 
levels, notably in cases of severe insulin insufficiency (Harrison and Bowen 1987a; 
Karjalainen et al. 1996) and consequently a heightened cariogenic challenge can be expected 
in such individuals.  Additonally, the presence of caries in diabetic patients was associated 
with increasing age, gingival recession and the presence of diabetes-related nephropathy 
(Moore et al. 2001a). 
Dental caries is a multifactorial infectious disorder involving various factors needing to 
coincide at a given point and time.  The development of caries is dependent on the presence 
of microorganisms, the host (tooth), nutrition, diet and the immune capacity of an individual.  
Twetman et al. reported a high proportion of caries-causing bacteria such as Streptococcus 
mutans in the aerobic flora of patients with diabetes (Twetman et al. 1989).  Other authors 
reported a decrease in salivary lactobacilli counts in these patients due to dietary restrictions 
(Swanljung et al. 1992; Collin et al. 1998), while Iughetti et al. observed similar counts of 
lactobacilli and Streptococcus mutans in patients with and without diabetes (Iughetti et al. 
1999). 
To date, there is no clear evidence to support an association between dental caries and 
T1DM, and epidemiological studies relating to the effect of T1DM on the prevalence of 
caries in children and adults have yielded contradictory results.  On one hand, some authors 
have reported lower caries experience (Matsson and Koch 1975; Leeper et al. 1985; Kirk and 
Kinirons 1991; Siudikiene et al. 2006; Orbak et al. 2008), while others have reported an 
increased presence of caries (Albrecht et al. 1988; Jones et al. 1992; Moore et al. 2001b; 
Lopez et al. 2003; Miralles et al. 2006) whereas some studies have shown similar caries 
experience in patients with T1DM compared to matched controls (Faulconbridge et al. 1981; 
Tenovuo et al. 1986; Harrison and Bowen 1987b; Twetman et al. 1989; Swanljung et al. 
1992; Edblad et al. 2001; Siudikiene et al. 2008; Tagelsir et al. 2011).  Miko et al.’s study 
found that adolescents with T1DM had significantly higher mean Deacayed Missing and 
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Filled teeth index scores, with fewer decayed teeth and more filled teeth compared to healthy 
controls (Miko et al. 2010). 
Earlier studies have reported low caries incidence in diabetic populations, mainly explained 
by the lifelong sucrose-free diet, restricted carbohydrate intake and insulin treatment 
regimens, with results indicating that diet modification had a positive impact on caries 
prevention (Matsson and Koch 1975; Leeper et al. 1985; Sarnat et al. 1985; Kirk and 
Kinirons 1991; Tavares et al. 1991; Lamster et al. 2008).  Previous research has also 
demonstrated that frequent main meals, a starch-rich diet and longer eating time in children 
with diabetes is associated with comparable caries prevalence in diabetics and healthy 
controls (Sarnat et al. 1985).  However, modern management of diabetes, characterised by 
flexibility of insulin treatment and blood glucose monitoring allows for less rigid meal 
planning and reduces the significance of dietary factors as an indicator for possible variations 
in caries development (Twetman et al. 2002; Siudikiene et al. 2006).  Children with T1DM 
were also found to have more daily main meals and fewer snacks than non-diabetic children, 
who had fewer main meals per day but consumed more snacks (Siudikiene et al. 2006). 
The probable relationship between cariogenic experience and metabolic control of diabetes is 
an investigation of much interest.  Due to disturbed glucose metabolism, these patients are 
considered to be at a higher risk for dental caries (Siudikiene et al. 2005b; Siudikiene et al. 
2006).  Poor metabolic control has been associated with reduced salivary secretion, elevated 
salivary glucose concentrations and pronounced yeast growth (Harrison and Bowen 1987a; 
Reuterving et al. 1987; Karjalainen et al. 1996; Karjalainen et al. 1997).  Therefore, chronic 
hyperglycaemia is known to cause shifts in the ecology and composition of saliva resulting in 
a cariogenic environment in the oral cavity.  Some authors have found that caries-active 
diabetic children have significantly higher HbA1c levels than caries-inactive diabetic children 
(Twetman et al. 1992; Karjalainen et al. 1997).  Other studies reported that poorly-controlled 
T1DM patients had a higher incidence of caries compared to matched controls (Twetman et 
al. 1992; Canepari et al. 1994; Karjalainen et al. 1997; Miko et al. 2010).  Twetman et al. 
reported that poorly-controlled T1DM patients developed three times more carious lesions 
during the study compared to those with well-controlled T1DM (Twetman et al. 2002).  
Siudikiene et al. showed that among the variables associated with caries risk, age and level of 
metabolic control were significantly associated with  caries experience in T1DM children 
(Siudikiene et al. 2005b).  Higher counts of Streptococci mutans, lactobacilli and yeasts were 
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found in poorly-controlled diabetics when compared to those with well-to-moderately 
controlled T1DM (Syrjala et al. 2003; Siudikiene et al. 2006).  Additionally, poor metabolic 
control has led to changes in certain behavioural factors such as poor adherence to diabetes 
treatment regimens and oral health recommendations (Syrjala et al. 2003).  The level of 
untreated dental decay was considerably higher in diabetic children, reflected by a 
significantly lower dental attendance in these patients than matched controls (Tagelsir et al. 
2011).  However, a few studies were unable to relate the prevalence of caries in T1DM 
patients to good or poor metabolic control (Leeper et al. 1985; Thorstensson et al. 1989; 
Edblad et al. 2001; Miralles et al. 2006). 
Saliva is essential for the preservation and maintenance of oral health, therefore the 
comprehensive evaluation of salivary flow rate must be included in the management of oral 
diseases in patients with diabetes (Moore et al. 2001b).  Lower salivary flow rates and self-
reported xerostomia have been frequently seen in patient with diabetes (Sreebny et al. 1992; 
Ben-Aryeh et al. 1993; Moore et al. 2001b; Siudikiene et al. 2006), especially if poorly-
controlled (Harrison and Bowen 1987a; Harrison and Bowen 1987b).  Diminished salivary 
flow has been linked to high caries prevalence in diabetic patients (Twetman et al. 1992; 
Karjalainen et al. 1997; Moore et al. 2001a; Siudikiene et al. 2006).  Hyperglycaemia-
induced reduced salivary flow rate is mainly characteristic of periods of poor metabolic 
control, during which there is a possibility of glucose leakage into the oral cavity, thereby 
facilitating the growth of acidogenic bacteria and development of carious lesions (Karjalainen 
et al. 1996; Siudikiene et al. 2006).  Good metabolic control can prevent salivary changes 
such as high glucose content and acidic pH, whereas a good diabetic diet rich in fibre and low 
in carbohydrates, can delay plaque accumulation and proliferation of acidogenic bacteria 
(Karjalainen et al. 1997; Orbak et al. 2008).  A 2-year longitudinal study by Siudikiene et al. 
demonstrated that salivary flow rates (stimulated and unstimulated) remained significantly 
lower in T1DM children compared to matched healthy controls (Siudikiene et al. 2008).  
Whereas another study found no differences in salivary flow rate between patients with 
diabetes and healthy controls (Miralles et al. 2006).  Multivariable regression analysis 
demonstrated that children with higher 2-year decayed, missing and filled surfaces (DMFS) 
index scores were more likely to have T1DM, be older in age, and have higher salivary 
glucose concentrations compared to those with lower 2-year DMFS scores (Siudikiene et al. 
2008).   
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1.4 Quality of life 
1.4.1 Definition and dimensions 
Since the 1990s, the research field in matters relating to quality of life (QoL) has increased 
greatly.  In 1994, the World Health Organization (WHO) defined QoL as “an individual’s 
perception of their position in life in the context of the culture and value system in which they 
live and in relation to their goals, expectations, standards and concerns.”  Considerable 
agreement confirms that QoL is an elusive, complex and multidimensional concept (Felce 
and Perry 1995).  Additionally, QoL can also be defined as the “value assigned to duration of 
life as modified by impairments, functional status, perceptions and social opportunities that 
are influenced by disease, injury, treatment or policy” (WHO 1994). 
An individual is said to have a good QoL if his or her hopes and experiences are matched; 
whereas a poor QoL is one in which an individual’s hopes are not matched with their 
experiences.  QoL has a tendency to change with time, age and experience (Calman 1984).  
As QoL assessments represent the effect an illness has on an individual, as perceived by the 
individual, and yields additional information to epidemiological or clinical data, it is often 
utilized as an outcomes measurement (Wandell 2005).  QoL measures have also been 
characterized as “the ultimate goal of all health interventions” (Rubin and Peyrot 1999). 
QoL is a dynamic construct and has a tendency to vary between individuals; despite this its 
dimensions and the content of each instrument measuring QoL are somewhat similar and 
typically involve assessment of: 
 Physical function - for example, mobility, self-care 
 Emotional function - for example, depression, anxiety 
 Social function - for example, intimacy, social support, social contact 
 Role performance - for example, work, housework 
 Pain 








In 1948, the WHO stated that disease is defined by the pathological process which affects the 
functioning and pathological integrity of the body.  However, health is defined as, “a state of 
complete physical, mental, and social well-being and not merely the absence of disease or 
infirmity” (WHO 1948).  Health-related QoL (HRQoL) is defined as, “the value assigned to 
duration of life as modified by the impairments, functional states, perceptions, and social 
opportunities that are influenced by disease, injury, treatment, or policy” (Patrick and 
Erickson 1988).  Although the definition of HRQoL varies across studies, the consensus in 
the literature identifies three major dimensions of HRQoL: physical symptoms, functional 
capacity and perceptions of well-being (Chen and Hunter 1996).  HRQoL primarily assesses 
the relationship between an individual’s health status and their QoL (Allen 2003).  Research 
related to HRQoL highlights two aspects: the “objective measure”, which is the functional 
status of an individual, and the “subjective measure” which is an individual’s opinion of their 
own health affecting their QoL (Testa and Simonson 1996; Muldoon et al. 1998). 
Oral health-related QoL 
An important aspect of HRQoL is “oral health-related QoL” (OHRQoL) (Naito et al. 2006), 
which is defined as “the impact of oral disorders on aspects of everyday life that are 
important to patients and persons, with those impacts, being of sufficient magnitude, whether 
in terms of severity, frequency or duration, to affect an individual’s perception of their life 
overall” (Locker and Allen 2007).  Over the last two decades, a number of patient-centred 
assessment tools have been developed and validated to evaluate patients’ subjective oral 
health with reference to how it affects their inter-personal relationships, daily activities and 
psychological well-being (McGrath and Bedi 2002).  The psychosocial experience of oral 
condition determines whether patients will seek treatment and follow advice, and could 
therefore influence treatment planning and treatment process (Ng and Leung 2006). 
Previous research suggests that oral health can have a profound negative impact on an 
individual’s QoL in terms of physical functioning and social well-being (Needleman et al. 
2004; Naito et al. 2006; Locker and Quinonez 2011), and it is often difficult to dissociate 
general health from oral health with regards to impacts on QoL (Fontanive et al. 2013).  Over 
the past few years, the increase in awareness that QoL is an important outcome for oral care 
has led to the development of a wide range of instruments to measure OHRQoL.  The main 





 Sensitive to change 
 Multidimensional construct 
 Appropriate to question or use 
 Practical utility (Fitzpatrick et al. 1992; Allen 2003). 
Dimensions of QoL  
In 1995, a conceptual model for HRQoL was proposed by Wilson and Cleary, which provides 
a causal pathway linking HRQoL and traditional clinical variables (Wilson and Cleary 1995).  
Conceptually, Wilson and Cleary’s model links five health concepts on a continuum, these 
being: symptoms, physiological factors, general health perceptions and HRQoL.  Starting at 
the clinical level (biological, objective) at one end of the continuum and moving outwards to 
the individual’s interaction with the environment to perceive a level of QoL (psychological, 
subjective) at the other end, this model integrates both social science and biomedical 
paradigms. 
 
Figure 1.5: Model linking HRQoL to physical function, psychosocial function, social 
function and environmental characteristics (Wilson and Cleary 1995). 
 
1.4.2 Impact of periodontal disease and treatment on QoL 
Periodontal disease in its initial stages is generally asymptomatic, and patients are unaware of 
their condition and hence, may underestimate their need for treatment.  However, as the 
disease progresses, it results in a number of signs and symptoms such as tooth mobility, eating 
difficulties, pain, discomfort and compromised aesthetics, which can be readily perceived by 
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patients and are highly relevant from their point of view.  Those who suffer from this 
condition often report a considerable negative impact on their daily lives and are known to 
experience in particular, physical functioning, psychosocial and pain impacts on their QoL 
due to their oral health status (Cunha-Cruz et al. 2007; O'Dowd et al. 2010; Durham et al. 
2013; Desai et al. 2014; Jansson et al. 2014; Simona et al. 2014). 
Locker in 1988 stated that periodontal disease causing inflammation and destruction of the 
periodontium giving rise to multiple signs and symptoms may have a considerable impact on 
an individual’s day-to-day QoL (Locker 1988).  Past research related to periodontal disease 
has usually focused on clinical and pathological mechanisms of the disease process rather 
than the impact the disease has on a patient’s QoL (O'Dowd et al. 2010).  Decades ago, 
Cohen and Jago proposed the use of socio-dental indicators, incorporating functional, 
psychological and social consequences of oral diseases for patients, and not merely 
evaluation of the signs and symptoms of various diseases (Cohen and Jago 1976).  In doing 
so, clinicians would better understand the impact of oral diseases such as periodontitis on 
QoL, and would assist in providing appropriate care by addressing patient needs and main 
concerns and assist in evaluating treatment outcomes from a patient’s point of view (McGrath 
and Bedi 1999). 
Several studies have evaluated the impact of periodontal disease on OHRQoL.  Needleman et 
al. utilised the UK oral health-related QoL (OHQoL-UK) measure and found that periodontal 
disease had substantial physical, psychological and social impact on OHRQoL as patients 
complained of halitosis, discomfort and unaesthetic facial appearance (Needleman et al. 
2004).  These impairments caused social impairments, financial setbacks and the patient’s 
appeared worried, with reduced happiness and self-confidence (Needleman et al. 2004).  Ng 
and Leung utilised the Oral Heath Impact Profile (OHIP-14S, Chinese version) and 
comparing OHIP-14S summary scores of patients with healthy or low CAL (CAL ≤2 mm) 
and high or severe CAL (CAL >3 mm) revealed significant differences in the domains of 
functional limitation, physical pain, psychological discomfort, physical and psychological 
disabilities, demonstrating a significant correlation between OHRQoL and periodontal 
disease (Ng and Leung 2006).  Patel et al. assessed smiling patterns and found that those with 
an increased number of mobile and missing teeth, and more gingival recession opened their 
mouth less widely while smiling or covered their mouth while laughing.  Poor periodontal 
health prevented these patients from expressing positive emotions leading to impairments in 
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self-confidence, social interactions and QoL (Patel et al. 2008).  O’ Dowd et al. examined the 
impact periodontal disease had on the daily lives of patients by conducting semi-structured 
interviews to record daily life experiences (O'Dowd et al. 2010).  The authors found that 
periodontal disease had a negative impact with regards to causing functional limitations, 
discomfort and physical, emotional and social disability (O'Dowd et al. 2010).  Durham et al. 
identified, while using the OHIP-49 measure, that patients with chronic periodontitis reported 
significantly poorer OHRQoL compared to those without chronic periodontitis, with 
significant functional, psychological and social impacts on OHRQoL (Durham et al. 2013).  
Another study by Desai et al. reported that patients with chronic periodontitis had the greatest 
impacts on the functional limitation and psychological disability and discomfort domains of 
the OHIP-49 (Desai et al. 2014).  Loss of periodontal structures can negatively affect 
masticatory performance and OHRQoL (Borges Tde et al. 2013).  Jansoon et al. reported that 
patients having severe marginal bone loss experienced worse OHRQoL compared to those 
with minor or no marginal bone loss, as assessed by the OHIP-14.  The authors emphasized 
the need for prevention and early periodontal treatment, as severe periodontitis leads to 
considerable negative impacts on OHRQoL (Jansson et al. 2014). 
Patient-based outcome measures are subjective measures used to capture patients’ perspective 
of disease and treatment and complement conventional clinical surrogate measures (Hujoel 
2004; Tsakos et al. 2012).  Traditionally, surrogate markers such as PD and LOA have been 
used to define and measure periodontal disease (Armitage 1996; Renvert and Persson 2002; 
Armitage et al. 2003; Savage et al. 2009), but these measures do no capture the total impact 
of treatment on a patient’s health status (Saito et al. 2010).  Patient’s perception regarding the 
provided care and HRQoL is increasingly recognized as a crucial outcome of care (Locker 
2004).  Patient-based outcome measures are more meaningful in assessing patient’s daily 
lives than objective changes in PD and LOA measurements (Locker 1988; Naito et al. 2006; 
Ng and Leung 2006), and are useful in detecting QoL changes before and after periodontal 
treatment (Needleman et al. 2004).  Although there is sound evidence to support the clinical 
efficacy of surgical and NSM, data related to patient-based outcomes are limited and more 
information is required regarding the impact of periodontal therapy on QoL (Heitz-Mayfield 
et al. 2002; Hung and Douglass 2002; Tunkel et al. 2002; Van der Weijden and Timmerman 
2002; Allen 2003; Locker and Allen 2007). 
Needleman et al.’s cross-sectional study found a correlation between OHQoL-UK scores and 
the number of teeth with PD ≥5 mm, also patients who had undergone periodontal care and 
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were in the maintenance phase had significantly higher OHQoL-UK scores (indicating better 
QoL) compared to patients who received no periodontal therapy (Needleman et al. 2004).  
Surgical therapy alone appeared to have no effect on OHRQoL (Ozcelik et al. 2007), whereas 
surgical therapy supplemented with Emdogain led to an improved OHRQoL as indicated by 
the OHIP-14 responses (Bajwa et al. 2007).  Aslund et al. investigated the impact of two 
modes of delivery of NSM (ultrasonic versus hand instruments) on OHRQoL and on patient 
experience of pain in patients with mild to moderate periodontitis (Aslund et al. 2008).  The 
authors reported that NSM was generally well tolerated, clinical outcomes of therapy were 
similar in both modes of therapy and NSM had a small positive impact on pain and 
contributed to changing patients’ perception from a negative effect of oral health on QoL to a 
positive one (Aslund et al. 2008).  Jowett et al. reported that patients with periodontal disease 
had significantly greater impacts on QoL compared to dentally healthy patients and, 
following 24-hour RSD the impact was significantly reduced but still greater than the QoL 
experienced by the dentally healthy patients (Jowett et al. 2009).  Saito et al. reported that 
pain, eating and chewing and psychological functioning were the most affected OHRQoL 
domains in patients with periodontitis, and a majority (97%) of patients perceived their oral 
health as poor.  On the other hand NSM resulted in a higher proportion of patients rarely or 
never having pain and eating difficulties, suggesting that NSM had the potential to ameliorate 
perception of oral health (Saito et al. 2010).  Jönsson et al.’s study to determine the 
minimally important differences 1-year following NSM in chronic periodontitis patients 
found that the OHRQoL significantly improved following therapy in these patients as 
assessed by the General Oral Health Assessment Index and the OHQoL-UK (Jonsson and 
Ohrn 2014).  A systematic review of the impact of periodontal therapy on OHRQoL found 
that routine NSM can moderately improve OHRQoL in patients with periodontal disease 
(Shanbhag et al. 2012).  Wong et al’s. study reported that successful NSM resulted in 
improvements in physical pain, psychological discomfort and disability domains of the 
OHIP-14S and the authors emphasized that clinicians must capitalize upon the positive 
psychological OHRQoL impacts of NSM for subsequent patient motivation during 
maintenance therapy (Wong et al. 2012).  The benefits of successful NSM were also seen in a 
previous study, in which patients perceived physical, psychological and social changes in 
OHRQoL following NSM, additionally, the positive effect of NSM was more pronounced in 
patients with PD of >7 mm (Brauchle et al. 2013). 
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1.4.3 QoL in patients with diabetes and tools available for assessment 
Diabetes can have a profound impact on health and QoL in terms of physical, psychological 
and social well-being (Glasgow et al. 1997).  Diabetes is related to an increased risk of 
developing macrovascular and microvascular complications, and national and international 
guidelines state that the overall goal for diabetes treatment is to prevent complications, while 
preserving a good QoL for the patient (Wandell 2005).  Diabetes management, taking insulin 
therapy, can substantially influence QoL either positively, for instance, by reducing high 
blood sugar level symptoms, or negatively, for example, by increasing low blood sugar level 
symptoms.  Patients often feel challenged by their illness and the substantial day-to-day 
management demands that come with it.  The diabetes-related psychosocial toll is often a 
great one, and this toll can in turn affect self-care behavior, long-term glycaemic control, the 
risk of developing diabetes-related complications and QoL (Rubin and Peyrot 1999). 
The prevalence of depression is known to be three times higher among patients with diabetes 
compared with the general population (Bradley 1994).  Psychopathological conditions such 
as anxiety and depression can negatively affect QoL, glycaemic control and the adherence to 
treatment, which in turn increases health care costs and the risk for acquiring diabetes-related 
complications (Rubin and Peyrot 1992; Jacobson 1996; Jacobson et al. 1997; Lustman et al. 
1998; Pouwer et al. 1999; Ciechanowski et al. 2000; Lustman et al. 2000; Talbot and Nouwen 
2000; Anderson et al. 2001).  Goldney et al.’s study involved personal interviews of patients 
with and without diabetes, and found the prevalence of depression in patients with diabetes 
was 24% compared with 17% of the non-diabetic controls (Goldney et al. 2004).  
Psychological conditions can be effectively treated, but their accurate recognition is often 
hampered in clinical practice (Penn et al. 1997; Kessler et al. 1999; Anderson et al. 2001).  
Intensified treatment regimens might be associated with changes in the psychological 
condition of the patient, and hence scales are needed to be sensitive to these changes and to 
the positive aspects of well-being (Bradley 1994). 
The findings related to duration of diabetes and QoL are mixed.  A few studies reported that 
an increase in duration of diabetes is associated with decreased QoL (Aalto et al. 1997; 
Glasgow et al. 1997; Klein et al. 1998), while others reported no significant relation between 
diabetes duration and QoL (Parkerson et al. 1993; Peyrot and Rubin 1997).  Past research has 
been consistent in finding that the presence of two or more diabetes-related complications is 
associated with a poorer QoL (Peyrot and Rubin 1997).  Some researchers have found an 
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increase in depression and negative life experiences during 2-years following diagnosis of 
diabetic retinopathy; the psychological disruptions existed irrespective of the severity of 
visual impairment and were existent even after lost vision was regained (Wulsin et al. 1987).  
Other researchers found that the presence of CVD, neuropathy or end-stage renal disease 
(ESRD) was associated with a poorer QoL (Ahroni et al. 1994; Peyrot and Rubin 1997).  The 
presence of ESRD in T1DM patients was associated with marked increase in functional 
impairment (Rodin 1990); and reduced perceived health and greater health worries were 
associated with nephropathy in patients with T1DM (Parkerson et al. 1993).  Trief et al. study 
of insulin-treated patients demonstrated that the number of complications was a strong 
predictor of disease impact and treatment satisfaction scores of the Diabetes Quality of life 
questionnaire (Trief et al. 1998).  The results of research related to the association between 
treatment regimens and QoL in diabetic patients are varied, some indicate that an increase in 
treatment intensity in T2DM patients from exercise and diet alone, to oral medications, to 
insulin leads to a worsening of QoL (Rubin and Peyrot 1999).  Jacobson et al. reported that 
diabetes-related worries were higher in patients taking oral medications compared to those 
who were controlling their diabetes with exercise and diet alone, also those who were on 
insulin therapy reported less satisfaction and higher burden of illness than those taking oral 
blood glucose lowering medication or no medication at all (Jacobson et al. 1994).  Similarly, 
some studies found lower scores (indicating poorer QoL) on Bradley’s Well-being and 
Treatment Satisfaction in T2DM patients taking insulin therapy compared to those who were 
not (Petterson et al. 1998).  In contrast, a study of T1DM patients found no association 
between treatment with twice-daily versus multiple insulin injection regimens (Eiser et al. 
1992).  The past decade has brought a burgeoning of research related to the association 
between glycaemic control and QoL in patients with diabetes. A few studies have suggested 
that a relation does exist, especially when QoL is assessed by diabetes-specific measures 
rather than generic questionnaires (Rubin and Peyrot 1999).  Mazze et al. found lower levels 
of anxiety and depression in T1DM patients with good glycaemic control compared to those 
with moderate or poor glycaemic control (Mazze et al. 1984). 
Methodologically, it is essential to use multidimensional assessments, including both generic 
and diabetes-specific measures as a guide to evaluate treatment interventions and to assess 
QoL (Rubin and Peyrot 1999).  Generic measures assess concepts which are relevant to 
everyone, i.e. they are not disease- or treatment-specific and are measures which are 
applicable to both health and illness groups (Speight et al. 2009).  Though these measures 
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appear to have an advantage of permitting comparison across disease entities, they are less 
suitable for measurement within disease type (Bradley et al. 1999).  Even a well-designed 
generic QoL measure will not address specific diabetes-related life aspects such as insulin 
injections, dietary restrictions, hypoglycemia and self-monitoring of blood glucose, which 
might be critical to a patient’s HRQoL. 
Over the years, several research studies have added disease-specific measures to generic 
ones, in order to increase the ability of the measures to identify trends most relevant to the 
HRQoL of patients with a specific disease.  Some studies have advocated a 3-level approach, 
incorporating disease-specific measures, generic measures, and finally situation-specific 
(condition or intervention) measures.  Diabetes-specific measures are more likely to be 
sensitive to change and responsive to subgroup differences.  These measures usually assess 
functioning levels, the impact and satisfaction of treatment, worries about the future effects of 
diabetes, worries about diabetes-related social and vocational issues, sexual functioning and 
overall well-being. (Speight et al. 2009). 
Previous research has found that patients with diabetes are more concerned about social and 
physical function, emotional and mental health, and burden of illness and treatments on daily 
life than with clinical parameters such as HbA1c, BP or lipid levels (Barr 1995; Krumholz 
2008).  Thus, patient-reported outcome measures are relevant and meaningful outcomes.  
Furthermore, evidence states that when HRQoL of patients with diabetes is appropriately 
measured and the results are incorporated into health care management, positive 
improvements in patient outcomes occur (Magwood et al. 2008; Tapp et al. 2010).  
Improvements in QoL, glycaemic control and a reduction in short-term diabetes-related 
complications have been observed when a combination of treatment and education approach 
has been used in patients with diabetes (Norris et al. 2002; Khanna et al. 2012). 
The Well-being questionnaire 
The Well-being Questionnaire (W-BQ) is one of the measures used to identify psychological 
problems in patients with diabetes.  The questionnaire was originally designed in 1982 for 
use in a study organised by the WHO evaluating new treatment options for the management 
of diabetes (Bradley 1994).  The original W-BQ consists of 22 items or questions divided 
among subscales evaluating depressed mood, anxiety, energy and positive well-being and an 
overall total well-being score can be calculated by combining the four subscales.  Questions 
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concerning somatic states were not included as they may lead to criterion contamination in 
diabetic patients, in whom somatic symptoms such as loss of appetite or fatigue might result 
from the physical state due to diabetes, rather than from depression. 
In 1994, the WHO/IDF advised the use of the W-BQ22 to monitor psychological well-being 
in diabetic patients and that this measure should be one of the routine clinical procedures 
employed in the management of diabetes (Bradley and Gamsu 1994).  The W-BQ22 has been 
utilised in studies evaluating the effects of new treatment regimens such as comparing 
subcutaneous insulin infusion pumps to conventional insulin-injections (Bradley 1992), 
insulin treatment in patients previously treated with tablets (Bradley and Lewis 1990; 
Jennings et al. 1991) and the influence of educational interventions in patients with tablet-
treated T2DM (Lewis 1994).  The W-BQ22 was further developed in the early 1990s to 
create the short-form, the W-BQ12 which has a balanced selection of positive and negative 
items, and consists of 12 items and can be scored on three subscales measuring negative well-
being, energy and positive well-being (Bradley 1994).  The W-BQ12 has been widely used, 
particularly in clinical trials, and is available in more than 35 languages.  To ensure that data 
obtained from the questionnaires are meaningful, it is important that they are validated, i.e. 
proved to be valid and reliable measures of the specific targeted concepts (Speight et al. 
2009).  Pouwer et al. carried out a study to evaluate the validity and reliability of the           
W-BQ12 in a group of both T1DM and T2DM patients (Pouwer et al. 1999).  The authors 
concluded the W-BQ12 to be a reliable and valid measure of psychological well-being for 
patients with diabetes.  Compared to the original 22-item questionnaire, the 12-item 
questionnaire is easier to administer and hence was considered to be a useful tool for both 
researchers and clinicians to assess the psychological health and well-being in patients with 
diabetes (Pouwer et al. 1999). 
A few studies have utilised the W-BQ12 to assess QoL in patients with diabetes. Pouwer et 
al. utilised the computerised version of the W-BQ12 to assess the differences in treatment 
strategies between psychological monitoring versus standard care in diabetic patients over a 
year (Pouwer et al. 2001).  Assessment of the W-BQ12 revealed that patients who received 
psychological monitoring reported significantly lower negative well-being, and significantly 
higher energy and general well-being compared to those who received standard care.  The 
authors concluded that although the W-BQ12 is a great measure to assess psychological well-
being in a few minutes, diabetes-related emotional disturbances, such as fear of 
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hypoglycaemia and worries about complications, cannot be detected easily with this 
instrument (Pouwer et al. 2001).  A previous study of T2DM patients utilised the W-BQ12 
along with other generic and diabetes-specific measures to assess the effects of intensive 
diabetes treatment versus routine care on patient reported outcomes after 5 years, and found 
no differences in W-BQ12 scores between the two interventions (Van den Donk et al. 2013).  
Although the W-BQ was designed for use in diabetic patients, the 12-item version is not 
actually diabetes-specific.  However, the W-BQ12 has proved sensitive to the positive 
benefits of new treatment regimens for diabetes, mostly as a result of its ‘energy’ and 
‘positive well-being’ subscales (Bradley 1994; Witthaus et al. 2001). 
The Audit of Diabetes Dependent Quality of Life 
In 1999, Bradley et al. developed the Audit of Diabetes Dependent Quality of Life 
(ADDQoL), an instrument aimed to measure QoL in both TIDM and T2DM patients 
(Bradley et al. 1999).  The ADDQoL was designed to provide an individualized questionnaire 
to measure of the impact of diabetes on QoL (Bradley et al. 1999).  It consists of diabetes-
specific questions which capture any negative psychological impact that diabetes may have 
on the patient.  The ADDQoL has important advantages over generic questionnaires as it 
allows patients to indicate which aspects of life apply to them; the perceived importance of 
each aspect of life on their QoL and whether the impact of diabetes on that aspect of life is 
positive or negative.  The selection of the ADDQoL domains was based on past research 
experience and derived from discussions with healthcare professionals in the field.  In 
addition, on a routine diabetes clinic, 12 in-depth face-to-face interviews were conducted 
where the interviewer elicited domains of importance for the interviewee’s QoL which were 
most affected by diabetes (Bradley and Speight 2002). 
The ADDQoL-19 consists of two overview items designed for audit purposes: a generic 
domain “present QoL” and a diabetes-specific domain “impact of diabetes on QoL”.  Further 
19 domains or questions are concerned with the impact of diabetes on specific life aspects.  
The 19 life domains are as follows: leisure activities, working life, local or long-distance 
journeys, holidays, physical health, family life, friendships and social life, close personal 
relationships, sex life, physical appearance, self-confidence, motivation to achieve things, 
people’s reactions, feelings about the future, financial situation, living conditions, dependence 
on others, freedom to eat, and freedom to drink.  The 19 questions ask respondents to rate 
how their life would be if they did not have diabetes.  For all applicable domains, the 
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respondents have to rate the impact of diabetes on the life aspect and the importance of that 
life aspect on their QoL.  For each domain, a weighted impact score is calculated and lower 
scores reflect a poorer QoL.  Lastly, a total ADDQoL-19 score is the mean of all the weighted 
impact scores of all applicable domains (Bradley et al. 1999; Bradley and Speight 2002; 
Costa et al. 2006). 
The ADDQoL has proven to be an acceptable, valid and reliable measure with good internal 
consistency (El Achhab et al. 2008).  The ADDQoL has proven sensitive to the benefits of 
switching from a traditional insulin regime to flexible, intensive insulin therapy (Group 
2002).  Whereas generic measures used to quantify health status may be strongly affected by 
non-diabetic co-morbidity in patients with diabetes, ADDQoL scores remain unaffected by 
co-morbidity.  They are affected by diabetes-related complications (Bradley et al. 1999; 
Woodcock et al. 2001) but not by unrelated conditions (Woodcock et al. 2001).  A 
longitudinal study utilised the ADDQoL-19 along with other generic (W-BQ12) and 
diabetes-treatment satisfaction measures to assess the effects of intensive diabetes treatment 
versus routine care in patients with T2DM (Van den Donk et al. 2013).  The authors reported 
no differences in health status, well-being and treatment satisfaction between the two 
treatment regimes.  Another previous study utilised the ADDQoL-19 to evaluate the QoL in 
patients with T2DM (aged ≥65 years) (Turk et al. 2013).  The authors reported that poorer 
QoL was significantly associated with heart attack episodes and to the perception of not 
having diabetes under control.  The findings of their study did highlight the impact of T2DM 
on QoL with particular reference placed on the freedom to eat, family life and dependence on 
others (Turk et al. 2013). 
The ADDQoL has received certain criticisms for its complex structure which focuses on a 
hypothetical situation that patients with diabetes may or may not be able to imagine, i.e. ‘if I 
did not have diabetes, my (domain) would be… (“very much better” to “very much worse”)’.  
In 2006, the Food and Drug Administration guidance draft on the utilization of patient-
reported outcome measures in clinical trials stated that it does not recommended the use of 
‘items that ask patients to respond hypothetically or that give the patients the opportunity to 
respond on the basis of their desired condition rather than on their actual condition’, due to 
the unreliability of self-reported data based on hypothetical situations (FDA 2006).  
Furthermore, despite the development of the ADDQoL Senior (Speight et al. 2003), it is 
possible that elderly patients or those with lower literacy levels may find the ADDQoL a 
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difficult task to complete due to its complex structure.  Additionally, critics have questioned 
the requirement for weighting of items according to personal importance, suggesting that 
such weightings have little consequence on the overall scores.  However, taking into account 
that an individual’s preferences and priorities are cardinal to understanding their distinctive 
QoL, the ADDQoL has better face or content validity compared to many other measures used 
to assess QoL in patients with diabetes (Speight et al. 2009). 
1.4.4 Impact of periodontal status and treatment on QoL in patients with diabetes 
Knowing that patients with diabetes have a higher prevalence and severity of periodontal 
disease compared to non-diabetics, it is of importance to evaluate the impact of periodontal 
disease on QoL in patients with diabetes (Albandar 2002).  Both periodontitis (Needleman et 
al. 2004; O'Dowd et al. 2010) and diabetes (Goldney et al. 2004; Wandell 2005) have been 
found to have negative impacts on QoL.  Patients with diabetes are known to have limited 
awareness of the potential effect of diabetes on their oral health, and of the potential effects 
that periodontal disease has on their general health (Bissett et al. 2013).  Hence, there is a 
need to ensure that diabetic patients are better informed of their risk for acquiring periodontal 
disease and the negative impact it can have on their oral and general health and overall well-
being (Allen et al. 2008). 
A majority of studies to date have focused on the impact periodontal disease has on the QoL 
in patients without diabetes.  Only a few QoL studies have focused on the impact that 
diabetes and periodontal disease together have on an individual’s QoL.  One such study 
identified that T2DM patients have a significant impact on their OHRQoL in the domains of 
general health, social functioning, physical functioning and role functioning when compared 
to non-diabetic patients (Sandberg and Wikblad 2003).   A previous study evaluated the 
impact of periodontal disease on QoL in patients with diabetes (n=159) utilizing the OHIP-14 
(Drumond-Santana et al. 2007).  The patients completed the OHIP-14 prior to clinical 
examination (PD, CAL and BOP) to evaluate how their oral health interfered with their QoL 
in the past year.  The clinical examination revealed that 15.7% of patients had healthy tissues, 
35.2% had gingivitis and 49.1%, 27.7% and 21.4% had mild, moderate and advanced 
periodontitis, respectively.  A significant association was seen between QoL and severity of 
periodontal disease, and PD, CAL ≥4 mm and BOP were associated with poorer QoL.  The 
authors concluded that diabetic patients with periodontitis had a greater negative impact on 
QoL in comparison to those with healthy tissues and gingivitis (Drumond-Santana et al. 
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2007).  Allen et al. assessed the attitudes and awareness of the risk for periodontal disease 
and OHRQoL in patients with T1DM (n=27) and T2DM  (n=74) (Allen et al. 2008).  The 
authors found that only 33% of the patients were aware of their increased risk for periodontal 
disease (40% of T1DM).  Only 43% had attended a dentist within the past year, while 34% 
had not attended a dentist for more than 5 years. 37% of the patients attended the dentist for 
treatment once a year, while 63% attended only when they had dental problems.  Assessment 
of the OHIP-20 revealed that 66% of the patients had problems related to food lodgment 
between their teeth and under their dentures, and 43% reported an unsatisfactory diet due to 
problems with their teeth.  Unfortunately, their study did not include a control group, hence 
no comparisons were made to OHRQoL in non-diabetic patients (Allen et al. 2008). 
A recent study by Irani et al. investigated the impact of periodontal status and treatment on 
OHRQoL in patients with (n=61) and without T2DM (n=74)  using the OHIP-49 (Irani et al. 
2015).  The authors reported no significant differences in the overall OHIP-49 summary score 
between patients with and without T2DM, suggesting that T2DM had no impact on the 
overall OHRQoL.  However, within the non-diabetic group patients with chronic 
periodontitis and gingivitis had poorer OHRQoL compared to those with periodontal health 
with evidence of improvements in QoL being noted, with significant reductions in the 
psychological discomfort and psychological disability domains of OHIP-49, following 
periodontal treatment (Irani et al. 2015).  The authors reported that the lack of significant 
differences in OHIP-49 scores among T2DM patients with periodontitis, gingivitis and 
healthy tissues could possibly indicate that patients with diabetes are less concerned about 
their oral health than they are about other health problems that they have to manage as part of 
their diabetes.  Potentially, systemically healthy patients who have chronic periodontitis 
might be more concerned about the signs and symptoms of periodontal disease compared to 
patients with diabetes, who need to address other pressing health issues, which might lead to 
lower expectation of oral health or better coping with the impact of periodontitis (Irani et al. 
2015).  Drumond-Santana et al.’s, Allen et al.’s and Irani et al.’s studies utilized versions of 
the OHIP questionnaire, to assess OHRQoL in patients with diabetes and periodontal disease.  
The OHIP has been used for many years to assess the impact of oral conditions on OHRQoL 
particularly in context to prosthodontic patients, however its use in patients with periodontal 
disease and its ability to detect a meaningful change following periodontal treatment has yet 
to be established (Irani et al. 2015).  The OHIP is useful in measuring OHRQoL, however the 
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OHIP contains no diabetes-specific questions hence might not to the full extent assess 
HRQoL in patients with diabetes. 
Given the important interactions between periodontal disease and diabetes, it is good practice 
to ensure optimal oral health care for patients with diabetes.  Investigations have shown an 
improvement in clinical periodontal status following NSM, based on clinical periodontal 
parameters.  Findings related to patient-based outcomes of periodontal disease are limited, 
especially in relation to other comorbidities of systemic disease, such as T1DM.  Considering 
that QoL measures are being increasingly used to give context to patient-centred outcomes of 
disease and treatment, it is important to explore the impact of periodontal status and treatment 




1. To study the presentation of periodontal disease and caries in a local population of 
young adults with T1DM. 
2. To investigate associations between glycaemic control and periodontal and oral 
health. 
3. To evaluate the effect of periodontal treatment on glycaemic control in T1DM 
patients with periodontitis. 
4. To study the local and systemic production of biomarkers and the initial response to 
therapy by monitoring markers of inflammation before and after periodontal 
treatment. 

























2 Chapter 2. Materials and methods 
2.1 Ethical approval  
For this research study, ethical approval was obtained from the Sunderland NHS Research 
Ethics Committee (ref 06/Q0904/16).  The application to the ethics committee included a 
protocol for the study, which highlighted the possible ethical issues pertaining to the study. 
The main ethical issues were related to the collection of samples for analysis (GCF and 
blood).  The samples were collected purely for research purposes and would otherwise not be 
collected.  The purpose and reason for collecting samples was made clear to the prospective 
participants in the information sheet.  The collection of GCF was non-invasive, painless and 
quick, however, the collection of blood samples had a possibility of being associated with 
some discomfort and there could have been a potential for unwanted events (e.g. bruising).  
To minimise the risks associated with venepuncture, trained and experienced clinicians were 
asked to obtain the blood samples. 
The periodontal examination and treatment provided as part of the study, constituted routine 
clinical care.  A possible benefit of this study was that the T1DM patients received oral and 
periodontal examinations and if they were found to have periodontal disease, treatment was 
offered to them, as part of the study.  All participants in the study were also given 
information and instructions on how to better maintain their oral health.  All data recorded 
and samples collected were stored securely and anonymously, using a coding system.  The 
information that was generated as part of this research study did not have an impact on the 
patient’s clinical care and treatment other than that relating to any required periodontal 
clinical management. 
2.2 Patient recruitment and discharge  
T1DM patients were recruited from databases held by Dr. Jolanta Weaver at the Queen 
Elizabeth Hospital in Gateshead and Professor Roy Taylor at the Newcastle Diabetes Centre.  
Some of these patients had periodontal disease, and others, were periodontally healthy.  
Patients on this database were evaluated regularly by Dr. Weaver, Professor Taylor and their 
teams.  The identified patients were then sent a letter informing them about the research study 
and inviting them to participate on an ‘opt-in’ basis.  If the patients then contacted the 
research team to indicate their interest in participating in the study, a short telephone 
screening was carried out to make sure they fitted within the inclusion and exclusion criteria.  
Following this, the patients were sent a detailed information sheet giving them information 
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about the arrangements for them to attend the dental hospital for a pre-treatment screening 
appointment. 
Recruitment of the non-T1DM patients involved the identification of suitable patients who 
met the inclusion and exclusion criteria and were either those referred from general dental 
practices to the Department of Restorative dentistry within the Newcastle Dental Hospital or 
were patients seen on student treatment clinics in the School of Dental Sciences.  Each non-
T1DM patient was matched to a previously recruited T1DM patient.  Patients were matched 
based on age (within 5 years), gender, smoking status and periodontal diagnosis.  Suitable 
non-T1DM patients were approached during their appointment at the dental hospital, 
informed about the study and what their potential participation in it would involve, and were 
given the opportunity to decide whether they wanted to participate. 
Recruited patients fulfilled the following inclusion criteria: 16-50 years old, male or female, 
with a minimum of 20 natural teeth.  The exclusion criteria included: pregnancy, any 
condition requiring prophylactic antibiotics prior to dental treatment, immunosuppression, 
bleeding disorders, and prolonged bleeding due to medication, drug-induced gingival 
overgrowth, any medical condition that could compromise safe participation in the study, or 
any patient who had undergone NSM in the past 6 weeks. 
At the screening appointment, patients who were diagnosed with periodontitis were offered 
the necessary treatment and were then monitored as part of the longitudinal component of the 
study. The patient’s general medical practitioner and general dental practitioner (GDP) were 
informed via a letter, of the patient’s involvement in the study.  Following completion of the 
study, the patients were discharged back to their GDP with a written discharge letter 
containing details of the periodontal maintenance plan for the GDP to follow.  For patients 
without periodontitis (those with healthy periodontal tissues and gingivitis), their 
participation in the study was limited to the screening appointment only.  These patients were 
given oral hygiene advice and dental prophylaxis at the screening appointment.  If the clinical 
examination revealed any other oral or dental problems, such as caries, appropriate 
management was arranged either with their GDP or in the dental hospital, for patients who 




At the start of the pre-treatment screening appointment, written informed consent was 
obtained from all patients.  This involved a clinician confirming that the patient had 
understood the written information leaflet they had received about the study.  Following this, 
the clinician verbally confirmed the background and aims of the study, and explained the 
potential benefits and risks that their participation in the study involved.  Every patient was 
given the opportunity to ask questions and a choice to opt out of participating in the study.  
Patients who wished to participate in the study were then asked to sign two copies of the 
consent form, one of which was retained in the patients’ hospital notes and the other copy 
was given to the patient to keep. 
2.4 Power calculation and estimation of sample size 
It was difficult to provide a definitive power calculation at the planning stage of the study due 
to the paucity of research studies that have investigated this area of research previously.  
Using data from a study of patients with T2DM (Kiran et al. 2005) it was estimated that 17-
20 patients would be required to provide an 85% power for detecting significant changes in 
HbA1c over 6 months, assuming α=0.05, δ=0.7% and σ=0.9%.  However, in order to identify 
these patients, and assuming a prevalence rate of periodontitis of 10% in this young cohort, 
then approximately 200 patients would be required for baseline assessment.  Of these, it was 
anticipated that approximately half would require further treatment for gingivitis, and 
approximately 10% (up to 20) would need treatment for periodontitis.  Those patients who 
received treatment would be those diagnosed with periodontitis.  These patients would be 
monitored longitudinally for 6 months following periodontal treatment, with assessments 
carried out by the research team at months 3 and 6. 
2.5 Periodontal disease case definition 
At the pre-treatment screening appointment, all patients received a full-mouth periodontal 
examination, which included recording PI, mGI, PD measurements, recession, LOA and BOP 
at 6 sites per tooth.  Clinically indicated radiographs were obtained, following which, clinical 
and radiographic data were used to confirm the periodontal diagnosis based on the diagnostic 
criteria (Table 2.1).  Robust case definitions for periodontal status were used to avoid the 




Table 2.1: Case definitions for healthy periodontal tissues, gingivitis and periodontitis. 
 
2.6 Clinical protocol 
2.6.1 Plaque index 
The Silness and Loe (Silness and Loe 1964) PI was used to assess the amount of plaque 
present on the surfaces of teeth, as follows: 
0 No plaque 
1 A film of plaque adhering to the free gingival margin and the adjacent area of the 
tooth.  The plaque may be seen in situ only after application of disclosing solution 
or by probing the tooth surface. 
2 Moderate accumulation of soft deposits within the gingival pocket, or on the tooth 
and gingival margin which can be seen with the naked eye. 
3 Abundance of soft matter within the gingival pocket and/or on the tooth and 
gingival margin.  
In order to record the PI score, the tooth was dried with a gentle stream of air and no 
disclosing solution was used.  Plaque scores of ‘2’ or ‘3’ were easily identified with visual 
examination.  If no plaque was seen with direct unaided visual examination, the probe was 
Periodontal diagnostic criteria 
Healthy periodontal 
tissues 
 BOP ≤15 %. 
 No PD sites >4 mm. 
 No LOA [disregard localised recession (e.g. due to tooth brush 
trauma)]. 
 No bone loss. 
Gingivitis  BOP >15 %. 
 No sites with PD >4 mm, except for up to 5 sites with 5 mm PD 
(e.g. at the distal surface of last standing molars). 
 No LOA [disregard localised recession (e.g. due to tooth brush 
trauma)]. 
Periodontitis  ≥6 sites with PD of ≥5 mm at separate teeth. 
 LOA and/or bone loss present. 
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swept along the gingival margin to be able to differentiate between a score of ‘1’ (if plaque 
was present at the probe tip) or a score of  ‘0’ (if plaque was absent at the probe tip).  The 
plaque score was recorded on 6 sites per tooth and four target teeth were selected; from these 
selected teeth GCF samples were also taken (section 2.8).  The PI scores were immediately 
recorded by an assistant. 
2.6.2 Modified gingival index 
The degree of gingival inflammation present was assessed using the mGI (Lobene et al. 
1986) as follows: 
0 No inflammation 
1 Mild inflammation; slight change in colour, little change in texture of any 
portion, but not the entire gingival margin or papillary unit. 
2 Mild inflammation; criteria as above but involving the entire gingival margin 
or papillary unit. 
3 Moderate inflammation; glazing, redness, oedema and/or hypertrophy of the 
gingival margin or papillary unit. 
4 Severe inflammation; marked redness, oedema and/or hypertrophy of the 
gingival margin or papillary unit with spontaneous bleeding, congestion or 
ulceration. 
In order to record the mGI score, the gingival tissues were dried with a gentle stream of air.  
A visual examination was carried out to allocate a score at 6 sites per tooth.  A score of ‘0’ 
was assigned if no gingival inflammation was present and a score of ‘4’ was assigned if the 
gingival tissues were severely inflamed and there was evidence of marked swelling or 
redness, spontaneous bleeding and/or ulceration.  A score of ‘1’ was assigned if only part of 
the gingival tissue was inflamed.  A score of ‘2’ and ‘3’ was assigned if mild or moderate 
gingival inflammation, respectively, had affected the entire gingival margin or papillary unit. 
2.6.3 Probing depth 
PD measurement was carried out using a University of North Carolina (UNC) 15 manual 
periodontal probe (Dentsply, Addlestone, UK) and was recorded as the distance from the 
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gingival margin to the base of the gingival sulcus or pocket.  The periodontal probe was 
inserted into the gingival sulcus and advanced apically, along the long axis of the tooth, until 
resistance of the tissue was felt at the base of the gingival sulcus or pocket.  The PD 
measurements were recorded in millimetres (mm) by direct visualisation of the markings on 
the probe.  PDs were recorded for all teeth present excluding the 3
rd
 molars, and 
measurements were taken at 6 sites per tooth. 
2.6.4 Bleeding on probing 
The BOP scores were recorded immediately following PD measurements within one aspect 
of a quadrant (for example, the buccal aspect of the upper right quadrant).  The probing sites 
were re-examined by visual examination to determine post-probing bleeding.  Bleeding status 
was recorded as the presence or absence of bleeding from the pocket base following probing 
and was determined dichotomously at 6 sites per tooth. 
2.6.5 Recession 
Recession was measured using the UNC 15 probe and was taken as the distance from the 
cementoenamel junction (CEJ) to the gingival margin.  The measurement was recorded 
whilst the probe was inserted into the gingival sulcus during PD measurement.  When the 
CEJ was located above the gingival margin, recession was recorded by direct visualisation of 
the probe markings.  When the CEJ was located below the gingival margin (e.g. in the case of 
false pocketing), the clinician estimated the position of the CEJ in relation to the gingival 
margin and a negative recording in mm was made.  Recession was recorded for all teeth 
present excluding the 3
rd
 molars, and measurements were taken at 6 sites per tooth. 
2.6.6 Loss of attachment 
The LOA measurement was the sum of the PD and recession, and therefore is, the distance 
from the CEJ to the base of the gingival sulcus or pocket.  LOA was calculated for all teeth 
present excluding the 3
rd
 molars. 
2.6.7 Smoking status 
Smoking habits self-reported of each patient were assessed at the pre-treatment screening 
visit and at month 6, according to whether the patients were current, non-, or ex-smokers.  
The smoking extent of the current and ex-smokers were further quantified according to the 
standardised measure of pack years, which equates the number of cigarettes (packs per day) 
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smoked by each patient by the number of years smoked.  A pack year equates to smoking 1 
pack of 20 cigarettes per day for 1 year. 
2.6.8 Demographic data 
At the pre-treatment screening appointment, demographic data were recorded which included 
age and gender. 
2.6.9 Diabetes history  
Diabetes history was recorded for all T1DM patients at the pre-treatment screening visit.  
Recorded data included years since diagnosis, age at diagnosis, family history of diabetes, 
method of diabetes control, patient-perceived level of glycaemic control in the past one year 
(good/moderate/poor), presence of macrovascular and microvascular diabetes complications 
and current medications. 
2.6.10 Physical examination 
The physical examination involved taking the patient’s blood pressure (BP), height and 
weight.  The BP was recorded using the patient’s right upper arm, with them being seated and 
using an automated BP machine.  Height and weight were recorded in order to calculate the 
body mass index (BMI) by dividing the weight [in kilograms (kg)] by the square of the height 
[in metres (m)]. 
2.6.11 Oral examination 
The oral examination comprised examination of soft tissues to identify any lesions, or 
problems such as xerostomia or oral candidiasis.  The number of teeth present and missing, 
and denture-use was also recorded.  The dentition was then assessed using pre-defined dental 
examination criteria (Kelly et al. 2000), recording the number of teeth for each category as 









Diagnostic criteria for hard tissue examination 
Sound and untreated teeth  No evidence of caries into dentine or restorations. 
 Including caries restricted to enamel. 
Restored teeth 
(1 to 3 surfaces) 
 Amalgam, composite, glass ionomer cement (GIC), 
fissure sealants, onlays, inlays and ¾ crowns – up to and 
including 3 surfaces. 
 Including veneers, shims and adhesive retainers for resin 
retained bridges. 
Extensively restored teeth 
(4 or more surfaces) 
 Amalgam, composite, GIC, onlays or inlays - 4 or more 
surfaces. 
 Temporary or permanent crowns, including full-coverage 
crowns and conventional bridge abutments. 
Carious teeth  Visual examination - manifests as showing under an 
occlusal surface or marginal ridge. 
 Cavitated – but without pulpal involvement.  
 Temporary dressing placed for treatment of caries.  
Broken down or teeth with 
pulpal involvement 
  Teeth so broken down that it is inconceivable that there 
is no pulpal involvement. 
Table 2.2: The dentition was examined and assessed against these pre-defined 
examination criteria (Kelly et al. 2000).
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2.6.12 Oral health behaviour 
At the pre-treatment screening appointment, patients were asked closed questions regarding 
their oral health behaviour which included questions regarding their frequency of tooth 
brushing, interproximal cleaning, as well as the timing and reason for their last dental visit to 
their GDP. 
2.6.13 Non-surgical periodontal management and follow-up 
Following the pre-treatment screening appointment, patients diagnosed with periodontitis 
received comprehensive targeted NSM.  The treatment day was the baseline time point, and 
was within 2 months of the screening appointment.  The baseline treatment constituted giving 
personalised oral hygiene instructions (OHI) and using a full-mouth instrumentation approach 
(Quirynen et al. 2000) to disrupt and remove biofilm and calculus.  A combination of hand 
instrumentation, using Gracey curettes and flexichange scalers (Dentsply, Addlestone, UK), 
and ultrasonic instrumentation, using a Cavitron Select machine (Dentsply, Addlestone, UK), 
were used to perform full-mouth instrumentation.  Simultaneously, periodontal pockets were 
irrigated with 0.2% chlorhexidine gluconate (Kent express, Kent, UK).  Effective tooth 
brushing and interproximal cleaning techniques were demonstrated to the patients. 
Following the baseline treatment appointment, the patients were seen at week 3 and week 6 
for OHI and further prophylaxis to disrupt reforming plaque biofilm deposits.  A periodontal 
examination was then carried out at month 3 and 6 after the initial instrumentation to assess 
periodontal healing after treatment.  Additional periodontal treatment in order to eliminate 
inflammation was undertaken at months 3 and 6, as clinically indicated (Table 2.3).  Pre-
treatment screening was undertaken on all patients, however, only those patients diagnosed 
with periodontitis proceeded beyond the screening appointment.  Patients diagnosed with 
gingivitis received OHI and full-mouth instrumentation and prophylaxis, as required at the 
screening appointment.  For patients with gingivitis and healthy periodontal tissues, their 
participation in the study was limited to the screening appointment itself and they were not 
followed-up further after this appointment.
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Table 2.3: An overview of the protocol followed highlighting the procedures undertaken at 
each time point in the study. 
GCF; gingival crevicular fluid, PI; plaque index, mGI; modified gingival index, PD; probing 
depth, LOA; loss of attachment, BOP; bleeding on probing, HbA1c; glycated haemoglobin, 
hsCRP; high-sensitivity C-reactive protein, OHI; oral hygiene instructions, FMI; full-mouth 














Informed consent         
Demographic data         
Medical history          
Diabetes history 
#
         
Smoking status         
Physical exam          
Oral health history         
Oral examination             
GCF samples           
Periodontal 
examination 
PI          
mGI          
PD          
Recession          
LOA          
BOP          
Blood samples HbA1c          
hsCRP          
Lipids          
Initial periodontal 
therapy 
OHI & FMI         
Prophylaxis            
Additional 
periodontal therapy 
As required         
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2.6.14 Data collection and storage 
All patients were allocated an identification number and each of them had a case report form 
(CRF) in which all data were recorded at the time of examination by the clinician or an 
assistant.  The results from the clinical biochemistry laboratory were also recorded in the 
patient’s CRF.  Subsequently, data were entered into a statistical software package. 
2.7 Statistical analysis 
Statistical analyses of the data were conducted using statistical software IBM SPSS Statistics, 
version 22.  Firstly, all variables to be tested were assessed for normality using the Shapiro 
Wilk test, supplemented with histograms.  For normal or parametric variables, means and 
standard deviations were calculated.  Where normality was rejected, for non-parametric 
variables, medians and interquartile ranges were calculated.  Chi-squared tests were used to 
analyse discrete variables.  The significance of all tests was assessed at the 5% level. 
Cross-sectional pre-treatment data were analysed, based on diabetes status using independent 
samples t-tests or Mann-Whitney tests for parametric or non-parametric variables, 
respectively.  Following this, cross-sectional data were analysed, based on diabetes status and 
periodontal diagnosis, with one-way analysis of variance (ANOVA) or the Kruskal Wallis 
test for parametric and non-parametric variables, respectively.  For post hoc analysis, 
independent samples t-tests or Mann-Whitney tests were used for parametric and non-
parametric data, respectively.  A P-value of <0.05 was considered significant.  For multiple 
comparisons, the p-values were corrected using the Bonferroni-Holm test.  The associations 
between clinical data and biomarker levels were assessed using Pearson’s correlation 
coefficient (r), if both variables were normally distributed, or using Spearman’s correlation 
coefficient (rho) if both variables were not normally distributed. Scatter diagrams were also 
constructed to illustrate associations. 
Longitudinal parametric data were analysed with repeated measures ANOVA and paired 
samples t-tests for post hoc analyses.  Longitudinal non-parametric data were analysed with 
the Friedman test, with the Wilcoxon Mann-Whitney test applied for post hoc analyses.  A P-
value of <0.05 was considered significant.  For multiple comparisons, the p-values were 
corrected using the Bonferroni-Holm test.  At each time point (pre-treatment, months 3 and 
6), for patients diagnosed with periodontitis only, cross-sectional data were analysed using 
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independent samples t-tests or Mann-Whitney tests for parametric and non-parametric data, 
respectively. 
2.8 Sampling, elution and storage of GCF 
GCF was collected with Periopaper strips (Oraflow Inc, New York) and the volume was 
quantified using a calibrated Periotron 6000 (Preshaw et al. 1996).  According to the 
manufacturer’s instructions, prior to its use, the Periotron was allowed to ‘warm up’ and then 
zeroed with a blank (dry) Periopaper.  The dial was adjusted until the digital display indicated 
a zero reading. 
To minimise sample contamination by blood, GCF was collected prior to probing the 
periodontal pockets.  At the pre-treatment screening appointment, 4 GCF samples were 
collected from each patient, from the mesio-buccal aspect of the four 1
st
 molars.  If the 1
st
 
molar was absent in any quadrant, the sample was collect from the 2
nd





 premolar, and canine or incisor teeth (the sampled teeth were designated target 
teeth).  The area was isolated using cotton rolls and a saliva ejector, and the teeth were dried 
with a gentle stream of air.  If supragingival plaque was present prior to sampling, it was 
carefully and gently removed with a curette.  A Periopaper was carefully placed into the 
gingival sulcus until mild resistance was felt and was held in position for 30 seconds. 
The Periopaper was immediately transferred to the jaws of the Periotron to minimise 
evaporation errors.  Care was taken to ensure that the Periopaper was in the exact 
standardised position between the jaws, with the black line on the paper positioned at the 
outer rim of the jaw plate.  After “mode II” illuminated on the Periotron display, the GCF 
volume (in Periotron units) was recorded by the assistant.  The Periopaper was then placed 
into a 0.5 ml sterile plastic microtube (Sarstedt, Leicester, UK) containing 150 µl autoclaved 
and filtered phosphate buffered saline (PBS).  Each sample was stored in a separate 
microtube and each microtube was labelled with the patient’s study number, tooth number 
and the date.  Between samples, the jaws of the Periotron were cleaned with an alcohol swab 
and allowed to dry.  At the chairside, the GCF samples were kept on ice and transferred 
within 20 minutes of sampling, to the laboratory and were frozen at -80°C (Cutler et al. 1999) 
to await subsequent elution and analysis.  The same procedure was followed to collect GCF 
samples at months 3 and 6 from the same 4 sites in patients diagnosed with periodontitis, who 
were entered into the longitudinal phase of the study. 
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For the elution of the GCF from the Periopapers, the samples were thawed on ice for 15 
minutes following which, 50 µl of 1% bovine serum albumin (BSA) in PBS (w/v) was added. 
The GCF samples were then centrifuged (Sigma 3K10 centrifuge) for 60 minutes at 300 rpm, 
at 4 °C, following which a second centrifuge step was carried out at 1200 rpm for 2 minutes, 
at 4 °C.  Lastly, the Periopapers were removed with college tweezers (with the ends of the 
tweezers being rinsed with PBS between samples) and the eluted GCF samples were frozen 
again at -80°C, until further analyses. 
Prior to analysis, the stored GCF samples were thawed on the benchtop and the 4 GCF 
samples collected from each patient, were pooled into a single microtube and these pooled 
GCF samples were further analysed by ELISA (section 2.15). 
2.9 Collection of venous blood samples 
A tourniquet was applied to the patient’s arm 8 cm above the antecubital fossa or the hand, 
and the veins were allowed to engorge with blood.  Venous access was achieved using a 21 
gauge and 1.5 inch Vacutainer needle (NHS Supply Chain, Derbyshire, UK) and a needle 
holder for 16 mm diameter tubes (NHS Supply Chain, Derbyshire, UK).  The venous blood 
sample was taken to fill the following three Vacutainer plastic tubes (BD, Oxford, UK): 3 ml 
ethylenediaminetetraacetic acid (EDTA) tube (lavender top), 5 ml serum separation tube 
(gold top) and 9 ml serum separation tube (gold top).  Once the blood samples were collected, 
the tourniquet was loosened, the needle was removed and pressure was applied with a cotton 
wool to the sample site until haemostasis was achieved.  All blood samples in the Vacutainer 
tubes were slowly inverted at least five times and then left to stand upright for 30 minutes 
prior to transferring them to the appropriate laboratory for analysis. 
2.10 Clinical biochemistry analysis 
The 3 ml EDTA (lavender top) and 5 ml serum separation (gold top) tubes were labelled with 
adhesive labels from the patient’s hospital notes and were sent to the Clinical Biochemistry 
Department of the Newcastle upon Tyne Hospitals NHS Foundation Trust Royal Victoria 
Infirmary for analysing the level of HbA1c, hsCRP, triglycerides, cholesterol, high density 
lipoprotein (HDL) and non-high density lipoprotein (non-HDL) for each patient.  The 




2.11 Serum separation and storage 
The 9 ml serum separation tube (gold top) was kept on ice at chair side and transferred, 
within 2 hours, to the laboratory.  The sample was then centrifuged at 1500 x g for 15 
minutes at 4 °C to separate the serum at the top of the tube via the formation of a polymer 
barrier.  The serum was aliquoted into six 0.5 ml microtubes using a Pasteur pipette.  The 
microtubes were labelled with the patient number and date, and were frozen at -80 °C for 
further analyses. 
2.12 Calculating GCF volume 
In order to calculate GCF volume, firstly, a quadratic equation was generated as part of the 
calibration of the Periotron 6000 (Preshaw et al. 1996) which was undertaken every 12 weeks 
during the study.  Software package Excel was used to solve the quadratic equation to 
calculate GCF volume from the Periotron units. 
2.13 Quantification of protein 
The serum and GCF samples were collected from 2006 to 2008 and were stored in the -80 °C 
freezer until analysis.  Given the long period of storage (albeit at -80 °C), a concern was that 
protein levels may have reduced due to sample degradation.  In order to determine the 
amount of protein present, the samples were tested following the Bradford method for protein 
quantification.  An assay which was originally described by Bradford (Bradford 1976) has 
become the preferred method for quantifying protein in samples in many laboratories.  The 
Bradford assay is based on the binding of the dye Coomassie Blue G520 to protein present in 
sample.  Following this the quantity of protein can be estimated by measuring the absorbance 
of the solution at 595 nm. 
The assay procedure was carried out on all baseline serum samples using a sterile, flat bottom 
96-well cell culture plate (Cellstar, Greiner Bio-One, Germany).  The first step involved 
diluting 0.4 g of BSA powder (Sigma, Poole, UK) in 2 ml of distilled water.  This dilution 
resulted in a protein solution of concentration 200 mg/ml (tube A).  The 200 mg/ml solution 
was then further diluted by taking 200 µl from tube A and diluting it into 1800 µl of distilled 
water, which resulted in a solution of protein concentration of 20 mg/ml (tube B).  Following 




Table 2.4: Standard curve protocol for the Bradford assay. 
BSA; bovine serum albumin. 
 
Figure 2.1 The Bradford assay standard curve. 
X-axis represents the absorbance of protein at 595 nm and Y-axis represents the quantity of 
protein in µg/ml.
µg/ml Standard / tube mg/ml Procedure 
 A 200 0.4 g BSA in 2 ml distilled water 
20000 B 20 200 µl of 200 mg/ml (tube A) + 1800 µl distilled water 
4000 1  200 µl of 20 mg/ml + 800 µl distilled water  
3500 2  175 µl of 20 mg/ml + 825 µl distilled water 
3000 3  750 µl of tube 1 + 250 µl distilled water 
2500 4  125 µl of 20 mg/ml (tube B) + 875 µl distilled water 
2000 5 2 200 µl of 20 mg/ml + 1800 µl distilled water 
1500 6  750 µl of tube 5 + 250 µl distilled water 
1000 7  500 µl of tube 5 + 500 µl distilled water 
750 8  300 µl of tube 7 + 100 µl distilled water 
500 9  300 µl of tube 7 + 300 µl distilled water 
250 10  300 µl of tube 9 + 300 µl distilled water 
125 11  200 µl of tube 10 + 200 µl distilled water 
25 12  100 µl of tube 10 + 900 µl distilled water 
0 13  Only distilled water 
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Following the preparation of standards, the serum samples were diluted in a ratio of 1:300, in 
distilled water.  Following this, 10 µl of each standard and diluted serum sample was pipetted 
in triplicate in a 96-well multidish.  Additionally, 150 µl of Bradford assay reagent (Pierce, 
Thermo Scientific) was added to each well of the 96-well multidish.  The multidish was 
incubated for 5 minutes at room temperature, following which the absorbance was measured 
at 595 nm using a plate reader (Synergy HT, BioTek, USA) following the Bradford protocol.  
Prior to reading, it was made sure that there were no air bubbles to avoid reading errors.  The 
Bradford protocol subtracts the water blank from all the standards and samples, it then uses 
the mean absorbance values for the standards to generate a standard curve (Figure 2.1). 
2.14 Cytokine array analysis 
The Proteome Profiler Human XL Cytokine Array Kit (R&D Systems) was used to determine 
the multiple cytokines present in the serum samples collected for the study.  The cytokine 
array is a membrane-based sandwich immunoassay and has the ability to detect 102 human 
cytokines simultaneously.  The cytokine array capture and control antibodies are spotted in 
duplicate on a nitrocellulose membrane, and bind to specific target antibodies present in the 
sample.  The array is capable of determining cytokines present in cell lysates, cell culture 
supernatants, plasma, serum, human milk, saliva, and urine or tissue lysates.  The samples are 
diluted and added to a multidish containing the nitrocellulose membranes and are incubated 
overnight at 2-8 °C.  Following this, the captured proteins are detected with biotinylated 
detection antibodies and are then visualised using chemiluminescent detection reagents.  The 
amount of analyte bound to the membrane is proportional to the signal produced on a 
radiograph. 
The nitrocellulose membranes were placed in separate wells of a multidish (number of the 
membrane facing upwards) and blocked with Array Buffer 6.  The multidish was incubated 
for 1 hour at room temperature on a 3D rocking platform shaker (STR9 Stuart Scientific, 
UK).  While the membranes were blocking, the serum samples were diluted in Array Buffer 
6.  After 1 hour, the Array Buffer 6 was aspirated from the wells of the multidish and the 
diluted serum samples were added to the membranes and incubated overnight at 2-8 °C, on a 
rocking platform shaker.  The next day, the membranes were placed in separate petri dishes 
(Cellstar, Greiner Bio-One, Germany) and washed with 20 ml wash buffer solution for 10 
minutes, and this was repeated twice for a total of three washes.  Following this, 1.5 ml of 
Detection Antibody cocktail diluted in Array Buffer 4/6 was added to the multidish 
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containing the membranes and incubated for 1 hour at room temperature, on a rocking 
platform shaker.  The wash step was repeated.  Following the washing step, 2 ml of 
Streptavidin-HRP was added on to each membrane and incubated for 30 minutes at room 
temperature, on a rocking platform shaker.  The wash step was repeated.  Following the 
washing step, the membranes were removed from the petri dish and placed on a transparent 
plastic sheet and 1 ml of Chemi Reagent Mix was pipetted evenly over each membrane.  The 
bottom plastic sheet was covered with a similar top sheet for 1 minute.  Excess Chemi 
Reagent Mix was gently removed and the membranes within the sheet were placed inside a 
radiographic cassette for exposure. 
The radiograph (Kodak, USA) of the membranes was scanned and the intensity of the 
membrane spots were analysed.  Each cytokine binds to their specific spot on the membrane.  
The intensity of each spot was quantified using computer software GeneTools, Syngene and 
graphs were plotted to compare intensities of the detected cytokines. 
2.15 Enzyme-linked immunosorbent assay 
To measure MMP-9, B-cell activating factor (BAFF), resistin and ENA-78/CXCL5 levels in 
serum samples and MMP-9 and IL-8 in GCF samples, Human Quantikine ELISA 
developmental system (R&D Systems) was used.  The assay employs the quantitative 
sandwich enzyme immunoassay principle.  A monoclonal antibody which is specific for each 
biomarker has been pre-coated onto their individual microplates.  The standards and samples 
are pipetted into the wells and any MMP-9, BAFF, resistin, ENA-78/CXCL5 or IL-8 present 
is bound by the immobilized antibody.  The unbound substances are washed away, following 
which an enzyme-linked polyclonal antibody specific for each biomarker is added to each 
well.  Following a wash step to remove any unbound antibody-enzyme reagent, substrate 
solution is added to each well and colour develops in proportion to the amount of MMP-9, 
BAFF, resistin, ENA-78/CXCL5 or IL-8 bound in the initial step.  The colour development is 
stopped and the intensity of the colour present is measured. 
All assays were performed at room temperature.  The procedure for the Human Quantikine 
ELISA, involved the addition of 100 µl of Assay Diluent (specific for each biomarker) to 
each well followed by addition of the standards and diluted samples.  The plate was incubated 
at room temperature either on the benchtop or on a horizontal orbital microplate shaker 
(0.12” orbit) set at 500±50 rpm (specific for each biomarker).  Following this, the contents of 
each well were aspirated and washed with wash buffer, repeating the process three times for a 
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total of three or four washes (as indicated for each biomarker).  Following the washing step, 
200 µl of Human Conjugate (specific for each biomarker) was added to each well and the 
plate was incubated either on the benchtop or on a horizontal orbital microplate shaker (0.12” 
orbit) set at 500±50 rpm (specific for each biomarker).  Following this, the washing step was 
repeated and 200 µl of Substrate Solution was added to each well and the plate incubated for 
30 minutes at room temperature, on the benchtop.  Care was taken to ensure the plate was 
protected from light.  Lastly, 50 µl of Stop solution was added to each well and the colour in 
the well changed from blue to yellow.  The optical density of each well was determined 
within 30 minutes, using a microplate reader set to 450 nm and 550 nm.  Table 2.5 and 2.6 
present the protocol for performing the Human Quantikine ELISA experiment for each 
biomarker for serum and GCF samples, respectively. 
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Table 2.5: Protocol for Human Quantikine ELISA for biomarker levels in serum. 
MMP-9; matrix metalloproteinase-9, BAFF; B-cell activating factor, ENA-78/CXCL5; epithelial neutrophil activating peptide-78. 
 
 MMP-9 BAFF Resistin ENA-78/CXCL5 
Assay diluent Assay diluent RD1-34 Assay diluent RD1-111 Assay diluent RD1-19 Assay Diluent RD1W 
Dilution 100-fold 2-fold 5-fold 2-fold 




Calibrator diluent Calibrator diluent RD5-10 Calibrator diluent RD6Q Calibrator diluent RD5K Calibrator diluent RD6-1 
Amount of standards & 
samples 
100 µl per well 50 µl per well 100 µl per well 50 µl per well 
Incubation of standards &  
samples 
2 hours on a horizontal orbital 
microplate shaker (0.12” orbit) 
set at 500±50 rpm 
3 hours on a horizontal orbital 
microplate shaker (0.12” orbit) 
set at 500±50 rpm 
2 hours on benchtop 
 
2 hours on benchtop 
 
Incubation of  
conjugate 
1 hour on shaker 1 hour on shaker 2 hours on benchtop 2 hours on benchtop 
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Table 2.6: Protocol for Human Quantikine ELISA for biomarker levels in GCF. 
MMP-9; matrix metalloproteinase-9 and IL-8; interleukin-8.
 MMP-9 IL-8 
Assay diluent Assay diluent RD1-34 Assay diluent RD1-85 
Conjugate Human MMP-9 Conjugate Human IL-8 Conjugate 
Calibrator diluent Calibrator diluent RD5-10 Calibrator diluent RD5P 
(diluted 1:5) 
Amount of standards & 
samples 
100 µl per well 50 µl per well 
Incubation of standards & 
samples  
2 hours on a horizontal orbital 
microplate shaker (0.12” orbit) 
set at 500±50 rpm 
2 hours on benchtop 
 
Incubation of conjugate 1 hour on shaker 1 hour on benchtop 
Dilution 100-fold None 
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2.16 Assessment of quality of life 
At baseline prior to any periodontal treatment, QoL in patients with T1DM was assessed 
using two validated measures routinely used to assess QoL in patients with diabetes, the       
W-BQ12 and the ADDQoL-19 questionnaire.  Only the T1DM patients enrolled in the study 
were asked to complete both questionnaires, using manual-self complete mode of 
administration.  For T1DM patients with healthy periodontal tissues and gingivitis their 
participation in the study was restricted to the baseline appointment where they were given 
OHI and oral prophylaxis.  Only T1DM patients with periodontitis underwent NSM and were 
seen for follow-up and necessary treatment at months 3 and 6, and were once again asked to 
complete the both questionnaires. 
2.16.1 The Well-being Questionnaire 12 
The W-BQ12 consists of 12 questions divided into 3 subscales, asking questions related to an 
individual’s negative well-being, energy levels and positive well-being (Table 2.7, Appendix 
A).  The W-BQ12 can be scored as 3 subscales, each of 4 items or questions: negative well-
being (item 1 to 4), energy (item 5 to 8) and positive well-being (item 9 to 12).  All the 
negative well-being questions are negatively worded, all the positive well-being questions are 
positively worded, and, the energy subscale consists of 2 positive and 2 negative questions.  
The responses to each question are on a Likert response scale and range from score ‘0’ to 
score ‘3’.  Score ‘0’ indicates that the item applied to the individual ‘not at all’ and score ‘3’ 
indicates that the item applied to the individual ‘all the time’, over the past few weeks (Table 
2.8).  Scores of each subscale were calculated separately (Table 2.9).  A higher score in each 
subscale indicates more of the mood described, indicating a greater sense of positive well-
being, energy level and negative well-being, and from these subscale scores an overall 
general well-being score can be generated (Table 2.9).  A higher overall general well-being 
score indicates a greater QoL. 
The associations between W-BQ12 scores and clinical data (age, duration of diabetes, 
diabetic complications, HbA1c and mean PD) were assessed using Pearson’s correlation 
coefficient (r), if both variables were normally distributed, or using Spearman’s correlation 
coefficient (rho) if both variables were not normally distributed. 
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Table 2.7: The 12 items of the W-BQ12.
Negative Well-being Energy Positive Well-being 
1. “I have crying spells or feel like it” 
2. “I feel downhearted & blue” 
3. “I feel afraid for no reason at all” 
4. “I get upset easily or feel panicky” 
 
5. “I feel energetic, active or vigorous” 
6. “I feel dull or sluggish” 
7. “I feel tired, worn out, used up or     
      exhausted”  
8. “I have been waking up feeling fresh &  
      rested”  
 
9. “I have been happy satisfied, or pleased  
      with my personal life” 
10. “I have lived the kind of life I wanted to” 
11. “I have felt eager to tackle my daily  
        tasks or make new decisions” 
12. “I have felt I could easily handle or cope  
        with any serious problem or major  




All the time   Not at all 
3 2 1 0 
Table 2.8: Likert scale responses to the W-BQ12. 
 
 
Negative Well-being Energy Positive Well-being General Well-being 
Add all 4 items 6 + item 5 – item 6 – item 7 + item 8 Add all 4 items 12 – Negative well-being + Energy + Positive well-being 
Table 2.9: Equation used to calculate the W-BQ12 scores.
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2.16.2 The Audit of Diabetes Dependent Quality of Life-19 
The ADDQoL-19 consists of 19 questions or domains and 2 overview items (Appendix B).  
Overview item 1 is a generic assessment of QoL and states, “In general, my present quality of 
life is…”, and its response ranges from score ‘3’ indicating ‘excellent’ to score ‘-3’ indicating 
‘extremely bad’ (Table 2.10).  Overview item 2 assesses the impact of diabetes on QoL and 
states, “If I did not have diabetes, my quality of life would be…” and its response ranges from 
score ‘-3’ indicating ‘very much better’ to score ‘1’ indicating ‘worse’ (Table 2.11).  The 2 
overview items are scored separately. 
The 19 domains of the ADDQoL include questions pertaining to the impact of diabetes on 
specific life aspects (Table 2.12), and ask the respondents to rate how their life would be if 
they did not have diabetes.  Each question has two parts, the impact of the life aspect (impact 
rating) and the importance of that life aspect (importance rating).  The responses to the 
‘impact rating’, range from score ‘-3’ indicating ‘very much greater’ to score ‘+1’ indicating 
‘less’ (Table 2.13).  The responses to the ‘importance rating’, range from score ‘+3’ 
indicating ‘very important’ to score ‘0’ indicating ‘not at all important’ (Table 2.14). 
In order to calculate the ADDQoL-19 scores, firstly, the responses of the ‘impact rating’ and 
the ‘importance rating’ are multiplied to obtain a ‘weighted impact score’.  Following this, an 
overall ADDQoL-19 score is generated by the sum of the ‘weighted impact score’ ratings of 
applicable domains divided by the number of applicable domains.  The overall ADDQoL-19 
score ranges from ‘-9’ to ‘+3’, where ‘-9’ indicates the ‘maximum negative impact of 
diabetes’ and ‘+3’ indicates the ‘maximum positive impact of diabetes’.  Lower scores reflect 
on a poorer QoL, whereas a score of ‘0’ indicates that the individual’s QoL is not affected by 
diabetes at all.  Interpreting the overall ADDQoL-19 score further involves dividing the 
patients into 2 groups by using quartiles, the group of patients having an overall ADDQoL-19 
score below the lower quartile were considered to have a poorer QoL compared to those 
having a score above the lower quartile.  Such a cut off strategy was utilized previously in 
literature (Chung et al. 2012; Turk et al. 2013). 
The associations between ADDQoL-19 scores and clinical data (age, duration of diabetes, 
diabetic complications, HbA1c and mean PD) were assessed using Pearson’s correlation 
coefficient (r), if both variables were normally distributed, or using Spearman’s correlation 
coefficient (rho) if both variables were not normally distributed. 
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Table 2.10: ADDQoL-19 overview item 1 and its responses. 
 
 
Overview item 2: If I did not have diabetes, my quality of life would be…. 
Very much better Much better A little better The same Worse 
-3 -2 -1 0 1 
Table 2.11: ADDQoL-19 overview item 2 and its responses. 
Overview item 1: In general, my present quality of life is…. 
Excellent Very good Good Neither good nor bad Bad Very bad Extremely bad 






















Much greater A little 
greater 
The same Less 
-3 -2 -1 0 1 




Very important Important Somewhat 
important 
Not at all 
important 
3 2 1 0 
Table 2.14: Importance rating responses to the ADDQoL-19 domains. 
 
 
1. Leisure activities 
2. Working life 
3. Journeys 
4. Holidays 
5. Physical health 
6. Family life 
7. Friendship & social life 
8. Personal relationships 
9. Sex life 
10. Physical appearance 
11. Self-confidence 
12. Motivation 
13. People’s reaction 
14. Feelings about the future 
15. Financial situation 
16. Living conditions 
17. Dependence on others 
18. Freedom to eat 
19. Freedom to drink 
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3 Chapter 3. Investigation of the general and oral health status of patients with 
T1DM prior to non-surgical periodontal management 
3.1 Introduction 
Periodontitis and diabetes are both highly prevalent diseases, and the association between 
these two conditions has been well recognised by dental professionals for many years.  A 
number of epidemiological studies have unequivocally confirmed diabetes as a major risk 
factor for periodontal disease, and that individuals with diabetes are at an approximately 2 to 
3 fold increased risk of developing periodontitis compared to those without diabetes, 
particularly if their glycaemic control is poor (Khader et al. 2006; Mealey and Ocampo 2007; 
Chavarry et al. 2009).  Individuals with diabetes are found to have more severe and extensive 
destruction of periodontal tissue compared to those free from diabetes (Thorstensson and 
Hugoson 1993; Sandberg et al. 2000).  Longitudinal studies have demonstrated a higher 
incidence of progressive periodontal disease in patients with diabetes (Seppala et al. 1993; 
Firatli 1997; Taylor et al. 1998).  Evidence to support the negative impact of periodontal 
disease on diabetes has also been established.  Studies have reported the increased risk of 
developing diabetes-related complications such as cardiovascular problems, retinopathy, 
neuropathy and nephropathy where patients have advanced periodontal disease (Karjalainen 
et al. 1994; Thorstensson et al. 1996; Moore et al. 1998; Moore et al. 1999). 
The severity of periodontal disease in patients with T1DM has not been consistently reported.  
A number of studies have demonstrated no significant differences in the periodontal status of 
patients with T1DM compared to non-diabetic subjects (Firatli 1997; Lalla et al. 2006b; Kaur 
et al. 2009), whereas other studies have demonstrated that T1DM patients have higher levels 
of periodontal tissue loss compared to non-diabetic subjects (Bridges et al. 1996; Firatli et al. 
1996; Alpagot et al. 2001; Silvestre et al. 2009).  Also, most studies have focused primarily 
on children and adolescents, and only a number of studies have focused on the prevalence 
and severity of periodontal disease in adults with T1DM. 
The aim of this chapter is to report on the presentation and severity of periodontal disease and 
dental caries, oral hygiene status, oral health behaviour, and the associations between 





A total of 100 patients were recruited into this study, 57 T1DM patients and 43 non-T1DM 
patients.  Demographic findings for the T1DM and non-T1DM patients are summarised in 
Table 3.1.  Of note, no statistically significant differences were found between the two groups 
for gender, ethnicity, IMD rank, smoking status and pack years of smoking, (P>0.05).  This 
demonstrates that the two groups were appropriately matched for gender, ethnicity and IMD, 
demonstrating that both groups were from similar ethnic origin, resided in similar areas and 
had similar lifestyles.  However, the age differed significantly between the T1DM [median 
(IQR), 28.0 (23.0-32.5) years, range 18 to 35 years] and non-T1DM [40.0 (35.0-47.0) years, 
range 26 to 50 years] patients, suggesting that T1DM patients were from a younger age group 
compared to the non-T1DM patients. 
With reference to smoking habits, no statistically significant differences were found for 
smoking status and pack years between T1DM and non-T1DM patients (P>0.05), suggesting 
that the two groups were appropriately balanced for smoking status.  Current smokers were 
21.1% in the T1DM group and 14% in the non-T1DM group.  Also, 22.8% of T1DM and 
30.2% of non-T1DM patients had a previous history of smoking.  However a majority of the 
T1DM (56.1%) and non-T1DM (55.8%) patients were non-smokers and had never smoked 
previously.  The demographic findings did highlight a difference between the two groups for 
diastolic BP, the non-T1DM group having significantly higher diastolic BP [80.0 (73.0-88.0) 
mmHg] compared to the T1DM group [74.0 (68.3-80.0) mmHg], (P<0.05).  No statistically 
significant differences between the T1DM and non-T1DM groups were found for systolic 
BP, (P>0.05).  With reference to BMI, no statistically significant differences were identified 
between the T1DM (mean±SD 26.3±4.66 kg/m
2
) and non-T1DM (25.3±4.52 kg/m
2
) patients, 
(P>0.05).  However, while considering BMI category, the T1DM group contained a higher 
proportion of obese (21.1%) and morbidly obese (5.30%) patients compared to the non-
T1DM group, of which 4.70% were either, obese and morbidly obese.  These differences in 
proportions were not statistically significant, (P>0.05) (Table 3.1 and Figure 3.1). 
Tables 3.2 and 3.3 summarize demographic data following further categorisation of the 
T1DM and non-T1DM patients based on periodontal diagnosis.  When the demographic data 
of six categories [T1DM patients with healthy periodontal tissues (DH); T1DM patients with 
gingivitis (DG); T1DM patients with periodontitis (DP); non-T1DM patients with healthy 
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periodontal tissues (HH); non-T1DM patients with gingivitis (HG) and non-T1DM patients 
with periodontitis (HP)] were analysed, there were no statistically significant differences 
between groups for gender.  Within the T1DM group, age differed significantly, the DP 
patients were significantly older [32.0 (27.0-34.0) years] compared to the DH patients [25.0 
(19.5-28.0) years], (P<0.05).  All the non-T1DM groups (HH, HG and HP) were significantly 
higher in age than the T1DM groups (DH, DG and DP), (P<0.001).  Based on periodontal 
diagnosis no statistically significant differences were found for ethnicity and IMD rank, 
(P>0.05). 
When considering smoking habits, within the T1DM group, the DP group contained a higher 
proportion of ex-smokers (42.1%) compared to the DG group (6.90%), whereas the DG 
group had a higher proportion of current smokers (27.6%) compared to the DP group 
(21.1%).  Similar findings were found within the non-T1DM group, where the HP group had 
a significantly higher proportion of ex-smokers (47.1%) compared to the HG group (23.5%).  
There was a 17.6% prevalence of current smokers in both HG and HP groups.  The DH and 
HH groups had no current smokers.  No statistically significant differences were found 
between the T1DM and non-T1DM groups for pack years (P>0.05). 
The systolic BP was significantly higher in DH patients [139 (126.8-148) mmHg] compared 
to the HH patients [120 (114.5–133) mmHg], (P<0.05) (Table 3.3).  Within the non-T1DM 
group, the HG patients had significantly higher systolic BP [135 (126-150) mmHg] compared 
to the HH patients [120 (114.5-133) mmHg], (P<0.05).  The diastolic BP was significantly 
higher in the HG patients [80.0 (75.0–88.0) mmHg] compared to the DG patients [74.0 (68.0-
80.5) mmHg], (P<0.05).  No statistically significant differences were found between groups 
for BMI and BMI category, (P>0.05).
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Table 3.1: Demographic data comparing T1DM and non-T1DM patients. 
Mean ± SD presented for parametric data, median (IQR) presented for non-parametric data and 
n (%) presented for discrete variables.  P-values determined using chi-squared test for discrete 
variables; Mann-Whitney U tests for continuous non-parametric variables and Independent t-
test for continuous parametric variables.  P indicates significant difference between T1DM and 
non-T1DM patients. BP; blood pressure, BMI; body mass index, IMD; index of multiple 


















Age (years) 28.0 (23.0-32.5) 40.0 (35.0-47.0) < 0.001 












IMD rank 12621 (7095-23926.8) 20804 (8511-24491) NS 

























Systolic BP (mmHg) 
 
132.5 (121.3-144.8) 131 (119-140) NS 
Diastolic BP (mmHg) 
 





26.3 ± 4.66 25.3 ± 4.52 NS 


























Figure 3.1: Categorization of T1DM and non-T1DM patients based on BMI.  
T1DM patients (underweight n=2, normal weight n=20, overweight n=20, obese n=12, 
morbidly obese n=3) and non-T1DM patients (underweight n=4, normal weight n=17, 
overweight n=18, obese n=2, morbidly obese n=2).   

























Table 3.2: Demographic data comparing T1DM and non-T1DM patients based on periodontal 
diagnosis. 
Mean ± SD presented for parametric data, median (IQR) presented for non-parametric data and n (%) 
presented for discrete variables.  P-values were determined using chi-squared test for discrete variables, 
Kruskal-Wallis test with Mann-Whitney U post hoc tests for continuous non-parametric variables and one-
way ANOVA test with post-hoc independent t-test for continuous parametric variables.  P* indicates 
overall p-value comparing across periodontal categories within T1DM or non-T1DM groups.  P-values 
under columns (P) relate to comparisons between T1DM and non-T1DM groups.  ***P<0.001 indicates 
statistically significant differences compared to health within the T1DM group.  DH; T1DM, periodontal 
health, DG; T1DM, gingivitis, DP; T1DM, periodontitis, HH; non-T1DM, periodontal health, HG; non-




(DH n=9)  
(HH n=9) 
Gingivitis 
(DG n=29)   
(HG n=17) 
Periodontitis  









































NS NS NS  
Age (years) T1DM 25.0 (19.5-28.0) 28.0 (22.0-32.5) 32.0 (27.0-34.0) *** < 0.01 
Non-T1DM 44.0 (39.0-46.5) 38.0 (34.5-45.5) 39.0 (34.5-47.0) NS 
P < 0.001 < 0.001 < 0.001  
Ethnicity  
































NS NS NS  
IMD rank 
 
















NS NS NS  
Smoking status  






































P NS NS NS  
Pack years T1DM 3.58 ± 2.98 7.73 ± 6.42 8.83 ± 7.12 NS 
Non-T1DM N/A 9.65 ± 9.74 9.44 ± 6.87 NS 




Table 3.3: Demographic data comparing T1DM and non-T1DM patients based on 
periodontal diagnosis. 
Mean ± SD presented for parametric data, median (IQR) presented for non-parametric data and n 
(%) presented for discrete variables.  P-values were determined using chi-squared test for 
discrete variables, Kruskal-Wallis test with Mann-Whitney U post hoc tests for continuous non-
parametric variables and one-way ANOVA test with post-hoc independent t-test for continuous 
parametric variables.  P* indicates overall p-value comparing across periodontal categories 
within T1DM or non-T1DM groups.  P-values under columns (P) relate to comparisons between 
T1DM and non-T1DM group.  *P<0.05 indicates statistically significant differences compared to 
health within the non-T1DM group.  DH; T1DM, periodontal health, DG; T1DM, gingivitis, DP; 
T1DM, periodontitis, HH; non-T1DM, periodontal health, HG; non-T1DM, gingivitis, HP; non-
T1DM, periodontitis, BP; blood pressure, BMI; body mass index, NS; not significant.






















Non-T1DM 120 (114.5-133) 135 (126-150) * 124 (118-143) < 0.05 
P 
 
< 0.05 NS NS  
Diastolic BP 
(mmHg) 
T1DM 79.0 (73.0- 88.5) 74.0 (68.0-80.5) 72.0 (66.0-80.0) NS 
Non-T1DM 80.0 (70.0-82.0) 80.0 (75.0-88.0) 80.0 (69.0-89.5) NS 





T1DM 26.0 ± 4.75 26.0 ± 4.67 27.0 ± 4.80 NS 
Non-T1DM  24.9 ± 4.18 26.2 ± 4.42 24.7 ± 4.91 NS 
P 
 
NS NS NS  
BMI category  






























































Figure 3.2: BMI category of T1DM and non-T1DM patients based on periodontal 
diagnosis. 
DH patients (underweight n=0, normal weight n=4, overweight n=4, obese n=0, morbidly 
obese n=1), DG patients (underweight n=1, normal weight n=11, overweight n=10, obese 
n=6, morbidly obese n=1) DP patients (underweight n=1, normal weight n=5, overweight 
n=6, obese n=6, morbidly obese n=1), HH patients (underweight n=0, normal weight n=6, 
overweight n=2, obese n=1, morbidly obese n=0), HG patients (underweight n=2, normal 
weight n=4, overweight n=9, obese n=1, morbidly obese n=1) and HP patients (underweight 
n=2, normal weight n=7, overweight n=7, obese n=0, morbidly obese n=1).  DH; T1DM, 
periodontal health, DG; T1DM, gingivitis, DP; T1DM, periodontitis, HH; non-T1DM, 
periodontal health, HG; non-T1DM, gingivitis, HP; non-T1DM, periodontitis. 
 



























Figure 3.3: Smoking status of T1DM and non-T1DM patients based on periodontal 
diagnosis.  
DH patients (current smoker n=0, ex- smoker n=3, never smoked n=6), DG patients (current 
smoker n=8, ex-smoker n=2, never smoked n=19), DP patients (current smoker n=4, ex-
smoker n=8, never smoked n=7), HH patients (current smoker n=0, ex-smoker n=1, never 
smoked n=9), HG patients (current smoker n=3, ex-smoker n=4, never smoked n=10) and HP 
patients (current smoker n=3, ex-smoker n=8, never smoked n=6).  DH; T1DM, periodontal 
health, DG; T1DM, gingivitis, DP; T1DM, periodontitis, HH; non-T1DM, periodontal health, 
HG; non-T1DM, gingivitis, HP; non-T1DM, periodontitis. 
   




3.2.2 Diabetes care 
Table 3.4 presents diabetes care data and demonstrates that of the 57 patients with T1DM, 
52.6% gave a family history of diabetes, and the mean duration since diagnosis of T1DM was 
14.0±7.47 years.  With reference to method of diabetes control, a majority of patients 
(87.7%) controlled their diabetes by a combination of diet modification, physical exercise and 
drug therapy.  Only a small proportion of patients (12.3%) were maintaining their glycaemic 
control with drug therapy alone.  With reference to type of drug therapy used, a majority of 
patients (86%) were taking only insulin therapy and a smaller proportion of patients (14%) 
were taking a combination therapy of oral glucose lowering drugs, lipid lowering drugs 
and/or antihypertensive drugs in addition to insulin therapy. 
With reference to diabetes-related complications, 22.8% of the T1DM patients presented with 
at least one self-reported diabetes complication, not including periodontitis.  Of these, 5.3% 
reported having neuropathy, 3.50% reported having nephropathy, 8.80% reported having eye 
damage and 5.30% reported having all three of these microvascular complications.  None of 
the patients reported having any macrovascular complication such as heart disease, stroke or 
peripheral vascular disease.  With reference to screening and ruling out diabetes-related 
complications within the past 12 months, 5.30% of the T1DM patients had only their eyes 
screened and 94.7% received a combination of diabetes-related education and examination of 
their eyes and feet. 
Based on glycaemic control category, a majority of the T1DM patients (n=24, 42.1%) were 
categorised as having poor glycaemic control (i.e. HbA1c >8.5 % / >69 mmol/mol), followed 
by 40.4% (n=23) of the T1DM patients having moderate glycaemic control (i.e. HbA1c 7.0-
8.5 % / 53–69 mmol/mol) and only a small proportion of these patients [n (%) 6 (10.5%)] had 
good glycaemic control (i.e. HbA1c <7.0 % / <53 mmol/mol) (WHO 1999). 
Table 3.5 and 3.6 presents diabetes care data following categorisation of the T1DM patients 
based on periodontal diagnosis.  With reference to duration of diabetes, the DP patients 
presented with a significantly longer history of diabetes (17.5±8.32 years) compared to the 
DG (12.5±6.86 years) and the DH (11.7±5.12 years) patients, (P<0.05).  With reference to 
diabetes management regimen, no statistically significant differences were found based on 
periodontal diagnosis, (P>0.05).  All the DH patients managed their diabetes by a 
combination of diet modification, physical exercise and drug therapy, followed by 93.1% of 
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the DG and 73.7% of the DP patients who manged their diabetes by combination therapy.  A 
lower proportion of the DP patients (26.3%) followed by the DG patients (6.90%) managed 
their diabetes with drug therapy alone.  With reference to type of drug therapy used, no 
statistically significant differences were found based on periodontal diagnosis, (P>0.05).  All 
the DH patients were taking insulin therapy only, followed by 84.2% of the DP and 82.8% of 
the DG patients who were on insulin therapy only.  A lower proportion of the DG (17.2%) 
and DP (15.8%) patients were taking a combination therapy of oral glucose lowering drugs, 
lipid lowering drugs and/or antihypertensive drugs in addition to insulin therapy.  With 
reference to glycaemic control category, no statistically significant differences were found 
based on periodontal diagnosis, (P>0.05).  Interestingly, a majority of the DP patients (n=10, 
52.6%) had poor glycaemic control whereas a majority of the DG (n=13, 44.8%) and the DH 
(n=5, 55.6%) patients had moderate glycaemic control. 
With reference to diabetes-related complications, no statistically significant differences were 
found based on periodontal diagnosis, (P>0.05).  Only 2 DH patients reported having 
neuropathy.  Within the DG group, 2 patients reported having neuropathy, 1 patient reported 
having eye damage and 2 patients reported having a combination of these complications.  
Within the DP group, 1 patient reported having neuropathy, 2 patients reported having 
nephropathy, 2 patients reported having eye damage and 1 patient reported having a 
combination all three microvascular complications.  With reference to screening for diabetes 
complications, no statistically significant differences were found based on periodontal 
diagnosis (P>0.05).  A majority of the DH (88.9%), DG (96.6%) and DP (94.7%) patients 
had received a combination of examination of eyes and feet, and were given diabetes-related 
education or information within the last 12 months.  Only a smaller proportion of these 
patients received examination of their eyes only. 
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Table 3.4: Diabetes care data for T1DM patients. 
Mean ± SD presented for parametric data and n (%) presented for discrete variables.  For 
glycaemic control categories: T1DM n=53.
 T1DM 
(n=57) 
History of diabetes (years) 
 
14.0  ± 7.50 
Family history [n (%)] 
 
30 (52.6) 
Methods of diabetes control [n (%)] 
Drug therapy only 





Current drug therapy [n (%)] 
Insulin 
Combination: Oral glucose lowering drug/ Insulin/ Lipid 































Macrovascular complications [n (%)] 
None 













Screening for complications [n (%)] 
Eye screened 







Table 3.5: Diabetes care data for T1DM patients based on periodontal diagnosis. 
Mean ± SD presented for parametric data and n (%) presented for discrete variables.  P-values determined using chi-square test for discrete 
variables, one way ANOVA test with post-hoc independent t-test for continuous parametric variables.  *P<0.05 indicates statistically significant 
differences compared to health and †P<0.05 indicates statistically significant differences compared to gingivitis within the T1DM group.  P* 










History of diabetes (years) 11.7 ± 5.12 12.5 ± 6.86 17.5 ± 8.32 
 
*
, † < 0.05 
Family history [n (%)] 
 
5 (55.6) 15 (51.7) 10 (52.6) NS 
Methods of diabetes control [n (%)] 
Drug therapy only 













Current drug therapy [n (%)] 
Insulin 
Combination: Oral glucose lowering drug/ Insulin/ 





















































Table 3.6: Diabetes care data for T1DM patients based on periodontal diagnosis. 
N (%) presented for discrete variables.  P-values determined using chi-square test for discrete variables.  P* indicates overall p-value comparing 


















Macrovascular complications [n (%)] 
None 
















































Screening for complications [n (%)] 
Eye screened 














3.2.3 Oral and dental 
Oral and dental findings comparing T1DM and non-T1DM patients are presented in Table 
3.7.  When comparing the two groups, significant differences were found relating to the 
number of teeth present and the number of sound and unrestored teeth.  The number of teeth 
present was significantly higher in T1DM patients (27.5±2.78) compared to the non-T1DM 
patients (26.0±2.91), (P<0.01).  Also the T1DM patients had a significantly higher number of 
sound and unrestored teeth (22.5±6.84) compared to the non-T1DM patients (18.8±5.62), 
(P<0.01).  Additionally, the T1DM patients had a significantly lower number of restored 
teeth (1–3 surfaces) (3.33±3.34 and n=40, 70.2%) compared to the non-T1DM patients 
(6.19±4.14 and n=39, 90.7%), (P<0.001). 
No statistically significant differences were found between the two groups for abnormal soft 
tissue findings, dry mouth (clinically assessed or patient reported), pain in the past one 
month, removable prosthesis, teeth with restoration including 4 or more surfaces, teeth with 
caries into dentine, broken down teeth with pulpal involvement, endodontically treated teeth 
and teeth with periapical radiolucencies, (P>0.05). 
Table 3.8 and 3.9 presents oral and dental data following further categorisation of T1DM and 
non-T1DM patients based on periodontal diagnosis.  With reference to the number of teeth 
present, the DH patients had a significantly greater number of teeth present (29.1±1.83) 
compared to the HH patients (27.0±1.87), (P<0.05).  Also the DG patients had a significantly 
higher number of teeth present (28.2±2.39) compared to the HG patients (24.2±2.83), 
(P<0.001).  Within the T1DM group, a significantly higher number of teeth was present in 
the DH (29.1±1.83) and the DG (28.2±2.39) patients compared to the DP patients 
(25.7±2.88), (P<0.01).  Within the non-T1DM group, the HH (27.0±1.87) and the HP 
(27.2±2.59) patients had a significantly higher number of teeth compared to the HG patients 
(24.2±2.83), (P<0.05 and P<0.01, respectively).  With reference to the number of sound and 
unrestored teeth, the DH patients had significantly more sound teeth compared to the HH 
patients (19.9±5.23), (P<0.01).  Also the DG patients had significantly more sound teeth 
(23.1±7.02) compared to the HG patients (16.0±5.49), (P<0.001).  Within the T1DM group, 
the DH (27.7±2.60) and the DG (23.1±7.02) patients had significantly more sound teeth 
compared to the DP patients (19.2±6.33), (P<0.001 and P<0.05 respectively).  However, 
within the non-T1DM group, the HP patients had significantly more sound teeth (21.0±5.00) 
compared to the HG patients (16.0±5.49), (P<0.01). 
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With reference to the number of restored teeth (1-3 surfaces), the HH patients had 
significantly more restored teeth (5.78±4.92 and n=8, 88.9%) compared to the DH patients 
(1.44±1.74 and n=5, 55.6%), (P<0.05).  Similarly, the HG patients had a significantly greater 
number of restored teeth (7.18±4.45 and n=15, 88.2%) compared to the DG patients 
(3.45±3.57 and n=20, 69%), (P<0.01).  Within the T1DM group, the DG (3.45±3.57 and 
n=20, 69%) and the DP (4.05±3.34 and n=15, 78.9%) patients had a significantly higher 
number of restored teeth compared to the DH patients (1.44±1.74 and n=5, 55.6%), (P<0.05 
and P<0.01 respectively).   
Of note, no other statistically significant differences for oral and dental data were found 




Table 3.7: Oral and dental data comparing T1DM and non-T1DM patients. 
Mean ± SD presented for parametric data and n (%) presented for discrete variables.  P-values 
determined using Independent t-test for continuous parametric variables and chi-squared test for 



































Pain in previous month [n (%)] 
 
8 (14.0) 4 (9.30)  
NS 

















27.5 ± 2.78 26.0 ± 2.91 < 0.01 
Sound and unrestored teeth 22.5 ± 6.84 18.8 ± 5.62 < 0.01 
Restored teeth (1-3 surfaces) 
[n (%) with at least one] 
 
3.33 ± 3.34 
40 (70.2%) 
6.19 ± 4.14 
39 (90.7%) 
< 0.001 
Restored teeth (+4 surfaces) 
[n (%) with at least one] 
 
0.65 ± 2.86 
9 (15.8%) 
0.63 ± 1.54 
11 (25.6%) 
NS 
Teeth with caries into dentine 
[n (%) with at least one] 
 
0.75 ± 1.87 
13 (22.8%) 
0.26 ± 0.93 
4 (9.30%) 
NS 
Broken down teeth 
[n (%) with at least one] 
 
0.23 ± 1.00 
5 (8.80%) 
0.23 ± 0.15 
1 (2.30%) 
NS 
Endodontically treated teeth 
[n (%) with at least one] 
 
0.02 ± 0.13 
1 (1.80%) 




[n (%) with at least one] 
0.19 ± 0.74 
6 (10.5%) 





Table 3.8: Oral and dental data comparing T1DM and non-T1DM patients based on 
periodontal diagnosis. 
Mean ± SD presented for parametric data and n (%) presented for discrete variables.  P-values 
determined using chi-squared test for discrete variables, and One way ANOVA test with post-
hoc Independent t-test for continuous parametric variables.  P* indicates overall p-value 
comparing across periodontal categories within T1DM or non-T1DM groups. P-values under 
columns (P) relate to comparisons between T1DM and non-T1DM groups.  *P<0.05, **P<0.01, 
***P<0.001 indicates statistically significant differences compared to health and †P<0.05, 
††P<0.01 indicates statistically significant differences compared to gingivitis within the T1DM 
and non-T1DM groups.  DH; T1DM, periodontal health, DG; T1DM, gingivitis, DP; T1DM, 
periodontitis, HH; non-T1DM, periodontal health, HG; non-T1DM, gingivitis, HP; non-T1DM, 
periodontitis, NS; not significant.







(DP n=19)  
(HP n=17) 
P* 














Non-T1DM 0 (0.00) 1 (5.90) 1 (5.90) NS 
P 
 
NS NS NS  
Clinician assessed dry 
mouth  
[n (%)]  
 
T1DM 0 (0.00) 0 (0.00) 0 (0.00) NS 
Non-T1DM 0 (0.00) 1 (5.90) 0 (0.00) NS 
P NS NS NS  
Patient reported dry mouth 
[n (%)]  
T1DM 0 (0.00) 2 (6.90) 0 (0.00) NS 
Non-T1DM  0 (0.00) 1 (5.90) 1 (5.90) NS 
P 
 
NS NS NS  
Pain in previous month 
[n (%)] 
 
T1DM 0 (0.00) 4 (13.8) 4 (21.1) NS 
Non-T1DM 0 (0.00) 2 (11.8) 2 (11.8) NS 
P 
 









































NS NS NS  
Teeth present 
 
T1DM 29.1 ± 1.83 28.2 ± 2.39 25.7 ± 2.88 **
, †† < 0.001 
Non-T1DM 27.0 ± 1.87 24.2 ± 2.83 * 27.2 ± 2.59 †† < 0.01 
P 
 
< 0.05 < 0.001 NS  
Sound & unrestored teeth T1DM  27.7 ± 2.60 23.1 ± 7.02 19.2 ± 6.33 ***
, † < 0.01 
Non-T1DM 19.9 ± 5.23 16.0 ± 5.49 21.0 ± 5.00 †† < 0.05 
 P < 0.01 < 0.001 NS  
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Table 3.9: Oral and dental data comparing T1DM and non-T1DM patients based on    
periodontal diagnosis.  
Mean ± SD presented for parametric data.  P-values were determined using One way ANOVA 
test with post-hoc Independent t-test for continuous parametric variables.  P* indicates overall 
p-value comparing across periodontal categories within T1DM or non-T1DM groups.  P-values 
under columns relate to comparisons between T1DM and non-T1DM groups.  *P<0.05, 
**P<0.01 indicates statistically significant differences compared to health within the T1DM 
group.  DH; T1DM, periodontal health, DG; T1DM, gingivitis, DP; T1DM, periodontitis, HH; 
non-T1DM, periodontal health, HG; non-T1DM, gingivitis, HP; non-T1DM, periodontitis, NS; 
not significant.

















1.44 ± 1.74 
5 (55.6) 
 
3.45 ± 3.57 * 
20 (69.0) 
 




Non-T1DM 5.78 ± 4.92 
8 (88.9) 
7.18 ± 4.45 
15 (88.2) 





< 0.05 < 0.01 NS  
Restored teeth 
(+4 surfaces) 
[n (%) with at least one] 
T1DM       - 
 0 (0.00) 
1.00 ± 3.92 
5 (17.2) 
0.42 ± 1.01 
4 (21.1) 
NS 
Non-T1DM 1.33 ± 2.69 
3 (33.3) 
0.29 ± 0.59 
4 (23.5) 
0.59 ± 1.37 
4 (23.5) 
NS 
P NS NS NS  
Teeth with caries into 
dentine 
[n (%) with at least one] 
T1DM -  
0 (0.00) 
0.52 ± 1.45 
5 (17.2) 
1.47 ± 2.59 * 
8 (42.1) 
NS 
Non-T1DM  - 
0 (0.00) 
 0.41 ± 1.28 
2 (11.8) 





NS NS NS  
Broken down teeth 
[n (%) with at least one] 
T1DM  - 
0 (0.00) 
0.10 ± 0.41 
2 (6.90) 












NS NS NS  
Endodontically treated teeth 
[n (%) with at least one] 
T1DM  - 
0 (0.00) 














NS NS NS  
Periapical radiolucencies 
[n (%) with at least one] 
T1DM - 
0 (0.00) 
0.07 ± 0.26 
2 (6.9) 







0.12 ± 0.33 
2 (11.8) 
NS 
P NS NS NS  
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3.2.4 Oral health behaviour 
Table 3.10 summarises oral health behaviour data for T1DM and non-T1DM patients.  Of 
note, when comparing the two groups, no statistically significant differences were found in 
the proportions of patients for all the oral health behaviours (attends GDP regularly, attended 
GDP within the last 12 months, reason for last visit at the GDP, and frequency of tooth 
brushing), except for frequency of interproximal teeth cleaning.  A significantly higher 
proportion of T1DM patients (n=40, 70.2%) reported to have never performed interproximal 
teeth cleaning compared to non-T1DM patients (n=15, 34.9%), (P<0.001).  On the other 
hand, a significantly higher proportion of the non-T1DM patients reported performing 
interproximal teeth cleaning once per week (n=8, 18.6%) and ≥ three times per week (n=20, 
46.5%) compared to the T1DM patients (once per week: n=7, 12.3%; and ≥ three times per 
week: n=8, 14%), respectively, (P<0.001). 
Table 3.11, Figures 3.4, 3.5 and 3.6 summarize oral health behaviour data comparing T1DM 
and non-T1DM patients based on periodontal diagnosis.  Within the non-T1DM group, a 
significantly higher proportion of the HP patients (n=15, 88.2%) reported to regularly visit 
their GDP compared to the HG patients (n=8, 47%), (P<0.05).  With reference to self-
reported interproximal teeth cleaning, a significantly higher proportion of the DH patients 
reported to have never performed or were not currently performing interproximal teeth 
cleaning (n=5, 55.6%) or carried out interproximal cleaning once per week (n=3, 33.3%) 
compared to HH patients (n=1, 11.1%) and (n=2, 22.2%) respectively, (P<0.05).  On the 
other hand, a significantly higher proportion of the HH patients (n=6, 66.7%) reported 
performing interproximal teeth cleaning ≥ three times per week compared to the DH patients 
(n=1, 11.1%), (P<0.05).  Within non-T1DM group, a significantly higher proportion of the 
HG patients reported to never have performed interproximal teeth cleaning (n=10, 58.8%) or 
carried out interproximal cleaning once per week (n=4, 23.5%) compared to the HH patients 
(n=1, 11.1%) and (n=2, 22.2%) respectively, (P<0.05).  Interestingly a higher proportion of 
the HP patients reported performing interproximal teeth cleaning ≥ three times per week 
(n=11, 64.7%) compared to the HG patients (n=3, 17.6%), (P<0.05).  Conversely, a 
significantly higher proportion of HG patients reported to have never performed 
interproximal teeth cleaning (n=10, 58.8%) or carried out interproximal cleaning once per 




Table 3.10: Oral health behaviour data comparing T1DM and non-T1DM patients. 
N (%) presented for discrete variables.  P-values were determined using chi-squared test for 
discrete variables.  P indicates significant difference between T1DM and non-T1DM patients. 
























































































Table 3.11: Oral health behaviour data comparing T1DM and non-T1DM patients based on periodontal 
diagnosis. 
N (%) presented for discrete variables.  P-values were determined using chi-squared test for discrete variables.  P* 
indicates overall p-value comparing across periodontal categories within T1DM or non-T1DM groups.  P-values 
under columns relate to comparisons between T1DM and non-T1DM groups.  *P<0.05 indicates statistically 
significant differences compared to health and †P<0.05 indicates statistically significant differences compared to 
gingivitis within the non-T1DM group.  DH; T1DM, periodontal health, DG; T1DM, gingivitis, DP; T1DM, 
periodontitis, HH; non-T1DM, periodontal health, HG; non-T1DM, gingivitis, HP; non-T1DM, periodontitis, GDP; 
general dental practitioner, N/A; not applicable, NS; not significant.










Attends GDP regularly 
[n (%)]  
T1DM 6 (66.7) 19 (65.5) 14 (73.7) NS 
Non-T1DM 6 (66.7) 8 (47.1) 15 (88.2) † NS 
P NS NS NS  
Attended GDP within 12 
months 
[n (%)]  
T1DM 6 (66.7) 21 (72.4) 16 (84.2) NS 
Non-T1DM 7 (77.8) 11 (64.7) 15 (88.2) NS 
P NS NS NS  




































































P NS NS NS  




















































































10 (58.8) * 
4 (23.5) * 
3 (17.6) * 
 
4 (23.5) † 
2 (11.8) † 
11 (64.7) † 
 
NS 





Figure 3.4: Attendance at GDP of T1DM and non-T1DM patients based on periodontal 
diagnosis. 
DH patients (regular attender n=6, irregular attender n=3), DG patients (regular attender 
n=19, irregular attender n=10), DP patients (regular attender n=14, irregular attender n=5), 
HH patients (regular attender n=6, irregular attender n=3), HG patients (regular attender n=8, 
irregular attender n=9) and HP patients (regular attender n=15, irregular attender n=2).  DH; 
T1DM, periodontal health, DG; T1DM, gingivitis, DP; T1DM, periodontitis, HH; non-









Figure 3.5: Frequency of tooth brushing of T1DM and non-T1DM patients based on 
periodontal diagnosis. 
DH patients  (< once per day n=0, once per day n=1, twice per day n=8, > twice per day n=0), 
DG patients (< once per day n=0, once per day n=7, twice per day n=17, > twice per day 
n=3), DP patients (< once per day n=2, once per day n=3, twice per day n=13, > twice per day 
n=1), HH patients (< once per day n=1, once per day n=0, twice per day n=7, > twice per day 
n=1), HG patients (< once per day n=0, once per day n=1, twice per day n=16, > twice per 
day n=0) and HP patients (< once per day n=0, once per day n=1, twice per day n=13, > twice 
per day n=3).  DH; T1DM, periodontal health, DG; T1DM, gingivitis, DP; T1DM, 
periodontitis, HH; non-T1DM, periodontal health, HG; non-T1DM, gingivitis, HP; non-
T1DM, periodontitis. 
    
Tooth brushing < 
once per day 
Tooth brushing once 
per day 
Tooth brushing twice 
per day 
Tooth brushing > 





Figure 3.6: Frequency of interproximal teeth cleaning of T1DM and non-T1DM  
patients based on periodontal diagnosis. 
DH patients (never n=5, once per week n=3, > thrice per week n=1), DG patients (never 
n=23, once per week n=2, > thrice per week n=2), DP patients (never n=12, once per week 
n=2, > thrice per week n=5), HH patients (never n=1, once per week n=2, > thrice per week 
n=6), HG patients (never n=10, once per week n=4, > thrice per week n=3) and HP patients 
(never n=4, once per week n=2, > thrice per week n=11).  DH; T1DM, periodontal health, 
DG; T1DM, gingivitis, DP; T1DM, periodontitis, HH; non-T1DM, periodontal health, HG; 
non-T1DM, gingivitis, HP; non-T1DM, periodontitis. 
   
Never performing 
interproximal cleaning 
Interproximal cleaning once 
per week 
Interproximal cleaning         




3.2.5 Pre-treatment clinical biochemistry parameters 
Table 3.12 summarises pre-treatment clinical biochemistry data for T1DM and non-T1DM 
patients.  Of note, when comparing the two groups, statistically significant differences were 
found for HbA1c, non-HDL and cholesterol levels.  As would be expected, the T1DM 
patients had a significantly higher HbA1c (%)/ (mmol/mol) [8.30 (7.60–9.35) %/ 67 (60-79) 
mmol/mol] compared to the non-T1DM patients [5.40 (5.30–5.60) %/ 36 (34-38) mmol/mol], 
(P<0.001).  Levels of hsCRP also appeared to be higher in patients with T1DM [1.70 (0.68–
5.58) mg/L] compared to the non-T1DM patients [1.00 (0.50–3.40) mg/L], however the 
difference was not statistically significant, (P>0.05).  On the other hand, T1DM patients had 
significantly lower levels of non-HDL [2.90 (2.50–3.53) mmol/L] compared to the non-
T1DM patients [3.50 (2.40–4.30) mmol/L], (P<0.05).  Similarly, T1DM patients had 
significantly lower levels of cholesterol (4.50±0.74 mmol/L) compared to the non-T1DM 
patients (5.10±0.93 mmol/L), (P<0.001).  Levels of triglycerides and HDL were higher in 
non-T1DM patients [1.40 (0.80–1.90) mmol/L and 1.60 (1.30–1.80) mmol/L] compared to 
the T1DM patients [1.30 (0.78–1.60) mmol/L and 1.40 (1.20–1.63) mmol/L], however, the 
differences were not statistically significant, (P>0.05). 
Table 3.13 summarises pre-treatment clinical biochemistry data for T1DM and non-T1DM 
patients based on periodontal diagnosis.  Interestingly, within the T1DM group, the HbA1c 
level appeared highest in the DP patients [8.95 (8.03-9.65) %/ 75 (64-83) mmol/mol] 
compared to the DG [8.25 (7.65-10.0) %/ 67 (61-86) mmol/mol] and DH [7.90 (7.30-8.58) 
%/ 63 (56-70) mmol/mol] patients, however these differences were not statistically 
significant, (P>0.05).  No statistically significant differences were found within the non-
T1DM group for HbA1c levels based on periodontal diagnosis (P>0.05).  Considering lipid 
profile, HDL levels were significantly higher in the HH patients [1.80 (1.60–2.05) mmol/L] 
compared to the DH patients [1.40 (1.13–1.65) mmol/L], (P<0.05).  Cholesterol levels were 
significantly higher in the HG (5.11±1.14 mmol/L) and the HP (5.18±0.86 mmol/L) patients 
compared to the DG (4.49±0.73 mmol/L) and the DP (4.52±0.83 mmol/L) patients, (P<0.05).  
Levels of hsCRP were significantly higher in the DH patients [1.40 (0.73–4.03) mg/L] 
compared to the HH patients [0.60 (0.20–1.10) mg/L], (P<0.05).  Within the T1DM group, 
triglyceride levels were significantly higher in the DG patients [1.35 (0.95-1.75) mmol/L] 
compared to the DH patients [0.80 (0.70-1.28) mmol/L], (P<0.05).  Similarly within the non-
T1DM group, the HG patients had significantly higher triglyceride levels [1.70 (1.30-1.90) 
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mmol/L] compared to the HH patients [0.90 (0.20-1.05) mmol/L], (P<0.05).  With reference 
to HDL levels, within the non-T1DM group, the HH patients had significantly higher HDL 
levels [1.80 (1.60-2.05) mmol/L] compared to the HG patients [1.50 (1.35-1.73) mmol/L], 
(P<0.05).  With reference to hsCRP levels, within the non-T1DM group, the HG patients had 
a significantly higher hsCRP levels [2.85 (0.73-5.45) mg/L] compared to the HH patients 
[0.60 (0.20–1.10) mg/L], (P<0.05).
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Table 3.12: Pre-treatment clinical biochemistry data comparing T1DM and non-T1DM 
patients. 
Mean ± SD presented for parametric data and median (IQR) presented for non-parametric data.   
P-values determined using Mann Whitney-U tests for continuous non-parametric variables and 
Independent t-test for continuous parametric variables.  P indicates significant difference between 
T1DM and non-T1DM patients.  HbA1c; glycated haemoglobin, HDL; high density lipoprotein, 

















1.30 (0.78–1.60) 1.40 (0.80-1.90) NS 
HDL (mmol/L) 
 
1.40 (1.20-1.63) 1.60 (1.30-1.80) NS 
Non-HDL (mmol/L) 
 
2.90 (2.50–3.53) 3.50 (2.40-4.30) < 0.05 
Cholesterol (mmol/L) 
 
4.50 ± 0.74 5.10 ± 0.93 < 0.001 
hsCRP (mg/L) 1.70 (0.68-5.58) 1.00 (0.50-3.40) NS 
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Table 3.13: Pre-treatment clinical biochemistry data comparing T1DM and non-T1DM   
patients based on periodontal diagnosis. 
Mean ± SD presented for parametric data and median (IQR) presented for non-parametric data.  
P-values determined using One-way ANOVA test with post-hoc independent t-test for 
continuous parametric variables and Kruskal-Wallis with Mann-Whitney U post hoc tests for 
continuous non-parametric variables.  P* indicates overall p-value comparing across 
periodontal categories within T1DM or non-T1DM groups.  P-values under columns (P) relate 
to comparisons between T1DM and non-T1DM groups.  *P<0.05 indicates statistically 
significant differences compared to health within the T1DM and non-T1DM groups.  DH; 
T1DM, periodontal health, DG; T1DM, gingivitis, DP; T1DM, periodontitis, HH; non-T1DM, 
periodontal health, HG; non-T1DM, gingivitis, HP; non-T1DM, periodontitis.  HbA1c; 
glycated haemoglobin, HDL; high density lipoprotein, non-HDL; non-high density lipoprotein, 
hsCRP; high-sensitivity C-reactive protein, NS; not significant.











































< 0.01 < 0.01 < 0.01  
Triglycerides 
(mmol/L) 
T1DM 0.80 (0.70-1.28) 1.35 (0.95-1.75) * 1.30 (0.75-1.80) NS  
Non-T1DM 0.90 (0.70-1.05) 1.70 (1.30-1.90) * 1.35 (0.75-1.98) < 0.05 
P 
 
NS NS NS  
HDL 
(mmol/L) 
T1DM 1.40 (1.13-1.65) 1.45 (1.20-1.70) 1.35 (1.23-1.60) NS 
Non-T1DM 1.80 (1.60-2.05) 1.50 (1.35-1.73) * 1.40 (1.13-1.75) < 0.05 
P 
 




T1DM 2.90 (2.58-3.50) 2.90 (2.50-3.45) 3.20 (2.30-3.88) NS 
Non-T1DM 3.20 (2.40-3.90) 3.85 (2.28-4.65) 3.55 (2.68-4.20) NS 
P 
 
NS NS NS  
Cholesterol 
(mmol/L) 
T1DM 4.47 ± 0.69 4.49 ± 0.73 4.52 ± 0.83 NS 
Non-T1DM 4.97 ± 0.76 5.11 ± 1.14 5.18 ± 0.86 NS 
P 
 
NS < 0.05 < 0.05  
hsCRP 
(mg/L) 
T1DM 1.40 (0.73-4.03) 2.20 (0.55-5.85) 1.80 (1.23-7.75) NS 
Non-T1DM 0.60 (0.20-1.10) 2.85 (0.73-5.45) * 1.50 (0.60-3.20) NS 
P < 0.05 NS NS  
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3.2.6 Pre-treatment clinical periodontal parameters 
Table 3.14 summarises pre-treatment clinical periodontal data for T1DM and non-T1DM 
patients.  While comparing the two groups, the T1DM patients had a significantly higher PI 
score (0.86±0.49) compared to the non-T1DM patients (0.56±0.31), (P<0.001).  Although % 
BOP was higher in the T1DM patients (36.9±19.3 %) compared to non-T1DM patients 
(33.8±25.3 %), this difference was not statistically significant, (P>0.05).  Of note, no 
statistically significant differences were found between the two groups for mGI score, mean 
PD, mean recession, mean LOA, the number (%) of PD sites 5mm or greater and the number 
(%) of PD sites 4mm or less. 
Table 3.15 presents pre-treatment clinical periodontal data for T1DM and non-T1DM patients 
based on periodontal diagnosis.  A number of significant differences were found between the 
groups based on periodontal diagnosis, while comparing across the two groups and while 
comparing within each group.  For ease of understanding, based on periodontal diagnosis first 
the differences between the T1DM and non-T1DM groups will be discussed, followed by the 
differences within the T1DM group and the non-T1DM group. 
Considering the amount of plaque present, the PI score was significantly higher in the DG 
patients (0.94±0.40) compared to the HG patients (0.66±0.23), (P<0.01).  Similarly, the DP 
patients had significantly higher PI score (0.98±0.54) compared to the HP patients 
(0.66±0.29), (P<0.05).  When considering PD measurements, the mean PD was significantly 
higher in the DH patients (1.73±0.20 mm), compared to the HH patients (1.57±0.11 mm), 
(P<0.05).  No statistically significant differences were found for mean PD between T1DM 
and non-T1DM gingivitis and periodontitis patients.  While considering LOA, no statistically 
significant differences were found for LOA measurements between T1DM and non-T1DM 
patients with periodontitis.  While considering BOP scores, % BOP was significantly higher 
in the DH patients (9.88±5.67 %) compared to the HH patients (0.83±1.17 %), (P<0.001).  
No statistically significant differences were found for % BOP scores between T1DM and 
non-T1DM gingivitis and periodontitis patients.  While considering PD sites measuring 5 mm 
or greater, the HP patients had a significantly higher number (%) of PD sites measuring 5 mm 
or greater [37.4±25.2 (23.7±15.5 %)] compared to the DP patients [20.3±21.7 (14.7±16.4 
%)], (P<0.05).  No statistically significant differences were found for PD sites measuring 
5mm or greater between T1DM and non-T1DM healthy tissue and gingivitis patients.  Of 
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note, no statistically significant differences were found for mGI, mean recession, and PD sites 
measuring 4mm or less, between the two groups based on periodontal diagnosis. 
Comparing pre-treatment periodontal data within the T1DM group, significant differences 
were found between patients for all periodontal parameters assessed.  The mGI score was 
significantly higher in the DG (1.61±0.40) and the DP (1.96±0.51) patients compared to the 
DH patients (0.66±0.55), (P<0.001).  Also, the mGI score was significantly higher in the DP 
patients (1.96±0.51) compared to the DG patients (1.61±0.40), (P<0.01).  The PI score was 
significantly higher in the DG (0.94±0.40) and the DP (0.98±0.54) patients compared to the 
DH patients (0.32±0.25), (P<0.001).  While considering PD measurements, the DG 
(2.16±0.23 mm) and the DP (3.02±0.81 mm) patients had significantly higher mean PD 
compared to the DH patients (1.73±0.20 mm), (P<0.001).  Also, the DP patients (3.02±0.81 
mm) had a significantly higher mean PD compared to the DG patients (2.16±0.23 mm), 
(P<0.001).  While considering gingival recession, the DP patients had a significantly higher 
amount of recession (0.43±0.64 mm) compared to the DG (0.08±0.26 mm) and the DH 
(0.09±0.15 mm) patients, (P<0.05).  While considering LOA, the DH and the DG patients 
had no LOA (0.00±0.00 mm) and the DP patients had significantly more LOA (3.45±1.18 
mm) compared to the DH and DG patients, (P<0.001).  While considering BOP scores, the 
DP patients had significantly higher % BOP (52.7±17.4 %) compared to the DG (35.0±11.5 
%) and the DH (9.88±5.67 %) patients, (P<0.001).  Also, the DG patients had a significantly 
higher % BOP (35.0±11.5 %) compared to the DH patients (9.87±5.67 %), (P<0.001).  With 
reference to PD sites measuring 5 mm or greater, the DP patients had a significantly higher 
number (%) of sites measuring 5mm or more [20.3±21.7 (14.7±16.4 %)] compared to the DG 
[0.76±1.35 (0.47±0.85 %)] and the DH [0.22±0.67 (0.13±0.4 %)] patients, (P<0.001).  With 
reference to PD sites measuring 4mm or less, the DH patients had significantly higher 
number (%) of sites measuring 4mm or less [162.4±6.58 (99.9±0.40 %)] compared to the DP 
patients [122.5±29.4 (85.3±16.4 %)], (P<0.001).  Also, the DG patients had a significantly 
higher number of sites measuring 4mm or less [158.8±9.87 (99.5±9.87 %)] compared to the 
DP patients [122.5±29.4 (85.3±16.4 %)], (P<0.001). 
Comparing pre-treatment periodontal data within the non-T1DM group, the HP patients had a 
significantly higher mGI score (2.29±0.53) compared to the HG (1.50±0.57) and the HH 
(0.56±0.61) patients, (P<0.001).  Also, the HG patients (1.50±0.57) had a significantly higher 
mGI score compared to the HH patients (0.56±0.61), (P<0.001).  While considering PI score, 
the HG (0.66±0.23) and the HP (0.66±0.29) patients had a significantly higher levels of 
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plaque compared to the DH patients (0.20±0.19), (P<0.001).  With reference to PD 
measurements, the HP patients had a significantly higher mean PD (3.31±0.75 mm) 
compared to the HG (2.04±0.24 mm) and the HH (1.57±0.11 mm) patients, (P<0.001).  Also, 
the HG patients had a significantly higher mean PD (2.04±0.24 mm) compared to the HH 
patients (1.57±0.11 mm), (P<0.001).  While considering LOA, the HH and the HG patients 
had no LOA (0.00±0.00 mm) and the HP patients had significantly higher mean LOA 
(3.55±0.75 mm) compared to the HH and HG patients, (P<0.001).  While considering BOP 
scores, the HP patients had significantly higher % BOP (53.9±21.1 %) compared to the HG 
(31.3±13.6 %) and the HH (0.83±1.17 %) patients, (P<0.001).  Also, the HG patients 
(31.3±13.6 %) had a significantly higher % BOP compared to the HH patients (0.83±1.17 %), 
(P<0.001).  With reference to PD sites measuring 5mm or greater, the HH patients had no 
sites measuring 5mm or greater, and the HP patients had a significantly higher number (%) of 
sites measuring 5mm or more [37.4±25.2 (23.7±15.5 %)] compared to the HG patients 
[0.94±1.81 (0.64±1.26 %)], (P<0.001).  With reference to PD sites measuring 4mm or less, 
the HH patients had a significantly higher number (%) of sites measuring 4mm or less 
[161.3±10.6 (100%)] compared to the HG [143.4±16.1 (99.4±1.26 %)] and the HP 
[119.0±25.1 (74.7±17.7 %)] patients, (P<0.01 and P<0.001 respectively).  Also the HG 
patients had a significantly higher number of sites measuring 4mm or less [143.4±16.1 




Table 3.14: Pre-treatment clinical periodontal data comparing T1DM and non-T1DM 
patients. 
Mean ± SD presented for parametric variables.  P-values determined using Independent t-test 
for continuous parametric variables.  mGI; modified gingival index, PI; plaque index, PD; 




  (n=43) 
P 
mGI 1.57 ± 0.63 1.62 ± 0.86 NS 
PI 
 
0.86 ± 0.49 0.56 ± 0.31 < 0.001 
Mean PD (mm) 
 
2.38 ± 0.69 2.45 ± 0.89 NS 
Mean recession (mm) 
 
0.20 ± 0.44 0.20 ± 0.34 NS 
Mean LOA (mm) 
 
2.04 ± 1.51 2.25 ± 1.43 NS 
BOP (%) 36.9 ± 19.3 33.8 ± 25.3 
 
NS 
Sites 5 mm or greater 
[n (%)] 
 
7.18 ± 15.5  
(5.16 ± 11.5) 
15.5 ± 24.2 
(9.84 ± 15.1) 
NS 
 
Sites 4 mm or less 
[n (%)] 
147.2 ± 25.4 
(94.8 ± 11.5) 
137.4 ± 25.4 




Table 3.15: Pre-treatment clinical periodontal data comparing T1DM and non-T1DM 
patients based on periodontal diagnosis. 
Mean ± SD presented for parametric data.  P-values were determined using One-way ANOVA 
with post-hoc Independent t-test for continuous parametric variables.  P* indicates overall p-
value comparing across periodontal categories within T1DM or non-T1DM groups.  P-values 
under columns relate to comparisons between T1DM and non-T1DM groups.  *P<0.05, 
**P<0.01, ***P<0.001 indicates statistically significant differences compared to health and 
†P<0.05, ††P<0.01, †††P<0.001 indicates statistically significant differences compared to 
gingivitis within T1DM and non-T1DM groups.  DH; T1DM, periodontal health, DG; T1DM, 
gingivitis, DP; T1DM, periodontitis, HH; non-T1DM, periodontal health, HG; non-T1DM, 
gingivitis, HP; non-T1DM, periodontitis.  mGI; modified gingival index, PI; plaque index, PD; 
probing depth, LOA; loss of attachment, BOP; bleeding on probing, NS; not significant.










mGI T1DM 0.66 ± 0.55 1.61 ± 0.40 *** 1.96 ± 0.51 ***
,
 †† < 0.001 
Non-T1DM 0.56 ± 0.61 1.50 ± 0.57 *** 2.29 ± 0.53 ***
,
 ††† < 0.001 
P 
 
NS NS NS  
PI T1DM 0.32 ± 0.25 0.94 ± 0.40 *** 0.98 ± 0.54 *** < 0.001 
Non-T1DM 0.20 ± 0.19 0.66 ± 0.23 *** 0.66 ± 0.29 *** < 0.001 
P 
 
NS < 0.01 < 0.05  
Mean PD (mm) T1DM 1.73 ± 0.20 2.16 ± 0.23 *** 3.02 ± 0.81 ***
,
 ††† < 0.001 
Non-T1DM 1.57 ± 0.11 2.04 ± 0.24 *** 3.31± 0.75 ***
,
 ††† < 0.001 
P 
 
< 0.05 NS NS  
Mean recession (mm) T1DM 0.09 ± 0.15 0.08 ± 0.26 0.43 ± 0.64 *
, 
† < 0.05 
Non-T1DM 0.29 ± 0.38 0.10 ± 0.17 0.24 ± 0.43 NS 
P 
 
NS NS NS  
Mean LOA (mm) T1DM 0.00 ± 0.00  0.00 ± 0.00 3.45 ± 1.18 ***
,
 ††† < 0.001 
Non-T1DM 0.00 ± 0.00  0.00 ± 0.00 3.55 ± 0.75 ***
,
 ††† < 0.001 
P 
 
N/A N/A NS  
BOP (%) T1DM 9.88 ± 5.67 35.0 ± 11.5 *** 52.7 ± 17.4 ***
,
 ††† < 0.001 
Non-T1DM 0.83 ± 1.17 31.3 ± 13.6 *** 53.9 ± 21.1 ***
,
 ††† < 0.001 
P 
 
< 0.001 NS NS  
Sites 5 mm or greater 
[n (%)] 
T1DM 0.22 ± 0.67 
(0.13 ± 0.40) 
0.76 ± 1.35 *** 






(14.7 ± 16.4) 
< 0.001 
Non-T1DM 0.00 ± 0.00 
(0.00) 
0.94 ± 1.81 
(0.64 ± 1.26) 
37.4 ± 25.2 ***
,
 ††† 




NS NS < 0.05   
Sites 4 mm or less 
[n (%)] 
T1DM 162.4 ± 6.86 
(99.9 ± 0.40) 
158.8 ± 9.87 
(99.5 ± 0.85) 
122.5 ± 29.4 ***
,
 ††† 
(85.3 ± 16.4) 
< 0.001 
Non-T1DM 161.3 ± 10.6 
(100) 
143.4 ± 16.1 ** 
(99.4 ± 1.26) 
119.0 ± 25.1 ***
,
 †† 
(74.7 ± 17.7) 
< 0.001 






Figure 3.7: Pre-treatment mGI score comparing T1DM and non-T1DM patients based  
on periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 57 
T1DM patients (health n=9, gingivitis n=29, periodontitis n=19) and 43 non-T1DM patients 
(health n=9, gingivitis n=17, periodontitis n=17).  Statistics: One-way ANOVA with post-
hoc Independent t-test: **P<0.01, ***P<0.001 (according to periodontal status within the 
T1DM or non-T1DM group).  ● indicates outlier more than 1.5 but less than 3 times the IQR 







Figure 3.8: Pre-treatment PI score comparing T1DM and non-T1DM patients based on 
periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 57 
T1DM patients (health n=9, gingivitis n=29, periodontitis n=19) and 43 non-T1DM patients 
(health n=9, gingivitis n=17, periodontitis n=17).  Statistics: One-way ANOVA with post-
hoc Independent t-test: ***P<0.001 (according to periodontal status within the T1DM or 
non-T1DM group); §P<0.05, §§P<0.01 (T1DM versus non-T1DM group within the 
corresponding periodontal status).  ● indicates outlier more than 1.5 but less than 3 times the 





Figure 3.9: Pre-treatment mean PD comparing T1DM and non-T1DM patients based  
on periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 57 
T1DM patients (health n=9, gingivitis n=29, periodontitis n=19) and 43 non-T1DM patients 
(health n=9, gingivitis n=17, periodontitis n=17).  Statistics: One-way ANOVA with post-
hoc Independent t-test: ***P<0.001 (according to periodontal status within the T1DM or 
non-T1DM group); §P<0.05 (T1DM versus non-T1DM group within the corresponding 






Figure 3.10: Pre-treatment % BOP comparing T1DM and non-T1DM patients based 
on periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 57 
T1DM patients (healthy periodontal tissues n=9, gingivitis n=29, periodontitis n=19) and 43 
non-T1DM patients (healthy periodontal tissues n=9, gingivitis n=17, periodontitis n=17).  
Statistics: One-way ANOVA with post-hoc Independent t-test: ***P<0.001 (according to 
periodontal status within the T1DM or non-T1DM group); §P<0.05 (T1DM versus non-
T1DM within the corresponding periodontal status).  ● indicates outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries, ▲ indicates outlier more than 3 times the 






Figure 3.11: Pre-treatment % PD sites 5 mm or greater comparing T1DM and non-
T1DM patients based on periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 57 
T1DM patients (health n=9, gingivitis n=29, periodontitis n=19) and 43 non-T1DM patients 
(health n=9, gingivitis n=17, periodontitis n=17).  Statistics: One-way ANOVA with post-
hoc Independent t-test: ***P<0.001 (according to periodontal status within the T1DM or 
non-T1DM group); §P<0.05 (T1DM versus non-T1DM within the corresponding 
periodontal status).  ● indicates outlier more than 1.5 but less than 3 times the IQR from the 







Figure 3.12: Pre-treatment % PD sites 4mm or less comparing T1DM and non-T1DM 
patients based on periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 57 
T1DM patients (health n=9, gingivitis n=29, periodontitis n=19) and 43 non-T1DM patients 
(health n=9, gingivitis n=17, periodontitis n=17).  Statistics: One-way ANOVA with post-hoc 
Independent t-test: ** P<0.01, ***P<0.001 (according to periodontal status within the T1DM 
or non-T1DM group).  ● indicates outlier more than 1.5 but less than 3 times the IQR from 




In this chapter, the pre-treatment demographic, metabolic and periodontal data were 
compared between the T1DM and non-T1DM patients and also within these two groups 
based on periodontal diagnosis. 
With reference to age, the non-T1DM patients were significantly older in age compared to 
the T1DM patients, (P<0.001) (Table 3.1).  This was a limitation in this study as during the 
time of patient recruitment, the control patients were under-recruited (n=12) and due to time 
constraints, it was not possible to recruit more.  Hence, in order to match the number of 
recruited T1DM patients (n=57), control patients for the T1DM study were recruited from the 
control group of another parallel study of T2DM patients, by matching for gender and 
periodontal status.  Unfortunately, the age range for the T2DM patients was higher than the 
range for this T1DM study.  A total of 31 control patients from the T2DM study were 
recruited into this T1DM study to achieve a total of 43 non-T1DM patients. 
High levels of obesity, unhealthy diet, physical inactivity, poor BP control and smoking are 
strongly associated with deprivation.  All these factors are inevitably associated with the risk 
of diabetes or the risk of developing serious diabetes-related complications.  The National 
Diabetes Audit data suggest that individuals in the most deprived quantile are at a 1.5 times 
higher risk of diabetes than those in the least deprived quantile (NDA 2014).  A variation in 
deprivation and diabetes is only seen in individuals with T2DM.  Deprivation does not have 
an effect on the development of T1DM, as it is not lifestyle related (NDA 2014).  This 
possibly explains the lack of significant difference seen for IMD rank scores comparing 
T1DM and non-T1DM patients, suggesting similar lifestyle experiences in both groups. 
Smoking is recognised as a major risk factor in the development and progression of 
periodontal disease (Tomar and Asma 2000).  In the present study, smoking habits were only 
self-reported by each patient.  Unfortunately this must be considered as a potential flaw in the 
study design.  Self-reported smoking status can lead to underestimation of smoking rates, 
especially because of the decreasing social acceptability of smoking (Gallus et al. 2011).  It 
would be beneficial in future studies to validate self-reported smoking status by the use of 
biochemical measures such as, determining nicotine or its metabolite cotinine in saliva, 
serum, plasma or urine (Binnie et al. 2004),  or measuring exhaled carbon monoxide levels 
(Middleton and Morice 2000).  Nevertheless, when considering the results of self-reported 
smoking status in this study, the prevalence of current smokers was 21.1% in the T1DM 
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group and 14% in the non-T1DM group.  The prevalence data for smoking in England at the 
time this study was initiated showed that 21% of the adult population were current smokers 
(Robinson and Dunstan 2011).  Compared to the prevalence rate of the 2009 National 
Statistics, the prevalence of smoking in this study was almost equal for T1DM patients 
(21.1%); and markedly lower than 21% for non-T1DM patients (14%).  However, the current 
prevalence rate for smoking in England is 19% (Niblett 2015) and compared to this value, the 
prevalence rate for T1DM current smokers was higher while in non-T1DM patients it was 
markedly lower.  The importance of smoking status and development of periodontitis is 
highlighted in the current study.  Interestingly, irrespective of diabetes status, patients with 
healthy periodontal tissues contained no current smokers and had the lowest pack years of 
smoking compared to the gingivitis and periodontitis patients.  Also, patients with 
periodontitis in both groups contained a significantly higher percentage of ex-smokers 
compared to patients with gingivitis and healthy tissues.  Although not statistically 
significant, pack years was highest in patients with periodontitis in both T1DM and non-
T1DM groups. 
With reference to BP values (Table 3.1 and 3.3), the non-T1DM patients had a significantly 
higher diastolic BP compared to the T1DM patients, (P<0.05).  Additionally, based on 
periodontal diagnosis, the T1DM patients with healthy tissues had significantly higher 
systolic BP compared to the non-T1DM patients with healthy tissues, (P<0.05).  And, 
diastolic BP was significantly higher in non-T1DM patients with gingivitis compared to 
T1DM patients with gingivitis, (P<0.05).  Within the non-T1DM group, the gingivitis 
patients had significantly higher systolic BP compared to those with healthy tissues, 
(P<0.05).  These differences in systolic and diastolic BP could possibly be a chance finding 
in this study, and the BP values of all groups were within limits of the recommended levels 
for patients with diabetes (≤140/80 mmHg) (NICE 2015). 
With reference to duration of diabetes, it is interesting to note that T1DM patients with 
periodontitis had a significantly longer history of diabetes compared to those with gingivitis 
and healthy tissues, (P<0.05) (Table 3.5).  This finding could likely be a manifestation of the 
patients who were recruited, as the periodontitis patients were significantly older in age 
compared to those with healthy tissues (P<0.001), and although not statistically significant, 
periodontitis patients were older in age compared to those with gingivitis (Table 3.2).  It has 
been well established that age is a common confounding factor for periodontal disease, with 
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older people having experienced more periodontitis (Genco and Borgnakke 2013).  A 
significantly longer duration of diabetes in the patients with periodontitis compared to those 
with gingivitis and healthy tissues, could also suggest that a longer duration of diabetes leads 
to the increased chances of individuals suffering from more severe periodontal disease.  Our 
findings are in agreement with previous studies which found that a longer duration of 
diabetes is related to poorer periodontal health (Cianciola et al. 1982; Thorstensson and 
Hugoson 1993; Firatli et al. 1996; Silvestre et al. 2009).  Silvestre et al.’s study found that 
patients with a longer history of T1DM had significantly higher bleeding index scores and 
periodontal attachment loss compared to those with a short duration of diabetes (Silvestre et 
al. 2009).  Our findings are in contrast to other studies which showed that the duration of 
diabetes had no effect on the severity of periodontal disease (de Pommereau et al. 1992; 
Tervonen and Oliver 1993; Sandberg et al. 2000).  Since the relationship between duration of 
diabetes and periodontal disease has been studied to a lesser extent and data are often 
conflicting, it would be advisable to carry out more research in this domain. 
It has been established that T1DM has a genetic predisposition; this study found that 52.6% 
of the T1DM patients had a family history of diabetes.  With reference to diabetes control, a 
majority of the T1DM patients controlled their diabetes with a combination of diet, physical 
exercise and drug therapy (87.7%).  Only a small proportion of patients controlled their 
diabetes with drug therapy alone (12.3%).  With reference to type of drug therapy, a majority 
of the patients were taking insulin therapy alone (86%), while only a minor proportion (14%) 
controlled their diabetes by taking a combination of insulin, oral glucose lowering drugs, 
lipid lowering drugs and/or anti-hypertensive medication. 
In this study based on glycaemic control categories, a majority of the T1DM patients were 
categorised as having poor glycaemic control (i.e. HbA1c >8.5 % / >69 mmol/mol).  
Although not statistically significant, it is interesting to note that a majority of the 
periodontitis patients (52.6%) had poor glycaemic control, whereas a majority of the 
gingivitis (44.8%) and heathy tissue (55.6%) patients had moderate glycaemic control.  This 
possibly supports evidence of a two-way relationship between diabetes and periodontal 
disease whereby poor glycaemic control increases the risk for severe periodontal disease and 
periodontal disease negatively affects glycaemic control (Preshaw et al. 2012). 
 In the current study, the T1DM patients were asked to self-report if they suffered from any 
diabetes-related complications other than periodontal disease.  None of the patients suffered 
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from any macrovascular complications.  However, of the 57 T1DM patients, 22.9% reported 
at least one microvascular complication.  Interestingly, a higher proportion reporting 
diabetes-related microvascular complications were patients with periodontitis (31.6%) 
followed by healthy tissue (22.2%) and gingivitis (17.2%) patients, although these differences 
were not statistically significant.  While considering patient care pathways within diabetes 
management, it is interesting to note that a majority of the T1DM patients (94.7%) had 
received examination of their eyes and feet and had also been educated on the importance of 
routine examinations for the betterment of their condition within the past 12 months.  This 
clearly demonstrates that a robust patient care pathway does exist for screening of diabetic 
complications.  Unfortunately, the same is not true for screening of oral complications of 
T1DM, with as many as 1/3 of the T1DM patients in this study reporting not being examined 
by a dentist in the past 12 months.  Hence, an opportunity to regularly screen for oral 
complications in this disease-susceptible population is clearly being lost. 
While considering oral and dental data (Table 3.7, 3.8 and 3.9), the T1DM patients were 
found to have a significantly higher number of unrestored teeth compared to the non-T1DM 
patients, (P<0.01).  This suggests that the T1DM patients had a more sound and untreated 
dentition compared to the non-diabetic patients.  The one possible reason for this difference 
could also be due to the difference in age between the two groups, with older patients having 
a higher possibility of having restored teeth.  While comparing the two groups based on 
periodontal diagnosis, patients with healthy tissues and gingivitis had significantly more 
number of teeth present compared to those with periodontitis, (P<0.01), indicating a possible 
loss of a greater number of teeth in T1DM patients with periodontitis.  However, in 
determining the likely cause of tooth loss, a distinction was not made between extractions due 
to, for example, orthodontic treatment and extraction due to dental diseases, which might be 
relevant information to take note of in further research related to periodontal disease.  Due to 
the disturbed glucose metabolism, patients with diabetes are considered to be at a higher risk 
of developing dental caries (Siudikiene et al. 2005b).  In the present study, the non-T1DM 
patients were found to have a significantly higher number restored teeth (1-3 surfaces) 
compared to the T1DM patients, (P<0.001).  A previous study assessed dietary and oral 
hygiene habits in children with T1DM, and found that the pattern of food consumption 
differed between T1DM and non-diabetic children, with T1DM children consuming more 
main meals per day and less snacking throughout the day, while the diet of non-diabetic 
children was characterised by the frequent consumption of sweet snacks (Siudikiene et al. 
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2005b).  This could also be a possible explanation for the significantly reduced number of 
restored teeth in T1DM patients compared to the non-T1DM patients in the current study.  No 
statistically significant differences were found between the two groups for number of teeth 
with caries, broken down teeth, endodontically treated teeth and teeth with periapical 
radiolucencies.  Our findings are similar to other research studies which also demonstrated no 
significant differences in dental findings between T1DM and non-diabetic patients 
(Faulconbridge et al. 1981; Tenovuo et al. 1986; Harrison and Bowen 1987b; Twetman et al. 
1989; Swanljung et al. 1992; Edblad et al. 2001; Siudikiene et al. 2008; Tagelsir et al. 2011), 
but contrast to other studies which found both significantly higher caries prevalence 
(Albrecht et al. 1988; Jones et al. 1992; Moore et al. 2001b; Lopez et al. 2003; Miralles et al. 
2006) and lower caries prevalence in T1DM patients compared to non-diabetic controls 
(Matsson and Koch 1975; Leeper et al. 1985; Kirk and Kinirons 1991; Siudikiene et al. 2006; 
Orbak et al. 2008). 
Since oral health behaviour is directly related to the amount of plaque accumulation, it is 
reasonable to presume that the level of oral hygiene in addition to an individual’s host 
response correlates with the prevalence and severity of periodontal disease and dental caries.  
In this study, no statistically significant differences were found in oral health behaviour (i.e. 
attendance at GDP, reason for last dental visit and frequency of tooth brushing) between 
T1DM and non-T1DM patients, suggesting that both groups had a similar outlook towards 
seeking and maintaining oral health.  These findings are similar to those of a previous study 
which found that a majority of the T1DM and non-diabetic patients reported brushing their 
teeth once or twice a day and did not differ with respect to the number of dental visits during 
the past year (Siudikiene et al. 2005a).  Interestingly, statistical differences were only found 
with regards to interproximal tooth cleaning, and the non-T1DM patients reported performing 
more frequent interproximal teeth cleaning compared to a majority of the T1DM patients who 
reported having never used interproximal cleaning aids (n=40, 70.2%), as opposed to a 
majority of the non-T1DM patients (n=20, 46.5%) who reported cleaning their teeth three or 
more times per week.  It is also interesting to note that within the non-T1DM group (Table 
3.11), a majority of the periodontitis patients (n=11, 64.7%) reported cleaning their teeth 
interproximally three or more times per week compared to the gingivitis and healthy tissue 
patients.  This suggests that the possible awareness of the advanced periodontal disease might 
lead to increased vigilance and motivation in performing and maintaining oral health in this 
cohort of patients by using interproximal cleaning aids.  It is also important to note that 
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irrespective of the diabetes status, a higher proportion of periodontitis patients reported 
having attended their GDP regularly within the past 12 months compared to patients with 
gingivitis and healthy tissues.  This suggests that the presence and possible awareness of oral 
disease leads to patients with periodontitis seeking professional help for the betterment and 
maintenance of their oral health condition. 
With reference to the clinical biochemistry analysis, in the current study, as expected the 
T1DM patients had a significantly higher %/ mmol/mol of HbA1c compared to the non-
T1DM patients, (P<0.001) (Table 3.12).  This study found higher HbA1c levels in T1DM 
patients with periodontitis and gingivitis compared to those with healthy tissues, suggesting a 
possible role for periodontal inflammation plays in elevating glycated haemoglobin levels in 
patients with gingivitis and periodontitis.  However, these differences did not reach statistical 
significance (Table 3.13).  The HbA1c level for patients with T1DM and periodontitis in this 
study was comparable to the HbA1c level reported in Lalla et al.’s study (8.49±1.74 %) 
(Lalla et al. 2007b) but higher than that in Silvestre et al.’s study (7.83±1.62 %) (Skaleric et 
al. 2004) and lower than the HbA1c levels reported in studies by Erhan Firatli (9.33±3.98 %), 
Moore et al. (11.0±0.1%) and Dakovic et al. (9.2±1.6 %) (Firatli 1997; Moore et al. 1999; 
Dakovic and Pavlovic 2008). 
Further clinical biochemistry data analysis in this study revealed that compared to the non-
T1DM patients, T1DM patients had significantly lower levels of non-HDL and cholesterol.  
Non-HDL and cholesterol are considered indicators for CVD, and are particularly useful 
parameters in predicting CVD risk in patients with diabetes (Lu et al. 2003).  The non-T1DM 
patients also had higher levels of triglycerides and HDL compared to the T1DM patients, 
however these differences were not statistically significant (Table 3.12).  These findings 
favourably reflect on the UK management guidelines for T1DM, which recommend the 
implementation of dietary advice and the annual screening for CVD risk factors for patients 
with T1DM to ensure that they have optimal lipid profile (including HDL, non-HDL, 
cholesterol and triglyceride) levels (NICE 2015).  Therefore, it is reasonable to presume that 
the T1DM patients in this study were receiving more aggressive management and monitoring 
of CVD risk factors compared to the control patients.  Also, 14% of the T1DM patients were 
taking lipid lowering and anti-hypertensive medication, however comparable data from non-




In the present study, levels of hsCRP appeared higher in patients with T1DM compared to the 
non-T1DM patients; however the difference was not statistically significant (Table 3.12).  
Interestingly, when comparing the two groups based on periodontal diagnosis, the T1DM 
patients with healthy tissues had significantly higher hsCRP levels than the non-T1DM 
patients with healthy tissues, (P<0.05) (Table 3.13).  Our findings are in support of an 
association of the increase in systemic inflammation in patients with T1DM (Devaraj et al. 
2007; Snell-Bergeon et al. 2010).  Similarly, a meta-analyses carried out on CRP levels in 
relation to periodontitis consistently found elevated hsCRP levels in patients with 
periodontitis compared to those with healthy tissues (Paraskevas et al. 2008).  Likewise this 
was confirmed in this study, as non-T1DM patients with gingivitis had significantly higher 
levels of hsCRP compared to those with healthy tissues (P<0.05) (Table 3.13).  However, 
within the T1DM group, similar differences were not found when comparing patients with 
gingivitis and those with healthy tissues.  A possible explanation of this effect would be that 
the elevated background levels of hsCRP in patients with T1DM masks additional differences 
in hsCRP levels caused by inflammatory periodontal disease.  It is interesting to note that 
irrespective of the diabetes status, the gingivitis patients had the highest hsCRP levels 
compared to patients with periodontitis and healthy tissues. 
Previous epidemiological research studies related to T1DM and periodontal disease have 
reported an increased prevalence and severity of periodontal disease in T1DM patients 
compared to non-diabetic individuals.  In the present study, when exploring pre-treatment 
periodontal status of the T1DM patients in comparison to those without diabetes, 
significantly higher levels of plaque were found in T1DM patients compared to the non-
T1DM patients, (P<0.001) (Table 3.14).  This finding could be explained by the fact that 
excessive glucose related to diabetes, enters the oral cavity through the GCF and saliva, a 
sugar-rich biofilm which forms will then, in general, enhance plaque growth.  A lack of 
understanding and knowledge about oral hygiene and maintaining optimal oral health may be 
factors related to higher plaque scores in patients with diabetes (Hugoson et al. 1989).  Our 
findings are similar to results of previous studies reporting significantly higher plaque scores 
in T1DM patients compared to non-diabetic individuals (Novaes et al. 1991; Aren et al. 2003; 
Lalla et al. 2006a).  Our finding was contrary to previous studies which found similar levels 
of plaque in patients with and without T1DM (Bay et al. 1974; Bernick et al. 1975; Hugoson 
et al. 1989; Sandholm et al. 1989a; de Pommereau et al. 1992; Firatli et al. 1996; Firatli 1997; 
Tervonen and Karjalainen 1997; Lalla et al. 2006b).  Similarly, when comparing the two 
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groups based on periodontal diagnosis, T1DM patients with gingivitis and periodontitis had 
significantly higher amounts of plaque compared to the non-T1DM patients with gingivitis 
and periodontitis, (P<0.01 and P<0.05 respectively) (Table 3.15 and Figure 3.8).  Although 
T1DM patients with healthy tissues had higher plaque scores compared to non-T1DM 
patients with healthy tissues, this difference was not statistically significant.  The results of 
this study in relation to plaque scores suggest that the T1DM patients had poorer oral hygiene 
compared to those without diabetes, which could also be due to the greater attention and 
importance placed by the T1DM patients in focusing and maintaining their systemic health 
and the necessary daily doses of insulin as opposed to maintaining optimal oral hygiene, 
which was found to be superior in the non-T1DM patients as measured by the Silness and 
Loe plaque index scoring system. 
With reference to periodontal probing depths, no statistically significant differences were 
found for PD measurements between T1DM and non-T1DM patients (Table 3.14).  Our 
findings are similar to previous studies which found similar PD measurements in patients 
with and without T1DM (Sandholm et al. 1989a; Novaes et al. 1991; Firatli 1997; Lalla et al. 
2006b; Luczaj-Cepowicz et al. 2006; Kaur et al. 2009).  The findings of the present study are 
in contrast to those of other studies which found deeper periodontal pockets in T1DM 
patients compared to non-diabetic controls (Hugoson et al. 1989; Dakovic and Pavlovic 2008; 
Silvestre et al. 2009; Hodge et al. 2012).  Interestingly, the PD measurements for this study 
are comparable to PD data from a number of previous studies (Aren et al. 2003; Lalla et al. 
2006b; Kaur et al. 2009) but  higher than a longitudinal study which evaluated the clinical 
status of periodontal tissues in children with T1DM (Firatli 1997), indicating variations in the 
extent of periodontal disease between different research studies.  However, it is important to 
note that most investigations of T1DM and periodontal disease included a cohort of a 
younger age group, which might limit the extent of periodontal disease and hence may not 
permit appropriate comparison to the results of this study.  Nevertheless irrespective of the 
age range, a majority of the T1DM patients had comparable PD measurements compared to 
non-T1DM patients.  In the current study, when comparing the two groups based on 
periodontal diagnosis, T1DM patients with healthy tissues had significantly higher mean PD 
compared to non-T1DM patients with healthy tissues, (P<0.05). However, no statistically 
significant differences were found for mean PD while comparing T1DM and non-T1DM 
patients with periodontitis (Table 3.15 and Figure 3.9). 
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In addition to PD measurements, a previous study calculated the % of PD sites with advanced 
periodontal disease, demonstrating that when considering the % of PD sites ≥5 mm, the 
differences between the T1DM patients (8.50±13.1 %) and the non-T1DM patients 
(5.30±9.00 %) was found to be statistically significant (Lalla et al. 2006b).  It is very rare that 
periodontal disease would affect all parts of the periodontium equally, and the measurement 
of mean PD alone provides a crude description of the pocket depths found in each patient.  
Hence, the utilization of reporting mean PD, without additional data such as the % of sites 
with advanced periodontal disease, can be seen as a limitation of all studies in this field of 
research.  In the present study, the % of PD sites measuring ≥5 mm was significantly lower in 
the T1DM patients with periodontitis compared to the non-T1DM patients with periodontitis 
(P<0.05), indicating the presence of more severe periodontal disease in non-T1DM patients 
compared to the T1DM patients (Table 3.15 and Figure 3.11).  This may reflect on the 
differences in the recruitment strategy utilised for T1DM and non-T1DM patients in the 
current study.  As previously described, the T1DM patients were recruited from medical 
databases of T1DM patients held in both primary and secondary care settings, whereas the 
non-T1DM patients were recruited from diagnostic or student treatment clinics within the 
School of Dental Sciences, who had been referred for periodontal diagnosis and care from 
their general dental practice.  Although the T1DM and non-T1DM patients were matched 
based on their periodontal diagnosis, the extent of their periodontal disease was not 
considered in the process.  This is a limitation in the present study, and highlights a need in 
future studies, to stratify periodontal case selection based on the extent and severity of 
periodontal disease to ensure a more meaningful and robust matching of groups with respect 
to the periodontal status of selected patients. 
With reference to clinical LOA, no statistically significant difference was found for mean 
LOA while comparing patients with and without T1DM.  Our findings are similar to a 
previous study which found no statistically significant difference in LOA levels between the 
two groups (Kaur et al. 2009), and contrast with those of previous studies which found 
significantly higher LOA in T1DM patients compared to non-diabetic controls (Firatli 1997; 
Lalla et al. 2006a; Silvestre et al. 2009; Hodge et al. 2012). 
In the current study, exploring data related to gingival inflammation indicates a difference in 
patterns for T1DM compared to non-T1DM patients.  The T1DM patients with healthy 
tissues had a significantly higher % BOP compared to the non-T1DM patients with healthy 
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tissues, (P<0.001) (Table 3.15 and Figure 3.10).  Also, the T1DM patients with healthy 
tissues had higher mGI scores compared to the non-T1DM patients with healthy tissues, but 
this difference was not statistically significant (Table 3.15 and Figure 3.7).  Our findings 
support data from past research studies that demonstrated significantly higher levels of 
gingival inflammation in T1DM patients compared to non-diabetic controls (Novaes et al. 
1991; Aren et al. 2003; Lalla et al. 2006a; Dakovic and Pavlovic 2008; Orbak et al. 2008; 
Silvestre et al. 2009).  A possible explanation for the presence of increased levels of gingival 
inflammation seen in T1DM patients is a manifestation of the upregulated diabetes-related 
systemic inflammation which presents itself even in patients diagnosed with healthy 
periodontal tissues.  The similar pattern of significantly higher levels of gingival 
inflammation in T1DM patients compared to non-T1DM patients was not replicated in 
patients with gingivitis and periodontitis and no statistically significant differences in levels 
of % BOP and mGI were seen between patients with T1DM and gingivitis and periodontitis 
compared to non-T1DM patients with gingivitis and periodontitis (Table 3.15).  It would not 
be unreasonable to presume that the more severe periodontal disease present in the non-
T1DM patients compared to the T1DM patients may have masked the presence of greater 
background level of gingival tissue inflammation in T1DM patients with periodontitis 
compared to non-T1DM patients with periodontitis. 
Summary of key findings from chapter 3 
 The non-T1DM patients were significantly older compared to the T1DM patients. 
 Diastolic BP was significantly higher in non-T1DM patients compared to the T1DM 
patients. 
 Patients with periodontitis in both T1DM and non-T1DM groups contained a 
significantly higher % of ex-smokers compared to those with gingivitis and healthy 
tissues. 
 The T1DM patients with periodontitis had a significantly longer duration of diabetes 
compared to those with gingivitis and healthy tissues. 
 The T1DM patients with healthy tissues controlled their diabetes with insulin alone, 
whereas patients with gingivitis and periodontitis controlled their diabetes with 
insulin, oral glucose lowering drugs, lipid lowering drugs and anti-hypertensive drugs. 
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 94.7% of the T1DM patients had received examination of their eyes and feet within 
the past 12 months.  However, 1/3 of the T1DM patients in the study had not visited 
the dentist in the past 12 months. 
 The T1DM patients had a significantly higher number of sound and unrestored teeth 
compared to the non-T1DM patients. 
 The T1DM patients reported poorer oral health behaviours with regards to 
interproximal teeth cleaning compared to the non-T1DM patients. 
  Levels of non-HDL and cholesterol were significantly lower in the T1DM patients 
compared to the non-T1DM patients. 
 Levels of hsCRP appeared higher in patients with T1DM compared to non-T1DM 
patients however this difference was not statistically significant.  Also, in non-T1DM 
patients, levels of hsCRP were significantly lower in patients with healthy tissues 
compared to those with gingivitis. 
 Although not statistically significant, T1DM patients with periodontitis had higher 
HbA1c levels compared to T1DM patients with gingivitis and healthy tissues. 
 No statistically significant differences were found for mean PD between T1DM and 
non-T1DM patients.  However, the non-T1DM patients with periodontitis had a 
significantly higher % of PD sites measuring ≥5 mm compared to the T1DM patients 
with periodontitis. 
 The T1DM patients with healthy tissues had a significantly higher % BOP compared 
to the non-T1DM patients with healthy periodontal tissues.
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4 Chapter 4. Quantification of protein levels, and detection and analysis of pre-
treatment local and systemic biomarker levels in patients with T1DM 
4.1 Introduction 
Clinical studies have demonstrated that T1DM is associated with an increase in circulating 
inflammatory mediators (AboElAsrar et al. 2012; Redondo et al. 2014).  Diabetes gives rise 
to impaired macrophage and neutrophil functioning, altered collagen production and 
exaggerated collagenase activity (Lalla et al. 2000; Noack et al. 2000a; Mealey and Rose 
2008b) and has the potential to lead to a heightened inflammatory state, as interactions of 
AGEs have been known to increase the production of pro-inflammatory mediators (Mealey 
and Rose 2008b). 
The tissue destruction that occurs in periodontal disease results mainly from an upregulated 
immune-inflammatory response which is caused by prolonged exposure to subgingival 
plaque bacteria.  The importance of the host immune response to dental plaque and the 
increase in local production of inflammatory mediators has been well established (Kornman 
et al. 1997).  Research studies have demonstrated elevated levels of inflammatory biomarkers 
in serum, plasma, GCF, saliva and gingival tissues of patients with periodontitis (Makela et 
al. 1994; Maeso et al. 2007; Marcaccini et al. 2009b; Marcaccini et al. 2010; Lappin et al. 
2011).  These inflammatory mediators have the ability to activate osteoclasts leading to bone 
resorption, increase collagen breakdown and impair wound healing, leading to clinical signs 
of periodontal disease. 
Over the last decade, the increasing recognition of the clinical and pathogenic association 
between periodontitis with general health and disease (including diabetes) has contributed to 
our understanding of periodontal pathogenesis with several potential clinical applications 
(Nassar et al. 2007; Lalla and Papapanou 2011; Preshaw et al. 2012).  A dysregulated 
immune response is central to the pathogenesis of diabetes and its related complications 
(Taylor et al. 2013).  Cytokines are critical in the development of T1DM and the modulation 
of cytokines is a likely therapeutic modality (Mandrup-Poulsen et al. 2010; Baumann et al. 
2012).  The cytokine literature related to T1DM patients with periodontitis is limited and the 
elevation of GCF IL-1β and PGE2 in T1DM patients compared to systemically healthy 
individuals with similar levels of periodontal disease is the only consistent finding (Salvi et 
al. 1997b; Salvi et al. 2010).  Other than cytokines, chemokines (IL-8 and ENA-78/CXCL5) 
and other mediators such as MMPs (MMP-9), have been detected in samples of GCF, saliva 
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and plasma and are possibly associated with the cross-susceptibility between T1DM and 
periodontal disease (Salvi et al. 2010; Dakovic et al. 2013; Lappin et al. 2015). 
As research investigating the pathogenic mechanisms of T1DM and periodontal disease is 
notably lacking, the experiments presented in this chapter reports the analysis of pre-
treatment inflammatory biomarkers in patients with T1DM compared to non-diabetic patients 
with and without periodontal disease. 
4.2 Results 
4.2.1 Quantification of protein 
The samples collected for the present study were collected from 2006 to 2008.  After 
collection, all samples were stored in a -80 °C freezer, until further analyses, which were 
performed in 2015.  Hence, protein content of samples was measured to ensure that there has 
not been substantial protein degradation or loss in the stored samples  Therefore, in order to 
assess protein levels in the samples, all baseline serum samples (n=96) were analysed using 
the Bradford assay protocol.  The GCF samples were not analysed due to the limited volume 
of GCF available from the sampling procedure. 
All patient and control samples were diluted (1:300) in distilled water.  Table 4.1 presents 
protein concentration data for all baseline serum samples.  The amount of protein present in 
the samples of all patients (T1DM and non-T1DM) was (mean±SD) 355.1±203.9 mg/ml.  
When analysing the samples based on diabetes status, no significant differences were found 
for protein levels in patients with T1DM (322.7±196.0 mg/ml) compared to non-T1DM 
patients (395.1±208.6 mg/ml), (P>0.05). 
Table 4.2 presents protein concentration data for T1DM and non-T1DM patients based on 
periodontal diagnosis.  Of note, no statistically significant differences were found for protein 
concentrations between the DH (424.4±287.4 mg/ml), DG (293.8±142.3 mg/ml) and DP 
(313.7±205.1 mg/ml) patients compared to the HH (459.0±174.2 mg/ml), HG (366.7±166.3 
mg/ml) and HP (389.5±261.3 mg/ml) patients, (P>0.05).  Similarly, no statistically 
significant differences were found within the T1DM and non-T1DM groups based on 
periodontal diagnosis, (P>0.05). 
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Table 4.1: Protein levels in baseline serum samples comparing T1DM and non-T1DM 
patients. 
Mean ± SD presented for parametric data.  P-values determined using Independent 
t-test for continuous parametric variables (no statistically significant differences 
were found). 
 













T1DM 424.4 ± 287.4 293.8 ± 142.3 313.7 ± 205.1 NS 
Non-T1DM 459.0 ± 174.2 366.7 ± 166.3 389.5 ± 261.3 NS 
P NS NS NS  
Table 4.2: Protein levels in baseline serum samples based on diabetes status and 
periodontal diagnosis. 
Mean ± SD presented for parametric data.  P-values were determined using One-way 
ANOVA with post-hoc Independent t-test for continuous parametric variables.  P* indicates 
overall p-value comparing across periodontal categories within T1DM or non-T1DM 
groups.  P-values under columns (P) relate to comparisons between T1DM and non-T1DM 
group.  DH; T1DM, periodontal health, DG; T1DM, gingivitis, DP; T1DM, periodontitis, 
HH; non-T1DM, periodontal health, HG; non-T1DM, gingivitis, HP; non-T1DM, 
periodontitis, NS; not significant.






Amount of protein 
(mg/ml) 
355.1 ± 203.9 322.7 ± 196.0 395.1 ± 208.6 
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4.2.2 Investigation of candidate biomarkers using cytokine arrays 
To investigate the biomarkers present in the samples collected, a cytokine array experiment 
was carried out using the Proteome Profiler Human XL Cytokine Array Kit (R&D Systems).  
Only serum samples were analysed using this technique.  The cytokine array experiment 
involved pooling three serum samples from each diabetes status and periodontal diagnosis 
category: DH, HH, DP and HP and incubating 4 separate nitrocellulose membranes (which 
constitute the antibody arrays) with these samples.  It was considered important to match the 
clinical periodontal parameters of the DH and HH group and the DP and HP group as closely 
as possible so that any differences in the results of the array experiment would be a 
manifestation of the diabetes status and not the periodontal condition.  Therefore, 3 patients 
from each group (DH, HH, DP and HP) were selected after matching for clinical periodontal 
parameters.  Table 4.3 presents the demographic (age) and clinical periodontal data of the 
T1DM and non-T1DM patients selected for the cytokine array analysis. 
Figure 4.1 shows radiographic images of the 4 nitrocellulose membranes as follows: DP 
(membrane 1), DH (membrane 2), HP (membrane 3), and HH (membrane 4).  The intensity 
of the spots (signals) on all 4 membranes, were compared to determine differences in 
biomarker levels between the four groups.  The radiograph was also cross-checked with a 
template provided in the kit, to rule out any false positive signals or any referred signals from 
a neighbouring spot.  Radiograph intensities were determined by densitometry and graphs 




Table 4.3: Demographic and clinical periodontal data of the T1DM and non-T1DM 
patients selected for the cytokine array analysis. 
This table presents the age and clinical periodontal data of the T1DM and non-T1DM patients 
selected for the cytokine array analysis.  Three patients from each diabetes status and 
periodontal diagnosis group (DH, HH, DP and HP) were selected after matching for clinical 
periodontal status.  Selection was made by comparing data of the DH and HH patients (in 
blue) and the DP and HP patients (in red).  DH; T1DM, periodontal health, HH; non-T1DM, 
periodontal health, DP; T1DM, periodontitis, HP; non-T1DM, periodontitis, mGI; modified 
gingival index, PI; plaque index, PD; probing depth, LOA; loss of attachment, BOP; bleeding 
on probing. 

































































































































Figure 4.1: Radiographic images of the four nitrocellulose membranes highlighting selected candidate biomarkers. 









Membrane 2: T1DM, periodontal health 
 
 
Membrane 3: Non-T1DM, periodontitis 
 
 
Membrane 4: Non-T1DM, periodontal health 
 155 
 
Table 4.4 presents results of the cytokine array experiment, with intensity values presented 
for biomarkers found present in all the four groups of diabetes status and periodontal 
diagnosis.  The intensity values of different biomarkers showed either differences in intensity 
values or similar intensity values while comparing the four groups (DP, HP, DH and HH).  
The decision to select a candidate biomarker was based on finding greater differences in 
intensity values and preferably higher intensity values in the periodontitis groups (with or 
without diabetes) compared to the healthy periodontal tissue groups.  Based on these results 
and after consideration of the relevant literature it was decided to further analyse the 
following 4 candidate biomarkers in serum samples: MMP-9, BAFF, resistin and ENA-
78/CXCL5.  Figure 4.2 shows bar graphs comparing intensities of biomarker MMP-9, BAFF, 
resistin and ENA-78/CXCL5 (intensity values highlighted in orange and bold in Table 4.4). 
The levels of MMP-9 [as assessed by relative intensity (RI) of the radiograph dots] were 
found to be highest in the DP group (RI 10427.5), followed by the HP group (RI 9185), the 
DH group (RI 8993) and was found least in the HH group (RI 6112).  Comparing the 
intensity of the signals, the intensity of MMP-9 was 1.16-fold higher in the DP group (RI 
10427.5) compared to the DH group (RI 8993).  The intensity of MMP-9 was 1.50-fold 
higher in the HP group (RI 9185) compared to the HH group (RI 6112).  The intensity of 
MMP-9 was 1.14-fold higher in the DP group (RI 10427.5) compared to the HP group (RI 
9185).  And the intensity of MMP-9 was 1.47-fold higher in the DH group (RI 8993) 
compared to the HH group (RI 6112).  Since MMP-9 was found highest in the DP group 
compared to the HP group, MMP-9 was selected for further analysis (Table 4.4, Figure 4.1 
and 4.2). 
The intensity of BAFF, was found to be highest in the DP group (RI 6807.5), followed by the 
HP group (RI 6318.5), the DH group (RI 3957) and was found least in the HH group (RI 
1318.5).  Comparing the intensity of the signals, the intensity of BAFF was 1.72-fold higher 
in the DP group (RI 6807.5), compared to the DH group (RI 3957).  The intensity of BAFF 
was 4.79-fold higher in the HP group (RI 6318.5) compared to the HH group (RI 1318.5).  
The intensity of BAFF was 1.08-fold higher in the DP group (RI 6807.5) compared to the HP 
group (RI 6318.5).  And the intensity of BAFF was 3-fold higher in the DH group (RI 3957) 
compared to the HH group (RI 1318.5).  Since BAFF was found highest in the DP group 




The apparent levels of resistin were highest in the DP group (RI 6215), followed by the HP 
group (RI 6125.5), the DH group (RI 4069.5) and lowest of all in the HH group (RI 491.5).  
Comparing the intensity of membrane signals, the intensity of resistin was 1.53-fold higher in 
the DP group (RI 6215) compared to the DH group (RI 4069.5).  The intensity of resistin was 
12.5-fold higher in the HP group (RI 6125.5) compared to the HH group (RI 491.5).  The 
intensity of resistin was 1.01-fold higher in the DP group (RI 6215) compared to the HP 
group (RI 6125.5).  The intensity of resistin was 8.28-fold higher in the DH group (RI 
4069.5) compared to the HH group (RI 491.5).  Since resistin was found highest in the DP 
group compared to the HP group, resistin was selected for further analysis (Table 4.4, Figure 
4.1 and 4.2). 
The intensity of ENA-78/CXCL5, was found to be highest in the DP group (RI 6062), 
followed by the DH group (RI 5523.5), the HP group (RI 4783) and was found least in the 
HH group (RI 2640).  Comparing the intensity of signals, the intensity of ENA-78/CXCL5 
was 1.10-fold higher in the DP group (RI 6062) compared to the DH group (RI 5523.5).  The 
intensity of ENA-78/CXCL5 was 1.81-fold higher in the HP group (RI 4783) compared to 
the HH group (RI 2640).  The intensity of ENA-78/CXCL5 was 1.27-fold higher in the DP 
group (RI 6062) compared to the HP group (RI 4783).  And the intensity of ENA-78/CXCL5 
was 2.09-fold higher in the DH group (RI 5523.5) compared to the HH group (RI 2640).  
Since ENA-78/CXCL5 was found highest in the DP group compared to the HP group,   












Table 4.4: Intensity values of biomarkers present. 
Intensity values for biomarkers detected in all groups of diabetes status and periodontal 
diagnosis.  Highlighted in orange and bold are the selected candidate biomarkers.  DP; 
T1DM, periodontitis, HP; non-T1DM, periodontitis, DH; T1DM, periodontal health, HH; 














Adiponectin 16066.5 14154 15104 12677.5 
Aggrecan 14736.5 12080 12850.5 8755 
Angiogenin 16147.5 14609 15430.5 12413 
Angiopoietin-1 10675.5 5141 9737.5 3981 
BAFF 6807.5 6318.5 3957 1318.5 
BDNF 9406.5 7395.5 7436 3179 
Complement Component C5/C5a 10073 7643.5 8350.5 5887.5 
CD14 6606 6508.5 5612 3889 
CD40 ligand 2168.5 2374 2041.5 3712 
Chitinase 3-like 1 20223.5 20485.5 20669 17482.5 
Complement Factor D  14234.5 14427.5 15119 14457 
C-Reactive Protein 20508.5 18408.5 20290.5 18360.5 
Cystatin C 10242.5 9440.5 7812.5 6369 
Dkk-1 3890 2362.5 2667.5 570.5 
DPPIV 11692 7704 10147.5 7092 
EGF 2260 1890 2271.5 784.5 
EMMPRIN 8829 10101 8219 5864.5 
ENA-78/CXCL5 6062 4783 5523.5 2640 
Endoglin 7637.5 8666 8923 8594 
Fas Ligand 958.5 683 1491.5 1081.5 
FGF basic 1505.5 1423.5 2157.5 2073.5 
FGF-19 1785 1605.5 1366.5 293.5 
GDF-15 2226 3874 2065.5 507.5 
ICAM-1 9634.5 5924 10882 9864 
IGFBP-2 7298 6326.5 6755.5 4055.5 
IGFBP-3 8510 8064.5 7245 5608.5 












IL-18 Bpa 2429 3077 2343 1301.5 
IP-10 2431 2924.5 2271 130 
Leptin 6402.5 2748.5 3662.5 4149 
Lipocalin-2 13355 12979 12816.5 10546.5 
MCP-1 1361 1520.5 1702 279.5 
MIF 1740 1386 1563.5 739 
MIP-3β 1409 2210.5 741 355.5 
MMP-9 10427.5 9185 8993 6112 
Myeloperoxidase 2713 2503 1983 417.5 
Osteopontin 5382.5 5685.5 4582.5 2664 
PDGF-AA 23259 23276 21004.5 16240 
PDGF-AB/BB 14782.5 14937.5 13350.5 10148.5 
PF4 13194.5 15113.5 13677.5 12191.5 
RANTES 14634.5 14033.5 11443.5 11617.5 
RBP4 21215.5 24127.5 24175.5 20151 
Resistin 6215 6125.5 4069.5 491.5 
SDF-1α 3667 3301.5 2142 528 
Serpin E1 16549.5 18098.5 15833.5 12952.5 
ST2 12286 9628 10458.5 7266.5 
TARC 5999.5 2081 3558 3306 
TFF3 2891 2750 1197.5 1406 
TfR 7213.5 1907.5 2099 4327.5 
Thrombospondin-1 6673.5 2236 4864.5 3068 
UPAR 2773.5 3230.5 3025 937 
Vitamin D BP 13811.5 11402 14343 10838.5 
 
Table 4.4: Intensity values of biomarkers present. 
Intensity values for biomarkers detected in all groups of diabetes status and periodontal 
diagnosis.  Highlighted in orange and bold are the selected candidate biomarkers.  DP; 
T1DM, periodontitis, HP; non-T1DM, periodontitis, DH; T1DM, periodontal health, HH; 







Figure 4.2: Bar graph presenting intensity values for selected candidate biomarkers. 
X-axis represents the intensity of the signal produced on the nitrocellulose membrane and      
Y-axis represents selected biomarkers.  DP; T1DM, periodontitis, HP; non-T1DM, 
periodontitis, DH; T1DM, periodontal health, HH; non-T1DM, periodontal health, MMP-9; 




4.2.3 Verification methods 
The accurate quantification of biomarkers in biological samples is largely dependent on the 
analytical technique used.  The intra-assay precision, inter-assay precision, recovery and 
sensitivity data for serum samples for selected candidate biomarkers are quoted from the 
R&D systems product datasheet for each biomarker and are presented in Table 4.5, 4.6, 4.7 
and 4.8.  Recovery experiments were performed for resistin, as the recovery value for serum 
was not provided in the resistin product datasheet. 
Intra-assay precision 
To test the precision within an assay, three samples of known concentration were tested 20 
times on one plate to determine intra-assay precision.  The intra-assay variations for the 
calculated lower limit of detection (LLOD) for candidate biomarkers in serum are presented 
in Table 4.5. 
Table 4.5: Intra-assay variation of LLOD for Human Quantikine ELISA. 
MMP-9; matrix metalloproteinase-9, BAFF; B-cell activating factor, ENA-78/CXCL5; 
epithelial neutrophil activating peptide-78, IL-8; interleukin-8, SD; standard deviation, CV; 



















n 20 20 20 20 20 
Mean 0.833 433 0.60 113 168 
SD 0.017 28.2 0.03 9.4 9.4 




To test the precision between assays, three samples of known concentration were tested in 40 
separate assays to determine inter-assay precision.  The inter-assay variations for the 
calculated LLOD for candidate biomarkers in serum are presented in Table 4.6. 
Table 4.6: Inter-assay variation of LLOD for Human Quantikine ELISA. 
MMP-9; matrix metalloproteinase-9, BAFF; B-cell activating factor, ENA-78/CXCL5; 
epithelial neutrophil activating peptide-78, IL-8; interleukin-8, SD; standard deviation, CV; 
coefficient of variation. 
Recovery 
The recovery experiment is important for analysing the accuracy of the ELISA for particular 
sample types.  The resulting “recovery” of the spiked sample or the resulting concentration, 
demonstrates is the expected value can be accurately measured.  The recovery experiment is 
important for analysing the accuracy of the ELISA for particular sample types.  To determine 
the recovery for each assay for human serum samples, a serum sample is spiked with the 
human recombinant protein provided as standard in each ELISA kit and the % recovery of 
the protein is calculated in reference to an unspiked, neat serum sample run in the same assay.  
If the serum samples require dilution to fit within the range of the standard curve, the 
dilutions are treated as the new “neat” samples. A spiked reagent diluent is used as a control 
(control spike). The % recovery is calculated by using the formula: (assay result for spiked 
sample – assay result for neat sample) / (amount spiked) x 100 (Jaedicke et al. 2012).  The 
















n 40 20 40 40 20 
Mean 0.972 474 0.61 109 196 
SD 0.077 46.8 0.05 10.1 14.5 
CV (%) 7.9 9.9 8.2 9.3 7.4 
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Table 4.7: Recovery for candidate biomarkers in serum. 
The R&D systems recommend an acceptable recovery range of 80-120%.  MMP-9; matrix 
metalloproteinase-9, BAFF; B-cell activating factor, ENA-78/CXCL5; epithelial neutrophil 
activating peptide-78, IL-8; interleukin-8. 
 
Sensitivity 
Sensitivity represents the smallest amount of substance in a sample which can accurately be 
measured by an assay (Saah and Hoover 1997), and which is statistically not equal to zero.  
To determine assay sensitivity, 20 zero standard replicates are run in one assay and sensitivity 
is calculated from the standard curve.  Sensitivity is defined as the mean of the assay result 
for the 20 zero standard replicates + 2 standard deviations of the means (Jaedicke et al. 2012).  











Range - 1.01-6.44 0.010-0.055 - 1.5-7.5 
Mean < 0.156 2.68 0.026 < 15 3.5 
Table 4.8: The minimum detectable dose of candidate biomarkers. 
MMP-9; matrix metalloproteinase-9, BAFF; B-cell activating factor, ENA-78/CXCL5; 
epithelial neutrophil activating peptide-78, IL-8; interleukin-8. 
 
4.2.4 Pre-treatment serum biomarker levels 
Table 4.9 summarises pre-treatment serum levels of candidate biomarkers (MMP-9, BAFF, 
resistin and ENA-78/CXCL5) comparing T1DM and non-T1DM patients.  The levels of 
MMP-9, resistin and ENA-78/CXCL5 were significantly higher in the T1DM patients 
(882.3±577.1 ng/ml, 11.3±4.78 ng/ml and 1664.0±886.8 pg/ml) compared to the non-T1DM 
patients (483.8±277.5 ng/ml, 8.98±3.25 ng/ml and 1296.3±805.6 pg/ml), (P<0.001, P<0.01 
and P<0.05 respectively) (Figure 4.3, 4.4 and 4.5).  The level of BAFF was higher in the 
 MMP-9 BAFF Resistin ENA-78/CXCL5 IL-8 
n 5 4 1 5 5 
Range (%) 91-99 84-106 - 93-109 88-106 
Mean (%) 95 93 110 101 98 
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T1DM patients (1179.2±290.7 pg/ml) compared to the non-T1DM patients (1155.0±286.7 
pg/ml), however this difference was not statistically significant (P>0.05). 
Table 4.10 summarises pre-treatment serum candidate biomarker levels following further 
categorization of T1DM and non-T1DM patients based on periodontal diagnosis.  While 
considering MMP-9 levels, the DP patients had significantly higher serum MMP-9 levels 
(1052.3±489.4 ng/ml) compared to the HP patients (502.2±272.2 ng/ml), (P<0.001).  
However, there were no statistically significant differences in serum MMP-9 levels in those 
with healthy tissues or gingivitis when comparing T1DM and non-T1DM patients.  Within 
the T1DM group, although the DP patients had higher serum MMP-9 levels (1052.3±489.4 
ng/ml) compared to the DG (796.1±652.7 ng/ml) and the DH (791.3±475.6 ng/ml) patients, 
this difference was not statistically significant, (P>0.05).  Likewise, serum MMP-9 levels 
showed no statistically significant differences between the DG (796.1±652.7 ng/ml) and the 
DH (791.3±475.6 ng/ml) patients, (P>0.05).  Similar findings were found within the non-
T1DM group, where serum MMP-9 levels showed no statistically significant differences 
between the HH (437.5±233.0 ng/ml), HG (490.0±315.1 ng/ml) and HP (502.2±272.2 ng/ml) 
patients, (P>0.05) (Table 4.10 and Figure 4.6). 
When considering serum BAFF levels, no statistically significant differences were found 
between T1DM and non-T1DM patients based on periodontal diagnosis.  Within the T1DM 
group, no statistically significant differences were found between the DH (1089.0±143.8 
pg/ml), DG (1199.7±279.0 pg/ml) and DP (1194.8±359.4 pg/ml) patients, (P>0.05).  
Likewise within the non-T1DM group, serum BAFF levels showed no statistically significant 
differences between the HH (1259.5±514.6 pg/ml), HG (1103.9±224.9 pg/ml) and HP 
(1150.7±154.3 pg/ml) patients, (P>0.05) (Table 4.10). 
When considering serum resistin, the levels were significantly higher in the DG patients 
(11.1±5.37 ng/ml) compared to the HG patients (8.06±2.58 ng/ml), (P<0.05).  Within the 
non-T1DM group, serum resistin levels were significantly higher in the HP patients 
(10.5±3.55 ng/ml) compared to the HG patients (8.06±2.58 ng/ml), (P<0.05).  No statistically 
significant difference was found for serum resistin levels between the HH (7.88±3.01 ng/ml), 
HG (8.06±2.58 ng/ml) and HP (10.5±3.55 ng/ml) patients, (P>0.05).  Within the T1DM 
group, serum resistin levels showed no statistically significant differences between the DH 
(11.0±4.70 ng/ml), DG (11.1±5.37 ng/ml) and DP (11.7±4.09 ng/ml) patients, (P>0.05) 
(Table 4.10 and Figure 4.7). 
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While considering serum ENA-78/CXCL5, the levels were significantly higher in the DG 
patients (1607.3±754.0 pg/ml) compared to the HG patients (1140.3±696.8 pg/ml), (P<0.05).  
Although the DH (1859.1±970.4 pg/ml) and DP (1648.4±1049.2 pg/ml) patients had higher 
levels of ENA-78/CXCL5 compared to the HH (1216.5±513.7 pg/ml) and HP 
(1494.5±1007.4 pg/ml) patients, these differences were not statistically significant, (P>0.05).  
Within the T1DM group, serum ENA-78/CXCL5 levels showed no statistically significant 
differences between the DH (1859.1±970.4 pg/ml), DG (1607.3±754.0 pg/ml) and DP 
(1648.4±1049.2 pg/ml) patients, (P>0.05).  Similarly, within the non-T1DM group, serum 
ENA-78/CXCL5 levels showed no statistically significant differences between the HH 
(1216.5±513.7 pg/ml), HG (1140.3±696.8 pg/ml) and HP (1494.5±1007.4 pg/ml) patients, 
(P>0.05) (Table 4.10 and Figure 4.8). 
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Table 4.9: Pre-treatment serum biomarker levels comparing T1DM and non-T1DM 
patients. 
Mean ± SD presented for parametric data.  P-values determined using Independent t-test for 
continuous parametric variables.  P indicates significant difference between T1DM and non-
T1DM patients.  MMP-9; matrix metalloproteinase-9, BAFF; B-cell activating factor,    







Serum MMP-9 (ng/ml) 
 
882.3 ± 577.1 483.8 ± 277.5 < 0.001 
Serum BAFF (pg/ml) 
 
1179.2 ± 290.7 1155.0 ± 286.7 NS 
Serum resistin (ng/ml) 
 
11.3 ± 4.78 8.98 ± 3.25 < 0.01 







Figure 4.3: Pre-treatment serum MMP-9 levels comparing T1DM and non-T1DM 
patients. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 
T1DM (n=53) and non-T1DM (n=43) patients.  Statistics: Independent t-test: ***P<0.001.  
● indicates outlier more than 1.5 but less than 3 times the IQR from the box boundaries, ▲ 





Figure 4.4: Pre-treatment serum resistin levels comparing T1DM and non-T1DM 
patients. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 
T1DM (n=53) and non-T1DM (n=43) patients.  Statistics: Independent t-test: **P<0.01.      





Figure 4.5: Pre-treatment serum ENA-78/CXCL5 levels comparing T1DM and non-
T1DM patients. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 
T1DM (n=53) and non-T1DM (n=43) patients.  Statistics: Independent t-test: *P<0.05.        
● indicates outlier more than 1.5 but less than 3 times the IQR from the box boundaries,     
▲ indicates outlier more than 3 times the IQR from the box boundaries. 
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Table 4.10: Pre-treatment serum biomarker levels comparing T1DM and non-T1DM groups based on periodontal diagnosis. 
Mean ± SD presented for parametric data.  P-values determined using One-way ANOVA with post-hoc Independent t-test for continuous parametric 
variables.  P* indicates overall p-value comparing across periodontal categories within T1DM or non-T1DM groups.  P-values under columns (P) 
relate to comparisons between T1DM and non-T1DM groups.  †P<0.05 indicates statistically significant differences compared to gingivitis within 
the non-T1DM group.  DH; T1DM, periodontal health, DG; T1DM, gingivitis, DP; T1DM, periodontitis, HH; non-T1DM, periodontal health, HG; 
non-T1DM, gingivitis, HP; non-T1DM, periodontitis.  MMP-9; matrix metalloproteinase-9, BAFF; B-cell activating factor, ENA-78/CXCL5; 
epithelial neutrophil activating peptide-78, NS; not significant.










Serum MMP-9 (ng/ml) T1DM 791.3 ± 475.6 796.1 ± 652.7 1052.3 ± 489.4 NS 
Non-T1DM 437.5 ± 233.0 490.0 ± 315.1 502.2 ± 272.2 NS 
P NS NS < 0.001  
Serum BAFF (pg/ml) T1DM 1089.0 ± 143.8 1199.7 ± 279.0 1194.8 ± 359.4 NS 
Non-T1DM 1259.5 ± 514.6 1103.9 ± 224.9 1150.7 ± 154.3 NS 
P NS NS NS  
Serum resistin (ng/ml) T1DM 11.0 ± 4.70 11.1 ± 5.37 11.7 ± 4.09 NS 
Non-T1DM 7.88 ± 3.01 8.06 ± 2.58  10.5 ± 3.55 † < 0.05 
P NS < 0.05 NS  
Serum ENA-78/CXCL5 (pg/ml) T1DM 1859.1 ± 970.4 1607.3 ± 754.0 1648.4 ± 1049.2 NS 
Non-T1DM 1216.5 ± 513.7 1140.3 ± 696.8 1494.5 ± 1007.4 NS 




Figure 4.6: Pre-treatment serum MMP-9 levels comparing T1DM and non-T1DM 
patients based on periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 53 
T1DM patients (health n=9, gingivitis n=26 and periodontitis n=18) and 43 non-T1DM 
patients (health n=9, gingivitis n=17 and periodontitis n=17).  Statistics: One-way ANOVA 
with post-hoc Independent t-test: §§§P<0.001 (T1DM versus non-T1DM group within the 
corresponding periodontal status).  ● indicates outlier more than 1.5 but less than 3 times the 





Figure 4.7: Pre-treatment serum resistin levels comparing T1DM and non-T1DM 
patients based on periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 53 
T1DM patients (health n=9, gingivitis n=26 and periodontitis n=18) and 43 non-T1DM 
patients (health n=9, gingivitis n=17 and periodontitis n=17).  Statistics: One-way ANOVA 
with post-hoc Independent t-test: *P<0.05 (according to periodontal status within the non-
T1DM group); §P<0.05 (T1DM versus non-T1DM group within the corresponding 
periodontal status).  ● indicates outlier more than 1.5 but less than 3 times the IQR from the 




Figure 4.8: Pre-treatment serum ENA-78/CXCL5 levels comparing T1DM and non-
T1DM patients based on periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 53 
T1DM patients (health n=9, gingivitis n=26 and periodontitis n=18) and 43 non-T1DM 
patients (health n=9, gingivitis n=17 and periodontitis n=17).  Statistics: One-way ANOVA 
with post-hoc Independent t-test: §P<0.05 (T1DM versus non-T1DM group within the 
corresponding periodontal status).  ● indicates outlier more than 1.5 but less than 3 times the 




Based on the ELISA results of the candidate biomarker analysis in pre-treatment serum 
samples, there is some evidence for differences in the levels of these potential biomarkers: 
MMP-9, resistin and ENA-78/CXCL5 between the clinical groups.  Although, serum resistin 
was found to be significantly higher in the T1DM patients compared to the non-T1DM 
patients, when correlations were performed, serum resistin levels had a significant positive 
correlation with the BMI of T1DM patients (Spearman’s rho=0.36, P<0.01), suggesting that 
higher the BMI value, higher the levels of resistin.  Interestingly, serum resistin levels were 
not significantly correlated with the BMI in non-T1DM patients (Spearman’s rho=-0.08, 
P>0.05).  Therefore, resistin may not be an ideal biomarker in establishing the link between 
T1DM and periodontal disease, as obesity is not a cardinal finding in patients with T1DM.  
Due to the limited volume of GCF samples available and considering the serum resistin 
results in this study, it was decided not to further analyse resistin in the GCF samples.  The 
analysis of serum BAFF failed to provide any evidence to suggest any differences in levels of 
BAFF between the clinical groups that were certainly significant.  Hence, it was decided to 
not analyse BAFF in the GCF samples collected in the study as there was a limited volume of 
GCF available. 
Following the cytokine array analysis, a screening ELISA experiment was carried out for 
ENA-78/CXCL5 and IL-8 using serum and GCF samples from 20 selected patients based on 
diabetes status and periodontal diagnosis (DP n=5, HP n=5, DH n=5 and HH n=5 samples).  
IL-8 is a chemokine with a similar function to ENA-78/CXCL5 and has been associated with 
various inflammatory conditions such as periodontal disease and T1DM.  Interestingly, ENA-
78/CXCL5 was detected only in the serum samples and not in the GCF samples.  Also, IL-8 
was detected only in the GCF samples and not in the serum samples.  This possibly explains 
why IL-8 was not detected during the cytokine array experiment.  The analysis of the IL-8 
ELISA experiment revealed higher GCF IL-8 levels in the DP patients compared to the HP 
patients.  Hence, it was decided to further analyse the GCF samples only for IL-8 and MMP-9 
levels.  The verification methods for IL-8 are presented in Table 4.5 to 4.8. 
4.2.5 Pre-treatment GCF biomarker levels 
Table 4.11 summarises pre-treatment levels of candidate biomarkers MMP-9 and IL-8 in 
GCF samples and GCF volume data for patients with and without T1DM.  GCF MMP-9 
levels were higher in T1DM patients (189.0±146.2 ng/ml) compared to MMP-9 levels in non-
T1DM patients (175.8±167.8 ng/ml), however, this difference was not statistically 
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significant, (P>0.05).  Similarly, GCF IL-8 levels were higher in T1DM patients 
(323.7±224.4 pg/ml) compared to IL-8 levels in non-T1DM patients (286.1±296.8 pg/ml), 
however, this difference was not statistically significant, (P>0.05).  With reference to GCF 
volume, no statistically significant difference was found for the amount of GCF collected in 
T1DM patients (0.48±0.24 µl) compared to non-T1DM patients (0.40±0.22 µl), (P>0.05). 
Table 4.12 presents pre-treatment GCF candidate biomarker levels and GCF volume 
following further categorization of T1DM and non-T1DM patients based on periodontal 
diagnosis.  With reference to GCF MMP-9 levels, the DH patients had significantly higher 
MMP-9 levels (126.2±76.6 ng/ml) compared to the HH patients (63.1±36.0 ng/ml), (P<0.05).  
The DG patients had higher MMP-9 levels (130.6±65.2 ng/ml) compared to the HG patients 
(108.3±60.3 ng/ml), however, this difference was not statistically significant, (P>0.05).  
Similarly, no statistically significant differences were found for GCF MMP-9 levels between 
the DP patients (304.8±186.8 ng/ml) and the HP patients (303.0±201.1 ng/ml), (P>0.05).  
Within the T1DM group, the DP patients had significantly higher GCF MMP-9 levels 
(304.8±186.8 ng/ml) compared to the DH (126.2±76.6 ng/ml), and the DG (130.6±65.2 
ng/ml) patients, (P<0.001).  Although the DG patients (130.6±65.2 ng/ml) had higher GCF 
MMP-9 levels compared to the DH patients (126.2±76.6 ng/ml), this difference was not 
statistically significant, (P>0.05).  Within the non-T1DM group, the HG patients had 
significantly higher GCF MMP-9 levels (108.3±60.3 ng/ml) compared to the HH patients 
(63.1±36.0 ng/ml), (P<0.05).  Also the HP patients had significantly higher GCF MMP-9 
levels (303.0±201.1 ng/ml) compared to the HH (63.1±36.0 ng/ml) and HG (108.3±60.3 
ng/ml) patients, (P<0.001) (Table 4.12 and Figure 4.9). 
With reference to GCF IL-8 levels, the DH patients had significantly higher GCF IL-8 levels 
(235.1±157.7 pg/ml) compared to the HH patients (102.7±68.2 pg/ml), (P<0.05).  The DG 
patients had higher GCF IL-8 levels (320.7±245.9 pg/ml) compared to the HG patients 
(226.4±167.0 pg/ml), however, this difference was not statistically significant, (P>0.05).  
Although, the HP patients had higher GCF IL-8 levels (442.9±390.2 pg/ml) compared to the 
DP patients (370.1±214.2 pg/ml) this difference was not statistically significant, (P>0.05).  
Within the T1DM group, the DP patients had higher GCF IL-8 levels (370.1±214.2 pg/ml) 
compared to the DG (320.7±245.9 pg/ml) and DH (235.1±157.7 pg/ml) patients, however 
these differences were not statistically significant, (P>0.05).  Within the non-T1DM group, 
the HP patients had significantly higher GCF IL-8 levels (442.9±390.2 pg/ml) compared to 
the HH (102.7±68.2 pg/ml) and HG (226.4±167.0 pg/ml) patients, (P<0.01 and P<0.05 
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respectively).  Also the HG patients had significantly higher GCF IL-8 levels (226.4±167.0 
pg/ml) compared to the HH patients (102.7±68.2 pg/ml), (P<0.01) (Table 4.12 and Figure 
4.10). 
With reference to GCF volume, although the DH (0.35±0.12 µl), DG (0.40±0.16 µl) and DP 
(0.66±0.26 µl) patients had higher GCF volume compared to the HH (0.19±0.08 µl), HG 
(0.32±0.16 µl) and HP (0.60±0.16 µl) patients, these differences were not statistically 
significant, (P>0.05).  Within the T1DM group, the DP patients (0.66±0.26 µl) had 
significantly higher GCF volume compared to the DG (0.40±0.16 µl) and DH (0.35±0.12 µl) 
patients, (P<0.001).  Similar findings were seen within the non-T1DM group, the HP patients 
(0.60±0.16 µl) had significantly higher GCF volume compared to the HG (0.32±0.16 µl) and 
HH (0.19±0.08 µl) patients, (P<0.001).  Additionally, the HG patients (0.32±0.16 µl) had 
significantly higher GCF volume compared to the HH patients (0.19±0.08 µl), (P<0.01) 
(Table 4.12 and Figure 4.11). 
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Table 4.11: Pre-treatment GCF biomarker levels and GCF volume comparing T1DM 
and non- T1DM patients. 
Mean ± SD presented for parametric data.  P-values determined using Independent t-test for 
continuous parametric variables.  P indicates significant difference between T1DM and non-
T1DM patients.  GCF; gingival crevicular fluid, MMP-9; matrix metalloproteinase-9, IL-8; 
interleukin-8, NS; not significant.
 T1DM 




GCF MMP-9 (ng/ml) 
 
189.0 ± 146.2 175.8 ± 167.8 NS 
GCF IL-8 (pg/ml) 323.7 ± 224.4 286.1 ± 296.8 NS 
GCF volume (µl) 0.48 ± 0.24 0.40 ± 0.22 NS 
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Table 4.12: Pre-treatment GCF biomarker levels and GCF volume comparing T1DM and non-T1DM groups based on periodontal 
diagnosis. 
Mean ± SD presented for parametric data.  P-values determined using One-way ANOVA with post-hoc Independent t-test for continuous parametric 
variables.  P* indicates overall p-value comparing across periodontal categories within T1DM or non-T1DM groups.  P-values under columns (P) 
relate to comparisons between T1DM and non-T1DM group.  *P<0.05, **P<0.01, ***P<0.001 indicates statistically significant differences 
compared to health, and †P<0.05, †††P<0.001 indicates statistically significant differences compared to gingivitis within the T1DM and non-T1DM 
groups.  DH; T1DM, periodontal health, DG; T1DM, gingivitis, DP; T1DM, periodontitis, HH; non-T1DM, periodontal health, HG; non-T1DM, 












GCF MMP-9 (ng/ml) T1DM 126.2 ± 76.6 130.6 ± 65.2 304.8 ± 186.8 ***
, ††† < 0.001 
Non-T1DM 63.1 ± 36.0 108.3 ± 60.3 * 303.0 ± 201.1 ***
, ††† < 0.001 
P < 0.05 NS NS  
GCF IL-8 (pg/ml) T1DM 235.1 ± 157.7 320.7 ± 245.9 370.1 ± 214.2 NS 
Non-T1DM 102.7 ± 68.2 226.4 ± 167.0 ** 442.9 ± 390.2 **
, † < 0.01 
P < 0.05 NS NS  
GCF volume (µl) T1DM 0.35 ± 0.12 0.40 ± 0.16 0.66 ± 0.26 ***
, ††† < 0.001 
Non-T1DM 0.19 ± 0.08 0.32 ± 0.16 ** 0.60 ± 0.16 ***
, ††† < 0.001 




Figure 4.9: Pre-treatment GCF MMP-9 levels comparing T1DM and non-T1DM patients 
based on periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 53 
T1DM patients (health n=9, gingivitis n=26 and periodontitis n=18) and 43 non-T1DM patients 
(health n=9, gingivitis n=17 and periodontitis n=17).  Statistics: One-way ANOVA with post-
hoc Independent t-test: *P<0.05, ***P<0.001 (according to periodontal status within the 
T1DM or non-T1DM group); §P<0.05 (T1DM versus non-T1DM group within the 
corresponding periodontal status).  ● indicates outlier more than 1.5 but less than 3 times the 




Figure 4.10: Pre-treatment GCF IL-8 levels comparing T1DM and non-T1DM patients 
based on periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 53 
T1DM patients (health n=9, gingivitis n=26 and periodontitis n=18) and 43 non-T1DM 
patients (health n=9, gingivitis n=17 and periodontitis n=17).  Statistics: One-way ANOVA 
with post-hoc Independent t-test: *P<0.05, **P<0.01 (according to periodontal status within 
the non-T1DM group); §P<0.05 (T1DM versus non-T1DM group within the corresponding 
periodontal status).  ● indicates outlier more than 1.5 but less than 3 times the IQR from the 




Figure 4.11: Pre-treatment GCF volume comparing T1DM and non-T1DM patients 
based on periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 53 
T1DM patients (health n=9, gingivitis n=28 and periodontitis n=19) and 43 non-T1DM patients 
(health n=9, gingivitis n=16 and periodontitis n=16.  Statistics: One-way ANOVA with post-
hoc Independent t-test: **P<0.01, ***P<0.001 (according to periodontal status within the 
T1DM or non-T1DM group).  ● indicates outlier more than 1.5 but less than 3 times the IQR 
from the box boundaries.
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4.2.6 Exploration of the association between clinical periodontal parameters,  
biomarker levels and clinical markers of diabetes control and inflammation 
All Spearman’s rank correlation coefficients (rho) were first undertaken using data for all 
patients (T1DM and non-T1DM), and were then repeated taking diabetes status into account. 
Association between HbA1c and hsCRP and clinical periodontal parameters 
While considering all patients (T1DM and non-T1DM), a significant positive (medium) 
correlation was demonstrated between HbA1c levels and PI (Spearman’s rho=0.34, P<0.01) 
(Cohen 1988).  All other correlations between HbA1c levels and mGI, % BOP and mean PD 
were not statistically significant (Table 4.13).  When the data were split according to diabetes 
status, in T1DM patients, a significant positive (medium) correlation was demonstrated 
between HbA1c levels and PI (Spearman’s rho=0.30, P<0.05).  All other correlations for 
T1DM patients were not statistically significant (Table 4.14).  In non-T1DM patients, no 
statistically significant correlations were found between HbA1c levels and mGI, PI, % BOP 
and mean PD (Table 4.15). 
While considering all patients and when data were split according to diabetes status, no 
statistically significant correlations were found between hsCRP levels and mGI, PI, % BOP 
and mean PD (Table 4.13, 4.14 and 4.15).
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Table 4.13: Correlations between HbA1c and hsCRP levels and clinical periodontal 
parameters for all patients. 
 Spearman’s Rank Correlation Coefficient 
 HbA1c (% & mmol/mol) hsCRP (mg/mL) 
mGI 0.26 0.03 
PI 0.30 * 0.02 
BOP (%) 0.21 0.02 
Mean PD (mm) 0.25 0.03 
Table 4.14: Correlations between HbA1c and hsCRP levels and clinical periodontal 
parameters for T1DM patients. 
 Spearman’s Rank Correlation Coefficient 
 HbA1c (% & mmol/mol) hsCRP (mg/mL) 
mGI -0.20 0.25 
PI -0.08 0.24 
BOP (%) -0.20 0.24 
Mean PD (mm) -0.14 0.20 
Table 4.15: Correlations between HbA1c and hsCRP levels and clinical periodontal 
parameters for non-T1DM patients. 
Tables 4.13, 4.14 and 4.15 showing Spearman’s rho highlighted with colour indicates strength 
of correlation: small (r=0.10 to 0.29), medium (r=0.30 to 0.49) and large (r=0.50 to 1.00) 
(Cohen 1988).  Significant correlation between clinical parameters and biochemistry 
parameters: *P<0.05 and ***P<0.001.  mGI; modified gingival index, PI; plaque index, BOP; 
bleeding on probing, PD; probing depth, HbA1c; glycated haemoglobin, hsCRP; high-
sensitivity C-reactive protein.
 Spearman’s Rank Correlation Coefficient 
 HbA1c (% & mmol/mol) hsCRP (mg/mL) 
mGI -0.00 0.13 
PI 0.34 *** 0.13 
BOP (%) 0.07 0.12 
Mean PD (mm) 0.05 0.11 
 183 
 
Association between HbA1c and hsCRP levels and candidate biomarker levels in serum and 
GCF 
While considering all patients (T1DM and non-T1DM), a significant positive (small) 
correlation was demonstrated between HbA1c and serum MMP-9 (Spearman’s rho=0.23, 
P<0.05) and ENA-78/CXCL5 (Spearman’s rho=0.27, P<0.01) levels.  All other correlations 
between HbA1c and serum biomarker levels were not statistically significant (Table 4.16).  
When the data were split according to diabetes status, in T1DM patients, no statistically 
significant correlations were found between HbA1c and serum MMP-9, BAFF, resistin and 
ENA-78/CXCL5 levels (Table 4.17).  In non-T1DM patients, a significant positive (medium) 
correlation was demonstrated between HbA1c and serum BAFF levels (Spearman’s rho=0.33, 
P<0.05).  All other correlations between HbA1c and serum biomarker levels were not 
statistically significant (Table 4.18).  Additionally, while considering all patients and T1DM 
patients, no statistically significant correlations were found between HbA1c and GCF MMP-9 
and IL-8 levels (Table 4.16 and 4.17).  In non-T1DM patients, a significant negative (medium) 
correlation was demonstrated between HbA1c and GCF MMP-9 levels (Spearman’s rho=-0.34, 
P<0.05) (Table 4.18). 
While considering all patients (T1DM and non-T1DM), a significant positive (medium) 
correlation was demonstrated between hsCRP and serum MMP-9 levels (Spearman’s rho=0.30, 
P<0.01).  All other correlations between hsCRP and serum biomarker levels were not 
statistically significant (Table 4.16).  When the data were split according to diabetes status, in 
T1DM patients, a significant positive (medium) correlation was demonstrated between hsCRP 
and serum MMP-9 levels (Spearman’s rho=0.36, P<0.01).  All other correlations between 
hsCRP and serum biomarker levels in T1DM patients were not statistically significant (Table 
4.17).  In non-T1DM patients, no statistically significant correlations were found between 
hsCRP and serum biomarker levels (Table 4.18). 
Additionally, while considering all patients and when data were split according to diabetes 
status no statistically significant correlations were found between hsCRP and GCF MMP-9 and 
IL-8 levels (Table 4.16, 4.17 and 4.18).
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Table 4.16: Correlations of HbA1c and hsCRP levels and biomarker levels in serum and 
GCF for all patients. 
 Spearman’s Rank Correlation Coefficient 
 Serum biomarkers GCF biomarkers 
MMP-9 BAFF Resistin ENA-78 MMP-9 IL-8 
HbA1c 
(% & mmol/mol) 
-0.25 0.04 -0.07 0.10 0.09 0.03 
hsCRP 
(mg/L) 
0.36 * 0.22 0.27 -0.18 -0.01 -0.02 
Table 4.17: Correlations of HbA1c and hsCRP levels and biomarker levels in serum and 
GCF for T1DM patients. 
 Spearman’s Rank Correlation Coefficient 
 Serum biomarkers GCF biomarkers 
MMP-9 BAFF Resistin ENA-78 MMP-9 IL-8 
HbA1c 
(% & mmol/mol) 
-0.07 0.33 * -0.07 0.21 -0.34 * -0.20 
hsCRP 
(mg/L) 
0.07 0.20 -0.03 -0.11 -0.28 0.25 
Table 4.18: Correlations of HbA1c and hsCRP levels and biomarker levels in serum and 
GCF for non-T1DM patients. 
Tables 4.16, 4.17 and 4.18 showing Spearman’s rho with colour indicates strength of correlation: 
small (r=0.10 to 0.29), medium (r=0.30 to 0.49) and large (r=0.50 to 1.00) (Cohen 1988).  
Significant correlation between biochemistry parameters and biomarkers: *P<0.05 and **P<0.01.  
HbA1c; glycated haemoglobin, hsCRP; high-sensitivity C-reactive protein, MMP-9; matrix 
metalloproteinase-9, BAFF; B-cell activating factor, ENA-78/CXCL5; epithelial neutrophil 
activating peptide-78, IL-8; interleukin-8, GCF; gingival crevicular fluid.
 Spearman’s Rank Correlation Coefficient 
 Serum biomarkers GCF biomarkers 
MMP-9 BAFF Resistin ENA-78 MMP-9 IL-8 
HbA1c 
(% & mmol/mol) 
0.23 * 0.11 0.19 0.27 ** 0.06 0.10 
hsCRP 
(mg/L) 
0.30 ** 0.21 0.16 -0.08 0.12 0.10 
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Association between candidate biomarker levels in serum and GCF and clinical periodontal 
parameters 
Whether considering all patients or when data were split according to diabetes status, no 
statistically significant correlations were found between serum MMP-9, BAFF, resistin and 
ENA-78/CXCL5 levels and any of the clinical periodontal parameters (Table 4.19, 4.20 and 
4.21). 
While considering all patients (T1DM and non-T1DM), a significant positive correlation was 
demonstrated between GCF MMP-9 levels and mGI (Spearman’s rho=0.42, P<0.01, medium 
correlation), % BOP (Spearman’s rho=0.51, P<0.01, large correlation) and mean PD 
(Spearman’s rho=0.53, P<0.01, large correlation) (Table 4.19 and Figure 4.12).  No 
statistically significant correlation was found between GCF MMP-9 levels and PI for all 
patients.  A significant positive correlation was found between GCF IL-8 levels and mGI 
(Spearman’s rho=0.34, P<0.01, medium correlation), PI (Spearman’s rho=0.20, P<0.05, small 
correlation), % BOP (Spearman’s rho=0.37, P<0.01, medium correlation) and mean PD 
(Spearman’s rho=0.33, P<0.01, medium correlation) in all patients (Table 4.19 and Figure 
4.13).  When the data were split according to diabetes status, in T1DM patients a significant 
positive correlation was demonstrated between GCF MMP-9 levels and % BOP (Spearman’s 
rho=0.42, P<0.01, medium correlation) and mean PD (Spearman’s rho=0.37, P<0.01, medium 
correlation).  No statistically significant correlation was found between GCF MMP-9 levels 
and mGI and PI for T1DM patients.  A significant positive (small) correlation was 
demonstrated between GCF IL-8 levels and % BOP (Spearman’s rho = 0.29, P<0.05).  No 
statistically significant correlation was found between GCF IL-8 levels and mGI, PI and mean 
PD for T1DM patients (Table 4.20).  In non-T1DM patients, a significant positive correlation 
was demonstrated between GCF MMP-9 levels and mGI (Spearman’s rho=0.67, P<0.01, large 
correlation), PI (Spearman’s rho=0.38, P<0.05, medium correlation), % BOP (Spearman’s 
rho=0.56, P<0.01, medium correlation) and mean PD (Spearman’s rho=0.61, P<0.01, large 
correlation).  Likewise, a significant positive correlation was demonstrated between GCF IL-8 
levels and mGI (Spearman’s rho=0.52, P<0.01, large correlation), PI (Spearman’s rho=0.32, 
P<0.05, medium correlation), % BOP (Spearman’s rho=0.48, P<0.01, medium correlation) and 




Table 4.19: Correlations of clinical parameters and biomarker levels in serum and GCF 
for all patients. 
 Spearman’s Rank Correlation Coefficient 
 Serum biomarkers GCF biomarkers 
MMP-9 BAFF Resistin ENA-78 MMP-9 IL-8 
mGI 0.06 0.15 0.17 -0.03 0.22 0.18 
PI 0.01 0.26 0.20 0.05 0.01 0.10 
BOP (%) 0.11 -0.04 0.04 0.02 0.42 ** 0.29 * 
Mean PD (mm) 0.13 -0.04 0.05 -0.11 0.37 ** 0.13 
Table 4.20: Correlations of clinical parameters and biomarker levels in serum and GCF 
for T1DM patients. 
 Spearman’s Rank Correlation Coefficient 
 Serum biomarkers GCF biomarkers 
MMP-9 BAFF Resistin ENA-78 MMP-9   IL-8 
mGI 0.21 0.10 0.20 0.14 0.67 ** 0.52 ** 
PI 0.06 0.02 -0.00 -0.00 0.38 * 0.32 * 
BOP (%) 0.11 0.03 0.29 -0.01 0.56 ** 0.48 ** 
Mean PD (mm) 0.13 0.01 0.28 0.13 0.61 ** 0.56 ** 
Table 4.21: Correlations of clinical parameters and biomarker levels in serum and GCF 
for non-T1DM patients. 
Tables 4.19, 4.20 and 4.21 showing Spearman’s rho with colour indicates strength of correlation: 
small (r=0.10 to 0.29), medium (r=0.30 to 0.49) and large (r=0.50 to 1.00) (Cohen 1988).  
Significant correlation between clinical parameters and biomarkers: *P<0.05 and **P<0.01.  mGI; 
modified gingival index, PI; plaque index, BOP; bleeding on probing, PD; probing depth, MMP-9; 
matrix metalloproteinase-9, BAFF; B-cell activating factor, ENA-78/CXCL5; epithelial neutrophil 
activating peptide-78, IL-8; interleukin-8, GCF; gingival crevicular fluid.
 Spearman’s Rank Correlation Coefficient 
 Serum biomarkers GCF biomarkers 
MMP-9 BAFF Resistin ENA-78 MMP-9 IL-8 
mGI 0.06 0.14 0.16 0.06 0.42 ** 0.34 ** 
PI 0.10 0.17 0.15 0.09 0.18 0.20 * 
BOP (%) 0.13 0.00 0.18 0.02 0.51 ** 0.37 ** 




Figure 4.12: Association between pre-treatment GCF MMP-9 levels and clinical 
periodontal parameters in all patients. 
Figures show Spearman’s Rank Correlation Coefficient (rho) GCF MMP-9 levels with mGI, 
PI, BOP and PD at baseline.    indicates T1DM patients (n=57) and     indicates non-T1DM 




Spearman’s rho = 0.42, P<0.01 Spearman’s rho = 0.51, P<0.01 





Figure 4.13: Association between pre-treatment GCF IL-8 levels and clinical periodontal 
parameters in all patients. 
Figures show Spearman’s Rank Correlation Coefficient (rho) GCF IL-8 levels with mGI, PI, 
BOP and PD at baseline.    indicates T1DM patients (n=57) and    indicates non-T1DM patients 





Spearman’s rho = 0.34, P<0.01 
 
Spearman’s rho = 0.20, P<0.05 
 
Spearman’s rho = 0.37, P<0.01 
 




In this chapter, the protein levels in serum were quantified, cytokine array analysis was 
carried out to determine biomarkers present in serum, and pre-treatment candidate biomarker 
levels in serum and GCF were compared between the T1DM and non-T1DM groups and 
according to periodontal category within groups. 
Quantification of protein 
The Bradford assay is considered practical, rapid, readily automated and relatively easy to 
perform (Bradford 1976; Okutucu et al. 2007).  This technique relies on the binding of dye to 
protein present in the sample to form a dye-protein complex with increase in molar 
absorbance (Bradford 1976), and has been proven to be more sensitive than other methods for 
protein quantification (Okutucu et al. 2007).  The results of the Bradford assay in this study 
revealed a protein content of 355.1±203.9 mg/ml in all baseline serum samples.  When 
dividing the serum samples based on diabetes status, no significant differences were found 
for protein levels between T1DM and non-T1DM patients.  Also, no significant differences 
were found between the two groups based on periodontal diagnosis (Table 4.1 and 4.2).  A 
previous study compared the Bradford technique to a new high-sensitivity protein assay 
based on decreased light scattering of zwitterionic gemini surfactant to determine protein 
levels in 3 serum samples. The results of their Bradford assay revealed a serum protein 
concentration of 67.1±1.00 mg/ml, 72.5±0.85 mg/ml and 74.6±1.70 mg/ml, respectively 
(Chen et al. 2009).  Another previous study analysed protein concentration in pooled plasma 
samples, comparing different protein quantification techniques including the Bradford assay.  
Additionally standards of BSA and human serum albumin (HSA) were used for calibration.  
The authors reported a protein concentration of 95.1±3.3 mg/ml in plasma, 89.5±3.1 mg/ml in 
BSA and 72.5±2.5 mg/ml in HSA (Okutucu et al. 2007).  Serum contains a total protein 
concentration of 60-80 mg/ml (Adkins et al. 2002).  However, in this study the levels 
detected seemed to be higher, a possible explanation for this could be the variations in 
Bradford assay protocols followed in various studies.  As per the Bradford protocol followed 
in this study the serum samples were found to be viable and the lack of significant differences 
in protein levels based on diabetes status and periodontal diagnosis provides further assurance 
that any differences found between groups during biomarker analysis using ELISA, were not 
attributed to variations in the protein levels of the serum samples being tested.  Only the 
baseline serum samples were tested using the Bradford assay protocol, and this provided 
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sufficient assurance regarding the viability of all serum samples collected.  Due to the limited 
volume of GCF samples obtained during sample collection and the amount needed to perform 
protein analysis, it was considered not feasible to analyse the studies’ GCF samples, which 
were collected during the same time period and stored in a similar manner as the serum 
samples. 
Serum is that component of blood which lacks clotting factors.  Serum and plasma are similar 
as both contain glucose, hormones, antibodies, electrolytes, antigens, nutrients and other 
particles except clotting factors which are present only in plasma.  Hence, one can say that 
serum is plasma minus clotting factors (Guyton and Hall 2016).  Both these terms have been 
used interchangeably in past literature and hence it is reasonable to assume that serum and 
plasma are two similar liquids and therefore, while making comparisons to the findings of 
this study, it has been considered that serum and plasma are similar. 
Cytokine array 
Based on the results of the cytokine array analysis and a review of the literature, it was 
decided to further analyse candidate biomarkers MMP-9, BAFF, resistin and ENA-
78/CXCL5 in the serum samples collected for the study. 
Matrix metalloproteinase-9 
MMPs are a family of zinc-dependent endopeptidases that degrade extracellular matrix, 
basement membrane, regulate fibrosis formation and are known to play a crucial role in the 
regulation of periodontal tissue turnover in disease and health (Uitto et al. 2003; Sorsa et al. 
2004; Sorsa et al. 2006; Li et al. 2012; Salazar et al. 2013).  MMPs can be divided into 5 
groups: collagenases (MMPs 1, 8 and 13); gelatinases (MMPs 2 and 9); stromelysins (MMPs 
3, 10 and 11); membrane-type MMPs (MMPs 14, 15, 16 and 17); and others (Sorsa et al. 
2004; Sorsa et al. 2006).  The main collagenase in periodontitis is MMP-8 followed by 
MMP-9 (Sorsa et al. 1995).  MMP-8, MMP-9 and MMP-13 are the most widely reported 
MMPs in GCF sites with active periodontal disease (Lee et al. 1995; Choi et al. 2004; Tuter 
et al. 2005; Beklen et al. 2006; Kumar et al. 2006; Soder et al. 2006).  The MMPs released 
from the inflamed periodontal tissues may have an impact on systemic health, as past 
research suggests that inflammatory markers may enter the circulation and stimulate 
inflammation in other parts of the body (Moutsopoulos and Madianos 2006).  An 
experimental gingivitis study found elevated MMP-9 levels after 7-14 days in patients with 
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T1DM compared to systemically healthy controls (Salvi et al. 2010).  Li et al.’s study in 
systemically healthy patients with and without chronic periodontitis confirmed a significant 
upregulation of serum MMP-9 concentrations in chronic periodontitis patients in comparison 
to healthy controls (Li et al. 2012).  Levels of MMP-9 have been found to be elevated in 
T1DM patients with other diabetes-related complications besides periodontitis.  Previous 
research related to T1DM and retinopathy found significantly higher serum MMP-9 and 
TIMP-1 levels in T1DM patients with retinopathy compared to those with T1DM alone and 
non-diabetic controls; also T1DM patients had higher serum MMP-9 and TIMP-1 levels 
compared to systemically healthy controls (Jacqueminet et al. 2006).  Similarly, significantly 
elevated serum MMP-2 and MMP-9 levels were found in T1DM patients with nephropathy 
compared to healthy controls (Gharagozlian et al. 2009).  Recent research studies have 
related several immune, hormonal or connective tissue impairments to periodontal disease.  A 
recent study by Silosi et al. investigated the association between inflammatory rheumatoid 
arthritis and chronic periodontitis, by quantifying MMP-9 levels in serum and GCF (Silosi et 
al. 2015).  The authors reported significantly elevated serum and GCF MMP-9 levels in 
patients with chronic periodontitis, rheumatoid arthritis and those with both rheumatoid 
arthritis and chronic periodontitis compared to the periodontally and systemically healthy 
controls.  Additionally, patients with both rheumatoid arthritis and chronic periodontitis were 
found to have the highest MMP-9 levels, suggesting that the periodontitis-associated 
rheumatoid arthritis was a reflection of the underlying MMP-9 local and systemic 
inflammatory response in their study (Silosi et al. 2015). 
Research related to MMP-9 levels in diabetes and periodontal disease has been carried out 
separately.  However, research related to serum and GCF MMP-9 levels in patients with 
T1DM and periodontal disease is lacking hence it was of interest to carry out further 
investigations in context to these two conditions.  Additionally, based on the results of the 
cytokine array experiment, MMP-9 was found to be highest in the T1DM with periodontitis 
group compared to the non-T1DM periodontitis group therefore, MMP-9 was selected for 
further analysis in serum samples using ELISA (Table 4.4 and Figure 4.2). 
B-cell activating factor 
BAFF is a member of the TNF superfamily, best known for its role in the survival and 
maturation of B cells.  BAFF is produced by several tissue and cell types including spleen, 
bone marrow, lymph node, macrophages, monocytes, dendritic cells, neutrophils, T 
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lymphocytes and epithelial cells (Mackay and Schneider 2009).  BAFF plays a role in human 
autoimmune disorders and has been found to be elevated in serum samples of patients with 
systemic lupus erythematosus and Sjögren’s syndrome (Zhang et al. 2001; Varin et al. 2010).  
BAFF is produced locally in the joints of patients with rheumatoid arthritis and serum levels 
correlate with antibody titres in Sjögren’s syndrome and rheumatoid arthritis (Nakajima et al. 
2007; Varin et al. 2010).  B cells play a pathogenic role as antigen-presenting cells and 
autoantibody secretors in the lead up to T cell-mediated autoimmune destruction of the 
insulin-producing β-cells of the pancreas in T1DM (Marino et al. 2011).  Likewise, advanced 
periodontal lesions have been associated with infiltration of B lymphocytes in patients with 
periodontitis, which when activated induce osteoclastic differentiation.  B cells in 
periodontitis have been found to be partly mediated by salivary BAFF in patients with 
Sjögren’s syndrome (Pers et al. 2005).  Research related to BAFF levels in patients with 
T1DM and periodontal disease is lacking, hence it was considered of interest to carry out 
further investigations in the context of these two inflammatory conditions.  Additionally, 
based on the results of the cytokine array experiment, BAFF was found to be highest in the 
T1DM with periodontitis group compared to the non-T1DM periodontitis group; therefore, 
BAFF was selected for further analysis in serum samples using ELISA (Table 4.4 and Figure 
4.2). 
Resistin 
Resistin is an adipokine, belonging to the cysteine-rich secretory protein family, known as 
resistin-like molecules (Bokarewa et al. 2005).  The most significant source of resistin is the 
mononuclear blood cells, but some human studies suggest that resistin is also expressed by 
adipose tissue.  Additionally, resistin is expressed by pre-adipocytes, pancreatic islets, 
placenta and primary leukaemia cells.  Resistin is well known for its potential role in linking 
obesity, insulin resistance and T2DM.  Recent studies have reported that resistin plays a role 
in inflammatory conditions such as rheumatoid arthritis, atherosclerosis and inflammatory 
bowel disease (Bokarewa et al. 2005; Reilly et al. 2005; Konrad et al. 2007).  T1DM is 
characterised by increases in inflammation independent of glycaemic control and adiposity 
(Geyikli et al. 2013).  A recent study by Geyikli and colleagues  found significantly higher 
serum resistin levels in children and adolescents with T1DM compared to healthy controls 
(Geyikli et al. 2013).  The authors suggested that resistin may possibly play a role in 
inflammation and in the pathophysiology of T1DM (Geyikli et al. 2013).  Knowledge about 
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the relationship between resistin, T1DM and periodontal disease is limited, hence it was 
considered interesting to investigate the levels of this biomarker in relation to these two 
conditions.  Additionally, based on the results of the cytokine array experiment, resistin was 
found to be highest in the T1DM with periodontitis group compared to the non-T1DM 
periodontitis group; therefore, resistin was selected for further analysis in serum samples 
using ELISA (Table 4.4 and Figure 4.2). 
Epithelial neutrophil activating peptide-78/CXCL5 
Neutrophils are fundamentally essential in contributing to host defence against bacterial 
infections and a defect or loss in neutrophil function significantly predisposes individuals to 
inflammatory conditions such as periodontitis (Nussbaum and Shapira 2011).  ENA-78 is a 
C-X-C chemokine (CXCL5) and is a major neutrophil chemoattractant and activator.     
ENA-78/CXCL5 is primarily expressed by epithelial cells, monocytes and platelets and, has 
also been detected in neutrophils and macrophages (Walz et al. 1997; Damas et al. 2000).  An 
increase in expression of ENA-78/CXCL5 has been associated with neutrophil influx in 
inflammatory conditions such as rheumatoid arthritis, adult respiratory distress syndrome, 
inflammatory bowel diseases and chronic pancreatitis (Walz et al. 1997).  A previous study 
by Lappin and colleagues, demonstrated significantly higher plasma ENA-78/CXCL5 levels 
in patients with periodontitis compared to those with healthy periodontal tissues (Lappin et al. 
2011).  Additionally, elevated plasma ENA-78/CXCL5 levels correlated with PD 
measurements, and ENA-78/CXCL5 was found to be a good systemic indicator of disease 
severity and inflammatory processes in patients with periodontitis (Lappin et al. 2011).  Very 
little is known about the role that ENA-78/CXCL5 plays in the pathogenesis of periodontal 
disease, T1DM and the cross-susceptibility between the two diseases.  A recent study by 
Lappin and colleagues demonstrated significantly higher plasma ENA-78/CXCL5 levels in 
patients with T1DM and periodontitis and T1DM alone compared to non-diabetic patients 
with healthy periodontal tissues (Lappin et al. 2015).  However, the authors found no 
statistically significant differences between T1DM patients with healthy tissues and those 
with T1DM and periodontitis (Lappin et al. 2015). 
In the current study, an ELISA experiment carried out following the cytokine array analysis 
on 20 serum and 20 GCF samples of the study, detected ENA-78/CXCL5 only in the serum 
samples.  ENA-78/CXCL5 was not detected in the GCF samples during the ELISA 
experiment.  Given the key role ENA-78/CXCL5 plays in various inflammatory conditions, 
 194 
 
and in order to increase our knowledge and the evidence of circulating ENA-78/CXCL5 in 
patients with T1DM and periodontal disease, it was considered interesting to analyse this 
biomarker in the serum samples of the current study.  Additionally, based on the results of the 
cytokine array experiment, ENA-78/CXCL5 was found to be highest in the T1DM with 
periodontitis group compared to the non-T1DM periodontitis group therefore, ENA-
78/CXCL5 was selected for further analysis in serum samples using ELISA (Table 4.4 and 
Figure 4.2). 
Interleukin-8 
Another major neutrophil and lymphocyte chemoattractant is IL-8 which is also known as 
CXCL8.  IL-8 belongs to the CXC chemokine family, and is known for its important role in 
the induction and maintenance of inflammation (Li et al. 2012).  IL-8 is mainly produced by 
epithelial cells and macrophages upon inflammatory stimulation (Harada et al. 1994; Okada 
and Murakami 1998).  Elevated circulating levels of IL-8 have been associated with poor 
clinical outcomes in patients with T1DM (AboElAsrar et al. 2012).  Additionally, IL-8 levels 
have been tightly linked to increased susceptibility for periodontitis (Figueredo and 
Gustafsson 2000).  IL-8 levels in GCF (Salvi et al. 2010) and saliva (Dakovic et al. 2013) 
have been linked to the cross-susceptibility between periodontal disease and T1DM.  The 
other major neutrophil chemoattractant ENA-78/CXCL5, shares 22% of its amino acid 
sequence identity with IL-8, additionally ENA-78/CXCL5 activity can be mediated through 
the IL-8 receptor system (Walz et al. 1997).  Similar to ENA-78/CXCL5, IL-8 has also been 
found to be increased in inflammatory conditions such as, rheumatoid arthritis, adult 
respiratory distress syndrome, inflammatory bowel diseases and chronic pancreatitis (Walz et 
al. 1997).  A recent study by Lappin and colleagues concluded that elevated plasma IL-8 
levels potentially contribute to the cross-susceptibility between T1DM and periodontitis 
(Lappin et al. 2015).  Engebretson et al.’s study in chronic periodontitis patients with and 
without T2DM, found significantly lower GCF IL-8 levels in T2DM patients compared to 
non-diabetic patients with similar periodontal status (Engebretson et al. 2006).  Other studies 
related to T2DM found no statistically significant differences between T2DM and non-
diabetic patients with periodontitis while analysing of IL-8 levels in gingival tissues (Duarte 
et al. 2007) and serum samples (Longo et al. 2014). 
In the current study, IL-8 was not detected in serum samples during the cytokine array 
experiment.  The ELISA experiment carried out following the cytokine array analysis on 20 
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serum and 20 GCF samples of the study, detected IL-8 detected only in the GCF samples.  
IL-8 was once again not detected in serum samples during the ELISA experiment.  Since IL-8 
shares a common identity and inflammatory role with ENA-78/CXCL5, is known for its role 
in periodontal disease and T1DM, and was detected in the GCF samples of the current study, 
it was considered interesting to further analyse this biomarker in the GCF samples of the 
current study. 
Pre-treatment biomarker levels in serum 
The current study found significantly higher serum MMP-9, resistin and ENA-78/CXCL5 
levels in T1DM patients compared to non-T1DM patients (Table 4.9, Figure 4.3, 4.4 and 4.5).  
Based on periodontal diagnosis, serum MMP-9 levels were significantly higher in T1DM 
patients with periodontitis compared to non-T1DM patients with periodontitis (P<0.001) 
(Table 4.10 and Figure 4.6).  Currently no research has been carried out related to serum 
MMP-9 levels in patients with T1DM and periodontal disease and hence, it is has not been 
possible to make comparisons with the findings of other studies.  With the non-T1DM group, 
in the current study, serum MMP-9 levels were higher in the periodontitis patients compared 
to those with gingivitis and healthy tissues; however these differences were not statistically 
significant.  A previous study analysed serum MMP-9 levels in systemically healthy patients 
with (n=122) and without (n=532) chronic periodontitis (aged 21-52 years) and found 
significantly higher MMP-9 levels in patients with chronic periodontitis (11.65±2.17 ng/ml) 
compared to the healthy controls (2.17±1.91 ng/ml), (P<0.001) (Li et al. 2012).  The authors 
suggested that serum concentrations of MMP-9 indicated the potential clinical significance of 
serum measurements in patients with chronic periodontitis (Li et al. 2012).  Another study 
evaluated plasma MMP-9 levels in patients with and without chronic periodontitis and found 
significantly elevated plasma MMP-9 levels in patients with chronic periodontitis compared 
to those with healthy tissues (Marcaccini et al. 2009b).  However, the authors presented the 
data only graphically and no numerical values were given, which limits the ability to directly 
compare their findings with those of the current study. 
In the current study, serum ENA-78/CXCL5 levels were significantly higher in T1DM 
patients with gingivitis (1607.3±754.0 pg/ml) compared to non-T1DM patients with 
gingivitis (1140.3±696.8 pg/ml), (P<0.05) (Table 4.10 and Figure 4.8).  A recently published 
study reported plasma ENA-78/CXCL5 levels in patients with T1DM and periodontal disease 
(Lappin et al. 2015).  T1DM patients with healthy periodontal tissues (n=28) had 
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significantly higher plasma ENA-78/CXCL5 levels [approximate levels from presented 
graph: 500 (100-1,800) pg/ml] compared to non-diabetic patients with healthy tissues (n=19) 
[approximate levels from presented graph: 200 (50-500) pg/ml], (P<0.01)  (Lappin et al. 
2015).  In the current study, within the T1DM group, no statistically significant differences 
were found between serum ENA-78/CXCL5 levels in patients with healthy tissues, gingivitis 
and periodontitis.  Our findings are similar to Lappin et al.’s study, which showed no 
statistically significant difference in plasma ENA-78/CXCL5 levels between T1DM patients 
with healthy tissues (n=28) [approximate levels from presented graph: 500 (100-1,800) 
pg/ml] and T1DM patients with periodontitis (n=34) [approximate levels from presented 
graph: 700 (100-2,000) pg/ml], (P>0.05) (Lappin et al. 2015).  In the current study, within the 
non-T1DM group although higher serum  ENA-78/CXCL5 levels were found in periodontitis 
patients compared to those with gingivitis and healthy tissues, the differences between the 
groups were not statistically significant.  The recent study by Lappin et al. found similar but 
significantly higher plasma ENA-78/CXCL5 levels in non-diabetic patients with periodontitis 
(n=23) [approximate levels from presented graph: 300 (150-1,000) pg/ml] compared to those 
with healthy periodontal tissues (n=19) [approximate levels from presented graph: 200 (50-
500) pg/ml], (P<0.1) (Lappin et al. 2015). 
In the current study, while considering serum resistin levels, within the non-T1DM group 
serum resistin levels were significantly higher in periodontitis patients (10.5±3.55 ng/ml) 
compared to those with gingivitis (8.06±2.58 ng/ml), (P<0.05) (Table 4.10 and Figure 4.7).  
The findings of this study are similar to a previous study which found significantly higher 
serum resistin levels in women with periodontitis (9.9±5.0 ng/ml) compared to those with 
gingivitis (8.0±5.2 ng/ml), (P<0.05) (Saito et al. 2008).  The authors also reported that 
women with periodontitis had significantly higher BMI compared to women with gingivitis 
(Saito et al. 2008).  On performing correlations, in the current study, serum resistin levels in 
the T1DM patients were significantly positively correlated with BMI (Spearman’s rho=-0.08, 
P<0.05), suggesting that T1DM patients with higher BMI scores had elevated serum resistin 
levels.  T1DM is not typically associated with obesity, and hence the findings in this study 
may demonstrate that resistin may not be an ideal biomarker to establish the mechanistic link 
between T1DM and periodontal disease. 
In the current study, the ELISA results of BAFF in serum revealed no statistically significant 
difference in levels between T1DM and non-T1DM patients and also found no differences 
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between the groups based on periodontal diagnosis.  Hence, it was decided not to further 
analyse this biomarker in the GCF samples.  The findings of the ELISA experiment for serum 
BAFF levels did not replicate the findings of the cytokine array analysis, which revealed the 
highest intensity of serum BAFF in the T1DM patients with periodontitis and the lowest 
intensity in the non-T1DM patients with healthy tissues.  The cytokine array experiment 
involved the pooling of three serum samples for each diagnosis, whereas the ELISA 
experiment involved all serum samples collected for the study.  The findings of the BAFF 
results were confirmed and quantified using ELISA.  It is evident from the ELISA results that 
the three selected samples from each group may not have been fully representative of all the 
patients in the study.  It might be beneficial in future research to pool more than three 
samples for array experiments.  Overall, these findings emphasize that, caution must be used 
in interpreting the outcomes of array experiments and the results must always be followed up 
and confirmed by ELISA. 
Pre-treatment biomarker levels in GCF 
The local host response in periodontal disease has been investigated by biochemical analysis 
of GCF samples (Chung et al. 1997).  In the current study, although GCF MMP-9 and IL-8 
levels were higher in T1DM patients compared to non-T1DM patients, the differences were 
not statistically significant (Table 4.11).  So far, no research studies have evaluated the GCF 
levels of MMP-9 or IL-8 in patients with T1DM and periodontal disease and hence, it is has 
not been possible to make comparisons to the findings of other studies. 
Looking at past literature related to T2DM, a previous study in chronic periodontitis patients 
with and without T2DM, found significantly lower GCF IL-8 levels in T2DM patients 
(33.0±33.4 pg/sample) compared to non-diabetic patients with similar periodontal disease 
status (90.8±83.2 pg/sample), (P<0.00001) (Engebretson et al. 2006).  Also, GCF IL-8 levels 
significantly correlated with PD measurements but not with HbA1c levels.  The authors 
reported that their findings were unexpected as diabetes is often associated with an increase 
in inflammatory mediators (Engebretson et al. 2006).  Duarte et al. investigated the 
expression of IL-8, IL-6, IL-1β and interferon-γ in the gingival tissues of T2DM patients with 
and without periodontitis, and concluded that T2DM was associated with elevated expression 
of IL-1β and IL-6 in patients with periodontitis compared to systemically healthy controls 
with comparable periodontitis, however no such differences were observed for IL-8 levels 
between periodontitis patients with and without T2DM (Duarte et al. 2007).  The authors 
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stated that although IL-8 is locally delivered in the gingival tissues during host defence 
mechanism in periodontitis, IL-8 may not directly be involved in the mechanism by which 
alveolar bone destruction is modulated in T2DM (Duarte et al. 2007).  A recent study 
analysed serum IL-8 levels in T2DM patients with and without periodontal disease (Longo et 
al. 2014).  The authors reported significantly more severe periodontal disease in the T2DM 
inadequate- and adequate-glycaemic control patient groups, compared to the non-diabetic 
patients with periodontitis, however despite this, no statistically significant differences were 
found for serum IL-8 levels between groups (Longo et al. 2014).  The findings of the above 
studies were in T2DM patients, based on glycaemic control categories and in gingival tissue 
and serum samples, hence may not be an ideal comparison to the IL-8 results of the present 
study. 
In the current study, based on periodontal diagnosis, GCF MMP-9 and IL-8 levels were 
significantly higher in T1DM patients with healthy tissues compared to non-T1DM patients 
with healthy tissues, (P<0.05) (Table 4.12, Figure 4.9 and 4.10).  This is an interesting 
finding, as even in the absence of inflammatory periodontal disease, elevated GCF MMP-9 
and IL-8 levels were present in T1DM patients compared to non-diabetic controls, possibly 
suggesting the manifestation of diabetes-related inflammation in the GCF of patients with 
T1DM.  Additionally, these findings are in accordance with the studies’ pre-treatment clinical 
periodontal data findings, where significantly higher levels of gingival inflammation 
(indicated by % BOP) was present in T1DM patients with healthy tissues (9.87±5.67 %) 
compared to non-T1DM patients with healthy tissues (0.83±1.17 %), (P<0.001) (Table 3.15 
and Figure 3.10).  No statistically significant differences in GCF MMP-9 and IL-8 levels 
were found between T1DM and non-T1DM patients with gingivitis and periodontitis, though 
drawing from conclusions in this regard is difficult because the non-T1DM patients with 
periodontitis presented with more severe periodontal disease than the T1DM patients with 
periodontitis (Table 3.15 and Figure 3.11). 
Currently, studies related to GCF biomarker levels in T1DM and periodontal disease are 
extremely limited, and no studies have evaluated biomarker levels based on a patient’s 
periodontal diagnosis as was considered in this study.  A previous experimental gingivitis 
study in T1DM patients found that GCF MMP-9 levels were highest at day 21 following oral 
hygiene cessation, for both T1DM and non-diabetic patients, and were also significantly 
higher in T1DM patients compared to non-diabetic patients with gingivitis (Salvi et al. 2010).  
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However, as the authors provided only graphical presentation of their data and numerical 
values were not reported, it is difficult to compare their findings directly to the results of the 
current study.  A study of IL-8 levels in saliva, found that T1DM patients with periodontally 
healthy tissues had significantly higher salivary IL-8 levels compared to non-diabetic controls 
(Dakovic et al. 2013).  Also, no statistically significant differences were found for salivary 
IL-8 levels between periodontitis patients with and without T1DM (Dakovic et al. 2013).  
The use of saliva (not GCF) prevents direct comparison to the IL-8 levels in the current 
study.  Additionally, the patients included in the Dakovic study were aged 7-18 years, and 
hence their data might not be an ideal comparison to the findings of the current study.  A 
study by Li et al. analysed serum IL-8 levels in systemically healthy patients with (n=122) 
and without (n=532) chronic periodontitis (aged 21-52 years) (Li et al. 2012).  Their analysis 
revealed significantly higher serum IL-8 levels in chronic periodontitis patients 
(155.28±57.20 pg/ml) compared to the periodontally healthy controls (58.69±6.70 pg/ml), 
(P<0.001) (Li et al. 2012).  The authors suggested that serum concentrations of IL-8 indicated 
the potential clinical significance of serum measurements in patients with chronic 
periodontitis.  GCF is a serum exudate which contains all the key molecular and cellular 
components of the immune response required to prevent tissue invasion by subgingival 
bacteria (Taylor and Preshaw 2016), however, in the serum samples of the current study, the 
ELISA experiment carried out revealed no IL-8, which was found to be present only in the 
GCF samples.  Another recent study found significantly higher plasma IL-8 levels in T1DM 
patients with periodontitis (n=34) [approximate levels from presented graph: 30 (20-80) 
pg/ml] compared to systemically healthy patients with periodontitis (n=23) [approximate 
levels from presented graph: 15 (10-30) pg/ml], (P<0.1) (Lappin et al. 2015).  However, the 
use of plasma (not GCF) limits the comparison of their results to those of the present study. 
Within the T1DM group, in the present study, significantly higher GCF MMP-9 levels were 
found in the periodontitis patients compared to those with gingivitis and healthy tissues, 
(P<0.001) (Table 4.12 and Figure 4.9).  These findings are in accordance with the clinical 
periodontal data of this study which revealed significantly higher gingival inflammation 
(indicated by % BOP), PD measurements and severity of periodontal disease in T1DM 
patients with periodontitis compared to those with gingivitis and healthy tissues (Table 3.15).  
Within the non-T1DM group, significantly higher GCF MMP-9 levels were found in the 
periodontitis patients compared to those with gingivitis and healthy tissues, (P<0.001).  Also, 
significantly higher GCF MMP-9 levels were found in the gingivitis patients compared to 
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those with healthy tissues, (P<0.05) (Table 4.12 and Figure 4.9).  The findings of this study 
are in agreement with previous research, which found elevated MMP-9 levels in GCF, whole 
saliva and mouth rinse samples in patients with periodontitis compared to those with healthy 
tissues (Makela et al. 1994).  The researchers utilised a gelatin zymogram to evaluate MMP-9 
levels and reported that gelatinase activity in the oral cavity was mainly due to MMP-9 
(Makela et al. 1994).  The utilization of gelatin zymography for biomarker quantification and 
not ELISA, limits the comparison of their findings to the data of the current study.  The GCF 
MMP-9 data from the non-T1DM patients in the present study are in contrast to those of a 
previous study in systemically healthy patients which compared GCF MMP-9 levels between 
those with healthy tissues (3607±2381 pg/ml), gingivitis (3999±7715 pg/ml) and 
periodontitis (4637±4581 pg/ml) (Maeso et al. 2007).  The authors reported that although 
GCF MMP-9 levels were higher in periodontitis patients compared to those with gingivitis 
and healthy tissues, the differences were not statistically significant (Maeso et al. 2007).  The 
findings of the present study are contrast to another study, which reported no differences in 
GCF MMP-9 levels in systemically healthy patients with periodontitis (n=27) [approximate 
levels from presented graph: 1,400 (100-3,500) ng/site in 30s] compared to healthy controls 
(n=15) [approximate levels from presented graph: 1,100 (400-2,000) ng/site in 30s] (P>0.05)  
(Marcaccini et al. 2010).  Patients with periodontitis had significantly higher PD and CAL 
(4.50±1.84 mm and 4.8±1.9 mm) compared to those with healthy tissues (2.24±0.68 mm and 
2.3±0.6 mm) (P<0.0001), and no statistically significant differences in BOP scores 
[periodontitis: n (%), 21 (77.78 %) and healthy tissues: n (%), 8 (53.34 %)].  In the current 
study, along with PD and LOA measurements the non-T1DM patients with periodontitis had 
significantly higher % BOP (53.9±21.1 %) compared to those with healthy tissues 
(0.83±1.17) (P<0.001), which was not seen in Marcaccini et al.’s study which could probably 
lead us to assume that an increase in gingival inflammation could attribute to an increases in 
GCF MMP-9 levels in patients with periodontitis.  Additionally, Marcaccini et al.’s study 
collected and analysed only a single GCF sample per patient and reported MMP-9 levels as 
ng/site in 30s, limits the comparison of their results to those of the current study, which 
collected and analysed four GCF samples per patient and reported MMP-9 levels in ng/ml. 
Within the T1DM group, in the current study, although GCF IL-8 levels were higher in 
periodontitis patients compared to those with gingivitis and healthy tissues, the differences 
were not statistically significant. Likewise, in Lappin et al.’s recent study although higher 
plasma  IL-8 levels were found in the T1DM patients with periodontitis (n=34) [approximate 
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levels from presented graph: 30 (20-80) pg/ml] compared to the T1DM patients with healthy 
tissues (n=28) [approximate levels from presented graph: 25 (15-35) pg/ml], these differences 
were not statistically significant, (P>0.05)  (Lappin et al. 2015).  The use of plasma (not 
GCF) limits the comparison to the data of the current study.  In the current study, within the 
non-T1DM group, GCF IL-8 levels were significantly higher in the periodontitis patients 
compared to those with gingivitis and healthy tissues, (P<0.01 and P<0.05, respectively) 
(Table 4.12 and Figure 4.10).  The findings of the present study are in agreement with those 
of a previous small study which reported significantly elevated GCF IL-8 levels in 
periodontitis patients (n=16, 203.8±136.3 ng/ml) compared to those with healthy tissues 
(n=5, 205.9±115.4 ng/ml), (P>0.05) (Tsai et al. 1995).  Our findings are in contrast to another 
study which found significantly higher GCF IL-8 levels in patients with healthy tissues 
(n=14, 2902.3±432.5 pg/µl) compared to those with periodontitis (n=30, 1471.5±231.4 pg/µl) 
(Chung et al. 1997).  The authors also reported that clinical periodontal data were 
significantly higher in periodontitis patients compared to those with healthy tissues, however, 
in spite this GCF IL-8 levels were higher in patients with healthy tissues.  The authors 
suggested that their findings demonstrated that there is an inverse relationship between PMN 
recruitment and IL-8 activity (Chung et al. 1997), consistent with Tonetti et al.’s study which 
demonstrated that IL-8 transcripts were more consistently detected in the gingival tissue 
biopsies from healthy tissues compared to biopsies from patients with periodontitis (Tonetti 
et al. 1993).  The findings of the current study are in agreement to Lappin et al.’s recent 
findings in systemically healthy patients, which found significantly higher plasma IL-8 levels 
in periodontitis patients (n=23) [approximate levels from presented graph: 15 (10-30) pg/ml] 
compared to those with healthy tissues (n=19) [approximate levels from presented graph:      
5 (0-10) pg/ml], (P<0.001) (Lappin et al. 2015).  The use of plasma (not GCF) limits the 
comparison of their findings to the data from the present study. 
The heterogeneity in methodology used between research studies is a possible explanation for 
the variations in GCF biomarker levels seen in the published literature and in the present 
study.  These differences could arise from variations in case definitions of periodontitis, 
analytical techniques, GCF sampling methods, techniques used for eluting GCF from 
Periopapers and storage of samples.  While considering methods used for eluting GCF from 
Periopapers, a variety of protocols were used within studies, for example, in Tsai et al.’s 
study following GCF collection the Periopaper strip was eluted twice in 100 µl of Hank’s 
balanced salt solution and centrifugation 3000 x g at 4 °C for 15 minutes before storing the 
 202 
 
sample at -70 °C (Tsai et al. 1995).  Chung et al.’s study used pre-cut methylcellulose filter 
paper strips for GCF collection, and GCF was eluted by adding 50 µl of PBS with 0.05% 
Tween 20 and centrifuging for 3 times following which the eluted GCF was frozen at -20 °C 
(Chung et al. 1997).  Gamonal et al.’s study placed 3 GCF Periopapers in vials containing 50 
µl of PBS with 0.05% Tween 20 and centrifuged at 10,000 g for 5 minutes at 4 °C and this 
was repeated 3 times (Gamonal et al. 2000).  Salvi et al.’s study, collected 4 GCF samples 
per quadrant and pooled them together, eluting each strip with 5 wash-centrifugation cycles 
with a buffer containing 200 mM phenylmethylsulfonyl fluoride in methanol, 1 mg/ml 
Aprotinin, 30% HSA, and PBS, following which the eluted GCF was frozen at -80 °C (Salvi 
et al. 2010).  By comparison, Marcaccini et al.’s study collected a single GCF sample and 
placed it in a vial containing 100 µl buffer for 30 minutes at 4 °C, after which the GCF was 
centrifuged at 13,000 g for 10 minutes at 4 °C and stored at -70 °C (Marcaccini et al. 2010).  
A lack of consistency in the literature in the methodologies used for GCF collection and 
elution will have likely increased inter-study variations in GCF biomarker levels and hence, 
prevent clear conclusions from being made regarding the role that GCF biomarkers play in 
patients with T1DM and periodontal disease. 
With reference to GCF volume, in the present study no statistically significant differences 
were found between T1DM and non-T1DM patients for the volume of GCF collected.  
However, based on periodontal diagnosis, in both T1DM and non-T1DM groups significantly 
higher GCF volumes were recorded in the periodontitis patients compared to those with 
gingivitis and healthy tissues, (P<0.001).  In only the non-T1DM group a significantly higher 
GCF volume was recorded in the gingivitis patients compared to those with healthy tissues, 
(P<0.01) (Table 4.12).  The findings of this study related to non-T1DM patients are in 
agreement to a previous study of systemically healthy patients, which found significantly 
higher GCF volume in patients with periodontitis (n=25, 1.11±0.39 µl) compared to those 
with gingivitis (n=18, 0.92±0.33 µl) and healthy tissues (n=16, 0.48±0.29 µl), (P<0.05 and 
P<0.001, respectively) (Maeso et al. 2007).  Also, patients with gingivitis (0.92±0.33 µl) had 
significantly higher GCF volume compared to those with healthy tissues (0.48±0.29 µl), 
(P<0.001) (Maeso et al. 2007).  Similarly, another small study found significantly higher 
GCF volume in patients with periodontitis (n=16, 0.46±0.39 µl) compared to those with 
healthy tissues (n=5, 0.07±0.06 µl), (P<0.001) (Tsai et al. 1995).  The GCF volume collected 
is the sum of two components i.e. the GCF void volume (the GCF resting volume which is 
independent of flow) and the GCF flow contribution (which is dependent upon the flow rate 
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and collection time).  The GCF resting void volume is dependent upon the pocket depth, as 
pocket depth increases from 3 mm to 6 mm there is a 50% increase in the GCF resting void 
volume (Barros et al. 2016).  In the current study, irrespective of diabetes status the 
periodontitis patients had significantly higher mean PD compared to those with heathy tissues 
(P<0.001) (Table 3.15).  The findings of the current study and those of past literature 
strengthened the observations that more severe periodontal disease leads to an increase in 
GCF volume. 
Correlations 
Association between HbA1c and hsCRP levels and clinical periodontal parameters 
A positive correlation between severity of periodontal disease and glycaemic control has been 
reported in literature (Tanwir and Tariq 2012; Costa et al. 2013).  In the current study, when 
considering all patients, the only positive significant correlation was found between PI and 
HbA1c levels.  However, no statistically significant correlations were found between HbA1c 
and mGI, % BOP and mean PD.  While categorising the patients based on diabetes status, in 
T1DM patients the only positive correlation was found between PI and HbA1c levels (Table 
4.14).  The findings of this study are in agreement with a study by Aren and colleagues in 
T1DM and non-diabetic children which found a significant correlation between PI scores and 
HbA1c levels, (Pearson’s r=0.31, P=0.03) (Aren et al. 2003).  On the other hand, our findings 
are in contrast to Firatli’s study of T1DM patients and non-diabetic controls which found no 
statistically significant correlation between clinical periodontal parameters (PI, mGI, PD and 
LOA) and laboratory parameters (glucose, fructosamine and HbA1c) (Firatli 1997).  Lappin 
et al.’s recent study of T1DM patients and non-diabetic controls (with and without 
periodontitis), found a significant positive correlation between % BOP and HbA1c levels, 
(P<0.001) (Lappin et al. 2015).  Our findings suggest that higher HbA1c levels are associated 
with an increase in the amount of plaque in patients with T1DM, and can be supported by the 
concept that excessive diabetes-related glucose enters the oral cavity through the GCF and 
saliva, a sugar-rich biofilm which forms will then, in general, enhance plaque growth.  A lack 
of knowledge about oral hygiene and maintaining optimal oral health in patients with 
diabetes plus increases in HbA1c levels could collectively lead to increases in plaque 
accumulation (Hugoson et al. 1989).  But, clearly, further work is needed to study the 




Association between HbA1c, hsCRP levels and inflammatory biomarkers 
In the current study, while considering all patients, a significant positive correlation was 
found between HbA1c and serum MMP-9 and ENA-78/CXCL5 levels (Table 4.16).  Similar 
correlations were demonstrated in Lappin et al.’s study in which plasma IL-8 and           
ENA-78/CXCL5 levels were significantly correlated with and HbA1c levels (P=0.001 and 
P=0.02) in T1DM and non-diabetic patients (with and without periodontitis) (Lappin et al. 
2015).  The finding of their study and ours, suggest that an increase in the systemic 
inflammatory burden is associated with an increase in HbA1c levels irrespective of diabetes 
status. 
In the current study, when considering all patients, a significant positive correlation was 
found between hsCRP and serum MMP-9 levels.  Similarly, when patients were split 
according to diabetes status, a significant positive correlation was found between hsCRP and 
serum MMP-9 levels in T1DM patients (Table 4.16 and 4.17).  The positive association 
observed between serum MMP-9 and hsCRP in this study, indicates that MMP-9 may reflect 
the chronic inflammatory state which is typical of periodontitis.  Our findings suggest a clear 
systemic association between hsCRP and MMP-9 levels particularly in patients with T1DM. 
Association between clinical periodontal parameters and inflammatory biomarkers 
While considering serum biomarker levels, in the current study, no statistically significant 
correlations were found for serum MMP-9, BAFF, resistin and ENA-78/CXCL5 levels and 
mGI, PI, % BOP and mean PD when considering all patients and when splitting the patients 
based on diabetes status.  Our findings are in contrast to Lappin et al.’s study of T1DM and 
non-diabetic controls (with and without periodontitis), which found a significant positive 
correlation between plasma ENA-78/CXCL5 levels and PD (P=0.02) and LOA (P=0.03) 
(Lappin et al. 2015).  Our findings are also in contrast to Lappin et al’s previous study in 
systemically healthy patients with and without periodontitis, which found a significant 
correlation between LOA and plasma ENA-78/CXCL5 levels (P=0.003) (Lappin et al. 2011).  
Clearly more research is required with regards to systemic inflammation and clinical 
periodontal status.  However, the findings of this study demonstrated that periodontal status 
had no association with the systemic inflammatory state. 
While considering GCF biomarker levels, in the current study, a significant positive 
correlation was found between GCF MMP-9 levels and mGI, % BOP and mean PD in all 
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patients.  Based on diabetes status, a significant positive correlation was found between GCF 
MMP-9 levels and % BOP and mean PD in T1DM patients.  In non-T1DM patients, a 
significant positive correlation was found between GCF MMP-9 levels and mGI, PI, % BOP 
and mean PD.  With reference to GCF IL-8 levels, a significant positive correlation was 
found between GCF IL-8 levels and mGI, PI, % BOP and mean PD in all patients.  Based on 
diabetes status, a similar significant positive correlation was found between GCF IL-8 levels 
and mGI, PI, % BOP and mean PD in non-T1DM patients.  However, in T1DM patients, a 
significant positive correlation was only found between GCF IL-8 levels and % BOP (Table 
4.19, 4.20 and 4.21).  Our findings demonstrate that poorer periodontal health is associated 
with increases in local inflammatory state which reflected in GCF.  Similar findings were 
seen in other studies, for example, Salvi et al.’s experimental gingivitis study in T1DM and 
non-diabetic patients found that in both groups, mGI correlated with GCF MMP-8, MMP-9 
and IL-8 levels at day 21, also in T1DM patients there was a significant correlation between 
mGI and GCF MMP-9 levels at day 0 (Salvi et al. 2010).  In non-diabetic patients a 
significant correlation was found between PI and GCF MMP-9 levels at day 0.  In T1DM 
patients, PI was significantly correlated with GCF MMP-9 levels at day 0 (Salvi et al. 2010).  
Lappin et al.’s study of T1DM and non-diabetic controls (with and without periodontitis), 
found a significant positive correlation between plasma IL-8 levels and PD (P=0.001) and 
LOA (P=0.005) (Lappin et al. 2015).  Marcaccini et al.’s study in systemically healthy 
patients with and without periodontitis, found a significant correlation between total GCF 
MMP-9 levels and PD (Spearman’s rho=0.67, P<0.001) (Marcaccini et al. 2010).  However, 
Marcaccini et al.’s correlations were related to total GCF MMP-9 levels and hence, may not 
be an ideal comparison to the GCF MMP-9 concentration levels in the current study.  Tsai et 
al’s. study in systemically healthy patients with and without periodontitis, found no 
statistically significant differences in GCF IL-8 concentration levels between the two groups, 
and found a significant negative correlations between GCF IL-8 concentration levels and 
clinical periodontal parameters: mGI (Spearman’s rho=-0.37, P<0.01),                                 
PD (Spearman’s rho=-0.42, P<0.01), LOA (Spearman’s rho=-0.44, P<0.01) and tooth 
mobility (Spearman’s rho=-0.43, P<0.01) (Tsai et al. 1995).  Their results suggest that a 
better periodontal condition is associated with elevated GCF IL-8 levels (Tsai et al. 1995).  
Gamonal et al.’s study of systemically healthy patients with and without moderate to 
advanced periodontitis found weak and non-significant correlations between total GCF IL-8 
levels and clinical parameters PI (Spearman’s rho=0.12), BOP (Spearman’s rho=0.01) and 
PD (Spearman’s rho=0.05), (P>0.05) (Gamonal et al. 2000).  Also, a significant positive 
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correlation was found between total GCF IL-8 and RANTES (regulated on activation, normal 
T cell expressed and secreted) and GCF volume (Spearman’s rho=0.71 and 0.74, P<0.05) 
(Gamonal et al. 2000).  However, these correlations were related to total GCF IL-8 levels and 
hence, may not be an ideal comparison to the GCF IL-8 concentration levels in the current 
study. 
The findings of the current study and a review of previous literature related to GCF 
biomarker levels in patients with periodontal disease with and without T1DM indicate in 
broad terms that an increase in periodontal disease leads to elevated levels of MMP-9 and  
IL-8 in GCF.  However, in the current study, a similar association was not found for serum 
biomarker levels and periodontal parameters.  Based on the evidence it would be reasonable 
to suggest that GCF is a good local indicator for periodontal inflammatory status due to its 
local production within the periodontal tissues.  The findings of this study related to serum 
biomarker levels found significantly elevated MMP-9, resistin and ENA-78/CXCL5 levels in 
T1DM patients compared to controls.  Furthermore, serum MMP-9 levels were significantly 
correlated with hsCRP levels suggesting that serum has potential of a systemic indicator for 
the inflammatory disease status in patients with periodontal disease and T1DM. 
Summary of key findings from chapter 4 
 Serum levels of MMP-9, resistin and ENA-78/CXCL5 were significantly higher in 
T1DM patients compared to non-T1DM patients.  Furthermore, serum MMP-9 levels 
were significantly higher in the T1DM patients with periodontitis compared to the 
non-T1DM patients with periodontitis. 
 Although serum levels of resistin and ENA-78/CXCL5 were apparently higher in the 
T1DM patients with periodontitis compared to the non-T1DM patients with 
periodontitis, these differences were not statistically significant. 
 Serum resistin and ENA-78/CXCL5 levels were significantly higher in the T1DM 
patients with gingivitis compared to the non-T1DM patients with gingivitis.  Also, 
within the non-T1DM group, serum resistin levels were significantly higher in the 
periodontitis patients compared to those with gingivitis. 
 Although the levels of MMP-9, resistin and ENA-78/CXCL5 in serum were 
apparently higher in the T1DM patients with healthy tissues compared to the non-




 Serum resistin levels were significantly correlated with BMI in T1DM patients. 
 Although GCF MMP-9 and IL-8 levels were higher in the T1DM patients compared 
to non-T1DM patients, these differences were not statistically significant. 
 In both T1DM and non-T1DM patients, GCF MMP-9 levels were significantly higher 
in the periodontitis patients compared to those with healthy tissues.  Also, MMP-9 
levels in GCF were significantly higher in periodontitis patients compared to those 
with gingivitis.  Within the non-T1DM group, GCF MMP-9 levels were significantly 
higher in the gingivitis patients compared to those with healthy tissues. 
 Interestingly, T1DM patients with healthy tissues had significantly higher GCF 
MMP-9 and IL-8 levels compared to non-T1DM patients with healthy tissues, 
possibly indicating upregulated periodontal inflammation unmasked by periodontal 
status in patients with T1DM. 
 In non-T1DM patients, significantly higher GCF IL-8 levels were found in the 
periodontitis patients compared to those with healthy tissues and gingivitis.  Also, 
patients with gingivitis had significantly higher GCF IL-8 levels compared to those 
with healthy tissues. 
 Considering all patients, significant positive correlations were found between GCF 
MMP-9 levels and mGI, % BOP and mean PD.  Also, a significant positive 
correlation was found between GCF IL-8 levels and mGI, PI, % BOP and mean PD.  
No statistically significant correlations were demonstrated between serum levels of 
MMP-9, BAFF, resistin and ENA-78/CXCL5 and any of the clinical periodontal 
parameters. 
 In patients with T1DM, significant positive correlations were found between serum 






5 Chapter 5.  Impact of non-surgical periodontal management on clinical 
periodontal status, markers of diabetes control and local and systemic biomarker levels 
in patients with T1DM 
5.1 Introduction 
The impact of diabetes on periodontal disease has been well established but whether there is 
any influence of periodontal treatment on diabetes control is less clear.  Clinical data 
supporting the existence of an effect of periodontal treatment on diabetes is limited.  Some 
publications have suggested that improvement in clinical periodontal status improves 
glycaemic control in diabetes (Miller et al. 1992; Grossi et al. 1996; Taylor et al. 1996; 
Grossi et al. 1997; Iwamoto et al. 2001; Stewart et al. 2001; Rodrigues et al. 2003; Kiran et 
al. 2005), while other studies have found no such relationship between periodontal treatment 
and diabetes (Seppala et al. 1993; Seppala and Ainamo 1994; Aldridge et al. 1995; Smith et 
al. 1996; Firatli 1997; Christgau et al. 1998; Jones et al. 2007; Llambes et al. 2008).  
Additionally, it has been reported that periodontal treatment can improve glycaemic control 
with reductions in HbA1c of up to 0.4% (Simpson et al. 2010; Teeuw et al. 2010; Liew et al. 
2013). 
A positive impact of NSM on clinical outcomes in patients with T1DM has been 
demonstrated in a small number of studies (Bay et al. 1974; Grossi et al. 1996; Smith et al. 
1996; Westfelt et al. 1996; Martorelli de Lima et al. 2004; Llambes et al. 2005).  NSM has 
been found to reduce MMP-9 and IL-8 levels in GCF in systemically healthy individuals 
(Marcaccini et al. 2010).  However, research related to the effect of NSM on circulating 
inflammatory biomarkers in patients with T1DM is notably lacking.  Hence, the aim of this 
chapter is to report on the effect of NSM on the clinical periodontal status, metabolic control 
and levels of inflammatory biomarkers in patients with T1DM. 
5.2 Results 
5.2.1 BMI, BP and medical history following NSM 
Table 5.1 summarises pre- and post-treatment (month 0 and 6) BMI data for T1DM and non-
T1DM patients with periodontitis.  Of note, no statistically significant differences were found 









), (P>0.05).  The BMI 




Table 5.2 summarises pre- and post-treatment (month 0 and 6) BP data for T1DM and non-
T1DM patients with periodontitis.  Of note, no statistically significant differences were found 
between T1DM and non-T1DM patients at month 0 and month 6, (P>0.05).  In T1DM 
patients, compared to pre-treatment [125 (113-138) mmHg], there was a significant increase 
in systolic BP at month 6 [132.5 (118-148.8) mmHg] following NSM, (P<0.05).  No 
statistically significant changes were observed for diastolic BP over the same timescale.  In 
non-T1DM patients, compared to pre-treatment [124 (118-143) mmHg], there was an 
increase in systolic BP levels at month 6 [136 (129-154) mmHg] following NSM, however, 
this was not statistically significant, (P>0.05).  No statistically significant difference was 
found for diastolic BP levels following NSM. 
With reference to the patient’s medical history, from the data collected at month 6, it 
appeared that there were minimal changes to the medical care for all patients over the study 
period.  Out of the 12 T1DM patients and 13 non-T1DM patients seen at month 6, medical 
history data was collected for 12 T1DM and 9 non-T1DM patients.  Of these, change in 
medical history was reported in 4 (33.3%) T1DM patients and the non-T1DM patients 
reported no change in medical history at month 6.
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Table 5.1: BMI data for T1DM and non-T1DM patients with periodontitis pre- and post- 
NSM. 
Mean ± SD presented for parametric data and n (%) presented for discrete variables.  For 
comparison between T1DM and non-T1DM patients, p-values determined using independent 
t-test for continuous parametric variables and p-values determined using chi-squared test for 
discrete variables.  For longitudinal comparisons, p-values determined using paired t-test for 
parametric variables (no statistically significant differences found).  P-values under columns 
(P) relate to comparisons between T1DM and non-T1DM group at that particular time point. 
BMI; body mass index, NS; not significant. 
 










T1DM 27.0 ± 4.80 26.9 ± 3.87 
Non-T1DM 24.7 ± 4.91 24.9 ± 2.40 





Underweight (<18.5  kg/m
2
) 


























Underweight (<18.5  kg/m
2
) 






















P NS NS 
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Table 5.2: BP data for T1DM and non-T1DM patients with periodontitis pre- and post-
NSM. 
Median (IQR) presented for non-parametric data.  For comparison between T1DM and non-
T1DM patients, p-values determined using Mann-Whitney U test for continuous non-
parametric variables (no statistically significant differences found).  For longitudinal 
comparisons, p-values determined using Friedman test with post-hoc Wilcoxon signed rank 
test for continuous non-parametric variables: significant difference from month 0 *P<0.05.  
 






T1DM Systolic BP (mmHg) 125 (113-138) 132.5 (118-148.8) * 
Diastolic BP (mmHg) 72 (66.0-80.0) 73 (64.5-77.8) 
Non-T1DM Systolic BP (mmHg) 124 (118-143) 136 (129-154) 
Diastolic BP (mmHg) 80 (69.0-89.5) 77 (75.0-83.0) 
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5.2.2 Clinical biochemistry parameters following NSM 
Table 5.3 and Figures 5.1 to 5.4 summarise pre- and post-treatment clinical biochemistry data 
for T1DM and non-T1DM patients with periodontitis.  As expected, at each time point, the 
T1DM patients had a significantly higher HbA1c (%/ mmol/mol) compared to non-T1DM 
patients, (P<0.001).  In T1DM patients, pre-treatment HbA1c levels [8.95 (8.03-9.65) %/ 75 
(64-83) mmol/mol] showed a reduction at 3 months [8.50 (6.60-9.60) %/ 69 (49-81) 
mmol/mol], and 6 months [8.05 (6.95-10.1) %/ 64 (53-87) mmol/mol] following NSM, which 
is a reduction of 0.45% and 0.90% respectively.  However, these reductions were not 
statistically significant, (P>0.05) (Table 5.3 and Figure 5.1).  Figure 5.2 shows a line and 
scatter plot of HbA1c levels for individual patients with T1DM and periodontitis at pre-
treatment and month 6, with the lines depicting variations in changes in HbA1c levels over 
this time period.  With reference to glycaemic control categories, no statistically significant 
changes were found between pre- and post-NSM glycaemic control categories (Table 5.4). 
When considering non-HDL levels, the non-T1DM patients had significantly higher non-
HDL levels at month 3 [4.05 (3.18-4.45) mmol/L] compared to the T1DM patients          
[3.00 (2.60-3.80) mmol/L], (P<0.05).  No statistically significant differences were found 
between the two groups at month 0 and 6.  Within the T1DM and non-T1DM groups, 
compared to pre-treatment, non-HDL levels showed no statistically significant changes 
following NSM (Table 5.3 and Figure 5.3). 
When considering cholesterol levels, the non-T1DM patients had significantly higher levels 
of cholesterol at pre-treatment (5.18±0.86 mmol/L) compared to the T1DM patients 
(4.52±0.83 mmol/L), (P<0.05).  However, no statistically significant differences were found 
for cholesterol levels between the two groups following NSM at months 3 and 6.  Within the 
T1DM and non-T1DM groups, compared to pre-treatment no significant changes in 
cholesterol levels were found following NSM (Table 5.3 and Figure 5.4). 
When considering levels of triglycerides, HDL and hsCRP, no statistically significant 
differences were found at any time point between T1DM and non-T1DM patients, (P>0.05).  
Compared to pre-treatment, triglycerides and HDL levels showed no statistically significant 
changes following NSM in either T1DM or non-T1DM patients at any time point (Table 5.3). 
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Table 5.3: Clinical biochemistry data for T1DM and non-T1DM patients with 
periodontitis pre- and post-NSM. 
Mean ± SD presented for parametric data.  For comparison between T1DM and non-T1DM 
patients, p-values determined using Independent t-test for continuous parametric variable and 
using Mann-Whitney U test for continuous non-parametric variables.  For longitudinal 
comparisons, p-values determined using Paired t-test for parametric variables and using 
Friedman test with post-hoc Wilcoxon signed rank test for continuous non-parametric variables 
(no statistically significant differences found).  P-values under columns (P) relate to 
comparisons between T1DM and non-T1DM group at that particular time point.  HbA1c; 
glycated haemoglobin, HDL; high density lipoprotein, non-HDL; non-high density lipoprotein, 
hsCRP; high-sensitivity C-reactive protein, NS; not significant.  At month 6: HbA1c (T1DM 
n=12 and non-T1DM n=13); triglycerides, HDL, non-HDL and cholesterol (T1DM n=12 and 
non-T1DM n=12); hsCRP (T1DM n=12 and non-T1DM n=11).



































P < 0.001 < 0.001 < 0.001 
Triglycerides 
(mmol/L) 
T1DM 1.30 (0.75-1.80) 0.90(0.70-1.70) 1.20 (0.73-1.58) 
Non-T1DM 1.35 (0.75-1.98) 1.55 (0.98-1.93) 1.40 (1.10-2.13) 
P NS NS NS 
HDL 
(mmol/L) 
T1DM 1.35 (1.23-1.60) 1.60 (1.20-2.10) 1.30 (1.03-1.80) 
Non-T1DM 1.40 (1.13-1.75) 1.40 (1.28-1.93) 1.40 (1.23-1.80) 
P NS NS NS 
Non-HDL 
(mmol/L) 
T1DM 3.20 (2.30-3.88) 3.00 (2.60-3.80) 2.85 (1.98-3.88) 
Non-T1DM 3.55 (2.68-4.20) 4.05 (3.18-4.45) 4.00 (3.13-4.58) 
P NS < 0.05 NS 
Cholesterol 
(mmol/L) 
T1DM 4.52 ± 0.83 4.66 ± 0.90 4.64 ± 1.49 
Non-T1DM 5.18 ± 0.86 5.27 ± 0.78 5.43 ± 0.91 
P < 0.05 NS  NS 
hsCRP 
(mg/L) 
T1DM 1.80 (1.23-7.75) 1.60 (0.50-6.00) 1.90 (0.33-5.28) 
Non-T1DM 1.50 (0.60-3.20) 0.85 (0.55-2.45) 1.60 (0.60-3.80) 
P NS NS NS 
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Table 5.4: Glycaemic control category of T1DM patients with periodontitis pre- and 
post-NSM. 
N (%) presented for discrete variables.  P-values determined using chi-squared test for 
discrete variables (no statistically significant differences found between time points).
 Month 0 





Glycaemic control categories [n (%)] 
Good (<7.0 %) 
Moderate (7.0-8.5 %) 

















Figure 5.1: HbA1c levels in T1DM and non-T1DM patients with periodontitis pre- and 
post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients (pre-treatment n=18, month 3 n=11, month 6 n=12) and non-T1DM patients (pre-
treatment n=16, month 3 n=14, month 6 n=13).  Statistics: Friedman test with post-hoc 
Wilcoxon signed rank test for longitudinal comparisons according to time point within T1DM 
or non-T1DM group (no statistically significant differences found); Mann-Whitney U test  for 
T1DM versus non-T1DM group at each time point: ***P<0.001.  ● indicates outlier more 























Figure 5.2: HbA1c levels in individual patients with periodontitis and T1DM pre- 
treatment and month 6. 
Line and scatter plot of HbA1c levels for individual patients with T1DM and periodontitis at 





Figure 5.3: Non-HDL levels in T1DM and non-T1DM patients with periodontitis pre- 
and post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients (pre-treatment n=18, month 3 n=11, month 6 n=12) and non-T1DM patients (pre-
treatment n=16, month 3 n=14, month 6 n=13).  Statistics: Friedman test with post-hoc 
Wilcoxon signed rank test for longitudinal comparisons according to time point within T1DM 
or non-T1DM group (no statistically significant differences found); Mann-Whitney U test: 





Figure 5.4: Cholesterol levels in T1DM and non-T1DM patients with periodontitis pre- 
and post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients (pre-treatment n=18, month 3 n=11, month 6 n=12) and non-T1DM patients (pre-
treatment n=16, month 3 n=14, month 6 n=13).  Statistics: Paired t-test for longitudinal 
comparisons according to time point within T1DM or non-T1DM group (no statistically 
significant differences found); Independent t-test: *P<0.05 (T1DM versus non-T1DM group 
at each time point).  ▲ indicates outlier more than 3 times the IQR from the box boundaries.
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5.2.3 Clinical periodontal parameters following NSM 
Table 5.5 and Figures 5.5 to 5.12 summarise pre- and post-treatment clinical periodontal data 
for T1DM and non-T1DM patients with periodontitis.  When considering gingival 
inflammation, no statistically significant differences in mGI scores were found between 
T1DM and non-T1DM patients at any time point, (P>0.05).  In patients with T1DM, 
compared to pre-treatment (1.96±0.51) mGI score showed significant reduction 
(improvement) following NSM at 3 months (0.87±0.53) and 6 months (1.12±0.76), 
(P<0.001).  Similarly in non-T1DM patients, compared to pre-treatment (2.29±0.53) mGI 
score showed significant reduction following NSM at 3 months (1.25±0.63) and 6 months 
(1.27±0.61), (P<0.001) (Table 5.5 and Figure 5.5). 
When considering plaque levels, no statistically significant differences in PI scores were 
found between T1DM and non-T1DM patients at any time point, (P>0.05).  In patients with 
T1DM, compared to pre-treatment levels (0.98±0.54), PI score showed significant reduction 
(improvement) following NSM at 3 months (0.44±0.23) and 6 months (0.50±0.24), (P<0.01).  
Similarly in non-T1DM patients, compared to pre-treatment levels (0.66±0.29) PI score 
showed significant reduction following NSM at 3 months (0.28±0.25) and 6 months 
(0.32±0.26), (P<0.001 and P<0.01 respectively) (Table 5.5 and Figure 5.6). 
When considering PD measurements, no statistically significant differences in mean PD were 
found between T1DM and non-T1DM patients at pre-treatment and following NSM at 
months 3 and 6, (P>0.05).  In patients with T1DM, compared to pre-treatment (3.02±0.81 
mm), mean PD showed significant reduction (improvement) following NSM at 3 months 
(2.40±0.81 mm) and 6 months (2.42±0.53 mm), (P<0.01 and P<0.001 respectively).  
Similarly in non-T1DM patients, compared to pre-treatment (3.31±0.75 mm), mean PD 
showed significant reduction following NSM at 3 months (2.70±0.37 mm) and 6 months 
(2.65±0.49 mm), (P<0.001 and P<0.01 respectively) (Table 5.5 and Figure 5.7). 
When considering gingival recession, no statistically significant differences were found 
between T1DM and non-T1DM patients at any time point, (P>0.05).  In patients with T1DM, 
compared to pre-treatment (0.43±0.64 mm), mean recession showed a significant increase 
following NSM at 6 months (0.55±0.61 mm), (P<0.01).  In non-T1DM patients, compared to 
pre-treatment (0.24±0.43 mm), mean recession showed a significant increase following NSM 




When considering clinical LOA, no statistically significant differences were found for mean 
LOA between T1DM and non-T1DM patients at any time point, (P>0.05).  In patients with 
T1DM, compared to pre-treatment (3.45±1.18 mm), mean LOA showed a significant 
reduction following NSM at 3 months (2.74±1.13 mm) and 6 months (2.97±0.94 mm), 
(P<0.05).  Similarly in non-T1DM patients, compared to pre-treatment (3.55±0.75 mm), 
mean LOA showed significant reductions following NSM at 3 months (3.24±0.50 mm) and 6 
months (3.26±0.54 mm), (P<0.01) (Table 5.5 and Figure 5.9). 
When considering BOP scores, no statistically significant differences were found between the 
T1DM and non-T1DM patients at any time point, (P>0.05).  In patients with T1DM, 
compared to pre-treatment scores (52.7±17.4 %), % BOP showed a significant reduction 
following NSM at 3 months (26.2±20.1 %), and 6 months (29.2±17.7 %), (P<0.01 and 
P<0.001 respectively).  Similarly in non-T1DM patients, compared to pre-treatment scores 
(53.9±21.1 %), % BOP showed significant reduction following NSM at 3 months (22.1±15.1 
%) and 6 months (20.6±16.2 %), (P<0.001) (Table 5.5 and Figure 5.10). 
For PD sites measuring ≥5 mm, the non-T1DM patients had significantly higher number (%) 
of PD sites ≥5 mm at pre-treatment [37.4±25.2 (23.7±15.5 %)] compared to T1DM patients 
[20.3±21.7 (14.7±16.4 %)], (P<0.05).  However, no statistically significant differences were 
found between the two groups at months 3 and 6, (P>0.05).  In patients with T1DM, 
compared to pre-treatment [20.3±21.7
 
(14.7±16.4 %)], there was a significant reduction 
(improvement) in number (%) of PD sites ≥5 mm following NSM at 3 months [11.0±17.5 
(7.94±13.8 %)] and 6 months [9.69±13.9 (6.97±10.9 %)], (P<0.01).  Similarly in non-T1DM 
patients, compared to pre-treatment [37.4±25.2 (23.7±15.5 %)] there was a significant 
reduction in number (%) of PD sites ≥5 mm following NSM at 3 months [20.6±13.1 
(12.8±7.59 %)] and 6 months [18.7±15.6 (12.6±9.29 %)], (P<0.001 and P<0.01 respectively) 
(Table 5.5 and Figure 5.11). 
For PD sites measuring ≤4 mm, no statistically significant differences were found between 
T1DM and non-T1DM patients at any time point, (P>0.05).  In patients with T1DM, 
compared to pre-treatment [122.5±29.4 (85.3±16.4 %)], there was a significant increase 
(improvement) in number (%) of PD sites ≤4 mm following NSM at 3 months [136.3±25.2 
(92.1±13.8 %)] and 6 months [136.6±20.7 (93.0±10.9 %)], (P<0.01).  Similarly in non-
T1DM patients, compared to pre-treatment [119.0±25.1 (74.7±17.7 %)], there was a 
significant increase in number (%) of PD sites ≤4 mm following NSM at 3 months 
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[135.8±14.4 (82.3±19.3 %)] and 6 months [136.8±15.7 (84.1±17.1 %)], (P<0.01) (Table 5.5 
and Figure 5.12). 
Table 5.6 and Figures 5.13 and 5.14 summarises the number (%) of sites displaying increase 
and decrease in PD from pre-treatment to month 3 and 6.  Compared to pre-treatment mean 
PD, at month 3 the number (%) of sites with ≥2 mm PD increase in T1DM patients 
[4.18±5.25 (3.04±4.18 %)] and non-T1DM patients [3.83±2.41 (2.45±1.50 %)] were not 
statistically significantly different, (P>0.05).  Similarly, compared to pre-treatment mean PD, 
at month 6 the number (%) of sites with ≥2 mm PD increase in T1DM patients [4.31±4.05 
(3.08±3.12 %)] and non-T1DM patients [3.09±2.74 (1.98±1.67 %)] were not statistically 
significantly different, (P>0.05). 
Compared to pre-treatment mean PD, at month 3 the number (%) of sites with 0+/-1 mm PD 
reduction in T1DM patients [123.2±20.2 (83.8±13.3 %)] and non-T1DM patients 
[120.4±23.8 (74.2±15.6 %)] were not statistically significantly different, (P>0.05).  However 
compared to pre-treatment, at month 6 the number (%) of sites with 0+/-1 mm PD reduction 
in T1DM patients [124.2±16.9 (84.9±9.83 %)] was significantly higher compared to non-
T1DM patients [113.7±26.1 (73.2±15.9 %)], (P<0.05) (Table 5.6 and Figure 5.13).  
Compared to pre-treatment mean PD, at month 3 the number (%) of sites with ≥2 mm PD 
reduction in T1DM [19.9±19.4 (13.2±12.5 %)] and non-T1DM patients [32.7±22.9 
(20.8±14.1 %)] were not statistically significantly different, (P>0.05).  However compared to 
pre-treatment, at month 6 the number (%) of sites with ≥2 mm PD reduction in non-T1DM 
patients [39.0±26.7 (24.9±16.4 %)] was significantly higher compared to T1DM patients 
[17.5±12.5 (12.1±8.44 %)], (P<0.05) (Table 5.6 and Figure 5.14). 
Of note, in both T1DM and non-T1DM patients a majority of PD sites had a reduction of  
0+/-1 mm, followed by a reduction of ≥2 mm and whereas only a small proportion of sites 
had an increase of PD ≥2 mm following NSM. 
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Table 5.5: Clinical periodontal data for T1DM and non-T1DM patients with periodontitis 
pre- and post-NSM. 
Mean ± SD presented for parametric variables.  For comparison between T1DM and non-T1DM 
patients, p-values determined using Independent t-test for continuous parametric variables.  For 
longitudinal comparisons, p-values determined using Paired t-test for parametric variables: 
significant difference from baseline *P<0.05, **P<0.01 and ***P<0.001.  P-values under columns 
(P) relate to comparisons between T1DM and non-T1DM group at that particular time point.  
mGI; modified gingival index, PI; plaque index, PD; probing depth, LOA; loss of attachment, 
BOP; bleeding on probing, NS; not significant.







  (n=13) 
(n=13) 
mGI T1DM 1.96 ± 0.51 0.87 ± 0.53 *** 1.12 ± 0.76 *** 
Non-T1DM 2.29 ± 0.53 1.25 ± 0.63 *** 1.27 ± 0.61 *** 
P NS NS NS 
PI T1DM 0.98 ± 0.54 0.44 ± 0.23 ** 0.50 ± 0.24 ** 
Non-T1DM 0.66 ± 0.29 0.28 ± 0.25 *** 0.32 ± 0.26 ** 
P NS NS NS 
Mean PD (mm) T1DM  3.02 ± 0.81 2.40 ± 0.81 ** 2.42 ± 0.53 *** 
Non-T1DM 3.31 ± 0.75 2.70 ± 0.37 *** 2.65 ± 0.49 ** 
P < 0.05 NS NS 
Mean recession (mm) 
 
T1DM 0.43 ± 0.64 0.34 ± 0.52 0.55 ± 0.61 ** 
Non-T1DM 0.24 ± 0.43 0.54 ± 0.55 *** 0.61 ± 0.66 *** 
P NS NS NS 
Mean LOA (mm) T1DM 3.45 ± 1.18 2.74 ± 1.13 * 2.97 ± 0.94 * 
Non-T1DM 3.55 ± 0.75 3.24 ± 0.50 ** 3.26 ± 0.54 ** 
P NS NS NS 
BOP (%) T1DM 52.7 ± 17.4 26.2 ± 20.1 ** 29.2 ± 17.7 *** 
Non-T1DM 53.9 ± 21.1 22.1 ± 15.1 *** 20.6 ± 16.2 *** 
P NS NS NS 
Sites 5 mm or greater 
[n (%)] 
T1DM 20.3 ± 21.7 
(14.7 ± 16.4) 
11.0 ± 17.5 ** 
(7.94 ± 13.8) 
9.69 ± 13.9 ** 
(6.97 ± 10.9) 
Non-T1DM 37.4 ± 25.2
 
(23.7 ± 15.5) 
20.6 ± 13.1 *** 
(12.8 ± 7.59) 
18.7 ± 15.6 ** 
(12.6 ± 9.29) 
P < 0.05  NS NS 
Sites 4 mm or less 
[n (%)] 
T1DM 122.5 ± 29.4 
(85.3 ± 16.4) 
136.3 ± 25.2 ** 
(92.1 ± 13.8) 
136.6 ± 20.7 ** 
(93.0 ± 10.9) 
Non-T1DM 119.0 ± 25.1 
(74.7 ± 17.7) 
135.8 ± 14.4 ** 
(82.3 ± 19.3) 
136.8 ± 15.7 ** 
(84.1 ± 17.1) 
P NS NS NS 
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Table 5.6: Changes in PD in T1DM and non-T1DM patients with periodontitis pre- 
and post-NSM. 
Mean ± SD presented for parametric variables.  For comparison between T1DM and non-
T1DM patients, p-values determined using Independent t-test for continuous parametric 
variables.  For longitudinal comparisons, p-values determined using Paired t-test for 
parametric variables (no statistically significant differences found).  P represents the 
significant difference between T1DM and non-T1DM patients at each time point.  PD; 
probing depth, NS; not significant.
 Month 0-Month 3 
(n=11) 
(n=14) 
Month 0-Month 6 
(n=13) 
(n=12) 
Sites 2 mm or greater PD 
increase 
[n (%)]  
T1DM 4.18 ± 5.25 
(3.04 ± 4.18) 
4.31 ± 4.05 
(3.08 ± 3.12) 
Non-T1DM 3.83 ± 2.41 
(2.45 ± 1.50) 
3.09 ± 2.74 
(1.98 ± 1.67) 
P NS NS 
Sites 0 +/- 1 mm PD 
reduction 
[n (%)] 
T1DM 123.2 ± 20.2 
(83.8 ± 13.3) 
124.2 ± 16.9 
(84.9 ± 9.83) 
Non-T1DM 120.4 ± 23.8 
(74.2 ± 15.6) 
113.7 ± 26.1 
(73.2 ± 15.9) 
P NS < 0.05 
Sites 2 mm or greater PD 
reduction 
[n (%)] 
T1DM 19.9 ± 19.4 
(13.2 ± 12.5) 
17.5 ± 12.5 
(12.1 ± 8.44) 
Non-T1DM 32.7 ±22.9 
(20.8 ± 14.1) 
39.0 ± 26.7 
(24.9 ± 16.4) 





Figure 5.5: mGI scores in T1DM and non-T1DM patients with periodontitis pre- and 
post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients (pre-treatment n=19, month 3 n=11, month 6 n=13) and non-T1DM patients (pre-
treatment n=17, month 3 n=15, month 6 n=13).  Statistics: Paired t-test for longitudinal 
comparisons: §§§P<0.001 (within the T1DM or non-T1DM group indicating significant 
differences from pre-treatment at each time point); Independent t-test for T1DM versus non-
T1DM group at each time point (no statistically significant differences found).  ● indicates 





Figure 5.6: PI scores in T1DM and non-T1DM patients with periodontitis pre- and post-
NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients (pre-treatment n=19, month 3 n=11, month 6 n=13) and non-T1DM patients (pre-
treatment n=17, month 3 n=15, month 6 n=13).  Statistics: Paired t-test for longitudinal 
comparisons: §§P<0.01, §§§P<0.001 (within the T1DM or non-T1DM group indicating 
significant differences from pre-treatment at each time point); Independent t-test for T1DM 
versus non-T1DM group at each time point (no statistically significant differences found).    





Figure 5.7: Mean PD in T1DM and non-T1DM patients with periodontitis pre- and 
post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 
T1DM patients (pre-treatment n=19, month 3 n=11, month 6 n=13) and non-T1DM patients 
(pre-treatment n=17, month 3 n=15, month 6 n=13).  Statistics: Paired t-test for longitudinal 
comparisons: §§P<0.01, §§§P<0.001 (within the T1DM or non-T1DM group indicating 
significant differences from pre-treatment at each time point); Independent t-test: *P<0.05 
(T1DM versus non-T1DM group at each time point).  ● indicates outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries, ▲ indicates outlier more than 3 times the 





Figure 5.8: Mean recession in T1DM and non-T1DM patients with periodontitis pre- 
and post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 
T1DM patients (pre-treatment n=19, month 3 n=11, month 6 n=13) and non-T1DM patients 
(pre-treatment n=17, month 3 n=15, month 6 n=13).  Statistics: Paired t-test for longitudinal 
comparisons: §§P<0.01, §§§P<0.001 (within the T1DM or non-T1DM group indicating 
significant differences from pre-treatment at each time point); Independent t-test for T1DM 
versus non-T1DM group at each time point (no statistically significant differences found).    
● indicates outlier more than 1.5 but less than 3 times the IQR from the box boundaries,     





Figure 5.9: Mean LOA in T1DM and non-T1DM patients with periodontitis pre- and 
post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 
T1DM patients (pre-treatment n=19, month 3 n=11, month 6 n=13) and non-T1DM patients 
(pre-treatment n=17, month 3 n=15, month 6 n=13).  Statistics: Paired t-test for longitudinal 
comparisons: §P<0.05, §§P<0.01 (within the T1DM or non-T1DM group indicating 
significant differences from pre-treatment at each time point); Independent t-test for T1DM 
versus non-T1DM group at each time point (no statistically significant differences found).   
● indicates outlier more than 1.5 but less than 3 times the IQR from the box boundaries,     





Figure 5.10: BOP (%) in T1DM and non-T1DM patients with periodontitis pre- and 
post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients (pre-treatment n=19, month 3 n=11, month 6 n=13) and non-T1DM patients (pre-
treatment n=17, month 3 n=15, month 6 n=13).  Statistics: Paired t-test for longitudinal 
comparisons: §§P<0.01, §§§P<0.001 (within the T1DM or non-T1DM group indicating 
significant differences from pre-treatment at each time point); Independent t-test for T1DM 
versus non-T1DM group at each time point (no statistically significant differences found).    





Figure 5.11: PD sites 5 mm or greater (%) in T1DM and non-T1DM patients with 
periodontitis pre- and post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 
T1DM patients (pre-treatment n=19, month 3 n=11, month 6 n=13) and non-T1DM patients 
(pre-treatment n=17, month 3 n=15, month 6 n=13).  Statistics: Paired t-test for longitudinal 
comparisons: §§P<0.01, §§§P<0.001 (within the T1DM or non-T1DM group indicating 
significant differences from pre-treatment at each time point); Independent t-test: *P<0.05 
(T1DM versus non-T1DM group at each time point).  ● indicates outlier more than 1.5 but 
less than 3 times the IQR from the box boundaries, ▲ indicates outlier more than 3 times the 





Figure 5.12: PD sites 4 mm or less (%) in T1DM and non-T1DM patients with 
periodontitis pre- and post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 
T1DM patients (pre-treatment n=19, month 3 n=11, month 6 n=13) and non-T1DM patients 
(pre-treatment n=17, month 3 n=15, month 6 n=13).  Statistics: Paired t-test for longitudinal 
comparisons: §§P<0.01 (within the T1DM or non-T1DM group indicating significant 
differences from pre-treatment at each time point); Independent t-test for T1DM versus non-
T1DM group at each time point (no statistically significant differences found).  ● indicates 
outlier more than 1.5 but less than 3 times the IQR from the box boundaries, ▲ indicates 





Figure 5.13: PD sites reduced by 0+/-1 mm (%) in T1DM and non-T1DM patients with 
periodontitis post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 
T1DM patients (month 0-month 3 n=11, month 0-month 6 n=13) and non-T1DM patients 
(month 0-month 3 n=14, month 0-month 6 n=12).  Statistics: Paired t-test for longitudinal 
comparisons within T1DM or non-T1DM group (no statistically significant differences 
found); Independent t-test: *P<0.05 (T1DM versus non-T1DM group at each time point).     





Figure 5.14: PD sites reduced by ≥2 mm (%) in T1DM and non-T1DM patients with 
periodontitis post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 
T1DM patients (month 0-month 3 n=11, month 0-month 6 n=13) and non-T1DM patients 
(month 0-month 3 n=14, month 0-month 6 n=12) with periodontitis.  Statistics: Paired t-test 
for longitudinal comparisons within T1DM or non-T1DM group (no statistically significant 
differences found); Independent t-test: *P<0.05 (T1DM versus non-T1DM group at each 




5.2.4 Local and systemic biomarker levels following NSM 
Serum biomarker levels following NSM 
Table 5.7 and Figure 5.15 to 5.18 summarise pre- and post-treatment candidate biomarker 
data in serum samples for T1DM and non-T1DM patients with periodontitis.  When 
considering levels of MMP-9 in serum, T1DM patients had significantly higher pre-treatment 
levels (1052.3±489.4 ng/ml) compared to non-T1DM patients (502.2±272.2 ng/ml), 
(P<0.001).  However, no statistically significant differences were found for serum MMP-9 
levels between T1DM and non-T1DM patients at months 3 and 6 following NSM, (P>0.05).  
In patients with T1DM, compared to pre-treatment (1052.3±489.4 ng/ml), serum MMP-9 
levels showed reductions following NSM at 3 months (620.9±404.4 ng/ml) and 6 months 
(732.7±448.8 ng/ml), however these reductions were not statistically significant, (P>0.05).  
Similarly in non-T1DM patients, compared to pre-treatment (502.2±272.2 ng/ml) serum 
MMP-9 levels showed reductions at 3 months (461.1±296.5 ng/ml) and 6 months 
(472.9±259.9 ng/ml), however these reductions were not statistically significant, (P>0.05) 
(Table 5.7 and Figure 5.15). 
When considering levels of BAFF in serum, no statistically significant differences were 
found between T1DM and non-T1DM patients at any time point, (P>0.05).  In T1DM 
patients, no statistically significant differences were found between pre-treatment and month 
3, and between pre-treatment and month 6 serum BAFF levels, (P>0.05).  In non-T1DM 
patients compared to pre-treatment (1150.7±154.3 pg/ml), serum BAFF levels showed 
significant reductions following NSM at month 3 (1011.5±219.1 pg/ml), (P<0.05).  No 
statistically significant differences were found in serum BAFF levels between pre-treatment 
and month 6, in non-T1DM patients, (P>0.05) (Table 5.7 and Figure 5.16). 
When considering levels of resistin in serum, no statistically significant differences were 
found between T1DM and non-T1DM patients at any time point, (P>0.05).  In T1DM 
patients, compared to pre-treatment (11.7±4.09 ng/ml), serum resistin levels showed 
reductions following NSM at month 6 (9.08±2.83 ng/ml), however this difference was not 
statistically significant, (P>0.05).  Also no statistically significant difference was found in 
serum resistin levels between pre-treatment and month 3 in T1DM patients, (P>0.05).  In 
non-T1DM patients, compared to pre-treatment (10.5±3.55 ng/ml), serum resistin levels 
showed significant reductions at month 6 (8.59±2.79 ng/ml), (P<0.05).  However, no 
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statistically significant differences were found in serum resistin levels between pre-treatment 
and month 3 in non-T1DM patients following NSM, (P>0.05) (Table 5.7 and Figure 5.17). 
When considering levels of ENA-78/CXCL5 in serum, no statistically significant differences 
were found between T1DM and non-T1DM patients at any time point, (P>0.05).  In T1DM 
patients, compared to pre-treatment (1648.4±1049.2 pg/ml), serum ENA-78/CXCL5 levels 
showed reductions following NSM at 3 months (1461.3±964.3 pg/ml) and 6 months 
(1630.7±925.8 pg/ml), however these reductions were not statistically significant (P<0.05).  
Similarly, in non-T1DM patients, compared to pre-treatment (1494.5±1007.4 pg/ml), serum 
ENA-78/CXCL5 levels showed no significant changes at month 3 (1533.6±1160.9 pg/ml) 




Table 5.7: Serum biomarker levels comparing T1DM and non-T1DM patients with periodontitis pre- and post-NSM. 
Mean ± SD presented for parametric variables.  For comparison between T1DM and non-T1DM patients, p-values determined using 
Independent t-test for continuous parametric variables.  For longitudinal comparisons, p-values determined using Paired t-test for parametric 
variables: significant difference from baseline *P<0.05 and ***P<0.001.  P-values under columns (P) relate to comparisons between T1DM 
and non-T1DM group at that particular time point.  MMP-9; matrix metalloproteinase-9, BAFF; B-cell activating factor, ENA-78/CXCL5; 
epithelial neutrophil activating peptide-78, NS; not significant.









Serum MMP-9 (ng/ml) T1DM 1052.3 ± 489.4 620.9 ± 404.4 732.7 ± 448.8 
Non-T1DM 502.2 ± 272.2 461.1 ± 296.5 472.9 ± 259.9 
P < 0.001 NS NS 
Serum BAFF (pg/ml) T1DM 1194.8 ± 359.4 1215.2 ± 313.1 1119.5 ± 240.3 
Non-T1DM 1150.7 ± 154.3 1011.5 ± 219.1 * 1092.5 ± 461.5 
P NS NS NS 
Serum resistin (ng/ml) T1DM 11.7 ± 4.09 11.9 ± 4.83 9.08 ± 2.83 
Non-T1DM 10.5 ± 3.55 9.80 ± 3.11 8.59 ± 2.79 * 
P NS NS NS 
Serum ENA-78/CXCL5 (pg/ml) T1DM 1648.4 ± 1049.2 1461.3 ± 964.8 1630.7 ± 925.8 
Non-T1DM 1494.5 ± 1007.4 1533.6 ± 1160.9 1302.5 ± 680.0 





Figure 5.15: Serum MMP-9 levels in T1DM and non-T1DM patients with periodontitis 
pre- and post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients (pre-treatment n=18, month 3 n=12, month 6 n=12) and non-T1DM patients (pre-
treatment n=17, month 3 n=13, month 6 n=12).  Statistics: Paired t-test for longitudinal 
comparisons within T1DM or non-T1DM group indicating significant differences from pre-
treatment at each time point (no statistically significant differences found); Independent t-
test: ***P<0.001 (T1DM versus non-T1DM group at each time point).  ● indicates outlier 





Figure 5.16: Serum BAFF levels in T1DM and non-T1DM patients with periodontitis 
pre- and post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients (pre-treatment n=18, month 3 n=12, month 6 n=12) and non-T1DM patients (pre-
treatment n=17, month 3 n=13, month 6 n=12).  Statistics: Paired t-test for longitudinal 
comparisons: §P<0.05 (within the T1DM or non-T1DM group indicating significant 
differences from pre-treatment at each time point); Independent t-test for T1DM versus non-
T1DM group at each time point (no statistically significant differences found).  ● indicates 
outlier more than 1.5 but less than 3 times the IQR from the box boundaries, ▲ indicates 





Figure 5.17: Serum resistin levels in T1DM and non-T1DM patients with periodontitis 
pre- and post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients (pre-treatment n=18, month 3 n=12, month 6 n=12) and non-T1DM patients (pre-
treatment n=17, month 3 n=13, month 6 n=12).  Statistics: Paired t-test for longitudinal 
comparisons: §P<0.05 (within the T1DM or non-T1DM group indicating significant 
differences from pre-treatment at each time point); Independent t-test for T1DM versus non-
T1DM group at each time point (no statistically significant differences found).  ● indicates 
outlier more than 1.5 but less than 3 times the IQR from the box boundaries, ▲ indicates 






Figure 5.18: Serum ENA-78/CXCL5 levels in T1DM and non-T1DM patients with 
periodontitis pre- and post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients (pre-treatment n=18, month 3 n=12, month 6 n=12) and non-T1DM patients (pre-
treatment n=17, month 3 n=13, month 6 n=12).  Statistics: Paired t-test for longitudinal 
comparisons within T1DM or non-T1DM group indicating significant differences from pre-
treatment at each time point (no statistically significant differences found); Independent t-test 
for T1DM versus non-T1DM group at each time point (no statistically significant differences 
found).  ● indicates outlier more than 1.5 but less than 3 times the IQR from the box 
boundaries, ▲ indicates outlier more than 3 times the IQR from the box boundaries.
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GCF biomarker levels following NSM 
Table 5.8 and Figure 5.19 to 5.21 summarise pre- and post-NSM candidate biomarker data in 
GCF samples and GCF volume for T1DM and non-T1DM patients with periodontitis.  When 
considering GCF MMP-9 levels, no statistically significant differences were found between 
T1DM and non-T1DM patients at any time point, (P>0.05).  In T1DM patients, compared to 
pre-treatment (304.8±186.8 ng/ml), GCF MMP-9 levels showed significant reduction 
following NSM at 3 months (135.4±130.4 ng/ml) and 6 months (225.2±113.7 ng/ml), 
(P<0.01 and P<0.05 respectively).  In non-T1DM patients, compared to pre-treatment 
(303.0±201.1 ng/ml) GCF MMP-9 levels showed a reduction at month 3 (209.8±243.8 
ng/ml), however this difference was not statistically significant, (P>0.05).  Also, there was a 
significant reduction in GCF MMP-9 levels in non-T1DM patients at month 6 (179.0±140.7 
ng/ml) compared to pre-treatment levels (303.0±201.1 ng/ml), (P<0.05) (Table 5.8 and 
Figure 5.19). 
When considering GCF IL-8 levels, no statistically significant differences were found 
between T1DM and non-T1DM patients at any time point, (P>0.05).  In T1DM patients, 
compared to pre-treatment (370.1±214.2 pg/ml) there was a significant reduction in GCF   
IL-8 levels following NSM at 3 months (146.6±111.1 pg/ml) and 6 months (249.7±192.7 
pg/ml), (P<0.001 and P<0.05 respectively).  In non-T1DM patients, compared to pre-
treatment (442.9±390.2 pg/ml) there was a significant reduction in GCF IL-8 levels following 
NSM at month 3 (318.3±284.1 pg/ml), (P<0.05).  Although there was a reduction in GCF  
IL-8 levels at month 6 (328.4±323.5 pg/ml) compared to pre-treatment (442.9±390.2 pg/ml), 
this reduction was not statistically significant, (P>0.05) (Table 5.8 and Figure 5.20). 
With reference to the GCF volume, in T1DM patients, compared to pre-treatment (0.66±0.26 
µl) there was a significant reduction in GCF volume recorded at month 3 (0.34±0.14 µl) 
following NSM, (P<0.01).  Although, there was a reduction in GCF volume at month 6 
(0.54±0.30 µl) following NSM compared to pre-treatment (0.66±0.26 µl), this reduction was 
not statistically significant, (P>0.05).  In non-T1DM patients, compared to pre-treatment 
(0.60±0.16 µl) there was a reduction in GCF volume at month 3 (0.57±0.30 µl) and month 6 
(0.41±0.21 µl) following NSM, however, this reduction was not statistically significant, 
(P>0.05).  Only at month 3, the non-T1DM patients had significantly higher GCF volume 




Table 5.8: GCF biomarker levels in T1DM and non-T1DM patients with periodontitis pre- and post-NSM. 
Mean ± SD presented for parametric variables.  For comparison between T1DM and non-T1DM patients, p-values determined using 
Independent t-test for continuous parametric variable.  For longitudinal comparisons, p-values determined using Paired t-test for parametric 
variables: significant difference from baseline *P<0.05, **P<0.01 and ***P<0.001.  P-values under columns (P) relate to comparisons between 
T1DM and non-T1DM group at that particular time point.  GCF; gingival crevicular fluid, MMP-9; matrix metalloproteinase-9, IL-8; 
interleukin-8, NS; not significant.  At month 3: GCF volume (T1DM n=11and non-T1DM n=15); at month 6: GCF volume (T1DM n=13 and 
non-T1DM n=13).









GCF MMP-9 (ng/ml) T1DM 304.8 ± 186.8 135.4 ± 130.4 ** 225.2 ± 113.7 * 
Non-T1DM 303.0 ± 201.1 209.8 ± 243.8 179.0 ± 140.7 * 
P NS NS NS 
GCF IL-8 (pg/ml) T1DM 370.1 ± 214.2 146.6 ± 111.1 *** 249.7 ± 192.7 * 
Non-T1DM 442.9 ± 390.2 318.3 ± 284.1 * 328.4 ± 323.5 
P NS NS NS 
GCF volume (µl) T1DM 0.66 ± 0.26 0.34 ± 0.14 ** 0.54 ± 0.30 
Non-T1DM 0.60 ± 0.16 0.57 ± 0.30 0.41 ± 0.21 





Figure 5.19: GCF MMP-9 levels in T1DM and non-T1DM patients with periodontitis 
pre- and post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients (pre-treatment n=19, month 3 n=12, month 6 n=12) and non-T1DM patients (pre-
treatment n=17, month 3 n=12, month 6 n=9).  Statistics: Paired t-test for longitudinal 
comparisons: §P<0.05, §§P<0.01 (within the T1DM or non-T1DM group indicating 
significant differences from pre-treatment at each time point); Independent t-test for T1DM 
versus non-T1DM group at each time point (no statistically significant differences found).    
● indicates outlier more than 1.5 but less than 3 times the IQR from the box boundaries,      





Figure 5.20: GCF IL-8 levels in T1DM and non-T1DM patients with periodontitis pre- 
and post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients (pre-treatment n=19, month 3 n=12, month 6 n=12) and non-T1DM patients (pre-
treatment n=17, month 3 n=12, month 6 n=9).  Statistics: Paired t-test for longitudinal 
comparisons: §P<0.05, §§§P<0.001 (within the T1DM or non-T1DM group indicating 
significant differences from pre-treatment at each time point); Independent t-test for T1DM 
versus non-T1DM group at each time point (no statistically significant differences found).    
● indicates outlier more than 1.5 but less than 3 times the IQR from the box boundaries,      





Figure 5.21: GCF volume in T1DM and non-T1DM patients with periodontitis pre- and 
post-NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 
T1DM patients (pre-treatment n=19, month 3 n=12, month 6 n=12) and non-T1DM patients 
(pre-treatment n=17, month 3 n=12, month 6 n=9).  Statistics: Paired t-test for longitudinal 
comparisons: §§P<0.01 (within the T1DM or non-T1DM group indicating significant 
differences from pre-treatment at each time point); Independent t-test: *P<0.05 (T1DM 
versus non-T1DM group at each time point).  ● indicates outlier more than 1.5 but less than 
3 times the IQR from the box boundaries, ▲ indicates outlier more than 3 times the IQR 





In this chapter, the effect of periodontal therapy on demographic, metabolic, periodontal and 
candidate biomarker levels was assessed.  Comparisons were made between the T1DM and 
non-T1DM patients with periodontitis to assess response of treatment in both patient groups. 
BP levels following NSM 
The current study found a significant increase in systolic BP in T1DM patients at month 6 
following NSM, (P<0.05) (Table 5.2).  This significant increase in systolic BP could possibly 
be a chance finding, nevertheless the BP values for all T1DM patients recorded pre- and post-
NSM were within limits of the recommended levels for patients with diabetes            
(≤140/80 mmHg) (NICE 2015). 
Clinical biochemistry parameters following NSM 
In the current study, pre-treatment HbA1c levels in T1DM patients showed a reduction at 
months 3 and 6 following NSM, which was a reduction of 0.45% and 0.90% respectively, 
however these reductions were not statistically significant (Table 5.3 and Figure 5.1).  Our 
findings are similar to those of a study which found a 0.43% non-significant reduction in 
HbA1c levels in T1DM patients 6 months following treatment with NSM plus adjunctive 
doxycycline therapy (Miller et al. 1992).  Our findings are also in line with previous studies 
which found no statistically significant improvement in HbA1c levels following periodontal 
treatment in patients with T1DM (Miller et al. 1992; Aldridge et al. 1995; Llambes et al. 
2008). 
An RCT investigated the effect of NSM with or without adjunctive doxycycline, on the 
metabolic control of 60 T1DM patients (Llambes et al. 2008).  Both treatment groups showed 
a good response to periodontal therapy indicated by improved PI, BOP, PD and LOA 
measurements (Llambes et al. 2005).  In the group receiving NSM and doxycycline, there 
was no statistically significant change in HbA1c from pre-treatment levels (7.64±1.81 %) 
compared to 3 months following NSM (7.71±1.74 %).  Likewise, in the group receiving only 
NSM, compared to pre-treatment HbA1c levels (7.51±1.36 %) there was no statistically 
significant change 3 months after NSM (7.45±1.29 %) (Llambes et al. 2008).  These findings 
are similar to the current study which found no improvement in metabolic control as 




appointment.  Aldridge and colleagues carried out 2 single-blinded clinical trials to determine 
the effect of periodontal treatment on metabolic control in T1DM patients (Aldridge et al. 
1995).  The first trial included 31 T1DM patients with gingivitis (aged 16-40 years) and the 
second included 22 T1DM patients with advanced periodontitis (aged 20-60 years).  In both 
trials, the authors reported no statistically significant improvement in HbA1c levels 2 months 
following periodontal therapy (Aldridge et al. 1995).  Another small study of 9 T1DM 
patients with moderate-to-severe periodontitis demonstrated a reduction in pre-treatment 
HbA1c from 9.4% to 9.0% at 2 months following NSM, however this reduction was not 
statistically significant (Miller et al. 1992).  Additionally, the authors reported that the T1DM 
patients having improvements in BOP scores were found to have a significant reduction in 
pre-treatment HbA1c levels from 8.7% to 7.8% at 2 months following NSM, whereas those 
who showed no improvement in BOP scores showed no improvement in post-treatment 
HbA1c levels (Miller et al. 1992). 
In a previous study, changes in HbA1c levels following periodontal treatment were assessed 
separately in well-controlled and poorly-controlled T1DM patients (Seppala and Ainamo 
1994).  T1DM patients (aged 35-56 years) were assessed based on the level of glycaemic 
control [well-controlled (n=6) and poorly-controlled (n=16)] (Seppala and Ainamo 1994).  
An improvement in HbA1c levels in both groups was found at the 2-year follow-up 
appointment, with a reduction in the HbA1c level in poorly-controlled patients from 9.9% to 
9.6% and from 9.5% to 7.6% in well-controlled patients, however these reductions were not 
statistically significant (Seppala and Ainamo 1994).  A study of 18 well-controlled T1DM 
patients with advanced periodontitis (aged 26-57 years) reported no statistically significant 
change in HbA1c level from baseline to 2 months following successful NSM (Smith et al. 
1996).  The stratification of patients based on HbA1c levels was not incorporated into the 
recruitment strategy for the present study and to avoid low numbers in each group, the data 
were not subsequently stratified during data analyses. 
A study including both T1DM and T2DM patients (n=91), performed a limited comparison 
of metabolic control in 46 patients based on if their periodontal condition did (n=23) and did 
not (n=23) improve following periodontal treatment (Wolf 1977).  The authors found that 
patients who responded well to periodontal treatment, with decreases in inflammation and 
improvement in periodontal parameters had a statistically significant improvement in 




glucose levels 8-12 months following periodontal therapy (Wolf 1977).  A longitudinal study 
of T1DM or T2DM patients (n=20) and non-diabetic controls (n=20) received NSM prior to 
the baseline examination 3 months later, found no statistically significant changes in HbA1c 
levels over a 5-year period (Westfelt et al. 1996).  The patients were followed up every 3 
months for 5 years during which they were provided necessary periodontal maintenance care.  
At each time-point, HbA1c levels were measured and there were no statistically significant 
changes in HbA1c levels in diabetic patients from baseline-to-24 months and from 24 
months-to-60 months (Westfelt et al. 1996).  Another longitudinal study included 20 well-
controlled T1DM (n=7) and T2DM (n=13) patients (aged 30-66 years) and 20 non-diabetic 
controls with moderate-to-advanced periodontitis (Christgau et al. 1998).  Following NSM, 
although both diabetic and non-diabetic patients showed statistically significant 
improvements in periodontal parameters, no statistically significant improvements were 
found in HbA1c levels at the 4 month follow-up (Christgau et al. 1998).  It is difficult to 
compare the findings of the current study to these studies due to the differences in study 
design.  Furthermore, the patients in the present study were only T1DM patients and were not 
categorised and compared based on success of periodontal treatment or glycaemic control 
categories. 
From the review of literature on the effects of periodontal treatment on glycaemic control in 
patients with T1DM, overall it appears that periodontal treatment does improve glycaemic 
control but the findings are not statistically significant.  Similar results were found in the 
current study where, even though HbA1c reduced following NSM by around 0.90% at 6 
months, the difference was not statistically significant.  One must bear in mind the 
heterogeneity among the studies such as, diabetes-related factors (type of diabetes, diabetes 
duration, baseline glycaemic control and type of diabetes treatment), periodontal-related 
factors (baseline periodontal disease status, methods utilised to assess periodontal status and 
periodontal treatment protocols), sample size and power to detect differences in metabolic 
and periodontal response, follow-up time frames for glycaemic control and periodontal status 
evaluation, inclusion of control groups and specific hypothesis tested.  Despite the variations 
and limitations, and though the evidence is not unequivocal there is evidence that supports 
the concept that periodontal disease contributes to poor glycaemic control in patients with 
diabetes and the treatment of periodontal disease can have a beneficial effect in patients with 




treating periodontal diseases with an aim to contribute to glycaemic control especially in 
patients with T1DM as this group of patients has been under-researched. 
Data from the current study showed that, non-HDL levels were higher in the non-T1DM 
patients compared to the T1DM patients at each time point, however this difference was 
statistically significant only at month 3 following NSM (P<0.05).  Similarly, cholesterol 
levels were higher in the non-T1DM patients compared to the T1DM patients at each time 
point, however this difference was statistically significant only at pre-treatment (P<0.05) 
(Table 5.3, Figures 5.3 and 5.4).  This is not surprising, given the key priority within the 
national management guidelines for T1DM involves the control of serum lipid levels (NICE 
2015).  Therefore, it is reasonable to presume that the T1DM patients in this study were 
receiving more aggressive management and monitoring of CVD risk factors compared to the 
control patients.  Also, pre-treatment diabetes care data showed that 15.8% of the T1DM 
patients with periodontitis were taking lipid lowering and anti-hypertensive medication; 
however comparable data from non-T1DM patients were not collected to confirm the 
influence of medication on lipid profile levels. 
While considering hsCRP levels, in the current study pre-treatment hsCRP levels in T1DM 
and non-T1DM periodontitis patients showed no statistically significant improvement 
following NSM (Table 5.3).  Our findings are similar to a meta-analysis which concluded that 
it is highly unlikely that periodontal treatment could modulate systemic hsCRP levels in 
patients with severe periodontal disease (Ioannidou et al. 2006).  Our findings are in contrast 
to studies which found a decrease in hsCRP levels after periodontal therapy (Ide et al. 2003; 
D'Aiuto et al. 2005; Marcaccini et al. 2009a; Marcaccini et al. 2009b).  An RCT which 
investigated the impact of periodontal therapy on serum inflammatory markers and 
cholesterol, in systemically healthy individuals with severe periodontitis using a three-arm 
intervention strategy, found a significant reduction in serum hsCRP levels 2 months 
following periodontal treatment (D'Aiuto et al. 2005).  The periodontal treatment groups 
comprised an untreated control group (n=24), NSM only group (n=21) and NSM and 
adjunctive local antibiotic group (n=20).  The NSM plus antibiotic groups showed a 
reduction from pre-treatment hsCRP levels [2.0±1.1 (1.5-2.5) mg/L] to month 2 follow-up 
[1.6±0.9 (1.2-2.0) mg/L] compared to the untreated controls in which hsCRP levels at 
baseline [2.4±1.6 (1.8-3.1) mg/L] and at 2 months [2.5±1.7 (1.8-3.2) mg/L] remained 




reducing the systemic inflammatory burden as assessed by hsCRP levels.  Similar to the lipid 
profile findings in the current study, their study found insignificant changes in total 
cholesterol, HDL, non-HDL and triglyceride levels following periodontal therapy in both 
treatment groups (D'Aiuto et al. 2005).  In the current study, it is also worth noting that the 
pre-treatment hsCRP levels in both T1DM and non-T1DM patients were not very high and 
thus these values may not be conducive to a large improvement with periodontal treatment.  
Additionally, the relatively small sample size at months 3 and 6 may have led to finding no 
significant effect following NSM (Table 5.3). 
Clinical periodontal parameters following NSM 
In the current study, in both T1DM and non-T1DM patients compared to pre-treatment there 
was a significant improvement seen at months 3 and 6 in all periodontal parameters: PI, mGI, 
mean PD, mean recession, mean LOA and % BOP measurements following NSM, (P<0.05) 
(Table 5.5 and Figures 5.5 to 5.10).  A significant increase in mean recession at months 3 and 
6 indicates a resolution of inflammation and improvement in periodontal status following 
periodontal therapy.  Additionally, in both T1DM and non-T1DM patients there was a 
significant reduction in the number of PD sites measuring ≥5 mm from pre-treatment to 
month 3 (P<0.01 and P<0.001 respectively) and month 6 (P<0.01), indicating a reduction in 
the severity of periodontal disease in both groups.  Prior to periodontal treatment, non-T1DM 
patients were found to have more severe periodontal disease compared to T1DM patients 
possibly due to the differences in recruitment strategy utilised for the two groups in the 
current study.  It is interesting to note that following NSM unlike pre-treatment, no 
statistically significant differences were found in severity of periodontal disease (PD sites 
measuring ≥5 mm) between T1DM and non-T1DM patients (Table 5.5 and Figure 5.11), 
indicating an improvement in periodontal status in this cohort of T1DM patients.  To confirm 
this, in both patient groups there was a significant increase in the number of PD sites 
measuring ≤4 mm at month 3 and 6  following NSM, (P<0.01) (Table 5.5 and Figure 5.12).  
While considering the amount of PD reduction, compared to pre-treatment, at month 6 the 
non-T1DM patients had significantly higher number of PD sites with a reduction ≥2 mm 
compared to the T1DM patients (P<0.05), these differences could possibly be a reflection of 
the fact that the non-T1DM patients had significantly deeper sites at the outset of the study 




The findings of this study confirm that the NSM was successful in both T1DM and non-
T1DM patients, showing improvements in periodontal parameters with a reduction in 
inflammation and severity of periodontal disease following treatment.  Our findings are 
similar to those of other studies in T1DM patients which found significant improvements in 
periodontal indices following periodontal therapy (Bay et al. 1974; Smith et al. 1996; 
Martorelli de Lima et al. 2004; Llambes et al. 2005).  Additionally, in this study the positive 
outcome of periodontal treatment was demonstrated in both T1DM and non-T1DM patients 
and both groups responded similarly to NSM.  Our findings are similar to previous research 
which found that patients with T1DM have a good response to periodontal management, and 
the short- and long-term response to periodontal treatment is similar to that seen in non-
diabetic patients (Bay et al. 1974; Westfelt et al. 1996; Christgau et al. 1998). 
Serum biomarker levels following NSM 
In the current study, compared to pre-treatment, serum BAFF levels in non-T1DM patients 
showed a significant reduction only at month 3 following NSM (P<0.05), and pre-treatment 
serum resistin levels showed a significant reduction only at month 6 following NSM 
(P<0.05) (Table 5.7 Figure 5.16 and 5.17).  In the literature, no study has evaluated the effect 
of NSM on levels of BAFF in serum.  From the results of this study, BAFF may not be an 
ideal biomarker to determine the severity of periodontal disease and the benefits of 
periodontal treatment in patients with or without T1DM. 
To the best of our knowledge, this is the first study to investigate the effect of periodontal 
treatment on serum resistin levels in patients with T1DM.  A previous study, assessed serum 
resistin levels in T2DM patients with periodontal disease (aged 35-75 years) and reported no 
significant reductions 6 months following periodontal therapy with adjunctive local 
antibiotics (Bharti et al. 2013).  The T2DM patients were allocated to either periodontal 
therapy with local antibiotics (intervention group n=28) or non-periodontal treatment (control 
group n=8).  In the T2DM intervention group, compared to pre-treatment periodontal 
measurements (PD 2.8±0.7 mm and BOP 32.4±21.8 %) there was a significant improvement 
seen at month 2 (PD 2.0±0.3 mm and BOP 7.0±5.0 %) and month 6 (PD 1.9±0.3 mm and 
BOP 7.9±5.2 %) following NSM.  Also, compared to pre-treatment HbA1c levels (7.1±0.8 
%) there was a significant reduction seen at month 6 (6.8±0.6 %) following NSM.  However, 
compared to pre-treatment serum resistin levels (12.5±10.6 ng/ml), no statistically significant 




following treatment.  Similarly, no statistically significant changes were seen in serum    
TNF-α, IL-6 and leptin levels in the T2DM patients following NSM with adjunctive 
antibiotics (Bharti et al. 2013).  Their study involved T2DM patients and had a different 
treatment strategy compared to the current study and hence the comparison to these findings 
is questionable.  In the current study, the post-treatment findings related to serum resistin 
levels in non-T1DM patients at month 3 are similar to a study in 40 systemically healthy 
patients (aged 20-50 years), with chronic periodontitis (n=20) and healthy periodontal tissues 
(n=20), which found no statistically significant reduction in serum resistin levels 6-8 weeks 
following NSM (Devanoorkar et al. 2012).  In patients with chronic periodontitis significant 
improvements in clinical periodontal parameters were seen pre- to post-NSM, additionally 
compared to pre-treatment (1.89±1.83 ng/ml) serum resistin levels decreased following NSM 
(1.59±1.01 ng/ml), but this decrease was not statistically significant (Devanoorkar et al. 
2012).  In the current study, in non-T1DM patients, serum resistin levels had a significant 
reduction at only month 6 following NSM (Table 5.7 and Figure 5.17). 
In the current study, at pre-treatment despite non-T1DM patients having more severe 
periodontal disease compared to T1DM patients, pre-treatment serum MMP-9 levels were 
significantly higher in the T1DM patients compared to the non-T1DM patients with 
periodontitis, (P<0.001) (Table 5.7 and Figure 5.15).  The possible explanation for this would 
be that circulating MMP-9 levels are elevated in patients with T1DM (Maxwell et al. 2001).  
Diabetes-associated pathophysiological processes such as oxidative stress, possibly enhances 
MMP-9 activity and production (Uemura et al. 2001).  MMP-9 has been demonstrated to be a 
potentially useful biomarker in serum, for T1DM patients at risk of progression to chronic 
kidney disease (Gharagozlian et al. 2009).  Results of T1DM studies and other diabetes-
related complications suggest that serum MMP-9 may contribute to the chronic inflammatory 
process inherent to diabetic retinopathy (Maxwell et al. 2001; Jacqueminet et al. 2006).  
Circulating MMP-9 levels have been found to be increased in T2DM patients with coronary 
artery disease, and elevated MMP-9 levels in serum have been linked to premature coronary 
atherosclerosis (Noji et al. 2001).  Circulating MMP-9 levels are raised in treated 
hypertensive patients with T2DM compared to normotensive control patients (Tayebjee et al. 
2004).  It has also been suggested that increases in serum MMP-9 levels occur prior to the 
development of microvascular renal complications in T2DM patients (Ebihara et al. 1998).  
In the current study, the T1DM patients with periodontitis having significantly higher serum 




from the literature and the results of this study one could conclude that this significant 
increase could possibly be due to increases in MMP-9 serum levels found routinely in T1DM 
patients.  Despite having less severe periodontal disease, increased diabetes-related 
inflammation may have led to increases in MMP-9 levels in serum. 
From the results of the current study, it is noteworthy that although not statistically 
significant, serum MMP-9 levels in both T1DM and non-T1DM patients were found to 
reduce following NSM.  It might be useful in future research studies to include larger sample 
sizes to investigate this further in both patient groups.  The reduction in serum MMP-9 levels 
following NSM could possibly be a reflection of the significant improvement in periodontal 
status and reduction in inflammation and severity of periodontal disease seen in both T1DM 
and non-T1DM patients.  Interestingly, post-treatment (month 6) serum MMP-9 levels in 
T1DM and non-T1DM patients with periodontitis were similar to the pre-treatment serum 
MMP-9 levels observed in T1DM and non-T1DM patients with healthy periodontal tissues 
(Table 4.9 and 5.7).  Until now, no studies have evaluated the effect of periodontal treatment 
on circulating serum MMP-9 levels in T1DM patients with periodontitis.  A study of 
systemically healthy patients with chronic periodontitis (n=28) and periodontally healthy 
controls (n=22) (aged 35-55 years) found a significant decrease in circulating plasma MMP-9 
concentrations and proteolytic activity in chronic periodontitis patients 3 months after 
effective NSM (P<0.01) (Marcaccini et al. 2009b).  However, the authors reporting post-
treatment data only graphically, limits the comparison to the findings of the current study. 
In the current study, pre-treatment serum ENA-78/CXCL5 levels in the T1DM and non-
T1DM patients showed no statistically significant changes at months 3 and 6 following NSM 
(P>0.05) (Table 5.7 and Figure 5.18).  Until now, no studies have the evaluated the effect of 
periodontal treatment on serum ENA-78/CXCL5 levels in periodontitis patients with and 
without T1DM.  The lack of any statistically significant differences in serum MMP-9 and 
ENA-78/CXCL5 levels following NSM between T1DM and non-T1DM patients could be 
due to the lack of statistically significant differences between the two groups with regards to 
clinical periodontal parameters, as both groups were found to have similar periodontal 
measurements and severity of periodontal disease following NSM.  The findings of this study 
relating to serum MMP-9 and ENA-78/CXCL5 levels indicate the possible role MMP-9 and           





GCF biomarker levels following NSM 
In the current study, pre-treatment GCF MMP-9 levels in T1DM patients significantly 
reduced at months 3 and 6 following NSM (P<0.01 and P<0.05, respectively).  In non-T1DM 
patients, pre-treatment GCF MMP-9 levels had a non-significant reduction at month 3 and a 
significant reduction at month 6 (P<0.05) following NSM (Table 5.8 and Figure 5.19).  In 
T1DM patients, pre-treatment GCF IL-8 levels significantly reduced at months 3 and 6 
following NSM (P<0.001 and P<0.05, respectively).  In non-T1DM patients pre-treatment 
GCF IL-8 levels significantly reduced only at month 3 (P<0.05), and although there was a 
reduction in GCF IL-8 levels month 6 this was not statistically significant (Table 5.8 and 
Figure 5.20).  Overall, in both T1DM and non-T1DM patients, reductions in GCF levels of 
these two candidate pro-inflammatory biomarkers appeared to mirror the improvement in 
periodontal status seen within this study following successful treatment. 
Successful periodontal therapy is known to significantly reduce GCF volume.  In the current 
study while considering GCF volume in T1DM patients, compared to pre-treatment volume 
there was a significant reduction at month 3 (P<0.01) and a non-significant reduction at 
month 6 following NSM.  In non-T1DM patients, compared to pre-treatment although there 
was a reduction in GCF volume at months 3 and 6, this reduction was not statistically 
significant (Table 5.8 and Figure 5.21).  A longitudinal study of systemically healthy patients 
with chronic periodontitis (n=27) and periodontally healthy controls (n=15) found a 
significant reduction in pre-treatment total MMP-9 GCF levels [approximate levels from 
presented graph -  chronic periodontitis: 1,400 (100-3,500) ng/site in 30s and periodontally 
healthy controls: 1,100 (400-2,000) ng/site in 30s]  following periodontal treatment at month 
3 follow-up [approximate levels from presented graph - chronic periodontitis: 950 (50-2,000) 
ng/site in 30s and periodontally healthy controls: 500 (100-1,100) ng/site in 30s], (P<0.0001 
and P=0.0006) respectively  (Marcaccini et al. 2010).  The authors also reported no 
statistically significant reductions in pre-treatment GCF volume in chronic periodontitis and 
control patients prior to (0.7±0.41 µl and 0.43±0.35 µl) and following periodontal treatment 
(0.6±0.41 µl and 0.42±0.27 µl) (Marcaccini et al. 2010).  Their findings for GCF volume are 
in agreement with the current study which found no statistically significant reduction in GCF 
volume in non-diabetic patients 3 months following NSM. 
Another longitudinal follow-up study of systemically healthy patients with moderate to 




NSM significantly reduced GCF IL-8 levels and that IL-10 and RANTES levels were 
undetectable following NSM (Gamonal et al. 2000).  Also, compared to pre-treatment GCF 
volume (0.72±0.3 µl) there was a significant reduction in GCF volume 2 months (0.38±0.1 
µl) following NSM.  Additionally compared to pre-treatment GCF IL-8 concentration levels 
(316.7±209 pg/µl) there was a non-significant reduction at 2 months (241.4±163 pg/µl) 
following NSM.  However, total GCF IL-8 levels significantly reduced from pre-treatment 
(212.5±133 pg) to 2 months (85.4±49.0 pg) following NSM, (P<0.01).  The authors also 
reported that IL-8 levels were significantly elevated in PD sites measuring >6 mm compared 
to PD sites <6 mm but following NSM, PD sites showed significantly reduced levels of IL-8 
(Gamonal et al. 2000).  Their findings for GCF volume and IL-8 concentration levels are in 
contrast to the results of the current study for non-diabetic patients.  The relatively small 
sample size and the differences in GCF elution method in their study, limits the comparison 
to the findings of the present study. 
A longitudinal, split-mouth interventional study in systemically healthy patients with 
moderate to advanced periodontitis (aged 35-75 years) reported increases in GCF IL-8 
concentration levels and a reduction in total GCF IL-8 levels following periodontal therapy 
(Goutoudi et al. 2012).  Two quadrants from either the maxillary or mandibular arch were 
randomly selected in each patient and a total of 72 diseased sites and 24 non-diseased sites 
were examined and treated.  One half of the mouth was treated with OHI and NSM and the 
other half was treated with NSM and surgical periodontal therapy.  In the diseased sites, 
following periodontal treatment irrespective of the treatment modality used, compared to pre-
treatment GCF volume (0.19±0.04 µl) there was a significant reduction in GCF volume at 6 
weeks (0.05±0.01 µl), 4 months (0.03±0.01 µl) and 8 months (0.04±0.01 µl), (P<0.05).  In 
the diseased sites, compared to pre-treatment GCF concentration IL-8 levels (1103.8±498.2 
pg/µl) there was a significant increase at 6 weeks (2085.3±664.0 pg/µl) (P<0.05) and a non-
significant increase at month 4 (3243.4±2271.1 pg/µl) and month 8 (3290.5±609.8 pg/µl) 
following periodontal therapy.  For total GCF IL-8 levels, compared to pre-treatment 
(95.5±40.0 pg/ 30s) there was a non-significant reduction seen at 6 weeks (59.7±24.8 pg/ 
30s), 4 months (62.6±17.9 pg/ 30s) and 8 months (71.3±14.6 pg/ 30s) following periodontal 
treatment.  The authors discussed that the increase in concentration of IL-8 following 
periodontal therapy could be due to the reduction in GCF volume following successful 




To the best of our knowledge, the current study is the first to investigate the effect of 
periodontal treatment on GCF MMP-9 and IL-8 levels in patients with T1DM.  From the 
results of this study, it can be concluded that MMP-9 and IL-8 are good local biomarkers to 
determine severity of periodontal disease and the benefit effective periodontal treatment has 
in patients with T1DM. 
Summary of key findings from chapter 5 
 In T1DM patients with periodontitis, HbA1c levels reduced from 8.95 (8.03-9.65) %/ 
75 (64-83) mmol/mol at baseline to 8.50 (6.60-9.60) %/ 69 (49-81) mmol/mol at 
month 3 and 8.05 (6.95-10.1) %/ 64 (53-87) mmol/mol at month 6.  HbA1c levels 
showed 0.45% and 0.90% reduction at month 3 and month 6 respectively following 
NSM, although these reductions were not statistically significant. 
 In both T1DM and non-T1DM patients, significant reductions in PI, mGI, mean PD, 
mean LOA and % BOP were found at months 3 and 6 after NSM indicating a good 
response to periodontal treatment.  Furthermore, PI, mGI, mean PD, mean recession, 
mean LOA and % BOP showed no statistically significant difference between T1DM 
and non-T1DM patients at months 3 and 6 following NSM, suggesting that 
periodontal treatment outcomes were similar in both groups. 
 In both T1DM and non-T1DM patients a significant reduction in % of PD sites 
measuring ≥5 mm was seen at months 3 and 6 after NSM.  Also, taking into account 
the pre-treatment difference in % of PD sites ≥5 mm, the differences between T1DM 
and non-T1DM patients at months 3 and 6 were not statistically significant. 
 The % of PD sites that reduced by ≥2 mm was significantly higher in non-T1DM 
patients compared to T1DM patients at month 6 following NSM. 
 At pre-treatment, serum MMP-9 levels were significantly higher in T1DM patients 
with periodontitis compared to non-T1DM patients with periodontitis. 
 In both T1DM and non-T1DM patients, there was a reduction in serum MMP-9 and 
ENA-78/CXCL5 following NSM, however, this reduction was not statistically 
significant.  Also, serum MMP-9 levels between T1DM and non-T1DM patients were 
not significantly different following NSM at months 3 and 6. 
 Although there was a reduction in serum resistin levels in both T1DM and non-T1DM 





 In both T1DM and non-T1DM patients there was a significant reduction in GCF 
MMP-9 levels at month 6 following NSM. 
 In T1DM patients there was a significant reduction in GCF IL-8 levels at months 3 
and 6 following NSM.  In non-T1DM patients there was also a reduction in GCF IL-8 
levels following NSM at months 3 and 6 however the reduction was statistically 






















6 Chapter 6. Impact of T1DM and periodontal status on quality of life 
6.1 Introduction 
Chronic periodontitis is a chronic inflammatory condition exhibiting clinical signs such as 
periodontal pockets which are usually painless (Cunha-Cruz et al. 2007).  As this condition is 
typically asymptomatic, especially in its initial stages, individuals might be unware of their 
periodontal condition (Gilbert and Nuttall 1999; Pitiphat et al. 2002; Dietrich et al. 2005) and 
hence may underestimate the need for treatment (Tervonen and Knuuttila 1988).  As 
periodontal disease progresses, it demonstrates a number of signs and symptoms that can be 
readily perceived by individuals, such as tooth mobility, eating difficulties, pain, discomfort 
and compromised aesthetics (Cunha-Cruz et al. 2007).  Clinicians usually document disease 
severity based on clinical parameters such as BOP, increased PD and LOA.  The signs and 
symptoms associated with periodontal disease are highly relevant from an individual’s point 
of view and those diagnosed with this condition often report a considerable negative impact 
on their daily lives.  Patients with chronic periodontal diseases are known to experience, in 
particular functional, psychological and social impacts on their QoL as a result of their oral 
health status (Brennan et al. 2007; O'Dowd et al. 2010; Durham et al. 2013).  Thus patients 
with periodontal diseases experience a worse OHRQoL, but this impact can partly be 
ameliorated by effective periodontal treatment (Jowett et al. 2009).  Investigations have 
demonstrated that periodontal treatment has a positive impact and may contribute to changing 
their perceptions from a negative effect on OHRQoL to a more positive one (Aslund et al. 
2008; Jowett et al. 2009; Saito et al. 2010). 
Periodontal disease has also been associated with diabetes, and both T1DM and T2DM are 
associated with an increased risk of developing macrovascular and microvascular 
complications, which have been found to affect HRQoL in diabetic patients (Wandell 2005).  
Diabetes also increases the prevalence of oral disorders such as xerostomia, sialosis, taste 
impairment, oral candidiasis and lichen planus (Manfredi et al. 2004).  Studies have indicated 
that patients with diabetes are 2 to 3 times more likely to develop periodontal disease 
(Seppala et al. 1993; Lalla et al. 2004; Campus et al. 2005).  There is emerging evidence 
which supports the two-way relation between diabetes and periodontal disease, with 
periodontal inflammation negatively affecting glycaemic control and diabetes increasing the 




periodontal disease include smoking and psychological conditions such as impaired coping 
abilities and stress (Genco et al. 1999b). 
With regards to the impact of diabetes on QoL, the prevalence of depression is known to be 
approximately three times higher in patients with diabetes compared to the general population 
(Gavard et al. 1993; Peyrot and Rubin 1997).  Psychological conditions such as depression 
and anxiety not only negatively impact QoL of patients with diabetes, but can also adversely 
affect their adherence to treatment and glycaemic control (Rubin and Peyrot 1992; Lustman 
et al. 1998).  Patients suffering from psychological conditions can be effectively treated, but 
the accurate recognition of these conditions in clinical practice is often misdiagnosed.  Hence, 
in order to facilitate the recognition of serious psychological problems it is important to use 
standardised and reliable psychological questionnaires in routine clinical practice (Pouwer et 
al. 1999). 
In order to establish patient perception of QoL related to their diabetes and periodontal 
condition in this study, QoL of T1DM patients with periodontal disease was assessed using 
the W-BQ12 and the ADDQoL-19 questionnaire before and after NSM.  For the QoL data 
collected, cross-sectional comparisons were made for all T1DM patients based on periodontal 
diagnosis at baseline and longitudinal comparisons were made only for T1DM patients with 
periodontitis. 
6.2 Results 
At baseline, a total of 57 T1DM patients were recruited into the study: 29 (50.9%) females 
and 28 (49.1%) males.  Each patient manually self-completed the W-BQ12 and the 
ADDQoL-19 questionnaire.  Of these, 1 patient’s questionnaires were misplaced during data 
collection (n=1), hence the final sample size comprised 56 T1DM patients, 29 females 
(51.8%) and 27 males (48.2%).  At baseline there were: 9 DH, 28 DG and 19 DP patients 
who completed both questionnaires.  Unfortunately, due to loss to follow-up, at months 3 and 





6.2.1 Analysis of the W-BQ12 
Table 6.1 summarises the subscale and overall W-BQ12 scores and Figure 6.1 shows the    
W-BQ12 subscale scores for all T1DM patients, at baseline. 
 T1DM 
(n=56) 
Negative well-being 1.93 ± 1.94 
Energy 6.13 ± 1.93 
Positive well-being 7.59 ± 2.15 
General well-being 23.8 ± 4.78 
Table 6.1: The W-BQ12 scores for all T1DM patients at baseline.  
Mean ± SD presented for all scores. 
Table 6.2 summarises baseline W-BQ12 scores based on periodontal diagnosis.  No 
statistically significant differences between any subscale scores (negative well-being, energy 
or positive well-being) were detected based on periodontal diagnosis, (P>0.05).  Although 
not significant, the DP patients had higher (poorer QoL) negative well-being score 
(2.42±2.09) compared to the DH (1.44±1.24) and the DG (1.75±2.01) patients.  Also, the DG 
patients had a higher (poorer QoL) negative well-being score (1.75±2.01) compared to the 
DH patients (1.44±1.24).  A higher score in the negative subscale possibly indicates a higher 
negative impact of diabetes and periodontal disease on QoL in these patient groups. 
With reference to the baseline general well-being score, the DH patients had a score of 
24.6±2.19, the DG patients had a score of 24.1±5.14 and the DP patients had a score of 
23.0±5.19.  The DH patients had a higher (better QoL) general well-being score compared to 
the DG and DP patients.  A higher general well-being score indicates a better QoL.  




Table 6.2: Comparing the W-BQ12 scores in T1DM patients based on periodontal 
diagnosis. 
Mean ± SD presented for all scores.  P-values determined using ANOVA with post-hoc 









Negative well-being 1.44 ± 1.24 1.75 ± 2.01 2.42 ± 2.09 NS 
Energy 6.56 ± 1.74 
 
6.18 ± 1.93 5.84 ± 2.06 NS 
Positive well-being 7.44 ± 1.33 
 
7.64 ± 2.57 7.58 ± 1.84 NS 





X-axis presents the mean ± SD scores and Y-axis indicates the subscales of the           
W-BQ12: negative well-being, energy and positive well-being. 














For patients with healthy periodontal tissues and gingivitis, their participation in the study 
was restricted to baseline (month 0).  Only patients diagnosed with periodontitis completed 
the W-BQ12 at months 3 and 6.  Table 6.3 presents the W-BQ12 scores in T1DM patients 
with periodontitis pre- and post-NSM.  The general well-being score at month 3 (25.7±5.85) 
was significantly higher (better QoL) than the general well-being score at pre-treatment 
(23.0±5.19), (P<0.05).  With regards to subscale scores, the energy subscale score at month 3 
score (6.60±2.17) was significantly higher (better QoL) than the pre-treatment energy 
subscale score (5.84±2.06), (P<0.05). 
Analysis of the baseline W-BQ12 scores based on gender (reporting only statistically 
significant findings), revealed that males had a significantly better QoL compared to females 
as indicated by higher general well-being score in males (25.2±4.06) compared to females 
(22.5±5.07), (P<0.05).  Females had a significantly higher negative impact on QoL as 
indicated by higher negative well-being subscale score in females (2.59±2.18) compared to 
males (1.22±1.37), (P<0.01). 
No statistically significant correlations were found between W-BQ12 scores and age, 






Table 6.3: The W-BQ12 scores in T1DM patients with periodontitis pre- and post-NSM. 
Mean ± SD presented for all scores. For longitudinal comparisons, p-values determined using 
Paired t-test: significant difference from baseline *P<0.05.






Negative well-being 2.50 ± 2.27 
 
1.60 ± 2.22 1.90 ± 2.47 
Energy  5.10  ± 1.73 
 
6.60 ± 2.17 * 6.00 ± 2.79 
Positive well-being 7.50 ± 1.72 
 
8.70 ± 2.06 7.10 ± 1.97 




6.2.2 Analysis of the ADDQoL-19 
Table 6.4 summarises the ADDQoL-19 scores for all T1DM patients at baseline.  The result 
of overview item 1 (generic assessment of QoL) was 1.45±0.76, indicating that the patients 
experienced a “good” to “very good” overall QoL.  The result of overview item 2 (diabetes 
assessment of QoL) was -1.23±0.87, indicating that the patients felt their QoL would have 
been a “little better” or “much better” if they did not have diabetes. 
The ADDQoL-19 score for all T1DM patients ranged from -6.68 to 0.00.  The ADDQoL-19 
score was -1.81±1.40 (Table 6.4, Figure 6.2).  The median ADDQoL-19 score was calculated 
at -1.37, lower quartile cut off was calculated at -2.59.  Based on the cut off strategy, 42 
(75%) T1DM patients reported an ADDQoL-19 score of -2.59 or greater and only 14 (25%) 
T1DM patients had an ADDQoL-19 score of less than -2.59 (lower QoL).  Only 1 (1.8%) 
patient reported an ADDQoL-19 score of 0, suggesting that their QoL was not affected by 
diabetes at all. 
The ‘impact rating’ signifies the impact of the particular life aspect on QoL and, the 
‘importance rating’ signifies the importance of that particular life aspect on the individual’s 
QoL.  In this cohort of T1DM patients, diabetes had the greatest impact on “freedom to eat” 
(impact rating -1.83±1.03) and the least impact on “living conditions” (impact rating              
-0.21±0.53).  “Family life” was rated as the most important (importance rating 2.76±1.47) 
and “journeys” was rated as the least important (importance rating 1.60±1.08) by the T1DM 
patients.  After considering weighting (weighted impact score) (Figure 6.3), the most 
negative impact of diabetes was on “freedom to eat” (weighted impact score -3.77±3.00) and 
the least negative impact of diabetes was on “financial situation” (weighted impact score        




Table 6.4: The ADDQoL-19 scores for all T1DM patients at baseline. 
Mean ± SD presented for overview 1, overview 2, impact rating, importance rating, 
weighted impact scores of all domains, and mean ± SD and median (IQR) presented for 










Overview item 1   1.45 ± 0.76 
Overview item 2   -1.23 ± 0.87 
Leisure activities -1.16 ± 1.04 1.91 ± 0.77 -2.43 ± 2.56 
Working life -0.86 ± 0.97 2.40 ± 0.76 -2.22 ± 2.72 
Journeys -1.00 ± 1.01 1.60 ± 1.08 -2.04 ± 2.61 
Holidays -1.19 ± 0.96 2.36 ± 0.74 -2.79 ± 2.59 
Physical health -1.04 ± 0.92 2.20 ± 0.68 -2.28 ± 2.36 
Family life -0.55 ± 0.85 2.76 ± 0.47 -1.49 ± 2.47 
Friendship and social life -0.73 ± 0.90 2.61 ± 0.53 -1.96 ± 2.57 
Personal relationships -0.55 ± 0.77 2.69 ± 0.63 -1.42 ± 2.13 
Sex life -0.40 ± 0.68 2.39 ± 0.65 -0.85 ± 1.58 
Physical appearance -0.64 ± 0.90 2.05 ± 0.88 -1.55 ± 2.49 
Self confidence -0.64 ± 0.82 2.21 ± 0.73 -1.46 ± 2.21 
Motivation -0.66 ± 0.90 2.14 ± 0.72 -1.52 ± 2.40 
People’s reaction -0.30 ± 0.63 1.75 ± 0.94 -0.64 ± 1.59 
Feelings about the future -1.41 ± 1.14 2.18 ± 0.77 -3.09 ± 3.07 
Financial situation -0.25 ± 0.69 2.16 ± 0.71 -0.46 ± 1.33 
Living conditions -0.21 ± 0.53 2.29 ± 0.62 -0.54 ± 1.40 
Dependence on others -0.58 ± 0.80 2.00 ± 0.83 -1.36 ± 2.20 
Freedom to eat -1.83 ± 1.03 1.92 ± 0.81 -3.77 ± 3.00 
Freedom to drink -1.72 ± 1.10 1.64 ± 1.04 -3.28 ± 3.29 
ADDQoL-19 score (mean ± SD) 
                           [median (IQR)] 
  -1.81 ± 1.40 






Figure 6.2: The overall ADDQoL-19 score for all T1DM patients at baseline. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for 56 
T1DM patients.  The lower quartile was calculated at -2.59.  Based on the cut off strategy 
75% of the T1DM patients reported an ADDQoL-19 score above the lower quartile and 25% 
of the T1DM patients reported an ADDQoL-19 score below the lower quartile (poorer QoL). 







Figure 6.3: The weighted impact scores of the ADDQoL-19 domains for all T1DM patients. 
The most negative impact of T1DM on QoL was on the “freedom to eat” domain and the least negative impact of T1DM on QoL was on the 




Table 6.5 summarises the baseline ADDQoL-19 scores based on periodontal diagnosis.  For 
the DH group, the overview item 1 score was 1.56±0.53 and overview item 2 was -1.11±0.60.  
For the DG group, the overview item 1 score was 1.50±0.75 and overview item 2 score was   
-1.14±0.85.  For the DP group, the overview item 1 score was 1.32±0.89 and overview item 2 
score was -1.42±1.01.  No statistically significant differences were detected for the overview 
item 1 and 2 scores based on periodontal diagnosis, (P>0.05). 
The ADDQoL-19 score for the DH group was -1.58±0.92, for the DG group was -1.79±1.35 
and for the DP group was -1.94±1.68.  Of note, no statistically significant differences were 
found for the ADDQoL-19 score based on periodontal diagnosis, (P>0.05). Interpreting the 
ADDQoL-19 score further based on quartiles, for the DH group, the median ADDQoL-19 
score was calculated at -1.39 and lower quartile cut off was calculated at -1.93 (Table 6.5 and 
Figure 6.4).  Based on the cut off strategy, 7 (77.8%) DH patients reported an ADDQoL-19 
score of -1.93 or more and only 2 (22.2%) DH patients had an ADDQoL-19 score of less than 
-1.93 (lower QoL).  For the DG group, the median ADDQoL-19 score was calculated at         
-1.55, lower quartile cut off was calculated at -2.59 (Table 6.5 and Figure 6.4).  Based on the 
cut off strategy, 21 (75%) DG patients reported an ADDQoL-19 score of -2.59 or more and 
only 7 (25%) DG patients had an ADDQoL-19 score of less than -2.59 (lower QoL).  For the 
DP group, the median ADDQoL-19 score was calculated at -1.26, lower quartile cut off was 
calculated at -2.94 (Table 6.5 and Figure 6.4).  Based on the cut off strategy, 5 (26.3%) DP 
patients reported an ADDQoL-19 score of -2.94 or more, and 14 (73.7%) DP patients had an 
ADDQoL-19 score of less than -2.94 (lower QoL). 
Considering baseline ADDQoL-19 weighted impact scores, for the DH group, T1DM had the 
most negative impact on “freedom to eat” (weighted impact score -3.00±2.35) and the least 
negative impact on “financial situation” (weighted impact score 0.00±0.00) domains, 
respectively.  For the DG group, T1DM had the most negative impact on “freedom to eat” 
(weighted impact score -3.93±3.17) and the least negative impact on “financial situation” 
(weighted impact score -0.29±-1.12) domains, respectively.  For the DP group, T1DM had 
the most negative impact on “freedom to eat” (weighted impact score -3.94±3.13) and the 
least negative impact on “people’s reaction” (weighted impact score -0.58±-1.22) domains 
(Table 6.5). 
With reference to the individual domain scores, at baseline, in the ‘holidays’ domain, the DG 




(weighted impact score -2.12±1.97) compared to the DP group (weighted impact score           
-3.72±3.30), (P<0.05) (Table 6.5).  Of note, no other statistically significant differences were 




Table 6.5: Comparing the ADDQoL-19 scores in T1DM patients based on periodontal 
diagnosis. 
Mean ± SD presented for overview 1, overview 2, weighted impact scores of all domains, and 
mean ± SD and median (IQR) presented for the ADDQoL-19 score.  P-values determined using 
ANOVA with post-hoc Bonferoni.  †P<0.05 indicates statistically significant difference 







Overview item 1 1.56 ± 0.53 1.50 ± 0.75 1.32 ± 0.89 
Overview item 2 -1.11 ± 0.60 -1.14 ± 0.85 -1.42 ± 1.01 
Leisure activities -2.11 ± 2.15 -2.43 ± 2.71 -2.58 ± 2.63 
Working life -1.25 ± 1.49 -2.13 ± 2.79 -2.78 ± 3.02 
Journeys -2.00 ± 2.06 -2.15 ± 2.98 -1.89 ± 2.38 
Holidays -2.89 ± 2.20 -2.12 ± 1.97 -3.72 ± 3.30 † 
Physical health -2.22 ± 1.79 -2.38 ± 2.61 -2.16 ± 2.34 
Family life -1.22 ± 2.99 -1.37 ± 2.37 -1.79 ± 2.46 
Friendship and social life -1.78 ± 2.05 -2.39 ± 2.85 -1.42 ± 2.36 
Personal relationships -0.78 ± 1.30 -1.64 ± 2.06 -1.39 ± 2.57 
Sex life -1.13 ± 1.64 -0.79 ± 1.45 -0.84 ± 1.80 
Physical appearance -1.33 ± 2.18 -1.46 ± 2.59 -1.79 ± 2.57 
Self confidence -0.89 ± 1.17 -1.64 ± 2.60 -1.47 ± 1.98 
Motivation -1.67 ± 2.55 -1.29 ± 2.31 -1.79 ± 2.55 
People’s reaction -0.44 ± 1.33 -0.75 ± 1.90 -0.58 ± 1.22 
Feelings about the future -3.67 ± 2.65 -2.64 ± 2.83 -3.47 ± 3.61 
Financial situation 0.00 ± 0.00 -0.29 ± 1.12 -0.95 ± 1.78 
Living conditions -0.22 ± 0.67 -0.43 ± 1.00 -0.84 ± 2.03 
Dependence on others -1.11 ± 1.36 -1.30 ± 2.09 -1.59 ± 2.79 
Freedom to eat -3.00 ± 2.35 -3.93 ± 3.17 -3.94 ± 3.13 
Freedom to drink -2.22 ± 2.22 -3.67 ± 3.43 -3.24 ± 3.56 
ADDQoL-19 score (mean ± SD) 
                           [median (IQR)] 
-1.58 ± 0.92 
-1.39 (-1.93 - -1.24) 
-1.79 ± 1.35 
-1.55 (-2.59 - -0.74) 
-1.94 ± 1.68 
-1.26 (-2.94 - -0.82) 
  




Figure 6.4: The ADDQoL-19 score for T1DM patients based on periodontal diagnosis. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients based on periodontal diagnosis.  For healthy tissue patients, the lower quartile was 
calculated at -1.93, 77.8% of these patients (n=9) reported an ADDQoL-19 score above -1.93 
and 22.2% had a score below -1.93 (poorer QoL).  For gingivitis patients, the lower quartile 
was calculated at -2.59, 75% of these patients (n=28) reported an ADDQoL-19 score above -
2.59 and 25% had a score below -2.59 (poorer QoL).  For periodontitis patients, the lower 
quartile was calculated at -2.94, 26.3% of these patients (n=19) reported an ADDQoL-19 
score above -2.94 and 73.7% reported a score below -2.94 (poorer QoL).  ● indicates outlier 
more than 1.5 but less than 3 times the IQR from the box boundaries,     indicates outlier 
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Table 6.6 summarises the baseline impact and importance ratings of the ADDQoL-19 
domains based on periodontal diagnosis.  In the DH group, diabetes had the greatest impact 
on “feelings about the future” (impact rating -1.67±1.00) and least impact on “financial 
situation” (impact rating 0.00±0.00).  “Family life” was rated as the most important 
(importance rating 2.78±0.44) and “people’s reaction” was rated as the least important 
(importance rating 1.44±0.53).  In the DG group, diabetes had the greatest impact on 
“freedom to eat” (impact rating -1.93±1.00) and least impact on “living conditions” (impact 
rating -0.18±0.39).  “Family life” was rated as the most important (importance rating 
2.74±0.53) and “journeys” was rated as the least important (importance rating 1.44±1.12).  In 
the DP group, diabetes had the greatest impact on “freedom to drink” (impact rating               
-1.88±1.22) and least impact on “living conditions” (impact rating -0.32±0.75).  “Family life” 
was rated as the most important (importance rating 2.79±0.42) and “journeys” was rated as 
the least important (importance rating 1.63±1.07). 
Of note, no statistically significant differences were found between impact and importance 
ratings based on periodontal diagnosis, (P>0.05).
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Table 6.6: Comparisons of the impact and importance ratings of the ADDQoL-19 in 
T1DM patients based on periodontal diagnosis. 
Mean ± SD presented for impact, impact rating and importance rating of the ADDQoL-19 
domains.  P-values determined using ANOVA with post-hoc Bonferoni (no statistically 
significant differences found).  Values in blue indicate impact rating scores and values in 











-1.00 ± 0.87 
1.89 ± 0.60 
 
-1.11 ± 1.03 
2.07 ± 0.86 
 
-1.32 ± 1.16 





-0.50 ± 0.53 
2.38 ± 0.92 
 
-0.79 ± 0.93 
2.38 ± 0.71 
 
-1.11 ± 1.13 





-1.00 ± 0.76 
2.00 ± 1.00 
 
-0.96 ± 1.06 
1.44 ± 1.12 
 
-1.05 ± 1.08 





-1.11 ± 0.78 
2.67 ± 0.50 
 
-1.04 ± 0.92 
2.19 ± 0.80 
 
-1.44 ± 1.10 





-0.89 ± 0.60 
2.22 ± 0.67 
 
-1.07 ± 0.96 
2.12 ± 0.65 
 
-1.05 ± 1.03 





-0.44 ± 1.01 
2.78 ± 0.44 
 
-0.54 ± 0.84 
2.74 ± 0.53 
 
-0.63 ± 0.83 
2.79 ± 0.42 




-0.67 ± 0.71 
2.67 ± 0.50 
 
-0.86 ± 0.97 
2.68 ± 0.55 
 
-0.58 ± 0.90 





-0.33 ± 0.50 
2.67 ± 0.71 
 
-0.61 ± 0.74 
2.68 ± 0.67 
 
-0.56 ± 0.92 





-0.50 ± 0.76 
2.63 ± 0.52 
 
-0.39 ± 0.63 
2.34 ± 0.67 
 
-0.37 ± 0.76 





-0.44 ± 0.73 
2.00 ± 1.12 
 
-0.61 ± 0.92 
2.14 ± 0.80 
 
-0.79 ± 0.98 





-0.44 ± 0.53 
2.33 ± 0.71 
 
-0.71 ± 0.98 
2.07 ± 0.60 
 
-0.63 ± 0.68 





-0.67 ± 0.87 
2.33 ± 0.87 
 
-0.54 ± 0.84 
2.04 ± 0.69 
 
-0.84 ± 1.01 





-0.22 ± 0.67 
1.44 ± 0.53 
 
-0.29 ± 0.66 
1.64 ± 1.03 
 
-0.37 ± 0.60 
2.05 ± 0.91 




-1.67 ± 1.00 
2.11 ± 0.33 
 
1.32 ± 1.09 
2.07 ± 0.86 
 
-1.42 ± 1.30 





0.00 ± 0.00 
2.22 ± 0.83 
 
-0.21 ± 0.69 
2.07 ± 0.66 
 
-0.42 ± 0.84 





-0.11 ± 0.33 
2.22 ± 0.67 
 
-0.18 ± 0.39 
2.21 ± 0.63 
 
-0.32 ± 0.75 
2.42 ± 0.61 




-0.67 ± 0.71 
2.00 ± 0.71 
 
-0.56 ± 0.75 
1.89 ± 0.75 
 
-0.59 ± 0.94 
2.18 ± 1.01 
Freedom to eat 
Impact rating 
Importance rating  
 
-1.56 ± 1.01 
1.78 ± 0.67 
 
-1.93 ± 1.00 
1.81 ± 0.88 
 
-1.82 ± 1.13 
2.18 ± 0.73 




-1.33 ± 1.00 
1.56 ± 0.53 
 
-1.74 ± 1.06 
1.63 ± 1.11 
 
-1.88 ± 1.22 
1.71 ± 1.60 
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Table 6.7 summarises pre- and post-treatment ADDQoL-19 scores in patients with 
periodontitis.  At pre-treatment, overview item 1 score was 1.60±0.84 and overview item 2 
score was -1.20±1.03.  At month 3, the overview item 1 score was 1.40±0.97 and overview 
item 2 score was -1.30±1.16.  At month 6, the overview item 1 score was 1.70±1.16 and 
overview item 2 score was -1.20±0.92.  No statistically significant differences were found for 
overview item 1 and 2 scores pre- and post-NSM, (P>0.05). 
At pre-treatment, the ADDQoL-19 score for the DP group (n=19) was -1.94±1.68 (Table 6.7 
and Figure 6.5).  The median ADDQoL-19 score was calculated at -1.26, and the lower 
quartile cut off was calculated at -2.94.  Based on the cut off strategy, 5 (26.3%) DP patients 
had an ADDQoL-19 score of -2.94 or more, and 14 (73.7%) DP patients had an ADDQoL-19 
score of less than -2.94 (poorer QoL).  At month 3, the ADDQoL-19 score for the DP group 
(n=10), was -1.89±1.81 (Table 6.7 and Figure 6.5).  The median ADDQoL-19 score was 
calculated at -1.44, and the lower quartile cut off was calculated at -2.54.  Based on the cut 
off strategy, 8 (80%) DP patients reported an ADDQoL-19 score of -2.54 or more, and 2 
(20%) DP patients had an ADDQoL-19 score of less than -2.54 (lower QoL).  At month 6, 
the ADDQoL-19 score for the DP group (n=10), was -2.22±2.11 (Table 6.7 and Figure 6.5).  
The median ADDQoL-19 score was calculated at -1.29, and the lower quartile cut off was 
calculated at -3.82.  Based on the cut off strategy, 8 (80%) DP patients reported an  
ADDQoL-19 score of -3.82 or more, and 2 (20%) patients had an ADDQoL-19 score of less 
than -3.82 (lower QoL).  No statistically significant differences were found for the  
ADDQoL-19 scores pre- and post-NSM, (P>0.05). 
The weighted impact score for the ‘working life’ domain score at month 6 (-1.29±2.36) was 
significantly higher than the pre-treatment score (-3.29±3.25), (P<0.05).  Also, the ‘feelings 
about the future’ weighted impact score at month 3 (-2.40±3.13) was significantly higher than 
the score at month 0 (-3.90±3.92) (P<0.05).  No other statistically significant findings were 
found in domain scores pre- and post-NSM, (P>0.05).
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Table 6.7: The ADDQoL-19 scores in T1DM patients with periodontitis pre- and post-NSM. 
Mean ± SD presented for overview 1, overview 2, weighted impact scores for all domains, and mean ± SD and median (IQR) presented for the 
overall ADDQoL-19 scores.  For longitudinal comparisons, p-values determined using Paired t-test: significant difference from baseline 
*P<0.05 and **P<0.01. 






Overview item 1 1.60 ± 0.84 1.40 ± 0.97 1.70 ± 1.16 
Overview item 2 -1.20 ± 1.03 -1.30 ± 1.16 -1.20 ± 0.92 
Leisure activities -3.56 ± 3.00 -3.78 ± 3.35 -2.90 ± 3.03  
Working life -3.00 ± 3.21 -3.25 ± 2.55      -1.29 ± 2.36 ** 
Journeys -2.10 ± 3.11 -2.10 ± 3.11 -2.60 ± 3.63 
Holidays -3.56 ± 3.64 -3.67 ± 2.96 -2.78 ± 3.03 
Physical health -2.33 ± 2.55 -3.67 ± 2.78 -3.10 ± 3.31 
Family life -2.00 ± 3.00 -2.00 ± 3.00 -1.00 ± 1.50 
Friendship and social life -1.44 ± 2.96 -1.33 ± 2.18 -2.10 ± 2.88 
Personal relationships -1.90 ± 3.28 -1.20 ± 2.90 -0.89 ± 2.03 
Sex life -1.00 ± 2.16 -0.30 ± 0.95 -0.33 ± 1.00 
Physical appearance -1.60 ± 1.90 -1.70 ± 1.57 -2.50 ± 2.88 
Self confidence -1.90 ± 2.42 -1.30 ± 2.98 -2.30 ± 2.98 
Motivation -1.90 ± 3.28 -1.90 ± 3.14 -2.30 ± 3.13 
People’s reaction -0.90 ± 1.52 -0.30 ± 0.95 -0.90 ± 1.52 
Feelings about the future -3.90 ± 3.92    -2.40 ± 3.13 * -2.60 ± 3.24 
Financial situation -0.80 ± 1.32 -0.60 ± 1.26 -1.50 ± 2.92 
Living conditions -0.60 ± 1.90 -0.30 ± 0.95 -0.90 ± 2.85 
Dependence on others  -1.38 ± 2.20 -1.25 ± 1.39 -0.83 ± 1.33 
Freedom to eat  -2.88 ± 2.10 -3.13 ± 3.72 -4.50 ± 4.04 
Freedom to drink  -2.38 ± 3.42 -3.13 ± 3.87 -3.83 ± 4.07 
ADDQoL-19 score (mean ± SD) 
                              [median (IQR)] 
-1.94 ± 1.68 
-1.26 (-2.94 - -0.82) 
-1.89 ± 1.81 
-1.44 (-2.54 - -0.71) 
-2.22 ± 2.11 
-1.29 (-3.82 - -0.66) 
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Figure 6.5: The ADDQoL-19 score in T1DM patients with periodontitis pre- and post-
NSM. 
Box plot figure showing medians, interquartile ranges, standard errors and outliers for T1DM 
patients with periodontitis.  At pre-treatment the lower quartile was calculated at -2.94, 
26.3% of patients (n=19) reported an ADDQoL-19 score above -2.94 and 73.7% reported a 
score below -2.94 (poorer QoL).  At month 3, the lower quartile was calculated at -2.54, 80% 
of patients (n=10) reported an ADDQoL-19 score above -2.54 and 20% reported a score 
below  -2.54 (poorer QoL).  At month 6, the lower quartile was calculated at -3.82, 80% of 
patients (n=10) reported an ADDQoL-19 score above -3.82 and 20% reported a score below -
3.82 (poorer QoL). ● indicates outlier more than 1.5 but less than 3 times the IQR from the 
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Table 6.8 summarises the impact and importance ratings of the ADDQoL-19 domains for 
T1DM patients with periodontitis pre- and post-NSM.  At pre-treatment, in the DP group, 
diabetes had the greatest impact on “freedom to drink” (impact rating -2.00±1.20) and least 
impact on “living conditions” (impact rating -0.20±0.63).  “Family life” was rated as the most 
important (importance rating 2.89±0.33) and “journeys” was rated as the least important 
(importance rating 1.90±1.10).  At month 3, diabetes had the greatest impact on “freedom to 
eat” (impact rating -1.56±1.24) and least impact on “sex life” (impact rating -0.10±0.32) and 
“living conditions” (impact rating -0.10±0.32).  “Family life” was rated as the most important 
(importance rating 2.89±0.33) and “freedom to drink” was rated as the least important 
(importance rating 1.67±1.00).  At month 6, diabetes had the greatest impact on “freedom to 
eat” (impact rating -1.86±1.21) and least impact on “sex life” (impact rating -0.11±0.33).  
“Family life” was rated as the most important (importance rating 3.00±0.00) and “journeys” 
was rated as the least important (importance rating 1.70±0.95). 
At pre-treatment, diabetes had a significantly greater impact on “working life” (impact rating 
-1.14±1.07), compared to month 6 (impact rating -0.43±0.79) following NSM, (P<0.05).  
Also, at pre-treatment, the DP group had a significantly greater impact on “feelings about the 
future” (impact rating -1.50±1.35) compared to month 3 (impact rating -0.90±1.10) following 
NSM, (P<0.05).  At month 3, the DP patients reported a significantly greater importance on 
“physical appearance” (importance rating 2.40±0.52) compared to pre-treatment (importance 
rating 2.00±0.47), (P<0.05).
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Table 6.8: The impact and importance ratings of the ADDQoL-19 in T1DM patients 
with periodontitis pre- and post-NSM. 
Mean ± SD presented for impact and importance rating of the ADDQoL-19 domains.  For 
longitudinal comparisons, p-values determined using Paired t-test: significant difference 
from baseline *P<0.05.  Values in blue indicate impact rating scores and values in red 
indicate importance rating scores.










-1.50 ± 1.27 
1.89 ± 0.78 
 
-1.50 ± 1.18 
1.89 ± 0.78 
 
-1.30 ± 0.95 





-1.00 ± 1.07 
3.00 ± 0.00 
 
-1.13 ± 0.83 
2.88 ± 0.35 
 
-0.43 ± 0.79 * 





-0.90 ± 0.99 
1.90 ± 1.10 
 
-0.80 ± 1.03 
1.90 ± 1.10 
 
-1.00 ± 1.25 





-1.22 ± 1.20 
2.56 ± 0.73 
 
-1.33 ± 1.00 
2.44 ± 0.73 
 
-1.00 ± 1.00 





-1.00 ± 1.00 
2.56 ± 0.73 
 
-1.33 ± 0.87 
2.56 ± 0.53 
 
-1.20 ± 1.03 
2.30 ± 0.82 
Family life 
Impact rating 
Importance rating  
 
-0.67 ± 1.00 
2.89 ± 0.33 
 
-0.67 ± 1.00 
2.89 ± 0.33 
 
-0.33 ± 0.50 
3.00 ± 0.00 




-0.56 ± 1.01 
2.56 ± 0.53 
 
-0.44 ± 0.73 
2.67 ± 0.50 
 
-0.80 ± 1.03 





-0.70 ± 1.16 
2.80 ± 0.42 
 
-0.40 ± 0.97 
2.80 ± 0.42 
 
-0.33 ± 0.71 
2.44 ± 0.73 




-0.40 ± 0.84 
2.60 ± 0.52 
 
-0.10 ± 0.32 
2.60 ± 0.52 
 
-0.11 ± 0.33 
2.44 ± 0.73 




-0.80 ± 0.92 
2.00 ± 0.47 
 
-0.70 ± 0.67 
  2.40 ± 0.52 * 
 
-1.10 ± 0.99 





-0.70 ± 0.82 
2.50 ± 0.71 
 
-0.50 ± 1.08 
2.20 ± 0.63 
 
-0.90 ± 0.99 





-0.70 ± 1.16 
2.40 ± 0.70 
 
-0.70 ± 1.06 
2.30 ± 0.67 
 
-0.90 ± 1.10 





-0.50 ± 0.71 
2.10 ± 0.99 
 
-0.20 ± 0.42 
1.90 ± 0.99 
 
-0.40 ± 0.70 
1.80 ± 0.79 




-1.50 ± 1.35 
2.60 ± 0.52 
 
  -0.90 ± 1.10 * 
2.30 ± 0.67 
 
-1.10 ± 1.10 





-0.30 ± 0.48 
2.30 ± 0.82 
 
-0.20 ± 0.42 
2.20 ± 0.79 
 
-0.50 ± 0.97 





-0.20 ± 0.63 
2.50 ± 0.53 
 
-0.10 ± 0.32 
2.50 ± 0.53 
 
-0.30 ± 0.95 
2.20 ± 0.92 




-0.50 ± 0.76 
2.13 ± 0.99 
 
-0.50 ± 0.53 
2.13 ± 0.83 
 
-0.33 ± 0.52 
2.67 ± 0.52 
Freedom to eat 
Impact rating 
Importance rating  
 
-1.63 ± 1.06 
2.00 ± 0.76 
 
-1.38 ± 1.19 
2.00 ± 0.93 
 
-1.67 ± 1.21 
2.17 ± 0.98 




-2.00 ± 1.20 
1.25 ± 1.28 
 
-1.50 ± 1.20 
1.75 ± 1.04 
 
-1.67 ± 1.21 
1.83 ± 0.98 
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Interpreting the baseline ADDQoL-19 scores based on gender (reporting only statistically 
significant findings), females had a significantly higher impact of T1DM on their physical 
appearance (weighted impact score -2.45±2.84) compared to males (weighted impact score    
-0.59±0.64), (P<0.01).  Females had a significantly higher impact of T1DM on their 
dependence on others (weighted impact score -2.00±2.78) compared to males (weighted 
impact score -0.64±0.95) (P<0.05), and females also had a significantly higher impact of 
T1DM on their freedom to eat (weighted impact score -4.54±3.34) compared to males 
(weighted impact score -2.92±2.22), (P<0.05). 
Of note, no statistically significant correlations were found between ADDQoL-19 scores and 
age, duration of diabetes, diabetic complications, HbA1c levels and mean PD (Spearman’s 
correlation P>0.05). 
6.3 Discussion 
In this study, QoL was assessed in patients with T1DM and periodontal disease pre-and post-
periodontal treatment using two validated QoL instruments routinely used to assess the 
impact of diabetes on QoL, the W-BQ12 and the ADDQoL-19 questionnaire.  Also, in this 
cohort of T1DM patients, QoL was further assessed based on periodontal diagnosis at 
baseline prior to any periodontal intervention. 
The baseline findings of the clinical periodontal data suggest that the T1DM patients with 
periodontitis had significantly higher PI, mGI, BOP and mean PD compared to the T1DM 
patients with healthy tissues (Table 3.15).  Longitudinal comparisons of the T1DM patients 
with periodontitis showed significant improvements in all clinical periodontal parameters 
(Table 5.5), thus indicating that periodontal treatment had a positive effect upon the clinical 
aspects of the condition, and the patients benefited from the treatment they received at the 
dental hospital.  There were no statistically significant differences or improvement in 
glycaemic control in T1DM patients with periodontitis following NSM, and HbA1c levels 
remained similar to those recorded at pre-treatment. 
The W-BQ12 and ADDQoL-19 questionnaires were analysed at baseline and, for the T1DM 
patients with periodontitis at months 3 and 6 following NSM.  Analysis of the baseline       
W-BQ12 scores, comparing T1DM patients based on periodontal diagnosis revealed no 
statistically significant differences in any subscale or general well-being scores, suggesting 
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that all T1DM groups (healthy periodontal tissues, gingivitis and periodontitis) had a similar 
perception of QoL as assessed by the W-BQ12. 
Analysis of post-treatment W-BQ12 scores in T1DM patients with periodontitis revealed that 
QoL did improve following NSM, as indicated by significantly higher (better QoL) post-
treatment (month 3) general well-being score compared to the pre-treatment general well-
being score.  This suggests that successful NSM has a short-term positive impact on QoL in 
T1DM patients with periodontitis.  The results of the current study are similar to previous 
research which showed that successful NSM had a positive impact and improves an 
individual’s QoL (Aslund et al. 2008; Jowett et al. 2009; Saito et al. 2010; Shanbhag et al. 
2012).  However, no statistically significant differences were found in the general well-being 
score between pre-treatment and month 6, suggesting that there was perhaps an initial 
improvement in QoL at month 3 following the first periodontal treatment appointment, which 
stabilised during the course of the study and was not evidently identified at month 6 
following NSM. 
Analysis of the ADDQoL-19 questionnaire for all T1DM patients at baseline revealed that 
the patients experienced a “good to very good” overall general QoL, as revealed by the 
generic assessment overview item 1.  However, assessment of the diabetes-specific overview 
item 2 revealed that the T1DM patients felt that their QoL would have been “a little better or 
much better” if they did not have diabetes.  No statistically significant differences were found 
between both overview item scores based on periodontal diagnosis suggesting that patients 
with healthy periodontal tissues, gingivitis and periodontitis had a similar perception of QoL 
as related to their diabetes, and perceived a “good to very good” overall QoL and felt that 
their life would have been “a little better or much better” if they did not have diabetes.  The 
analysis of the baseline ADDQoL-19 scores further revealed that for all T1DM patients, the 
greatest impact of diabetes on QoL was on their “freedom to eat”, whereas their “living 
conditions” had the least impact.  “Family life” for this cohort of patients was the most 
important and the least important was their “journeys” or the ability to travel. 
Comparing the T1DM patients based on periodontal diagnosis, revealed no statistically 
significant differences in the overall ADDQoL-19 score.  This suggests that all groups of 
periodontal diagnosis had a similar perception of the impact of diabetes on their QoL prior to 
periodontal treatment as assessed by the ADDQoL-19 questionnaire.  Interestingly, 
interpreting the ADDQoL-19 score based on quartiles revealed that a majority of the 
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periodontitis patients (73.7%) experienced a poorer QoL in contrast to a majority of the 
healthy tissue (77.8%) and gingivitis (75%) patients who experienced a better QoL. 
In all groups of periodontal diagnosis, “freedom to eat” had the highest weighted impact.  
T1DM patients with periodontitis had significantly higher impact on their “holidays” domain 
compared to those with gingivitis.  The T1DM patients with healthy tissues had the greatest 
impact on their “feelings about the future”, the gingivitis patients had their greatest impact on 
their “freedom to eat”, whereas in periodontitis patients the greatest impact was on their 
“freedom to drink”.  All groups of periodontal diagnosis placed greatest importance on their 
“family life”. 
Analysis of the post-treatment overall ADDQoL-19 scores in T1DM patients with 
periodontitis revealed no statistically significant differences between pre-treatment, month 3 
and month 6 ADDQoL-19 (overview 1 and 2, weighted impact, overall ADDQoL-19) scores.  
This suggests that the QoL remained the same pre- and post-NSM in this group of patients as 
assessed by the ADDQoL-19 questionnaire.  Interestingly, at pre-treatment, 73.7% of the 19 
DP patients reported ADDQoL-19 scores below the lower QoL cut off compared to only 20% 
of the 10 DP patients who reported ADDQoL-19 score below the lower QoL cut off at 
months 3 and 6, suggesting that following NSM fewer patients experienced a poorer QoL 
compared to pre-treatment.  While considering impact and importance ratings in T1DM 
patients with periodontitis, at pre-treatment the greatest impact was on their “freedom to 
drink”, at months 3 and 6 the greatest impact was on their “freedom to eat”.  At all three time 
points, the greatest importance was their “family life”.  At pre-treatment, periodontitis 
patients had a significantly greater impact on their “feelings about the future” and “working 
life” compared to the impact in these domains at months 3 and 6, respectively.  At month 3 
periodontitis patients had a significantly greater impact on their “physical appearance” 
compared to pre-treatment. 
We found that T1DM patients in all groups of periodontal diagnosis, placed great importance 
on their “freedom to eat and drink” domains as assessed by the ADDQoL-19 questionnaire.  
The findings of the current study are consistent with those of previous studies (Bradley and 
Speight 2002; Trief et al. 2003; Costa et al. 2006; Holmanova and Ziakova 2009; Turk et al. 
2013), which found the greatest negative impact of diabetes on the domain “freedom to eat”, 
indicating a strong influence of dietary restrictions on QoL in this group of patients.  Patients 
with T1DM have to prioritise their dietary intake in order to prevent diabetes-related 
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complications (Daneman 2006).  Their nutritional intake has to be tailored to their age, stage 
of development, weight, culture, lifestyle and personal preferences (Franz 2004; Evert et al. 
2013).  Their daily diet is usually regulated by the intake of their medications and the time of 
day, and hence we found in this group of T1DM patients, their freedom to eat and drink had a 
major impact and importance on their daily lives. 
In the current study, males had significantly better QoL compared to females, and females 
had a significantly higher negative impact on QoL compared to males as assessed by the    
W-BQ12.  Females also had a significantly higher impact on their physical appearance, 
dependence on others and their freedom to eat as assessed by the ADDQoL-19 questionnaire.  
The findings of the present study are consistent with previous research that suggests QoL is 
better among diabetic males than diabetic females (Rubin and Peyrot 1992; Unden et al. 
2008).  Our findings are also consistent with reported gender differences in HRQoL in the 
general population, which suggest that males have a better perception of QoL compared to 
females (Hagedoorn et al. 2000; Riedinger et al. 2001; Emery et al. 2004; Mrus et al. 2005). 
Our study has some limitations.  Firstly, we did not analyse QoL in our control non-T1DM 
patients, hence we cannot compare QoL findings of the T1DM patients to the control 
patients.  Secondly, we under-recruited T1DM patients according to our a priori power 
calculation due to difficulties in recruitment.  Thirdly, the T1DM patients were recruited from 
a diabetes clinic which might be a disadvantage, as these patients are often at an extreme end 
of the disease spectrum and they may not be representative of the whole T1DM population.  
Lastly, the W-BQ12 is a general health assessment questionnaire and the ADDQoL-19 is a 
diabetes-specific questionnaire, specifically designed to asses QoL in patients with diabetes, 
hence, these measures might not to a full extent have analysed OHRQoL, the effect of 
periodontal disease and its treatment in this cohort of patients, as they contain limited oral-
health related questions.  
In conclusion, analyses of the W-BQ12 and the ADDQoL-19 questionnaire revealed that 
T1DM did impact on certain life aspects in this cohort of patients.  However, T1DM did not 
have an impact on QoL based on periodontal diagnosis, and that patients with healthy tissues, 
gingivitis and periodontitis had a similar perception of QoL, suggesting that the severity of 
their periodontal disease did not reveal any additional negative effects on their QoL as 
assessed by these questionnaires.  Although T1DM patients with periodontitis showed 
statistically significant improvements in their clinical periodontal condition following NSM, 
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the W-BQ12 and the ADDQoL-19 questionnaire did not appear to be useful in capturing the 
impact of periodontal disease and the positive outcomes of its treatment, in this cohort of 
patients.  This suggests that although these validated QoL measures are ideal for assessing 
HRQoL in patients with diabetes, they but might not be beneficial in assessing OHRQoL in 
patients with periodontal disease and T1DM. 
Summary of key findings from chapter 6 
 At baseline, T1DM patients with periodontitis had higher (poorer QoL) negative well-
being scores compared to those with healthy tissues and gingivitis.  However, these 
differences were not statistically significant. 
 The T1DM patients perceived that their QoL would be “a little better or much better” 
if they did not have diabetes. 
 For all T1DM patients the most negative impact of diabetes on QoL was on their 
“freedom to eat” followed by their “freedom to drink”. 
 At baseline, no statistically significant differences were found for the W-BQ12 and 
the ADDQoL-19 scores based on periodontal diagnosis, suggesting that T1DM 
patients with healthy tissues, gingivitis and periodontitis had a similar perception of 
QoL. 
 Following successful NSM, no statistically significant improvements were seen in the 
W-BQ12 and ADDQoL-19 scores in T1DM patients with periodontitis.  
 Interestingly compared to pre-treatment, where a majority 73.7% of T1DM patients 
experienced a poorer QoL, only 20% of the patients experienced a poorer QoL 
following NSM. 
 Based on gender, males had significantly better perception of QoL than females, and 
females reported to have a greater negative impact of diabetes and periodontal disease 
on their QoL.  Females also had a higher negative impact of diabetes compared to 
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7 Chapter 7. Discussion 
Diabetes is one of the largest global health emergencies of the 21
st
 century.  Every year more 
and more people are diagnosed with this condition that results in life-threatening 
complications.  The estimated global prevalence of diabetes for adults for 2015 was 415 
million, and it is predicted to affect 642 million individuals by 2040 (International Diabetes 
Federation 2015).  Diabetes can pose a threat to oral health.  There is an increased risk for 
inflammatory periodontal disease in patients with poor glycaemic control.  It is important to 
effectively manage periodontal disease in diabetic patients as optimal oral hygiene is the key 
to prevent tooth loss, promote a healthy diet and improve metabolic control (International 
Diabetes Federation 2015).  Since the prevalence of periodontal and oral diseases in patients 
with T1DM is largely under-researched, this study aimed to investigate the prevalence and 
severity of periodontal and oral diseases in T1DM patients, to establish the inflammatory 
links between T1DM and periodontal disease by investigating local and systemic markers of 
inflammation in biological samples and to further investigate the effect of periodontal 
treatment on clinical and biological parameters.  Furthermore, while establishing scientific 
links between the two diseases it was considered important to assess QoL in patients with 
diabetes and periodontal disease, as both these inflammatory conditions are known to have a 
profound impact on QoL in terms of physical, psychological and social well-being (Glasgow 
et al. 1997; O'Dowd et al. 2010; Durham et al. 2013; Desai et al. 2014). 
Analysis of the demographic data in the present study revealed that the patients with T1DM 
were significantly lower in age [28.0 (23.0-32.5) years] compared to the non-T1DM patients 
[40.0 (35.0-47.0) years].  This difference in age reflects the recruitment pattern of controls 
from a parallel T2DM study which included a higher age range than the current study, and 
unfortunately must be regarded as a weakness in this study.  The under-recruitment of control 
patients during the time period granted for the study, and in order to match the number of 
recruited T1DM patients, 31 control patients were selected from the T2DM study based on 
periodontal diagnosis and matching as closely as possible for clinical periodontal parameters.  
Case definitions used to define healthy periodontal tissues, gingivitis and periodontitis were 
exactly the same in both studies.  To be precise, the selection of controls included, 9 patients 
with healthy periodontal tissues, 13 patients with gingivitis and 9 patients with periodontitis.  
Nevertheless, it is not unreasonable to presume that irrespective of age, patients with healthy 
periodontal tissues did not have or never had periodontal disease and patients with gingivitis 
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and periodontitis were recruited with exactly the same case definition criteria set in both 
studies. 
With reference to oral and dental findings, the current study found that patients with T1DM 
had significantly more sound and unrestored teeth (22.5±6.84) compared to the non-T1DM 
patients (18.8±5.62).  Based on periodontal diagnosis, T1DM patients with periodontitis had 
less sound and unrestored teeth (19.2±6.33) compared to those with gingivitis (23.1±7.02) 
and healthy tissues (27.7±2.60).  This finding could be a manifestation of age, as T1DM 
patients with periodontitis were significantly higher in age compared to those with gingivitis 
and healthy tissues.  As age progresses, patients are more likely to have a greater number of 
restored teeth, which was also reflected in our study with non-T1DM patients having a 
significantly higher number of restored teeth compared to the T1DM patients, and T1DM 
patients with periodontitis having a significantly higher number of restored teeth compared to 
the T1DM patients with gingivitis and healthy tissues.  The prevalence of caries in patients 
with T1DM compared to non-diabetic controls has been an area of research with inconsistent 
findings.  In the current study, although in T1DM patients, a higher proportion of teeth had 
caries into dentine compared to the non-T1DM patients, this difference was not statistically 
significant, suggesting no difference in caries experience between the two groups.  Our 
findings are similar to those of other studies which found similar caries experience in patients 
with and without T1DM (Faulconbridge et al. 1981; Tenovuo et al. 1986; Harrison and 
Bowen 1987b; Twetman et al. 1989; Swanljung et al. 1992; Edblad et al. 2001; Siudikiene et 
al. 2008; Tagelsir et al. 2011), and are in contrast to other studies which reported either a 
higher caries prevalence (Albrecht et al. 1988; Jones et al. 1992; Moore et al. 2001b; Lopez et 
al. 2003; Miralles et al. 2006) and lower caries prevalence (Matsson and Koch 1975; Leeper 
et al. 1985; Kirk and Kinirons 1991; Siudikiene et al. 2006; Orbak et al. 2008) in patients 
with T1DM compared to non-diabetic controls.  The similar caries experience in patients with 
and without T1DM in the current study could be supported by the fact that modern 
management of diabetes, characterised by flexibility of insulin treatment and blood glucose 
monitoring, allows for less rigid meal planning and reduces the significance of dietary factors 
as an indicator for possible variations in caries development (Twetman et al. 2002; Siudikiene 
et al. 2006).  Additionally, patients with T1DM were known to have more daily main meals 
and fewer snacks than non-diabetic children, who had fewer main meals per day but 
consumed more snacks (Siudikiene et al. 2006), which could possibly explain the similar 
caries experience in both groups in the present study.  Lower salivary flow rates and self-
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reported xerostomia have been frequently seen in patient with diabetes (Sreebny et al. 1992; 
Ben-Aryeh et al. 1993; Moore et al. 2001b; Siudikiene et al. 2006), especially if poorly-
controlled (Harrison and Bowen 1987a; Harrison and Bowen 1987b).  Diminished salivary 
flow has been linked to high caries prevalence in diabetic patients (Twetman et al. 1992; 
Karjalainen et al. 1997; Moore et al. 2001a; Siudikiene et al. 2006).  In the current study, no 
statistically significant differences were found between T1DM and non-T1DM patients for 
both clinically assessed and patient-reported xerostomia.  Only 2 patients with T1DM 
(3.50%) and 2 non-diabetic patients (4.70%) self-reported having xerostomia.  This finding 
could also possibly explain the low caries prevalence in this cohort of patients and lack of 
significant differences in caries experience between the diabetic and non-diabetic in the 
present study. 
In the current study, T1DM patients with periodontitis presented with a significantly longer 
history of diabetes (17.5±8.32 years) compared to those with healthy tissues (11.7±5.12 
years).  Although not statistically significant, periodontitis patients presented with a longer 
history of T1DM compared to those with gingivitis (12.5±6.86 years).  Our findings could be 
a manifestation of the patients who were recruited, as the periodontitis patients were 
significantly older compared to those with healthy tissues and non-significantly older 
compared to those with gingivitis.  It has been well established that age is a common 
confounding factor for periodontal disease, and older individuals may present with more 
severe periodontal disease (Genco and Borgnakke 2013).  Additionally the greater duration of 
diabetes in the patients with periodontitis compared to those with gingivitis and healthy 
tissues could suggest that a longer history of diabetes increases the chances of individuals 
experiencing more severe periodontal disease.  Data from previous studies also demonstrate 
that a longer duration of diabetes is related to poorer periodontal health (Cianciola et al. 1982; 
Thorstensson and Hugoson 1993; Firatli et al. 1996; Silvestre et al. 2009).  However, our 
findings are in contrast to other studies which found no influence of duration of diabetes on 
periodontal health (de Pommereau et al. 1992; Tervonen and Oliver 1993; Sandberg et al. 
2000). 
In the present study, 42.1% of the T1DM patients were categorised as having poor glycaemic 
control, and although the differences in glycaemic control categories were not statistically 
significant, it is interesting to note that 52.6% of the periodontitis patients had poorly-
controlled T1DM, whereas 44.8% of the gingivitis patients and 55.6% of the healthy tissue 
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patients had moderately-controlled T1DM.  These findings possibly support the concept of a 
two-way relationship between diabetes and periodontal disease, in which poor glycaemic 
control increases the risk for severe periodontal disease and severe periodontal disease 
negatively affects glycaemic control (Preshaw et al. 2012).  The baseline HbA1c level for all 
T1DM patients was 8.30 (7.60-9.35) % / 67 (60-79) mmol/mol, which was categorised as a 
moderate metabolic control.  Further comparing HbA1c levels based on periodontal status, 
T1DM patients with periodontitis had higher HbA1c levels [8.95 (8.03-9.65) %/ 75 (64-83) 
mmol/mol] compared to the gingivitis [8.25 (7.65-10.0) %/ 67 (61-86) mmol/mol] and 
healthy tissue [7.90 (7.30-8.58) %/ 63 (56-70) mmol/mol] patients, suggesting a possible role 
of periodontal inflammation in elevating HbA1c levels in patients with gingivitis and 
periodontitis, however these differences were not statistically significant.  Following NSM, in 
the current study the HbA1c levels of T1DM patients with periodontitis reduced by 0.45% 
and 0.90% at months 3 and 6, respectively, although these reductions were not statistically 
significant.  Our findings are similar to those of a study which found a 0.43% non-significant 
reduction in HbA1c levels in T1DM patients 6 months following treatment with NSM plus 
adjunctive doxycycline therapy (Miller et al. 1992).  The findings of the current study are 
also in agreement with those of previous studies in T1DM patients, which found no 
significant improvement in HbA1c levels following periodontal treatment (Miller et al. 1992; 
Aldridge et al. 1995; Llambes et al. 2008).  From a review of the literature it appears that 
overall periodontal treatment does improve glycaemic control in patients with T1DM, 
however the findings are not statistically significant (Miller et al. 1992; Seppala et al. 1993; 
Aldridge et al. 1995; Smith et al. 1996; Llambes et al. 2008).  One must bear in mind the 
heterogeneity among the studies such as diabetes-related and periodontal-related factors, 
sample sizes and power to detect differences in metabolic and periodontal response, follow-
up time frames for glycaemic control and periodontal status evaluation, inclusion of control 
groups and specific hypothesis tested.  Despite such variations and although the evidence is 
equivocal there is evidence that supports the concept that periodontal disease contributes to 
poor glycaemic control and the treatment of periodontal disease has a beneficial effect in 
patients with T1DM (Taylor 2003).  There is need to further investigate the effect of treating 
periodontal disease on glycaemic control especially in T1DM patients, as this cohort of 
patients has been under-researched. 
In the current study, levels of hsCRP appeared higher in T1DM patients compared to non-
T1DM patients, although this difference was not statistically significant.  Interestingly, when 
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patients were further categorised based on periodontal status, patients with T1DM and 
healthy tissues had significantly higher hsCRP levels [1.40 (0.73-4.03) mg/L] compared to 
non-T1DM patients with healthy tissues [0.60 (0.20-1.10) mg/L].  These findings may reflect 
the diabetes-associated inflammation present in T1DM patients, where even in the absence of 
inflammatory periodontal disease, higher hsCRP levels were detected.  Additionally, hsCRP 
levels were significantly lower in non-T1DM patients with healthy tissues [0.60 (0.20-1.10) 
mg/L] compared to those with gingivitis [2.85 (0.73-5.45) mg/L], and although non-T1DM 
patients with healthy tissues had lower hsCRP levels compared to patients with periodontitis 
this difference was not statistically significant.  Similar findings were seen in the T1DM 
group, where periodontitis and gingivitis patients had higher hsCRP levels compared to those 
with healthy tissues; however these differences were also not statistically significant.  In 
patients with diabetes, clinical interventional trials have shown a significant reduction of 
acute phase protein levels, such as fibrinogen (Christgau et al. 1998), and CRP (Lalla et al. 
2007a) following periodontal therapy.  However, in the current study no statistically 
significant improvements were seen in hsCRP levels in both T1DM and non-T1DM patients 
following NSM.  Our findings are similar to those of a meta-analysis which concluded that it 
is highly unlikely that periodontal treatment could modulate systemic hsCRP levels in 
patients with severe periodontal disease (Ioannidou et al. 2006), and are in contrast to studies 
which found a decrease in hsCRP levels after periodontal therapy (Ide et al. 2003; D'Aiuto et 
al. 2005; Marcaccini et al. 2009a; Marcaccini et al. 2009b). 
Data from the current study show that cholesterol levels were significantly higher in non-
T1DM patients than T1DM patients.  Also, although triglyceride, HDL and non-HDL were 
higher in non-T1DM patients compared to T1DM patients, these differences were not 
statistically significant.  Following NSM, cholesterol was higher in non-T1DM patients at 
each time point; however this difference was statistically significant only at pre-treatment.  
This is not surprising, given that a key priority within the national management guidelines for 
T1DM involves the control of serum lipid levels (NICE 2015).  Therefore, it is reasonable to 
presume that the T1DM patients in this study were receiving more aggressive management 
and monitoring of CVD risk factors compared to the control patients. Additionally, in the 
present study, NSM had no significant influence on triglyceride, HDL, non-HDL and 
cholesterol levels in both T1DM and non-T1DM patients 
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The prevalence and severity of periodontal diseases are higher in patients with diabetes 
compared to healthy individuals (Grossi et al. 1997; Poplawska-Kita et al. 2014).  Patients 
with diabetes are at a three-fold increased risk of developing periodontitis compared to non-
diabetic patients (Mealey and Oates 2006).  In the current study, when analysing pre-
treatment periodontal data, no significant differences were found for mGI scores, mean PD, 
mean recession, mean LOA and % BOP between patients with T1DM and periodontitis and 
non-T1DM patients with periodontitis.  However T1DM patients with gingivitis and 
periodontitis had significantly higher amounts of plaque (0.94±0.40 and 0.98±0.54, 
respectively) compared to the non-T1DM patients with gingivitis and periodontitis 
(0.66±0.23 and 0.66±0.29, respectively).  Although not statistically significant, T1DM 
patients with healthy tissues had higher amounts of plaque compared to the non-T1DM 
patients with healthy tissues.  Our findings are in agreement with previous research which 
showed significantly higher plaque scores in T1DM patients compared to non-diabetic 
controls (Novaes et al. 1991; Aren et al. 2003; Lalla et al. 2006a).  The significantly higher 
amounts of plaque in diabetic patients can be explained by the fact that excessive glucose in 
diabetes enters the oral cavity via saliva and GCF, the sugar-rich biofilm which forms will 
then, in general, enhance plaque accumulation.  The lack of understanding and knowledge 
about oral hygiene and maintenance of optimal oral health in patients with diabetes, may be 
factors related to the higher plaque scores seen in these patients (Hugoson et al. 1989).  Our 
findings are in contrast to previous studies which found similar levels of plaque in patients 
with and without T1DM (Bay et al. 1974; Bernick et al. 1975; Hugoson et al. 1989; 
Sandholm et al. 1989a; de Pommereau et al. 1992; Firatli et al. 1996; Firatli 1997; Tervonen 
and Karjalainen 1997; Lalla et al. 2006b).  The poorer oral hygiene found in T1DM patients 
compared to non-diabetic patients could also be due to the greater attention and importance 
placed by T1DM patients in maintaining their systemic health with daily doses of insulin, as 
opposed to maintaining optimal oral hygiene, which was found to be superior in the non-
diabetic patients.  A previous study assessed the attitudes and awareness of the risk for 
periodontal disease in patients with diabetes (n=101)  and highlighted that  only 33% of the 
patients were aware of their increased risk for periodontal disease, 43% had attended a dentist 
within the past year, 34% had not attended a dentist for >5 years, 37% of the patients 
attended the dentist for treatment once a year, while 63% attended only when they had dental 
problems (Allen et al. 2008).  In the present study, while considering patient care pathways 
within diabetes management, a majority (94.7%) of the T1DM patients had received 
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examination of their eyes and feet and were educated on the importance of routine 
examinations for the betterment of their condition within the past 12 months.  This clearly 
demonstrates that a robust patient care pathway does exist for screening of diabetic 
complications.  Unfortunately, the same is not true for screening of oral complications of 
T1DM, with as many as 1/3 of the T1DM patients in this study reporting not being examined 
by a dentist in the past 12 months.  Hence, an opportunity to regularly screen for oral 
complications in this disease-susceptible population is clearly being lost.  This finding could 
also possibly explain the poorer oral hygiene experienced by T1DM patients compared to 
non-diabetic patients and needs to be addressed and included in the overall management of 
patients with diabetes. 
It is extremely rare that periodontal disease would affect all parts of the periodontium 
equally, and measuring mean PD solely provides a crude description of the PD found in each 
patient.  Hence, the utilization of reporting mean PD, without the % of sites with advanced 
periodontal disease, can be seen as a limitation of studies carried out in this research field.  In 
the current study, based on severity of periodontal disease at pre-treatment, the % of PD sites 
≥5 mm was significantly lower in patients with T1DM and periodontitis (14.7±46.4 %) 
compared to non-T1DM patients with periodontitis (23.7±15.5 %), indicating that more 
severe periodontal disease was present in non-T1DM patients compared to T1DM patients.  
This finding likely reflects the differences in the recruitment strategy utilized for both patient 
groups.  The T1DM patients were recruited from medical databases of T1DM patients held in 
both primary and secondary care settings, whereas the non-T1DM patients were recruited 
from diagnostic or student treatment clinics within the School of Dental Sciences, Newcastle 
University who were referred in for periodontal diagnosis and care by their general dental 
practice.  Although both groups were matched for periodontal diagnosis, the extent of their 
periodontal disease was not considered in the process.  This is a limitation in the current 
study, and highlights a need in future studies to stratify periodontal case selection based on 
the extent and severity of periodontal disease to establish a more meaningful and robust 
matching of groups by periodontal status for the selected patients.  With reference to the 
amount of gingival inflammation present, in the current study, interestingly the T1DM 
patients with healthy periodontal tissues had significantly higher % BOP (9.88±5.67 %) 
compared to the non-T1DM patients with healthy periodontal tissues (0.83±1.17 %).  Our 
findings support data from previous studies that demonstrated significantly higher levels of 
gingival inflammation in patients with diabetes compared to non-diabetic controls (Aren et al. 
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2003; Dakovic and Pavlovic 2008).  The possible explanation for the increase in gingival 
inflammation seen in patients with T1DM could be a manifestation of the upregulated 
diabetes-related systemic inflammation which manifests itself even in T1DM patients with 
healthy tissues.  The similar pattern of significantly higher levels of gingival inflammation in 
T1DM patients compared to non-diabetic patients was not replicated in those with gingivitis 
and periodontitis.  It is not unreasonable to conclude that the more severe periodontal disease 
present in non-T1DM patients compared to patients with T1DM may have masked the 
presence of greater background level of gingival tissue inflammation in T1DM patients with 
gingivitis and periodontitis. 
Patients with T1DM have been found to have a good response to appropriate periodontal 
therapy and their response to therapy is similar to that seen in non-diabetic controls (Westfelt 
et al. 1996; Christgau et al. 1998).  In the current study, following NSM both T1DM and non-
T1DM patients demonstrated significant improvements in PI, mGI, mean PD, mean LOA and 
% BOP at months 3 and 6 following NSM.  Compared to pre-treatment, a statistically 
significant increase in mean recession was seen in T1DM patients at month 6 and in non-
T1DM patients at months 3 and 6 following NSM.  A significant increase in mean recession 
following periodontal therapy indicates a resolution in inflammation and improvement in the 
periodontal condition.  Both T1DM and non-T1DM patients also showed significant 
reductions in % of PD sites ≥5 mm at months 3 and 6 following NSM, and taking into 
account the pre-treatment differences in % of PD sites ≥5 mm, the differences between 
T1DM and non-T1DM patients with periodontitis at months 3 and 6 following NSM were not 
statistically significant.  Our findings indicate a reduction in the severity of periodontal 
disease, and the lack of differences between the two groups following NSM indicates an 
improvement in the periodontal status of both patient groups.  The significantly higher % of 
PD sites reducing by ≥2 mm seen in non-T1DM patients most probably reflects the greater 
pre-treatment severity of periodontal disease seen in the non-T1DM patients.  The results of 
the current study confirm that NSM was successful in both patient groups, with significant 
reductions in inflammation and severity of periodontal disease following treatment.  Our 
findings are similar to those of other studies in T1DM patients which showed significant 
improvements in periodontal parameters following periodontal therapy (Bay et al. 1974; 
Seppala and Ainamo 1994; Smith et al. 1996; Westfelt et al. 1996; Christgau et al. 1998; 
Martorelli de Lima et al. 2004; Llambes et al. 2005).  Additionally, in the present study both 
T1DM and non-T1DM patients responded similarly to the periodontal treatment provided, 
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and our findings are similar to those of other studies which found that patients with T1DM 
had a good response to periodontal treatment, and their short- and long-term response to 
treatment was similar to that seen in non-diabetic patients (Bay et al. 1974; Westfelt et al. 
1996; Christgau et al. 1998). 
While considering biomarker levels in serum, in the present study, significantly higher pre-
treatment serum MMP-9, resistin and ENA-78/CXCL5 levels were detected in patients with 
T1DM compared to non-T1DM patients, and significantly higher serum MMP-9 levels were 
found in T1DM patients with periodontitis compared to non-T1DM patients with 
periodontitis.  Although higher serum levels of resistin and ENA-78/CXCL5 were seen in 
T1DM patients with periodontitis compared to non-T1DM patients with periodontitis, these 
differences were not statistically significant.  Significantly higher serum resistin and       
ENA-78/CXCL5 levels were seen in T1DM patients with gingivitis compared to non-T1DM 
patients with gingivitis, and although higher serum MMP-9 levels were seen in T1DM 
patients with gingivitis compared to non-T1DM with gingivitis, this difference was not 
statistically significant.  It is interesting to note that, although not statistically significant, 
serum MMP-9, resistin and ENA-78/CXCL5 levels were higher in the T1DM patients with 
healthy periodontal tissues compared to then non-T1DM patients with healthy tissues.  To the 
best of our knowledge, this is the first study to analyse levels of MMP-9 in serum in T1DM 
patients with periodontal disease, hence it has not been possible to make comparisons with 
findings of other studies.  It is a key finding in this study that despite non-T1DM patients 
having more severe periodontal disease compared to the T1DM patients (indicated by % of 
PD sites ≥5 mm), pre-treatment serum MMP-9 levels were significantly higher in T1DM 
patients with periodontitis compared to non-T1DM patients with periodontitis.  The possible 
explanation for this could be that patients with T1DM have elevated circulating MMP-9 
levels (Maxwell et al. 2001).  Diabetes-associated pathophysiological processes such as 
oxidative stress could potentially enhance MMP-9 activity and production (Uemura et al. 
2001).  MMP-9 has proved to be a useful biomarker in serum in T1DM patients at a risk of 
progression of other diabetes-related complications, and chronic kidney disease 
(Gharagozlian et al. 2009), and serum MMP-9 levels possibly contribute to the inflammatory 
process inherent to diabetic retinopathy in T1DM patients (Maxwell et al. 2001; Jacqueminet 
et al. 2006).  Studies involving T2DM patients have shown elevated serum MMP-9 levels in 
T2DM patients with coronary artery disease and premature atherosclerosis (Noji et al. 2001), 
and elevated circulating MMP-9 levels have been found in T2DM hypertensive patients 
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compared to normotensive patients (Tayebjee et al. 2004).  Additionally, elevated serum 
MMP-9 levels occur prior to the onset of T2DM-associated renal complications (Ebihara et 
al. 1998).  In the present study, patients with T1DM and periodontitis having significantly 
elevated serum MMP-9 levels compared to the non-diabetic patients with periodontitis is a 
key finding, and from the review of literature and the findings of this study, one can conclude 
that in the absence of more severe periodontal disease, the significant increase in serum 
MMP-9 levels in T1DM patients with periodontitis could likely be due to an increase in 
diabetes-related inflammation routinely observed in patients with T1DM.  Our findings 
related to serum ENA-78/CXCL5 are similar to those of a recent study which reported 
significantly higher plasma ENA-78/CXCL5 in T1DM patients with healthy periodontal 
tissues compared to non-diabetic patients with healthy tissues (Lappin et al. 2015). 
Following successful periodontal treatment, in the current study, compared to pre-treatment 
levels in both T1DM and non-T1DM patients, serum resistin levels reduced at month 6, 
however this reduction was statistically significant only in the non-T1DM patients.  To the 
best of our knowledge, this is the first study to investigate the effect of periodontal treatment 
on resistin levels in serum in patients with T1DM.  A study investigating the impact of 
periodontal therapy with adjunctive antibiotics in T2DM patients with periodontitis reported 
that despite significant improvements in clinical periodontal parameters and HbA1c levels in 
these patients, no statistically significant reduction in serum resistin levels was observed 
following treatment (Bharti et al. 2013).  Similarly, a study in systemically healthy patients 
with periodontitis reported that despite significant improvements in clinical periodontal 
parameters, no statistically significant reduction was seen in serum resistin levels following 
periodontal treatment (Devanoorkar et al. 2012).  A similar effect has been observed in the 
present study.  On performing correlations, serum resistin levels were significantly correlated 
with BMI only in patients with T1DM and not in the non-diabetic patients.  Therefore, 
resistin may not be an ideal biomarker in studying the link between T1DM and periodontal 
disease as obesity is not a cardinal finding in T1DM patients.  Due to the limited volume of 
GCF samples available and considering our findings of resistin levels in serum, it was 
decided not to further analyse this biomarker in the GCF samples. 
In the current study, compared to pre-treatment, both T1DM and non-T1DM patients with 
periodontitis showed non-significant reductions in serum ENA-78/CXCL5 levels at month 6 
following NSM.  To the best of our knowledge, this is the first study to investigate the effect 
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of periodontal therapy on levels of ENA-78/CXCL5 in serum in periodontitis patients with 
and without T1DM.  As ENA-78/CXCL5 was only detected in serum samples of the study 
and not in GCF, this possibly suggests that this chemokine may potentially be a useful 
systemic indicator to study the effect of diabetes on periodontal status.  It may be useful in 
future studies to ensure larger sample sizes to investigate the effects of periodontal therapy 
further in patients with and without T1DM. 
In the current study, compared to pre-treatment, both T1DM and non-T1DM patients with 
periodontitis showed a reduction in serum MMP-9 levels at 3 and 6 months following NSM, 
however these differences were not statistically significant.  It may be useful in future studies 
to ensure larger sample sizes to investigate the effects of periodontal therapy further in 
patients with and without T1DM.  The reduction in serum MMP-9 levels in both patient 
groups following NSM could possibly be a reflection of the significant improvement in 
clinical periodontal status and reduction in inflammation and severity of periodontal disease 
seen in both groups.  A study of systemically healthy patients with periodontitis showed a 
significant reduction in circulating plasma MMP-9 concentration and proteolytic activity 3 
months following effective NSM (Marcaccini et al. 2009b).  To the best of our knowledge, 
the current study is the first study to evaluate the effect of periodontal treatment on MMP-9 
levels in serum in patients with T1DM and periodontitis.  It is worth noting that post-
treatment serum MMP-9 levels in T1DM and non-T1DM patients with periodontitis 
(732.7±448.8 ng/ml and 472.9±259.9 ng/ml, respectively) were comparable to the pre-
treatment serum MMP-9 levels recorded in T1DM and non-T1DM patients with healthy 
periodontal tissues (791.3±475.6 ng/ml and 437.5±233.0 ng/ml, respectively).  These findings 
could potentially suggest that a resolution in periodontal inflammation leads to a reduction in 
the burden of circulating inflammatory biomarker MMP-9 to the level observed in 
periodontal health. 
While considering biomarker levels in GCF, the present study revealed higher pre-treatment 
GCF MMP-9 and IL-8 levels in patients with T1DM compared to non-T1DM patients; 
however these differences were not statistically significant.  To the best of our knowledge 
this is the first study to analyse MMP-9 and IL-8 levels in GCF in patients with T1DM and 
periodontal disease, hence it has not been possible to make comparisons with findings of 
other studies.  A previous study in T2DM patients unexpectedly reported significantly lower 
GCF IL-8 levels in T2DM patients with periodontitis compared to non-diabetic patients with 
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periodontitis (Engebretson et al. 2006).  Other T2DM studies reported no statistically 
significant differences in expression of IL-8 in gingival tissues (Duarte et al. 2007) and IL-8 
levels in serum (Longo et al. 2014) in periodontitis patients with and without T2DM.  In the 
current study, significantly higher GCF MMP-9 and IL-8 levels were detected in T1DM 
patients with healthy periodontal tissues compared to non-T1DM patients with healthy 
tissues.  The elevated inflammatory biomarker levels present in T1DM patients compared to 
non-diabetic patients is a key finding as it signifies that even in the absence of inflammatory 
periodontal disease, the manifestation of diabetes-related inflammation was presented in the 
GCF of patients with T1DM.  The pre-treatment biomarker findings in GCF were in 
accordance with the pre-treatment clinical periodontal findings, in which significantly higher 
levels of gingival inflammation (indicated by % BOP) was present in T1DM patients with 
healthy periodontal tissues compared to non-T1DM patients with healthy tissues.  Also, no 
statistically significant differences in GCF MMP-9 and IL-8 levels were found between 
T1DM and non-T1DM patients with gingivitis and periodontitis.  It is not unreasonable to 
presume that the more severe periodontal disease (indicated by higher % of PD sites ≥5 mm) 
in the non-T1DM patients compared to T1DM patients, may have masked the presence of 
greater background levels of GCF MMP-9 and IL-8 in T1DM patients with gingivitis and 
periodontitis.  Our findings related to GCF IL-8 levels are in agreement with a previous study 
which found significantly elevated salivary IL-8 levels in T1DM patients with healthy tissues 
compared to non-diabetic controls, and no statistically significant differences in salivary IL-8 
levels between periodontitis patients with and without T1DM (Dakovic et al. 2013).  The 
findings of this study are in contrast to those of a previous study which found significantly 
higher plasma IL-8 levels in patients with T1DM and periodontitis compared to non-diabetic 
patients with periodontitis (Lappin et al. 2011).  Currently, research related to GCF biomarker 
levels in patients with T1DM and periodontal disease is extremely limited and no studies 
have evaluated biomarker levels based on periodontal diagnosis as was considered in this 
study.  An experimental gingivitis study reported elevated GCF MMP-9 levels in both T1DM 
and non-diabetic patients, with significantly higher levels seen in T1DM patients with 
gingivitis compared to non-diabetic patients with gingivitis at the end of the study (Salvi et al. 
2010). 
In the current study, within the T1DM and non-T1DM group, significantly higher GCF 
MMP-9 levels were seen in periodontitis patients compared to those with gingivitis and 
healthy periodontal tissues.  These findings are in accordance with the clinical periodontal 
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findings of the study which showed significantly greater gingival inflammation (indicated by 
% BOP), mean PD and severity of periodontitis disease in patients with periodontitis with 
and without T1DM compared to those with gingivitis and healthy periodontal tissues.  A 
previous study reported significantly elevated MMP-9 levels in GCF, saliva and mouth rinse 
samples in periodontitis patients compared to those with healthy tissues (Makela et al. 1994).  
The results of the non-diabetic patients of the present study are in contrast with other studies 
which reported no significant differences in GCF MMP-9 levels while comparing patients 
with periodontitis, gingivitis and healthy periodontal tissues (Maeso et al. 2007), and while 
comparing patients with periodontitis and healthy periodontal tissues (Marcaccini et al. 
2010).  In the current study, within the T1DM and non-T1DM group, higher GCF IL-8 levels 
were seen in periodontitis patients compared to those with gingivitis and healthy periodontal 
tissues; however these differences were statistically significant only in the non-T1DM 
patients.  The results of the non-T1DM patients are in agreement with other studies of 
systemically healthy individuals which reported significantly elevated IL-8 levels in GCF 
(Tsai et al. 1995), plasma (Lappin et al. 2011) and serum (Li et al. 2012) in periodontitis 
patients compared to those with healthy tissues, and in contrast to results of a study which 
reported that despite significantly greater periodontal disease severity in patients with 
periodontitis, patients with healthy periodontal tissues had significantly higher GCF IL-8 
levels compared to those with periodontitis (Chung et al. 1997).   
Following periodontal therapy, in the current study T1DM patients with periodontitis showed 
significant reductions in GCF MMP-9 and IL-8 levels at months 3 and 6 following NSM.  
Similarly in non-T1DM patients there was a reduction in GCF levels of MMP-9 and IL-8 at 
months 3 and 6 following NSM; however this was statistically significant for GCF MMP-9 
only at month 6 and for GCF IL-8 only at month 3.  Overall, in both T1DM and non-T1DM 
patients, reductions in GCF levels of these two pro-inflammatory biomarkers appeared to 
mirror the improvement in clinical periodontal status following NSM.  The difficulty in 
comparing results of previous studies to the present study lies in the heterogeneity in 
methodologies used, and is a possible explanation for the variations in GCF biomarker levels 
seen in the published literature and the present study.  The differences in results could arise 
from variations in case definitions of periodontitis, analytical techniques, GCF sampling 
methods, techniques used for eluting GCF and storage of samples.  A review of past literature 
tells us that there is also a lack of consistency in the reporting of GCF data as some studies 
report biomarker concentration levels, while others report total biomarker levels and some 
  
 298  
 
authors report both total and concentration levels of the biomarkers in GCF.  All these factors 
collectively have increased inter-study variations in GCF biomarker levels, preventing clear 
conclusions from being made regarding the role biomarkers in GCF play in patients with 
T1DM and periodontal disease. 
To the best of our knowledge, this is the first study to investigate in T1DM patients the effect 
of periodontal treatment on MMP-9 and IL-8 levels in GCF, and from the results of this study 
it can be concluded that MMP-9 and IL-8 are potentially good local biomarkers to determine 
severity of periodontal disease and the benefit effective periodontal treatment has in patients 
with T1DM.  The lack of significant differences between inflammatory biomarkers in serum 
and GCF between T1DM and non-T1DM patients with periodontitis following NSM could 
possibly be due to the lack of significant differences between the two groups with regards to 
clinical periodontal status, as both groups were found to have no statistically significant 
differences in periodontal measurements and severity of periodontal disease following 
treatment. 
A positive correlation between severity of periodontal disease and glycaemic control has been 
reported in literature (Tanwir and Tariq 2012; Costa et al. 2013).  In the current study, the 
only positive significant correlation was found between PI score and HbA1c levels in all 
patients.  No statistically significant correlations were found between HbA1c and other 
clinical periodontal parameters.  While considering HbA1c levels and serum biomarker 
levels, a significant positive correlation was found between HbA1c and serum MMP-9 and          
ENA-78/CXCL5 levels in all patients, possibly suggesting that an increase in HbA1c levels is 
associated with an increase in the inflammatory burden in the serum, irrespective of diabetes 
status.  A significant positive correlation was also found between hsCRP and serum MMP-9 
levels in all patients and in patients with T1DM.  This may indicate that MMP-9 may reflect 
the chronic inflammatory state which is typical of periodontitis and is indicative of the 
association between hsCRP and serum MMP-9 levels particularly in patients with T1DM.  It 
is meaningful to note that serum biomarker levels did not statistically significantly correlate 
with clinical periodontal indices, whereas GCF MMP-9 and IL-8 levels showed a statistically 
significant positive correlation with clinical periodontal parameters.  The findings of the 
current study related to GCF biomarker levels indicate, in broad terms, that an increase in 
periodontal disease leads to elevated levels of MMP-9 and IL-8 in GCF.  However, a similar 
association was not found for serum biomarker levels and periodontal parameters.  It would 
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be reasonable to suggest that GCF is a good local indicator for periodontal inflammatory 
status due to its local production within the periodontal tissues.  Furthermore, the fact that 
serum MMP-9 levels significantly correlated with hsCRP levels implies that serum is 
potentially a good systemic indicator for the inflammatory disease status in patients with 
periodontal disease and T1DM. 
With regards to QoL in patients with T1DM and periodontal disease, this study assessed QoL 
in patients with T1DM using two routinely used, validated questionnaires, the W-BQ12 and 
the ADDQoL-19.  The pre-treatment analyses of the W-BQ12 revealed no statistically 
significant differences in any subscale scores (negative, energy and positive well-being) and 
overall general well-being score when comparing the T1DM patients based on periodontal 
diagnosis.  Our findings suggest that despite having statistically significant differences in 
severity of periodontal disease, patients with healthy tissues, gingivitis and periodontitis had a 
similar perception of the effect their diabetes and periodontal condition had on their QoL.  
Analysis of the ADDQoL-19 questionnaire revealed that all T1DM patients experienced an 
overall “good to very good” general QoL, however while considering their diabetes status the 
patients felt that their QoL would have been “a little better or much better” if they did not 
have diabetes.  Our findings captured the negative impact of T1DM on QoL in this study 
group.  Based on periodontal diagnosis, no statistically significant differences were found for 
general and diabetes-specific overview items and overall ADDQoL-19 score suggesting that 
patients with healthy tissues, gingivitis and periodontitis had a similar perception of the effect 
their diabetes and periodontal condition had on their QoL.  Our findings of the W-BQ12 and 
ADDQoL-19 are similar to those of a recent study investigating the impact of periodontal 
status and treatment on OHRQoL in patients with and without T2DM utilizing the OHIP-49 
questionnaire (Irani et al. 2015).  The OHIP-49 contains oral health-related questions, 
however despite this there was a lack of significant differences in OHIP-49 scores among 
T2DM patients with periodontitis, gingivitis and healthy tissues.  The authors reported that 
this could possibly indicate that diabetic patients are less concerned about their oral health 
than they are about other health problems that they have to manage as part of their diabetes.  
However, within their non-diabetic group, patients with periodontitis and gingivitis had 
poorer OHRQoL compared to those with periodontal health (Irani et al. 2015).  Potentially, 
systemically healthy patients might be more concerned about the signs and symptoms of 
periodontitis than diabetic patients who have to address other pressing health issues, and this 
might lead to lower expectations of oral health or better coping with the impact of 
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periodontitis (Irani et al. 2015).  In the current study, interpreting the ADDQoL-19 scores 
further (based on quartiles) revealed that a majority (73.7%) of the periodontitis patients 
experienced a poorer QoL, while a majority of the gingivitis (75%) and healthy periodontal 
tissue (77.8%) patients experienced a better QoL.  Our findings demonstrate that poorer 
periodontal health has a negative impact on QoL in people with T1DM. 
Analysis of post-treatment W-BQ12 scores in T1DM patients with periodontitis revealed a 
significant improvement in QoL at month 3 following NSM, suggesting that successful NSM 
has a short-term positive impact by improving QoL in diabetic patients with periodontitis.  
Our findings are in agreement to those of previous studies which reported that effective NSM 
improves QoL (Aslund et al. 2008; Jowett et al. 2009; Saito et al. 2010; Shanbhag et al. 
2012).  However, compared to pre-treatment, no statistically significant differences were 
found in the W-BQ12 scores at month 6 following NSM, suggesting a possible initial 
improvement in QoL following the first periodontal treatment appointment, which stabilised 
during the course of the study and was not evidently identified at month 6.  Analysis of the 
ADDQoL-19 scores at months 3 and 6 in T1DM patients with periodontitis revealed no 
statistically significant changes from pre- to post-treatment.  Interestingly, interpreting scores 
based on quartiles revealed that compared to pre-treatment, where as 73.7% of the 19 T1DM 
patients with periodontitis reported a poorer QoL, only 20% of the 10 T1DM patients with 
periodontitis reported a poorer QoL at months 3 and 6 following NSM.  Our findings could 
possibly suggest that effective periodontal treatment has the potential to change an 
individual’s negative perception of QoL to positive one.  In all groups of periodontal 
diagnosis, T1DM patients placed great importance and impact on their “freedom to eat and 
drink”, these  findings are consistent with those of previous studies which reported the 
greatest negative impact of diabetes is on “freedom to eat” (Bradley and Speight 2002; Trief 
et al. 2003; Costa et al. 2006; Holmanova and Ziakova 2009; Turk et al. 2013), which 
confirms the strong influence of dietary restrictions on QoL in patients with diabetes.  Our 
findings are also similar to a previous study in patients with T2DM (aged ≥65 years) which 
utilised the ADDQoL-19 and highlighted that the greatest impact of diabetes on QoL was on 
their freedom to eat, family life and dependence on others (Turk et al. 2013).  Patients with 
T1DM need to prioritise their dietary intake in order to prevent diabetes-related 
complications (Daneman 2006).  Their daily diet is usually regulated by the intake of their 
medications and the time of day, and hence the current study also found that “freedom to eat 
and drink” had a major impact and importance on the daily lives in patients with T1DM.   
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In the current study, analysing QoL in patients with T1DM did reveal a number of 
meaningful findings, however QoL was not assessed in the non-diabetic patients, hence it 
was not possible to make comparisons between the two groups.  Unfortunately, this must be 
regarded as a limitation in this study.  The W-BQ12 is a general health assessment 
questionnaire and the ADDQoL-19 is a diabetes-specific questionnaire, specifically designed 
to evaluate QoL in patients with diabetes, and both questionnaires contain limited oral health-
related questions.  Although T1DM patients with periodontitis showed statistically significant 
improvements in clinical periodontal parameters following NSM, these questionnaires were 
unable to capture the positive outcomes of this treatment.  Therefore, although these 
measures did provide some meaningful results, they were unable to capture to a full extent 
the effect of periodontal disease and the positive impact of treatment on QoL.  It would be 
beneficial in future studies to assess QoL in both diabetic and non-diabetic patients 
simultaneously, utilising both generic questionnaires (for diabetic and non-diabetic patients) 
and diabetes-specific questionnaires (for diabetic patients only) in order to provide a robust 
assessment of oral health and systemic health-related QoL in patients with and without 
diabetes. 
In conclusion, the findings of the present study contribute to the knowledge of the clinical 
and biological links between T1DM and periodontal disease and the response to periodontal 
therapy in both T1DM and non-diabetic patients.  Furthermore, the present study highlights 
the importance of analysing pro-inflammatory biomarkers in both diabetes and periodontal 
disease, and more specifically, the pro-inflammatory enzyme MMP-9 and chemokines         
ENA-78/CXCL5 and IL-8 which show potential as contributors to the inflammatory 
mechanisms linking diabetes and periodontal disease, with a consideration of MMP-9 in 
serum and GCF, ENA-78/CXCL5 in serum and IL-8 in GCF as prognostic markers for 
periodontitis in patients with and without diabetes.  Although not statistically significant, it is 
encouraging that a reduction in HbA1c levels was observed following successful periodontal 
treatment.  Additional research is warranted to investigate these findings further, ensuring 
that the T1DM and non-diabetic groups are well matched, especially with regards to 
periodontal status. 
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